Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof

ABSTRACT

The present invention provides methods of detecting infection using biomarkers. The methods disclosed herein include measuring the expression level of one or more polypeptide determinants in which the alteration of the expression level indicates infection of the patient. The methods provided herein are for distinguishing between bacterial infection, mixed infection, and/or viral infection. The methods disclosed herein may also further comprise measuring one or more non-polypeptide determinants. The present disclosure also provides methods for selection of a treatment regimen for the subject based on whether the subject is identified as having a bacterial or mixed infection, or a viral infection.

RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No.15/713,722 filed on Sep. 25, 2017, which is a continuation of U.S.patent application Ser. No. 15/015,309 filed on Feb. 4, 2016, now U.S.Pat. No. 9,791,446, which is a division of U.S. patent application Ser.No. 13/090,893 filed on Apr. 20, 2011, now U.S. Pat. No. 9,709,565,which claims the benefit of priority of Provisional Patent ApplicationNo. 61/326,244 filed on Apr. 21, 2010. The contents of the aboveapplications are all incorporated by reference as if fully set forthherein in their entirety.

FIELD OF THE INVENTION

The present invention relates generally to the identification ofbiological signatures and determinants associated with bacterial andviral infections and methods of using such biological signatures in thescreening diagnosis, therapy, and monitoring of infection.

BACKGROUND OF THE INVENTION

Antibiotics (Abx) are the world's most prescribed class of drugs with a25-30 billion $US global market. Numerous studies have shown that 40-70%of Abx are wrongly prescribed (Linder and Stafford 2001; Scott, Cohen etal. 2001; Davey, Brown et al. 2006; Cadieux, Tamblyn et al. 2007;Pulcini, Cua et al. 2007; 2011), making Abx the world's most misuseddrug (CDC 2011). Abx misuse can be classified into two types: (i)prescription to treat non-bacterial disease, such as a viral infection,for which Abx are ineffective and (ii) prescription in the case of abacterial disease, but applying the wrong Abx spectrum. For example,according to the USA center for disease control and prevention over 60Million wrong Abx prescriptions are given annually to treat flu in theUS, for which they are ineffective and inappropriate. The major factorsthat limit the effectiveness of current diagnostic solutions forreducing erroneous prescription include: (i) time to diagnosis; (ii)inaccessible infection site; (iii) false positives due to non-pathogenicbacteria and (iv) the challenge of diagnosing mixed infection (i.e.,bacterial and viral co-infection).

These factors are causing a diagnostic gap, which in turn often leadsphysicians to either over-prescribe Abx (the “Just-in-case-approach”),or under-prescribe Abx (the “Wait-and-see-approach”) (Little andWilliamson 1994; Little 2005; Spiro, Tay et al. 2006), both of whichhave far reaching health and financial consequences.

Ideally, a technological solution for assisting physicians in correctlyprescribing Abx should enable diagnosis that: (i) accuratelydifferentiates between a bacterial and viral infections; (ii) is rapid(within minutes); (iii) is able to differentiate between pathogenic andnon-pathogenic bacteria that are part of the body's natural flora, (iv)can differentiate between mixed and pure viral infections and (v) isapplicable in cases where the pathogen is inaccessible. Currentsolutions (such as culture, PCR and immunoassays) do not fulfill allthese requirements: (i) most assays (with the exception of multiplexPCRs) are often constrained to a limited set of bacterial or viralstrains; (ii) they usually require hours to days (e.g. culture andnucleic acid based assays); (iii) they often do not distinguish betweenpathogenic and non-pathogenic bacteria (Del March 1992); (iv) they areoften incapable of distinguishing between a mixed and a pure viralinfection and (v) they require direct sampling of the infection site inwhich traces of the disease causing agent are searched for. The latterprohibits diagnosis in cases where the pathogen resides in aninaccessible tissue, which is often the case.

Accordingly, a need exists for a method that accurately differentiatesbetween bacterial viral and mixed infections.

SUMMARY OF THE INVENTION

The present invention is based on the identification of signatures anddeterminants associated with bacterial, viral and mixed (i.e., bacterialand viral co-infections) infections. The methods of the invention allowfor the identification of type of infection a subject is suffering from,which in turn allows for the selection of an appropriate treatmentregimen. Importantly, not only do the signatures and determinants of thepresent invention discriminate between viral and bacterial infections,the signatures and determinant also discriminate between mixed and viralinfections. Thus, the methods of the invention allow for the selectionof subjects whom antibiotic treatment is desired and prevent unnecessaryantibiotic treatment of subject having only a viral infection or anon-infectious disease.

Accordingly, one aspect of the invention provides methods with apredetermined level of predictability for identifying an infection in asubject by measuring the expression level of one or more polypeptidesselected from ABTB1, ADIPOR1, ARHGDIB, ARPC2, ATP6V0B, C1orf83, CD15,CES1, CORO1A, CSDA, EIF4B, EPSTI1, GAS7, HERC5, IFI6, KIAA0082, IFIT1,IFIT3, IFITM1, IFITM3, LIPT1, IL7R, ISG20, LOC26010, LY6E, LRDD, LTA4H,MAN1C1, MBOAT2, NPM1, OAS2, PARP12, PARP9, QARS, RAB13, RAB31, RAC2,RPL34, PDIA6, PTEN, RSAD2, SART3, SDCBP, SMAD9, SOCS3, TRIM 22, UBE2N,XAF1 and ZBP1 in a sample from the subject. A clinically significantalteration in the level of the one or more polypeptides in the sampleindicates an infection in the subject. In some aspects the level of theone or more polypeptides is compared to a reference value, such as anindex value.

In various aspects the method distinguishes a virally infected subjectfrom either a subject with non-infectious disease or a healthy subject;a bacterially infected subject, from either a subject withnon-infectious disease or a healthy subject; a subject with aninfectious disease from either a subject with an non-infectious diseaseor a healthy subject; a bacterially infected subject from a virallyinfected subject or a mixed infected subject and a virally infectedsubject.

Optionally, the method further comprises measuring one or morenon-protein features (i.e., non protein DETERMINANTS) such as whiteblood count, neutrophil %, Lymphocyte %, monocyte %, absolute lymphocytecount, absolute neutrophil count and maximimal temperature or measuringthe expression level of CRP or MX1.

The sample is for example, whole blood or a fraction thereof. A bloodfraction sample contains cells that include lymphocytes, monocytes andgranulocytes. The expression level of the polypeptide is determined byelectrophoretically, or immunochemically. The immunochemical detectionis for example, by flow cytometry, radioimmunoassay, immunofluorescenceassay or by an enzyme-linked immunosorbent assay.

In some aspects of the invention the DETERMINANTS are preferablyselected such that their MCC is >=0.4.

In various aspects the method distinguishes a virally infected subjectfrom either a subject with non-infectious disease or a healthy subject.In such methods, one or more polypeptides including IFIT3, IFITM3,LOC26010, MAN1C1, MX1, OAS2, RAB13, RSAD2, and SART3 are measured. Invarious embodiments, two or more DETERMINANTS are measured, for example:

-   -   a) C1orf83 is measured and a second DETERMINANT selected from        IFIT3, IFITM3, LOC26010, LRDD, Maximaltemperature, MX1, OAS2,        PTEN, RAB13, RPL34, RSAD2, and SART3 is measured.    -   b) IFIT3 is measured and a second DETERMINANT selected from of        IFITM3, LOC26010, LRDD, Maximaltemperature, MX1, OAS2, PTEN,        RAB13, RPL34, RSAD2, and SART3 is measured.    -   c) LOC26010 is measured and a second DETERMINANT selected from        LRDD, Maximaltemperature, MX1, OAS2, PTEN, RAB13, RPL34, RSAD2,        and SART3 is measured.    -   d) LRDD is measured and a second DETERMINANT selected from the        group consisting of Maximaltemperature, MX1, OAS2, PTEN, RAB13,        RPL34, RSAD2, and SART3.    -   e) Maximaltemperature is measured and a second DETERMINANT        selected from the group consisting of OAS2, PTEN, RAB13, RPL34,        RSAD2, and SART3 is measured.    -   f) MX1 is measured and a second DETERMINANT selected from the        group consisting of Maximaltemperature, MX1, OAS2, PTEN, RAB13,        RPL34, RSAD2, and SART3.    -   g) OAS2 is measured and a second DETERMINANT selected from the        group consisting of PTEN, RAB13, RPL34, RSAD2, and SART3 is        measured.    -   h) PTEN is measured and a second DETERMINANT selected from the        group consisting of RAB13, RPL34, RSAD2, and SART3 is measured.    -   i) RAB13 is measured and a second DETERMINANT selected from the        group consisting of RPL34, RSAD2, and SART3 is measured.    -   j) RPL34 is measured and RSAD2 or SART3 is measured.

In various other aspects the method distinguishes a bacterially infectedsubject, from either a subject with non-infectious disease or a healthysubject. In such methods, one or more polypeptides selected from HERC5,KIAA0082, LOC26010, MX1, OAS2, RAB13 and SMAD9 is measured. In variousembodiments, two or more DETERMINANTS are measured, for example: a) ANCis measured and a second DETERMINANT selected from C1orf83, CD15, CRP,IFIT3, ISG20, LOC26010, LRDD, LTA4H, Lym (%), Maximaltemperature, MX1,OAS2, PARP9, QARS, RAB13, RAB31, RAC2, RPL34, SART3, TRIM22, WBC, XAF1,or ZBP1 is measured.

-   -   b) C1orf83 is measured and a second DETERMINANT selected from        CD15, CRP, IFIT3, ISG20, LOC26010, LRDD, LTA4H, Lym (%),        Maximaltemperature, MX1, OAS2, PARP9, QARS, RAB13, RAB31, RAC2,        RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   c) CD15 is measured and a second DETERMINANT selected from CRP,        IFIT3, ISG20, LOC26010, LRDD, LTA4H, Lym (%),        Maximaltemperature, MX1, OAS2, PARP9, QARS, RAB13, RAB31, RAC2,        RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   d) CRP is measured and a second DETERMINANT selected from IFIT3,        ISG20, LOC26010, LRDD, LTA4H, Lym (%), Maximaltemperature, MX1,        OAS2, PARP9, QARS, RAB13, RAB31, RAC2, RPL34, SART3, TRIM22,        WBC, XAF1, and ZBP1 is measured.    -   e) IFIT3 is measured and a second DETERMINANT selected from        ISG20, LOC26010, LRDD, LTA4H, Lym (%), Maximaltemperature, MX1,        OAS2, PARP9, QARS, RAB13, RAB31, RAC2, RPL34, SART3, TRIM22,        WBC, XAF1, and ZBP1 is measured.    -   f) ISG20 is measured and a second DETERMINANT selected from        LOC26010, LRDD, LTA4H, Lym (%), Maximaltemperature, MX1, OAS2,        PARP9, QARS, RAB13, RAB31, RAC2, RPL34, SART3 is measured and a        TRIM22, WBC, XAF1, and ZBP1 is measured.    -   g) LOC26010, second DETERMINANT selected from LRDD, LTA4H, Lym        (%), Maximaltemperature, MX1, OAS2, PARP9, QARS, RAB13, RAB31,        RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   h) LRDD is measured and a second DETERMINANT selected from        LTA4H, Lym (%), Maximaltemperature, MX1, OAS2, PARP9, QARS,        RAB13, RAB31, RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is        measured.    -   i) LTA4H is measured and a second DETERMINANT selected from Lym        (%), Maximaltemperature, MX1, OAS2, PARP9, QARS, RAB13, RAB31,        RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   j) Lym (%) is measured and a second DETERMINANT selected from        Maximaltemperature, MX1, OAS2, PARP9, QARS, RAB13, RAB31, RAC2,        RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   k) Maximaltemperature is measured and a second DETERMINANT        selected from OAS2, PARP9, QARS, RAB13, RAB31, RAC2, RPL34,        SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   l) MX1 is measured and a second DETERMINANT selected from        Maximaltemperature, OAS2, PARP9, QARS, RAB13, RAB31, RAC2,        RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   m) OAS2 is measured and a second DETERMINANT selected from        PARP9, QARS, RAB13, RAB31, RAC2, RPL34, SART3, TRIM22, WBC,        XAF1, and ZBP1 is measured.    -   n) PARP9 is measured and a second DETERMINANT selected from        QARS, RAB13, RAB31, RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and        ZBP1 is measured.    -   o) QARS is measured and a second DETERMINANT selected from        RAB13, RAB31, RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is        measured.    -   p) RAB13 is measured and a second DETERMINANT selected from        RAB31, RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is        measured.    -   q) RAB31 is measured and a second DETERMINANT selected from        RAC2, RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   r) RAC2 is measured and a second DETERMINANT selected from        RPL34, SART3, TRIM22, WBC, XAF1, and ZBP1 is measured.    -   s) RPL34 is measured and a second DETERMINANT selected from        SART3, TR1M22, WBC, XAF1, and ZBP1 is measured.    -   t) SART3 is measured and a second DETERMINANT selected from        TRIM22, WBC, XAF1, and ZBP1 is measured.    -   u) TRIM22 is measured and a second DETERMINANT selected from        WBC, XAF1, and ZBP1 is measured.    -   v) WBC is measured and XAF1 or ZBP1 is measured.    -   w) XAF1 and ZBP1 are measured.

In various other aspects the methods distinguish a subject with aninfectious disease from either a subject with a non-infectious diseaseor a healthy subject. In such methods, one or polypeptides selected fromIFIT3, LOC26010, MAN1C1, MX1, OAS2, RAB13, RSAD2, and SMAD9 is measured.In various embodiments, two or more DETERMINANTS are measured, forexample:

-   -   a) C1orf83 is measured and a second DETERMINANT selected from        CRP, IFIT3, LOC26010, LRDD, MX1, Maximaltemperature, OAS2, QARS,        RAB13, RPL34, RSAD2, and SART3 is measured.    -   b) CRP is measured and a second DETERMINANT selected from IFIT3,        LOC26010, LRDD, MX1, Maximaltemperature, OAS2, QARS, RAB13,        RPL34, RSAD2, and SART3 is measured.    -   c) IFIT3 is measured and a second DETERMINANT selected from        LOC26010, LRDD, MX1, Maximaltemperature, OAK, QARS, RAB13,        RPL34, RSAD2, and SART3 is measured.    -   d) LOC26010 is measured and a second DETERMINANT selected from        LRDD, MX1, Maximaltemperature, OAS2, QARS, RAB13, RPL34, RSAD2,        and SART3 is measured.    -   e) LRDD is measured and a second DETERMINANT selected from MX1,        Maximaltemperature, OAS2, QARS, RAB13, RPL34, RSAD2, and SART3        is measured.    -   f) MX1 is measured and a second DETERMINANT selected from        Maximaltemperature, OAS2, QARS, RAB13, RPL34, RSAD2, and SART3.    -   g) Maximaltemperature is measured and a second DETERMINANT        selected from OAS2, QARS, RAB13, RPL34, RSAD2, and SART3 is        measured.    -   h) OAS2 is measured and a second DETERMINANT selected from QARS,        RAB13, RPL34, RSAD2, and SART3 is measured.    -   i) QARS is measured and a second DETERMINANT selected from        RAB13, RPL34, RSAD2, and SART3 is measured.    -   j) RAB13 is measured and a second DETERMINANT selected from        RPL34, RSAD2, and SART3 is measured.    -   k) RPL34 is measured and RSAD2 or SART3 is measured.    -   l) RSAD2 and SART3 are measured.

In various aspects the methods distinguish bacterially infected subjectfrom a virally infected subject. In such methods one ore morepolypeptides selected from ABTB1, ADIPOR1, ARHGDIB, ARPC2, CD15, CORO1A,CSDA, EIF4B, EPSTI1, GAS7, HERC5, IFI6, IFIT1, IFIT3, IFITM1, IFITM3,IL7R, LOC26010, LY6E, MAN1C1, MBOAT2, MX1, NPM1, OAS2, PARP12, PARP9,PDIA6, PTEN, RSAD2, SDCBP, and TRIM 22 is measured. In variousembodiments, two or more DETERMINANTS are measured, for example:

-   -   a) ANC is measured and a second DETERMINANT selected from        CORO1A, CRP, EIF4B, IFIT3, IFITM1, IFITM3, LOC26010, Lym (%),        MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12, PTEN, RSAD2, SDCBP and        WBC is measured;    -   b) CORO1A is measured and a second DETERMINANT selected from        CRP, EIF4B, IFIT3, IFITM1, IFITM3, LOC26010, Lym (%), MAN1C1,        MX1, Neu (%), NPM1, OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is        measured;    -   c) CRP is measured and a second DETERMINANT selected from EIF4B,        IFIT3, IFITM1, IFITM3, LOC26010, Lym (%), MAN1C1, MX1, Neu (%),        NPM1, OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   d) EIF4B is measured and a second DETERMINANT selected from        IFIT3, IFITM1, LOC26010, Lym (%), MAN1C1, MX1, Neu (%), NPM1,        OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   e) IFIT3 is measured and a second DETERMINANT selected from        IFITM1, IFITM3, LOC26010, Lym (%), MAN1C1, MX1, Neu (%), NPM1,        OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   f) IFITM1 is measured and a second DETERMINANT selected from        IFITM3, LOC26010, Lym (%), MAN1C1, MX1, Neu (%), NPM1, OAS2,        PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   g) IFITM3 is measured and a second DETERMINANT selected from        LOC26010, Lym (%), MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12,        PTEN, RSAD2, SDCBP, and WBC is measured;    -   h) LOC26010 is measured and a second DETERMINANT selected from        Lym (%), MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12, PTEN, RSAD2,        SDCBP, and WBC is measured,    -   i) Lym (%) is measured and a second DETERMINANT selected from        MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12, PTEN, RSAD2, SDCBP,        and WBC is measured;    -   j) MAN1C1 is measured and a second DETERMINANT selected from        MX1, Neu (%), NPM1, OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is        measured,    -   k) MX1 is measured and a second DETERMINANT selected from Neu        (%), NPM1, OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is        measured;    -   l) Neu (%) is measured and a second DETERMINANT selected from        OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   m) NPM1 is measured and a second DETERMINANT selected from Neu        (%), OAS2, PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   n) OAS2 is measured and a second DETERMINANT selected from        PARP12, PTEN, RSAD2, SDCBP, and WBC is measured;    -   o) PARP12 is measured and a second DETERMINANT selected from        PTEN, RSAD2, SDCBP, and WBC is measured,    -   p) PTEN is measured and a second DETERMINANT selected from        RSAD2, SDCBP, and WBC is measured,    -   q) RSAD2 is measured SDCBP or WBC is measured; or    -   r) SDCBP and WBC are measured.

Alternatively:

-   -   CRP and RSAD2 are measured;    -   CRP and PARP12 are measured;    -   CRP and MX1 are measured;    -   CRP and Lym (%) are measured;    -   CRP and IFIT3 are measured;    -   CRP and LOC26010 are measured;    -   CRP and PTEN are measured;    -   CRP and IFITM3 are measured;    -   Neu (%) and RSAD2 are measured;    -   OAS2 and RSAD2 are measured;    -   CRP and EIF4B are measured;    -   CRP and NPM1 are measured;    -   CRP and Neu (%) are measured;    -   CRP and OAS2 are measured;    -   CRP and SDCBP are measured;    -   CRP and IFIT1 are measured;    -   CRP and IFI6 are measured;    -   CRP and PDIA6 are measured; or    -   CRP and PARP9 are measured.

In another aspect for example, CRP and one or more DETERMINANTS selectedfrom RSAD2, MX1, IFITM3, EIF4B, OAS2, IFITM1, IFIT3, PARP12, LOC26010,PTEN, CORO1A, MAN1C1, NPM1, SDCBP, IFIT1, IFI6, PDIA6, and PARP9 aremeasured.

In a further aspect CRP and one or more DETERMINANTS selected fromRSAD2, IFITM3, EIF4B, MX1, OAS2, IFITM1, IFIT3, PARP12, LOC26010, PTEN,CORO1A, MAN1C1, NPM1, SDCBP, IFIT1, IFI6, PDIA6, PARP9, Neu (%), Lym(%), ANC, and WBC are measured

In yet another aspect for example, one or more DETERMINANTS selectedfrom Neu (%), Lym (%), ANC, WBC, and CRP is measured and one or moreDETERMINANTS selected from RSAD2, IFITM3, EIF4B, OAS2, IFITM1, IFIT3,PARP12, LOC26010, PTEN, CORO1A, MAN1C1, NPM1, SDCBP, IFIT1, IFI6, PDIA6,and PARP9 is measured.

In a further aspect for example, two or more DETERMINANTS selected fromRSAD2, CRP, MX1, IFITM3, EIF4B, OAS2, IFITM1, IFIT3, PARP12, LOC26010,PTEN, CORO1A, MAN1C1, NPM1, SDCBP, IFIT1, IFI6, PDIA6 and PARP9 aremeasured.

In yet a further aspect for example, two or more DETERMINANTS selectedfrom RSAD2, CRP, Neu (%), Lym (%), MX1, ANC, IFITM3, EIF4B, OAS2,IFITM1, IFIT3, PARP12, WBC, LOC26010, PTEN, CORO1A, MAN1C1, NPM1, SDCBP,IFI6, PDIA6, and PARP9 are measured.

In another aspect for example, three or more DETERMINANTS selected fromRSAD2, CRP, MX1, IFITM3, EIF4B, OAS2, IFITM1, IFIT3, PARP12, LOC26010,PTEN, CORO1A, MAN1C1, NPM1, SDCBP, IFI6, PDIA6, and PARP9 are measured.

In a further aspect for example three or more DETERMINANTS selected fromRSAD2, CRP, Neu (%), Lym (%), MX1, ANC, IFITM3, EIF4B, OAS2, IFITM1,IFIT3, PARP12, WBC, LOC26010, PTEN, CORO1A, MAN1C1, NPM1, SDCBP, IFI6,PDIA6, and PARP9 are measured.

In another aspect for example, two or more DETERMINANTS selected fromABTB1, ANC, CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, IFI6, IFIT3, IFITM1,IFITM3, LOC26010, LY6E, Lym (%), MAN1C1, MX1, Neu (%), NPM1, OAS2,PARP12, PARP9, PD1A6, PTEN, RSAD2, SDCBP, and WBC are measured and wherethe DETERMINANTS are selected such that their p-value is less than 10⁻⁴.

In a further aspect for example, two or more DETERMINANTS selected fromABTB1, ANC, ARHGDIB, ARPC2, CD15, CORO1A, CRP, CSDA, EIF4B, EPSTI1,GAS7, HERC5, IF16, IFIT1, IFIT3, IFITM1, IFITM3, IL7R, KIAA0082,LOC26010, Lym (%), MBOAT2, MX1, Neu (%), OAS2, PARP12, PARP9, PTEN,RSAD2, SDCBP, TRIM 22, WBC, ARHGDIB, ARPC2, HERC5, IFI6, IFIT3, MBOAT2,and TRIM 22 are measured and where the DETERMINANTS are selected suchthat the p-value is less than 10⁻³.

In yet a further aspect for example,

-   -   a) ABTB1 is measured and a second DETERMINANT selected from ANC,        CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, IFI6, IFIT3, IFITM1,        IFITM3, LOC26010, LY6E, Lym (%), MAN1C1, MX1, Neu (%), NPM1,        OAS2, PARP12, PARP9, PDIA6, PTEN, RSAD2, SDCBP, and WBC is        measured.    -   b) CSDA is measured and a second DETERMINANT selected from        EIF4B, EPSTI1, GAS7, IFI6, IFIT3, IFITM1, IFITM3, LOC26010,        LY6E, Lym (%), MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12, PARP9,        PDIA6, PTEN, RSAD2, SDCBP, and WBC is measured.    -   c) EPSTI1 is measured and a second DETERMINANT selected from        GAS7, IFI6, IFIT3, IFITM1, IFITM3, LOC26010, LY6E, Lym (%),        MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12, PARP9, PDIA6, PTEN,        RSAD2, SDCBP, and WBC is measured.    -   d) GAS7 is measured and a second DETERMINANT selected from IFI6,        IFIT3, IFITM1, IFITM3, LOC26010, LY6E, Lym (%), MAN1C1, MX1, Neu        (%), NPM1, OAS2, PARP12, PARP9, PDIA6, PTEN, RSAD2, SDCBP, and        WBC is measured.    -   e) IFI6 is measured and a second DETERMINANT selected from        IFIT3, IFITM1, IFITM3, LOC26010, LY6E, Lym (%), MAN1C1, MX1, Neu        (%), NPM1, OAS2, PARP12, PARP9, PDIA6, PTEN, RSAD2, SDCBP, and        WBC is measured.    -   f) LY6E is measured and a second DETERMINANT selected from Lym        (%), MAN1C1, MX1, Neu (%), NPM1, OAS2, PARP12, PARP9, PDIA6,        PTEN, RSAD2, SDCBP, and WBC is measured.    -   g) PARP9 is measured and a second DETERMINANT selected from        PDIA6, PTEN, RSAD2, SDCBP, and WBC is measured.    -   h) PDIA6 is measured and a second DETERMINANT selected from        PTEN, RSAD2, SDCBP, and WBC is measured.

In various aspects the methods distinguish between a mixed infectedsubject and a virally infected subject. In such methods, one or morepolypeptides selected from ANC, ARHGDIB, ARPC2, ATP6V0B, CD15, CES1,CORO1A, HERC5, IFIT3, LIPT1, LOC26010, MX1, OAS2, PARP12, PARP9, PBS,PTEN, RSAD2, SART3, SOCS3, and UBE2N is measured.

For example:

-   -   a) ANC is measured and a second DETERMINANT selected from        ARHGDIB, ARPC2, ATP6V0B, CES1, CORO1A, CRP, HERC5, IFIT3, LIPT1,        LOC26010, Lym (%), MX1, Neu (%), OAS2, PARP12, PARP9, PTEN,        RSAD2, SOCS3, or UBE2N is measured;    -   b) ARHGDIB is measured and a second DETERMINANT selected from        ARPC2, ATP6V0B, CES1, CORO1A, CRP, HERC5, IFIT3, LIPT1,        LOC26010, Lym (%), MX1, Neu (%), OAS2, PARP12, PARP9, PTEN,        RSAD2, SOCS3, and UBE2N is measured;    -   c) ARPC2 is measured and a second DETERMINANT selected from        ATP6V0B, CES1, CORO1A, CRP, HERC5, IFIT3, LIPT1, LOC26010, Lym        (%), MX1, Neu (%), OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3, and        UBE2N is measured;    -   d) ATP6V0B is measured and a second DETERMINANT selected from        CES1, CORO1A, CRP, HERC5, IFIT3, LIPT1, LOC26010, Lym (%), MX1,        Neu (%), OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N is        measured;    -   e) CES1 is measured and a second DETERMINANT selected from        CORO1A, CRP, HERC5, IFIT3, LIPT1, LOC26010, Lym (%), MX1, Neu        (%), OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N is        measured;    -   f) CORO1A is measured and a second DETERMINANT selected from        CRP, HERC5, IFIT3, LIPT1, LOC26010, Lym (%), MX1, Neu (%), OAS2,        PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   g) CRP is measured and a second DETERMINANT selected from HERC5,        IFIT3, LIPT1, LOC26010, Lym (%), MX1, Neu (%), OAS2, PARP12,        PARP9, PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   h) HERC5 is measured and a second DETERMINANT selected from        IFIT3, LIPT1, LOC26010, Lym (%), MX1, Neu (%), OAS2, PARP12,        PARP9, PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   i) IFIT3 is measured and a second DETERMINANT selected from        LIPT1, LOC26010, Lym (%), MX1, Neu (%), OAS2, PARP12, PARP9,        PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   j) LIPT1 is measured and a second DETERMINANT selected from        LOC26010, Lym (%), MX1, Neu (%), OAS2, PARP12, PARP9, PTEN,        RSAD2, SOCS3, and UBE2N is measured;    -   k) LOC26010 is measured and a second DETERMINANT selected from        Lym (%), MX1, Neu (%), OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3,        and UBE2N is measured;    -   l) Lym (%) is measured and a second DETERMINANT selected from        MX1, Neu (%), OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N        is measured;    -   m) MX1 is measured and a second DETERMINANT selected from Neu        (%), OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N is        measured;    -   n) Neu (%) is measured and a second DETERMINANT selected from        OAS2, PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   o) OAS2 is measured and a second DETERMINANT selected from        PARP12, PARP9, PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   p) PARP12 is measured and a second DETERMINANT selected from        PARP9, PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   q) PARP9 is measured and a second DETERMINANT selected from        PTEN, RSAD2, SOCS3, and UBE2N is measured;    -   r) PTEN is measured and a second DETERMINANT selected from        RSAD2, SOCS3, and UBE2N is measured;    -   s) RSAD2 is measured and SOCS3 or UBE2N is measured; or    -   t) SOCS3 and UBE2N are measured.

Any of the above described methods are useful in distinguishing betweena bacterial or a mixed infected subject and a viral infection, anon-infectious disease or a healthy subject. Optionally, a treatmentregimen for the subject is selected. For example, a subject identifiedas having a bacterial or a mixed infection is selected to receive anantibiotic treatment regimen whereas a subject identified as having aviral infection, a non-infectious disease or healthy is not selected toreceive an antibiotic treatment regimen.

The invention also provides methods of selecting a treatment regimen fora subject by identifying an infection in accordance to any of the abovedescribed methods; and selecting a treatment regimen, thereby treatingthe subject suspected of having an infection.

The invention further provides methods with a predetermined level ofpredictability for monitoring the effectiveness of treatment for aninfection by: detecting the level of one or more polypeptides selectedfrom ABTB1, ADIPOR1, ARHGDIB, ARPC2, ATP6V0B, C1orf83, CD15, CES1,CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, HERC5, IFI6, KIAA0082, IFIT1,IFIT3, IFITM1, IFITM3, LIPT1, IL7R, ISG20, LOC26010, LY6E, LRDD, LTA4H,MAN1C1, MBOAT2, MX1, NPM1, OAS2, PARP12, PARP9, QARS, RAB13, RAB31,RAC2, RPL34, PDIA6, PTEN, RSAD2, SART3, SDCBP, SMAD9, SOCS3, TRIM 22,UBE2N, XAF1 and ZBP1 in a first sample from the subject at a firstperiod of time; and detecting the level of one or more polypeptidesselected from ABTB1, ADIPOR1, ARHGDIB, ARPC2, ATP6V0B, C1orf83, CD15,CES1, CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, HERC5, IFI6, KIAA0082,IFIT1, IFIT3, IFITM1, IFITM3, LIPT1, IL7R, ISG20, LOC26010, LY6E, LRDD,LTA4H, MAN1C1, MBOAT2, MX1, NPM1, OAS2, PARP12, PARP9, QARS, RAB13,RAB31, RAC2, RPL34, PDIA6, PTEN, RSAD2, SART3, SDCBP, SMAD9, SOCS3, TRIM22, UBE2N, XAF1 and ZBP1 in a second sample from the subject at a secondperiod of time. The level of the one or more polypeptides detected atthe first period of time is compared to the level detected at the secondperiod of time. Optionally, the level of the one or more polypeptidesdetected is compared to a reference value. The effectiveness oftreatment is monitored by a change in the level of one or morepolypeptides.

The subject has previously been treated for the infection. Alternativelythe subject has not been previously treated for the infection. In someaspects the first sample is taken from the subject prior to beingtreated for the infection and the second sample is taken from thesubject after being treated for the infection. In some aspects, thesecond sample is taken from the subject after recurrence of theinfection or prior to recurrence of the infection.

The invention further comprises an infection reference expressionprofile, containing a pattern of polypeptide levels of two or morepolypeptides selected from ABTB1, ADIPOR1, ARHGD1B, ARPC2, ATP6V0B,C1orf83, CD15, CES1, CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, HERC5,IFI6, KIAA0082, IFIT1, IFIT3, IFITM1, IFITM3, LIPT1, IL7R, ISG20,LOC26010, LY6E, LRDD, LTA4H, MAN1C1, MBOAT2, MX1NPM1, OAS2, PARP12,PARP9, QARS, RAB13, RAB31, RAC2, RPL34, PDIA6, PTEN, RSAD2, SART3,SMAD9, SDCBP, TRIM 22, SART3, SOCS3, UBE2N, XAF1 and ZBP1.

Also included in the invention is a kit containing a plurality ofpolypeptide detection reagents that detect the correspondingpolypeptides selected from ABTB1, ADIPOR1, ARHGDIB, ARPC2, ATP6V0B,C1orf83, CD15, CES1, CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, HERC5,IFI6, KIAA0082, IFIT1, IFIT3, IFITM1, IFITM3, LIPT1, IL7R, ISG20,LOC26010, LY6E, LRDD, LTA4H, MAN1C1, MBOAT2, MX1, NPM1, OAS2, PARP12,PARP9, QARS, RAB13, RAB31, RAC2, RPL34, PDIA6, PTEN, RSAD2, SART3,SMAD9, SDCBP, TRIM 22, SART3, SOCS3, UBE2N, XAF1 and ZBP1. Preferably,the detection reagent comprises one or more antibodies or fragmentsthereof.

The invention further includes a machine readable media containing oneor more infection reference expression profiles according to theinvention, and optionally, additional test results and subjectinformation.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention pertains. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice of the present invention, suitable methods and materials aredescribed below. All publications, patent applications, patents, andother references mentioned herein are expressly incorporated byreference in their entirety. In cases of conflict, the presentspecification, including definitions, will control. In addition, thematerials, methods, and examples described herein are illustrative onlyand are not intended to be limiting.

Other features and advantages of the invention will be apparent from andencompassed by the following detailed description and claims.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

FIG. 1 is an illustration of the protein immuno-signature baseddiagnostics. The proteomic signatures of healthy, bacterial and viralinfected individuals are illustrated with bars representing the normlevels of different proteins.

FIG. 2 is an illustration of the clinical study workflow.

FIGS. 3A-3G are a series of bar charts showing patient and infectioncharacteristics.

FIG. 4A Measurements of DETERMINANTS whose levels were differentiallyexpressed in patients with viral versus bacterial infections. Pointscorrespond to patients and bars correspond to group means (left panel).DETERMINANT distributions were estimated using maximum likelihood (rightpanel). The abbreviations lym, gran, mono, mean and total are used toindicate whether a DETERMINANT polypeptide was differentially expressedin lymphocytes, granulocytes, monocytes, mean signal over all leukocytesor total signal of leukocytes respectively.

FIG. 4B Measurements of DETERMINANTS whose levels were differentiallyexpressed in patients with mixed infections versus pure viralinfections.

FIG. 4C Measurements DETERMINANTS whose levels were differentiallyexpressed in viral versus non-infectious disease and healthy patients.

FIG. 4D Measurements DETERMINANTS whose levels were differentiallyexpressed in bacterial versus non-infectious disease and healthypatients.

FIG. 4E Measurements of DETERMINANTS whose levels were differentiallyexpressed in infectious disease versus non-infectious disease andhealthy patients

FIG. 5 Proteins that have an established immunological role in the hostresponse to an infection are not necessarily differentially expressed inviral versus bacterial infected patients. Each point represents adifferent patient whose protein levels were measured in lympocytes (blueand red are viral and bacterial infected patients respectively) and barsindicate group means.

FIG. 6 is a scatter graph showing diagnosis of viral and bacterialinfected patients using a combination of two DETERMINANTS. Viral andbacterial infected patients are indicated by red ‘+’ and blue ‘o’ marksrespectively. Patient classification was performed using a linear SVMtrained on 90% of the data, where white and black regions indicate thespace of DETERMINANT combinations that were classified as viral andbacterial respectively. Each plot corresponds to a different combinationof two DETERMINANTS.

FIG. 7 Some DETERMINANT combinations exhibit an improved diagnosticaccuracy compared to that of the corresponding individual DETERMINANT,whereas other combinations exhibit a reduced accuracy. (A)Classification accuracy in terms of MCC of viral versus bacterialinfected patients attained for pairs of DETERMINANTS using a linear SVMmodel with a leave-10%-out cross-validation scheme. (B) The change inclassification accuracy (dMCC) for pairs of DETERMINANTS compared to theaccuracy obtained for the corresponding single DETERMINANT is computedas follows: MCCi,j−max(MCCi, MCCj), where MCCi and MCCj correspond tothe MCC obtained for DETERMINANT i and j individually and MCCi,j isobtained for the pair. Hot and cold colors indicate pairs ofDETERMINANTS whose combined classification accuracy compared to theindividual DETERMINANT accuracy is higher and lower respectively.

FIG. 8 Genes whose mRNA levels are differentially expressed in bacterialand viral infected patients often do not exhibit the same differentialbehavior in the corresponding proteins.

FIG. 9 The expression levels of some proteins are not well correlatedacross different cells types of the immune system. Two examples ofproteins (PARP12 and OAS2) are shown whose expression levels ongranulocytes and lymphocytes are poorly correlated.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the identification of signatures anddeterminants associated with bacterial, viral and mixed (i.e., bacterialand viral co-infections) infections. More specifically it was discoveredthat certain polypeptides are differentially expressed in astatistically significant manner in patients with bacteria, viral ormixed (i.e., bacterial and viral co-infections). These polypeptidesinclude ABTB1, ADIPOR1, ARHGDIB, ARPC2, ATP6V0B, C1orf83, CD15, CES1,CORO1A, CSDA, EIF4B, EPSTI1, GAS7, HERC5, IFI6, KIAA0082, IFIT1, IFIT3,IFITM1, IFITM3, LIPT1, IL7R, ISG20, LOC26010, LY6E, LRDD, LTA4H, MAN1C1,MBOAT2, NPM1, OAS2, PARP12, PARP9, QARS, RAB13, RAB31, RAC2, RPL34,PDIA6, PTEN, RSAD2, SART3, SMAD9, SDCBP, SOCS3, TRIM 22, UBE2N, XAF1 andZBP1.

Different infectious agents have unique molecular patterns that can beidentified and targeted by the immune system. Pathogen-associatedmolecular patterns (PAMPs) are an example of such molecules that areassociated with different groups of pathogens and may be recognized bycells of the innate immune system using Toll-like receptors (TLRs) andother pattern recognition receptors (e.g. NOD proteins) (Akira, Uematsuet al. 2006; Murphy, Travers et al. 2008). These patterns may varyconsiderably between different classes of pathogens and thus elicitdifferent immune responses. For example, TLR-4 can recognizelipopolysaccharide, a constituent of gram negative bacteria, as well aslipoteichoic acids, constituent of gram positive bacteria, hencepromoting an anti-microbial response of the immune system (Akira,Uematsu et al. 2006; Murphy, Travers et al. 2008). TLR-3 can recognizesingle stranded RNA (often indicative of a viral infection) and thusprompt the appropriate anti-viral response (Akira, Uematsu et al. 2006;Murphy, Travers et al. 2008). By distinguishing between differentclasses of pathogens (e.g bacterial versus viral) the immune system canmount the appropriate defense.

In the past few decades, several host markers have been identified thatcan be used for differential diagnosis of infection source in variousindications. One example is Procalcitonin (PCT), a precursor of thehormone calcitonin produced by the C-cells of the thyroid gland. PCTlevels in the blood stream of healthy individuals is hardly detectable(in the pg/ml range) but it might increase dramatically, as a result ofa severe infection with levels rising up to 100 ng/ml. PCT is heavilyused to diagnose patients with systemic infection, sepsis, withsensitivity of 76% and specificity of 70% (Jones, Fiechtl et al. 2007).However, studies that tested the diagnostic value of PCT in othernon-systemic infection such as pneumonia or upper respiratory tractinfections found it to be limited. (Brunkhorst, Al-Nawas et al. 2002).

Another widely used marker is the acute phase protein, C-reactiveprotein (CRP). CRP levels in the blood may rise in response toinflammation. However in some indications such as sepsis its specificityand sensitivity were found to be considerably lower than PCT (Hatherill,Tibby et al. 1999). Other proposed markers for detection of differentsources of infection and sepsis include CD64 (Rudensky, Sirota et al.2008), and HNL (Fjaertoft, Foucard et al. 2005). The reliability andaccuracy of these markers for the purpose of diagnostics of viral versusbacterial infections in a broad setting is limited.

The present invention seeks to overcome the above mentioned diagnosticchallenges by: (i) enabling accurate differentiation between a bacterialand a viral infection; (ii) enabling rapid diagnostics (within minutes);(iii) avoiding the “false positive” identification of non-pathogenicbacteria that are part of the body's natural flora, (iv) allowingaccurate differentiation between mixed and pure viral infections and (v)allowing diagnosis in cases where the pathogen is inaccessible.

To this end the inventors sought to identify and test a novel set ofbiomarkers whose levels are differentially expressed in viral, bacterialand mixed infected patients, and to use the combined measurements ofthese biomarkers coupled with pattern recognition algorithms toaccurately identify the source of infection with the aim of assistingphysicians to accurately prescribe antibiotics.

To facilitate a solution that is generally applicable, the inventorsrecruited a heterogeneous cohort of patients (168 patients) comprisingof different ages, ethnicities, pathogen types, clinical syndromes andtime from appearance of symptoms (see FIG. 3), on which the solution wasdeveloped and tested.

To address the challenge of rapid diagnosis the invention focuses onbiomarkers that can be rapidly measured, such as proteins, rather thanbiomarkers whose measurement may require hours to days, such asnucleic-acid based biomarkers. Note that high-throughput quantitativemeasurements of nucleic-acids for the purpose of biomarker discoveryhave become feasible in recent years using technologies such asmicroarrays and deep sequencing. However, performing such quantitativehigh-throughput measurements on the proteome level remains a challenge.The present invention focuses on the latter.

To address the clinical challenge of mixed infection diagnosis andtreatment, the present invention includes a method for differentiatingbetween mixed infections (which require Abx treatment despite thepresence of a virus) and pure viral infections (which do not require Abxtreatment).

The present invention also addresses the issue of “false-positive”diagnostics due to non-pathogenic strains of bacteria that are part ofthe body's natural flora. This is achieved by measuring biomarkersderived from the host rather than the pathogen.

Importantly, the current invention does not require direct access to thepathogen, because the immune system circulates in the entire body,thereby facilitating diagnosis in cases in which the pathogen isinaccessible.

Accordingly the invention provides methods for identifying subjects whohave an infection by the detection of DETERMINANTS associated with aninfection, including those subjects who are asymptomatic for theinfection. These signatures and DETERMINANTS are also useful formonitoring subjects undergoing treatments and therapies for infection,and for selecting or modifying therapies and treatments that would beefficacious in subjects having an infection.

Exemplary Polypeptides Measured in the Present Invention

ABTB1: This gene encodes a protein with an ankyrin repeat region and twoBTB/POZ domains, which are thought to be involved in protein-proteininteractions. Expression of this gene is activated by the phosphataseand tensin homolog, a tumor suppressor. Alternate splicing results inthree transcript variants. It may act as a mediator of the PTENgrowth-suppressive signaling pathway. It may play a role indevelopmental processes.

ADIPOR1: ADIPOR1 is a receptor for globular and full-length adiponectin(APM1), an essential hormone secreted by adipocytes that acts as anantidiabetic. It is probably involved in metabolic pathways thatregulate lipid metabolism such as fatty acid oxidation. It mediatesincreased AMPK, PPARA ligand activity, fatty acid oxidation and glucoseuptake by adiponectin. ADIPOR1 has some high-affinity receptors forglobular adiponectin and low-affinity receptors for full-lengthadiponectin.

ARHGDIB: Regulates the GDP/GTP exchange reaction of the Rho proteins byinhibiting the dissociation of GDP from them, and the subsequent bindingof GTP to them.

ARPC2: Functions as actin-binding component of the Arp2/3 complex whichis involved in regulation of actin polymerization and together with anactivating nucleation-promoting factor (NPF) mediates the formation ofbranched actin networks. Seems to contact the mother actin filament.

ATP6V0B: H⁺-ATPase (vacuolar ATPase, V-ATPase) is an enzyme transporterthat functions to acidify intracellular compartments in eukaryoticcells. It is ubiquitously expressed and is present in endomembraneorganelles such as vacuoles, lysosomes, endosomes, the Golgi apparatus,chromaffin granules and coated vesicles, as well as in the plasmamembrane. H⁺-ATPase is a multi-subunit complex composed of two domains.The V1 domain is responsible for ATP hydrolysis and the V0 domain isresponsible for protein translocation. There are two main mechanisms ofregulating H⁺-ATPase activity; recycling of H⁺-ATPase-containingvesicles to and from the plasma membrane and glucose-sensitiveassembly/disassembly of the holo-enzyme complex. These transporters playan important role in processes such as receptor-mediated endocytosis,protein degradation and coupled transport. They have a function in bonereabsorption and mutations in the A3 gene cause recessive osteopetrosis.Furthermore, HtATPases have been implicated in tumor metastasis andregulation of sperm motility and maturation.

C1orf83: Function not fully characterized.

CD15 (FUT4): The product of this gene transfers fucose toN-acetyllactosamine polysaccharides to generate fucosylated carbohydratestructures. It catalyzes the synthesis of the non-sialylated antigen,Lewis x (CD15).

CES1: Involved in the detoxification of xenobiotics and in theactivation of ester and amide prodrugs. Hydrolyzes aromatic andaliphatic esters, but has no catalytic activity toward amides or a fattyacyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to formbenzoylecgonine. Catalyzes the transesterification of cocaine to formcocaethylene. Displays fatty acid ethyl ester synthase activity,catalyzing the ethyl esterification of oleic acid to ethyloleate.

CORO1A: May be a crucial component of the cytoskeleton of highly motilecells, functioning both in the invagination of large pieces of plasmamembrane, as well as in forming protrusions of the plasma membraneinvolved in cell locomotion. In mycobacteria-infected cells, itsretention on the phagosomal membrane prevents fusion between phagosomesand lysosomes.

CSDA: Binds to the GM-CSF promoter and seems to act as a repressor.Binds also to full length mRNA and to short RNA sequences containing theconsensus site 5′-UCCAUCA-3′. May have a role in translation repression

CRP: C-reactive protein. The protein encoded by this gene belongs to thepentaxin family. It is involved in several host defense relatedfunctions based on its ability to recognize foreign pathogens anddamaged cells of the host and to initiate their elimination byinteracting with humoral and cellular effector systems in the blood.

EIF4B: Required for the binding of mRNA to ribosomes. Functions in closeassociation with EIF4-F and EIF4-A. It binds near the 5′-terminal cap ofmRNA in the presence of EIF-4F and ATP. It promotes the ATPase activityand the ATP-dependent RNA unwinding activity of both EIF4-A and EIF4-F.

EPSTI1: Function was not fully characterized yet.

GAS7: Growth arrest-specific 7 is expressed primarily in terminallydifferentiated brain cells and predominantly in mature cerebellarPurkinje neurons. GAS7 plays a putative role in neuronal development.Several transcript variants encoding proteins which vary in theN-terminus have been described. It might play a role in promotingmaturation and morphological differentiation of cerebellar neurons.

HERC5: Major E3 ligase for ISG15 conjugation. Acts as a positiveregulator of innate antiviral response in cells induced by interferon.Makes part of the ISGylation machinery that recognizes target proteinsin a broad and relatively non-specific manner. Catalyzes ISGylation ofIRF3 which results in sustained activation. It attenuates IRF3-PIN1interaction, which antagonizes IRF3 ubiquitination and degradation, andboosts the antiviral response. Catalyzes ISGylation of influenza A viralNS1 which attenuates virulence; ISGylated NS1 fails to form homodimersand thus to interact with its RNA targets. It catalyzes ISGylation ofpapillomavirus type 16 L1 protein which results in dominant-negativeeffect on virus infectivity. Physically associated with polyribosomes,broadly modifies newly synthesized proteins in a co-translationalmanner. In an interferon-stimulated cell, newly translated viralproteins are primary targets of IS G15.

IFI6: This gene was first identified as one of the many genes induced byinterferon. The encoded protein may play a critical role in theregulation of apoptosis. A mini satellite that consists of 26 repeats ofa 12 nucleotide repeating element resembling the mammalian splice donorconsensus sequence begins near the end of the second exon. Alternativelyspliced transcript variants that encode different isoforms by using thetwo downstream repeat units as splice donor sites have been described.

IFIT1: Interferon-induced protein with tetratricopeptide repeats.

IFIT3: Function was not fully characterized yet.

IFITM1: IFN-induced antiviral protein that mediate cellular innateimmunity to at least three major human pathogens, namely influenza AH1N1 virus, West Nile virus, and dengue virus by inhibiting the earlystep(s) of replication. Plays a key role in the antiproliferative actionof IFN-gamma either by inhibiting the ERK activition or by arrestingcell growth in G1 phase in a p53-dependent manner. Implicated in thecontrol of cell growth. Component of a multimeric complex involved inthe transduction of antiproliferative and homotypic adhesion signals.

IFITM3/IFITM2: IFN-induced antiviral protein that mediates cellularinnate immunity to at least three major human pathogens, namelyinfluenza A H1N1 virus, West Nile virus (WNV), and dengue virus (WNV),by inhibiting the early step(s) of replication.

IL7R: The protein encoded by this gene is a receptor for interleukine 7(IL7). The function of this receptor requires the interleukin 2receptor, gamma chain (IL2RG), which is a common gamma chain shared bythe receptors of various cytokines, including interleukin 2, 4, 7, 9,and 15. This protein has been shown to play a critical role in the V(D)Jrecombination during lymphocyte development. This protein is also foundto control the accessibility of the TCR gamma locus by STATS and histoneacetylation. Knockout studies in mice suggested that blocking apoptosisis an essential function of this protein during differentiation andactivation of T lymphocytes. The functional defects in this protein maybe associated with the pathogenesis of the severe combinedimmunodeficiency (SCID).

ISG20: Exonuclease with specificity for single-stranded RNA and, to alesser extent for DNA. Degrades RNA at a rate that is approximately35-fold higher than its rate for single-stranded DNA. Involved in theantiviral function of IFN against RNA viruses.

KIAA0082 (FTSJD2): S-adenosyl-L-methionine-dependent methyltransferasethat mediates mRNA cap1 2′-O-ribose methylation to the 5′-cap structureof mRNAs. Methylates the ribose of the first nucleotide of am(7)GpppG-capped mRNA to produce m(7)GpppNmp (cap1). Cap1 modificationis linked to higher levels of translation. May be involved in theinterferon response pathway.

LIPT1: The process of transferring lipoic acid to proteins is a two-stepprocess. The first step is the activation of lipoic acid bylipoate-activating enzyme to form lipoyl-AMP. For the second step, theprotein encoded by this gene transfers the lipoyl moiety to apoproteins.Alternative splicing in the 5′ UTR of this gene results in fivetranscript variants that encode the same protein. (provided by RefSeq)

LOC26010 (SPATS2): Function was not fully characterized yet.

LRDD: The protein encoded by this gene contains a leucine-rich repeatand a death domain. This protein has been shown to interact with otherdeath domain proteins, such as Fas (TNFRSF6)-associated via death domain(FADD) and MAP-kinase activating death domain-containing protein (MADD),and thus may function as an adaptor protein in cell death-relatedsignaling processes. The expression of the mouse counterpart of thisgene has been found to be positively regulated by the tumor suppressorp53 and to induce cell apoptosis in response to DNA damage, whichsuggests a role for this gene as an effector of p53-dependent apoptosis.Alternative splicing results in multiple transcript variants.

LTA4H: Hydrolyzes an epoxide moiety of leukotriene A4 (LTA-4) to formleukotriene B4 (LTB-4). The enzyme also has some peptidase activity.

LY6E: Function was not fully characterized yet.

MAN1C1: Mannosidases are divided into two subtypes; I and II, (ECnumbers 3.2.1.113 and 3.2.1.114 respectively) which display a wideexpression pattern. Mannosidase I hydrolyzes (1,2)-linkedalpha-D-mannose residues in the oligo-mannose oligosaccharideMan9(GlcNAc)2 and mannosidase II hydrolyzes (1,3)- and (1,6)-linkedalpha-D-mannose residues in Man5(GlcNAc)3. Both subtypes require adivalent cation cofactor. Mutations in mannosidases can causemannosidosis (mannosidase I deficiency).

MBOAT2: Acyltransferase which mediates the conversion oflysophosphatidyl-ethanolamine (1-acyl-sn-glycero-3-phosphoethanolamineor LPE) into phosphatidyl-ethanolamine(1,2-diacyl-sn-glycero-3-phosphoethanolamine or PE) (LPEAT activity).Catalyzes also the acylation of lysophosphatidic acid (LPA) intophosphatidic acid (PA) (LPAAT activity). Has also a very weaklysophosphatidyl-choline acyltransferase (LPCAT activity). Prefersoleoyl-CoA as the acyl donor. Lysophospholipid acyltransferases (LPLATs)catalyze the reacylation step of the phospholipid remodeling pathwayalso known as the Lands cycle.

MX1/MXA: In mouse, the interferon-inducible Mx protein is responsiblefor a specific antiviral state against influenza virus infection. Theprotein encoded by this gene is similar to the mouse protein asdetermined by its antigenic relatedness, induction conditions,physicochemical properties, and amino acid analysis. This cytoplasmicprotein is a member of both the dynamin family and the family of largeGTPases. Two transcript variants encoding the same protein have beenfound for this gene.

NPM1: It is involved in diverse cellular processes such as ribosomebiogenesis, centrosome duplication, protein chaperoning, histoneassembly, cell proliferation, and regulation of tumor suppressorsTP53/p53 and ARF. It binds ribosome presumably to drive ribosome nuclearexport. It is associated with nucleolar ribonucleoprotein structures andbinds single stranded nucleic acids. Acts as a chaperonin for the corehistones H3, H2B and H4.

OAS2: This gene encodes a member of the 2-5A synthetase family,essential proteins involved in the innate immune response to viralinfection. The encoded protein is induced by interferons and usesadenosine triphosphate in 2′-specific nucleotidyl transfer reactions tosynthesize 2′,5′-oligoadenylates (2-5As). These molecules activatelatent RNase L, which results in viral RNA degradation and theinhibition of viral replication. The three known members of this genefamily are located in a cluster on chromosome 12. Alternatively splicedtranscript variants encoding different isoforms have been described.

PARP9: Poly (ADP-ribose) polymerase (PARP) catalyzes thepost-translational modification of proteins by the addition of multipleADP-ribose moieties. PARP transfers ADP-ribose from nicotinamidedinucleotide (NAD) to glu/asp residues on the substrate protein, andalso polymerizes ADP-ribose to form long/branched chain polymers. PARPinhibitors are being developed for use in a number of pathologiesincluding cancer, diabetes, stroke and cardiovascular diseases.

PARP12: Poly (ADP-ribose) polymerase (PARP) catalyzes thepost-translational modification of proteins by the addition of multipleADP-ribose moieties. PARP transfers ADP-ribose from nicotinamidedinucleotide (NAD) to glu/asp residues on the substrate protein, andalso polymerizes ADP-ribose to form long/branched chain polymers. PARPinhibitors are being developed for use in a number of pathologiesincluding cancer, diabetes, stroke and cardiovascular diseases.

PDIA6: Protein disulfide isomerases (EC 5.3.4.1), such as PDIA6, areendoplasmic reticulum (ER) resident proteins that catalyze formation,reduction, and isomerization of disulfide bonds in proteins and arethought to play a role in folding of disulfide-bonded proteins. It mightfunction as a chaperone that inhibits aggregation of mis-foldedproteins. Plays a role in platelet aggregation and activation byagonists such as convulxin, collagen and thrombin.

PTEN: Tumor suppressor. Acts as a dual-specificity protein phosphatase,ephosphorylating tyrosine-, serine- and threonine-phosphorylatedproteins. Also acts as a lipid phosphatase, removing the phosphate inthe D3 position of the inositol ring from phosphatidylinositol (PI)3,4,5-trisphosphate, PI 3,4-diphosphate, PI 3-phosphate and inositol1,3,4,5-tetrakisphosphate with order of substrate preference in vitroPtdIns(3,4,5)P3>PtdIns(3,4)P2>PtdIns3P>Ins(1,3,4,5)P4. The lipidphosphatase activity is critical for its tumor suppressor function.Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylatingphosphoinositides and thereby modulating cell cycle progression and cellsurvival. The un-phosphorylated form cooperates with AIP1 to suppressAKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesionkinase and inhibits cell migration and integrin-mediated cell spreadingand focal adhesion formation. Plays a role as a key modulator of theAKT-mTOR signaling pathway controlling the tempo of the process ofnewborn neurons integration during adult neurogenesis, including correctneuron positioning, dendritic development and synapse formation. May bea negative regulator of insulin signaling and glucose metabolism inadipose tissue. The nuclear monoubiquitinated form possesses greaterapoptotic potential, whereas the cytoplasmic nonubiquitinated forminduces less tumor suppressive ability.

RAB13: could participate in polarized transport, in the assembly and/orthe activity of tight junctions.

QARS: Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA bytheir cognate amino acid. Because of their central role in linking aminoacids with nucleotide triplets contained in tRNAs, aminoacyl-tRNAsynthetases are thought to be among the first proteins that appeared inevolution. In metazoans, 9 aminoacyl-tRNA synthetases specific forglutamine (gln), glutamic acid (glu), and 7 other amino acids areassociated within a multienzyme complex. Although present in eukaryotes,glutaminyl-tRNA synthetase (QARS) is absent from many prokaryotes,mitochondria, and chloroplasts, in which Gln-tRNA(G1n) is formed bytransamidation of the misacylated Glu-tRNA(Gln). Glutaminyl-tRNAsynthetase belongs to the class-I aminoacyl-tRNA synthetase family.

RAB13: could participate in polarized transport, in the assembly and/orthe activity of tight junctions

RAB31: Small GTP-binding proteins of the RAB family, such as RAB31, playessential roles in vesicle and granule targeting.

RAC2: Small G proteins (small GTPases) are homologous to Galpha proteinsand are often referred to as the Ras proto-oncogene superfamily. The Rassuperfamily contains over 100 small GTPases grouped into eight families;Ras, Rho, Rab, Rap, Arf, Ran, Rheb and Rad. Small GTPases regulate awide variety of processes in the cell, including growth,differentiation, movement and lipid vesicle transport Like Galphaproteins, small GTPases alternate between an ‘on’ state (bound to GTP)and an ‘off’ state (bound to GDP). This cyclic process requires guaninenucleotide exchange factor (GEF) and GTPase-activating protein (GAP).Small GTPases are the downstream effectors of most receptor tyrosinekinases (RTKs) and are linked via two proteins, GRB2 and SOS. They arecoupled to intracellular signaling cascades including the MAPK pathway,through interactions with Raf kinase. Normally, activation of smallGTPases is induced by ligand binding to a RTK. In many transformed cellsactivating mutations of GTPases, often Ras, produce a cellular responsein the absence of a ligand, thus promoting malignant progression.

RPL34: Ribosomes, the organelles that catalyze protein synthesis,consist of a small 40S subunit and a large 60S subunit. Together thesesubunits are composed of 4 RNA species and approximately 80 structurallydistinct proteins. This gene encodes a ribosomal protein that is acomponent of the 60S subunit. The protein belongs to the L34E family ofribosomal proteins. It is located in the cytoplasm. This gene originallywas thought to be located at 17q21, but it has been mapped to 4q.Transcript variants derived from alternative splicing, alternativetranscription initiation sites, and/or alternative polyadenylationexist; these variants encode the same protein. As is typical for genesencoding ribosomal proteins, there are multiple processed pseudogenes ofthis gene dispersed through the genome.

RSAD2: Involved in antiviral defense. May impair virus budding bydisrupting lipid rafts at the plasma membrane, a feature which isessential for the budding process of many viruses. Acts through bindingwith and inactivating FPPS, an enzyme involved in synthesis ofcholesterol, farnesylated and geranylated proteins, ubiquinone dolicholand heme. Plays a role in the cell antiviral state induced by type I andtype II interferon. Displays antiviral effect against HIV-1 virus,hepatitis C virus, human cytomegalovirus, and aphaviruses, but notvesiculovirus.

SART3: The protein encoded by this gene is an RNA-binding nuclearprotein that is a tumor-rejection antigen. This antigen possesses tumorepitopes capable of inducing HLA-A24-restricted and tumor-specificcytotoxic T lymphocytes in cancer patients and may be useful forspecific immunotherapy. This gene product is found to be an importantcellular factor for HIV-1 gene expression and viral replication. It alsoassociates transiently with U6 and U4/U6 snRNPs during the recyclingphase of the spliceosome cycle. This encoded protein is thought to beinvolved in the regulation of mRNA splicing.

SDCBP: The protein encoded by this gene was initially identified as amolecule linking syndecan-mediated signaling to the cytoskeleton. Thesyntenin protein contains tandemly repeated PDZ domains that bind thecytoplasmic, C-terminal domains of a variety of transmembrane proteins.This protein may also affect cytoskeletal-membrane organization, celladhesion, protein trafficking, and the activation of transcriptionfactors. The protein is primarily localized to membrane-associatedadherens junctions and focal adhesions but is also found at theendoplasmic reticulum and nucleus. Alternative splicing results inmultiple transcript variants encoding different isoforms. It seems tocouple transcription factor SOX4 to the IL-5 receptor (IL5RA). May playa role in vesicular trafficking and seems to be required for thetargeting of TGFA to the cell surface in the early secretory pathway.

SMAD9: The protein encoded by this gene is a member of the SMAD family,which transduces signals from TGF-beta family members. The encodedprotein is activated by bone morphogenetic proteins and interacts withSMAD4. Two transcript variants encoding different isoforms have beenfound for this gene. Transcriptional modulator activated by BMP (bonemorphogenetic proteins) type 1 receptor kinase. SMAD9 is areceptor-regulated SMAD (R-SMAD).

SOCS3: SOCS family proteins form part of a classical negative feedbacksystem that regulates cytokine signal transduction. SOCS3 is involved innegative regulation of cytokines that signal through the JAK/STATpathway. Inhibits cytokine signal transduction by binding to tyrosinekinase receptors including gp130, LIF, erythropoietin, insulin, IL12,GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity.Suppresses fetal liver erythropoiesis. Regulates onset and maintenanceof allergic responses mediated by T-helper type 2 cells. Regulates IL-6signaling in vivo (By similarity). Probable substrate recognitioncomponent of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3ubiquitin-protein ligase complex which mediates the ubiquitination andsubsequent proteasomal degradation of target proteins. Seems torecognize IL6ST (By similarity).

TRIM22: Interferon-induced antiviral protein involved in cell innateimmunity. The antiviral activity could in part be mediated byTRIM22-dependent ubiquitination of viral proteins. Plays a role inrestricting the replication of HIV-1, encephalomyocarditis virus (EMCV)and hepatitis B virus (HBV). Acts as a transcriptional repressor of HBVcore promoter. May have E3 ubiquitin-protein ligase activity.

UBE2N: The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze thesynthesis of non-canonical ‘Lys-63’-linked polyubiquitin chains. Thistype of polyubiquitination does not lead to protein degradation by theproteasome. It mediates transcriptional activation of target genes. Itplays a role in the control of progress through the cell cycle anddifferentiation. Plays a role in the error-free DNA repair pathway andcontributes to the survival of cells after DNA damage. Acts togetherwith the E3 ligases, HLTF and SHPRH, in the ‘Lys-63’-linked polyubiquitination of PCNA upon genotoxic stress, which is required for DNArepair. It appears to act together with E3 ligase RNF5 in the‘Lys-63’-linked polyubiquitination of JKAMP thereby regulating JKAMPfunction by decreasing its association with components of the proteasomeand ERAD.

XAF1: Seems to function as a negative regulator of members of the IAP(inhibitor of apoptosis protein) family. Inhibits anti-caspase activityof BIRC4. Induces cleavage and inactivation of BIRC4 independent ofcaspase activation. Mediates TNF-alpha-induced apoptosis and is involvedin apoptosis in trophoblast cells. May inhibit BIRC4 indirectly byactivating the mitochondrial apoptosis pathway. After translocation tomitochondra, promotes translocation of BAX to mitochondria andcytochrome c release from mitochondria. Seems to promote theredistribution of BIRC4 from the cytoplasm to the nucleus, probablyindependent of BIRC4 inactivation which seems to occur in the cytoplasm.The BIRC4-XAF1 complex mediates down-regulation of BIRC5/survivin; theprocess requires the E3 ligase activity of BIRC4. Seems to be involvedin cellular sensitivity to the proapoptotic actions of TRAIL. May be atumor suppressor by mediating apoptosis resistance of cancer cells.

ZBP1: DLM1 encodes a Z-DNA binding protein. Z-DNA formation is a dynamicprocess, largely controlled by the amount of supercoiling. May play arole in host defense against tumors and pathogens. Binds Z-DNA (Bysimilarity).

Definitions

“Accuracy” refers to the degree of conformity of a measured orcalculated quantity (a test reported value) to its actual (or true)value. Clinical accuracy relates to the proportion of true outcomes(true positives (TP) or true negatives (TN) versus misclassifiedoutcomes (false positives (FP) or false negatives (FN)), and may bestated as a sensitivity, specificity, positive predictive values (PPV)or negative predictive values (NPV), or as a likelihood, odds ratio,among other measures.

“DETERMINANTS” in the context of the present invention encompass,without limitation, polypeptides, peptide, proteins, protein isoforms(e.g. decoy receptor isoforms). DETERMINANTS can also include mutatedproteins.

“DETERMINANT” OR “DETERMINANTS” encompass one or more of allpolypeptides whose levels are changed in subjects who have an infection.Individual DETERMINANT include ABTB1, ADIPOR1, ARHGDIB, ARPC2, ATP6V0B,C1orf83, CD15, CES1, CORO1A, CRP, CSDA, EIF4B, EPSTI1, GAS7, HERC5,IFI6, KIAA0082, IFIT1, IFIT3, IFITM1, IFITM3, LIPT1, IL7R, ISG20,LOC26010, LY6E, LRDD, LTA4H, MAN1C1, MBOAT2, MX1, NPM1, OAS2, PARP12,PARP9, QARS, RAB13, RAB31, RAC2, RPL34, PDIA6, PTEN, RSAD2, SART3,SDCBP, TRIM 22, SMAD9, SOCS3, UBE2N, XAF1 and ZBP1 and are collectivelyreferred to herein as, inter alia, “infection-associated proteins orinfection-associated polypepetides”, “DETERMINANT polypeptides”,“polypeptide DETERMINANTS”, “DETERMINANT proteins” or “proteinDETERMINANTS”. Unless indicated otherwise, “DETERMINANT”,“infection-associated proteins” or “infection-associated polypepetide”,is meant to refer to any of the proteins and polypeptides disclosedherein.

DETERMINANTS also encompass non-polypeptide factors, non-blood bornefactors or non-analyte physiological markers of health status, such as“clinical parameters” defined herein, as well as “traditional laboratoryrisk factors”, also defined herein.

For example, as used herein DETERMINANTS include non-polypeptidefeatures (i.e. non-polypeptide DETERMINANTS) such as neutrophil %(abbreviated Neu (%)), lymphocyte % (abbreviated Lym (%)), monocyte %(abbreviated Mon (%)), absolute neutrophil count (abbreviated ANC) andabsolute lymphocyte count (abbreviated ALC), white blood count(abbreviated WBC), age, gender, and maximal temperature (i.e. maximalcore body temperature since initial appearance of symptoms).

DETERMINANTS also include any calculated indices created mathematicallyor combinations of any one or more of the foregoing measurements,including temporal trends and differences. Where available, and unlessotherwise described herein, DETERMINANTS which are gene products areidentified based on the official letter abbreviation or gene symbolassigned by the international Human Genome Organization Naming Committee(HGNC) and listed at the date of this filing at the US National Centerfor Biotechnology Information (NCBI) web site, also known as EntrezGene.

In preferred embodiments, DETERMINANTS include protein and non-proteinfeatures.

“Clinical parameters” encompass all non-sample or non-analyte biomarkersof subject health status or other characteristics, such as, withoutlimitation, age (Age), ethnicity (RACE), gender (Sex), core bodytemperature or family history (FamHX).

A “Infection Reference Expression Profile,” is a set of valuesassociated with two or more DETERMINANTS resulting from evaluation of abiological sample (or population or set of samples).

A “Subject with non-infectious disease” is one whose disease is notcaused by an infectious disease agent (e.g. bacterial or virus). In thestudy presented herein this includes patients with acute myocardialinfarction, physical injury, epileptic attack etc.

“FN” is false negative, means a result that appears negative but failsto reveal a situation. For example in the context of the presentinvention a FN, is for example but not limited to, falsly classifying abacterial infection as a viral infection.

“FP” is false positive, means test result that is erroneously classifiedin a positive category. For example in the context of the presentinvention a FP, is for example but not limited to, falsly classifying aviral infection as a bacterial infection

A “formula,” “algorithm,” or “model” is any mathematical equation,algorithmic, analytical or programmed process, or statistical techniquethat takes one or more continuous or categorical inputs (herein called“parameters”) and calculates an output value, sometimes referred to asan “index” or “index value.” Non-limiting examples of “formulas” includesums, ratios, and regression operators, such as coefficients orexponents, biomarker value transformations and normalizations(including, without limitation, those normalization schemes based onclinical parameters, such as gender, age, or ethnicity), rules andguidelines, statistical classification models, and neural networkstrained on historical populations. Of particular use in combiningDETERMINANTS are linear and non-linear equations and statisticalclassification analyses to determine the relationship between levels ofDETERMINANTS detected in a subject sample and the subject's probabilityof having an infection or a certain type of infection. In panel andcombination construction, of particular interest are structural andsyntactic statistical classification algorithms, and methods of indexconstruction, utilizing pattern recognition features, includingestablished techniques such as cross-correlation, Principal ComponentsAnalysis (PCA), factor rotation, Logistic Regression (LogReg), LinearDiscriminant Analysis (LDA), Eigengene Linear Discriminant Analysis(ELDA), Support Vector Machines (SVM), Random Forest (RF), RecursivePartitioning Tree (RPART), as well as other related decision treeclassification techniques, Shrunken Centroids (SC), StepAIC, Kth-NearestNeighbor, Boosting, Decision Trees, Neural Networks, Bayesian Networks,and Hidden Markov Models, among others. Other techniques may be used insurvival and time to event hazard analysis, including Cox, Weibull,Kaplan-Meier and Greenwood models well known to those of skill in theart. Many of these techniques are useful either combined with aDETERMINANT selection technique, such as forward selection, backwardsselection, or stepwise selection, complete enumeration of all potentialpanels of a given size, genetic algorithms, or they may themselvesinclude biomarker selection methodologies in their own technique. Thesemay be coupled with information criteria, such as Akaike's InformationCriterion (AIC) or Bayes Information Criterion (BIC), in order toquantify the tradeoff between additional biomarkers and modelimprovement, and to aid in minimizing overfit. The resulting predictivemodels may be validated in other studies, or cross-validated in thestudy they were originally trained in, using such techniques asBootstrap, Leave-One-Out (LOO) and 10-Fold cross-validation (10-FoldCV). At various steps, false discovery rates may be estimated by valuepermutation according to techniques known in the art. A “health economicutility function” is a formula that is derived from a combination of theexpected probability of a range of clinical outcomes in an idealizedapplicable patient population, both before and after the introduction ofa diagnostic or therapeutic intervention into the standard of care. Itencompasses estimates of the accuracy, effectiveness and performancecharacteristics of such intervention, and a cost and/or valuemeasurement (a utility) associated with each outcome, which may bederived from actual health system costs of care (services, supplies,devices and drugs, etc.) and/or as an estimated acceptable value perquality adjusted life year (QALY) resulting in each outcome. The sum,across all predicted outcomes, of the product of the predictedpopulation size for an outcome multiplied by the respective outcome'sexpected utility is the total health economic utility of a givenstandard of care. The difference between (i) the total health economicutility calculated for the standard of care with the intervention versus(ii) the total health economic utility for the standard of care withoutthe intervention results in an overall measure of the health economiccost or value of the intervention. This may itself be divided amongstthe entire patient group being analyzed (or solely amongst theintervention group) to arrive at a cost per unit intervention, and toguide such decisions as market positioning, pricing, and assumptions ofhealth system acceptance. Such health economic utility functions arecommonly used to compare the cost-effectiveness of the intervention, butmay also be transformed to estimate the acceptable value per QALY thehealth care system is willing to pay, or the acceptable cost-effectiveclinical performance characteristics required of a new intervention.

For diagnostic (or prognostic) interventions of the invention, as eachoutcome (which in a disease classifying diagnostic test may be a TP, FP,TN, or FN) bears a different cost, a health economic utility functionmay preferentially favor sensitivity over specificity, or PPV over NPVbased on the clinical situation and individual outcome costs and value,and thus provides another measure of health economic performance andvalue which may be different from more direct clinical or analyticalperformance measures. These different measurements and relativetrade-offs generally will converge only in the case of a perfect test,with zero error rate (a.k.a., zero predicted subject outcomemisclassifications or FP and FN), which all performance measures willfavor over imperfection, but to differing degrees.

“Measuring” or “measurement,” or alternatively “detecting” or“detection,” means assessing the presence, absence, quantity or amount(which can be an effective amount) of either a given substance within aclinical or subject-derived sample, including the derivation ofqualitative or quantitative concentration levels of such substances, orotherwise evaluating the values or categorization of a subject'snon-analyte clinical parameters.

“Negative predictive value” or “NPV” is calculated by TN/(TN+FN) or thetrue negative fraction of all negative test results. It also isinherently impacted by the prevalence of the disease and pre-testprobability of the population intended to be tested. See, e.g.,O'Marcaigh A S, Jacobson R M, “Estimating The Predictive Value Of ADiagnostic Test, How To Prevent Misleading Or Confusing Results,” Clin.Ped. 1993, 32(8): 485-491, which discusses specificity, sensitivity, andpositive and negative predictive values of a test, e.g., a clinicaldiagnostic test. Often, for binary disease state classificationapproaches using a continuous diagnostic test measurement, thesensitivity and specificity is summarized by Receiver OperatingCharacteristics (ROC) curves according to Pepe et al, “Limitations ofthe Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic,or Screening Marker,” Am. J. Epidemiol 2004, 159 (9): 882-890, andsummarized by the Area Under the Curve (AUC) or c-statistic, anindicator that allows representation of the sensitivity and specificityof a test, assay, or method over the entire range of test (or assay) cutpoints with just a single value. See also, e.g., Shultz, “ClinicalInterpretation Of Laboratory Procedures,” chapter 14 in Teitz,Fundamentals of Clinical Chemistry, Burtis and Ashwood (eds.), 4^(th)edition 1996, W.B. Saunders Company, pages 192-199; and Zweig et al.,“ROC Curve Analysis: An Example Showing The Relationships Among SerumLipid And Apolipoprotein Concentrations In Identifying Subjects WithCoronory Artery Disease,” Clin. Chem., 1992, 38(8): 1425-1428. Analternative approach using likelihood functions, odds ratios,information theory, predictive values, calibration (includinggoodness-of-fit), and reclassification measurements is summarizedaccording to Cook, “Use and Misuse of the Receiver OperatingCharacteristic Curve in Risk Prediction,” Circulation 2007, 115:928-935.

“Analytical accuracy” refers to the reproducibility and predictabilityof the measurement process itself, and may be summarized in suchmeasurements as coefficients of variation, and tests of concordance andcalibration of the same samples or controls with different times, users,equipment and/or reagents. These and other considerations in evaluatingnew biomarkers are also summarized in Vasan, 2006.

“Performance” is a term that relates to the overall usefulness andquality of a diagnostic or prognostic test, including, among others,clinical and analytical accuracy, other analytical and processcharacteristics, such as use characteristics (e.g., stability, ease ofuse), health economic value, and relative costs of components of thetest. Any of these factors may be the source of superior performance andthus usefulness of the test, and may be measured by appropriate“performance metrics,” such as AUC, MCC. time to result, shelf life,etc. as relevant.

“Positive predictive value” or “PPV” is calculated by TP/(TP+FP) or thetrue positive fraction of all positive test results. It is inherentlyimpacted by the prevalence of the disease and pre-test probability ofthe population intended to be tested.

A “sample” in the context of the present invention is a biologicalsample isolated from a subject and can include, by way of example andnot limitation, whole blood, serum, plasma, leukocytes or blood cells.Preferably, the sample is whole blood, serum or leukocytes.

“Sensitivity” is calculated by TP/(TP+FN) or the true positive fractionof disease subjects.

“Specificity” is calculated by TN/(TN+FP) or the true negative fractionof non-disease or normal subjects.

“MCC” (Mathwes Correlation coefficient) is calculated as follows:

MCC=(TP*TN−FP*FN)/{(TP+FN)*(TP+FP)*(TN+FP)*(TN+FN)}{circumflex over( )}0.5

where TP, FP, TN, FN are true-positives, false-positives,true-negatives, and false-negatives, respectively. Note that MCC valuesrange between −1 to +1, indicating completely wrong and perfectclassification, respectively. An MCC of 0 indicates randomclassification. MCC has been shown to be a useful for combiningsensitivity and specificity into a signle metric (Baldi, Brunak et al.2000). It is also useful for measuring and optimizing classificationaccuracy in cases of unbalanced class sizes (Baldi, Brunak et al. 2000).

By “statistically significant”, it is meant that the alteration isgreater than what might be expected to happen by chance alone (whichcould be a “false positive”). Statistical significance can be determinedby any method known in the art. Commonly used measures of significanceinclude the p-value, which presents the probability of obtaining aresult at least as extreme as a given data point, assuming the datapoint was the result of chance alone. A result is often consideredhighly significant at a p-value of 0.05 or less.

A “subject” in the context of the present invention is preferably amammal. The mammal can be a human, non-human primate, mouse, rat, dog,cat, horse, or cow, but are not limited to these examples. A subject canbe male or female. A subject can be one who has been previouslydiagnosed or identified as having an infection, and optionally hasalready undergone, or is undergoing, a therapeutic intervention for theinfection. Alternatively, a subject can also be one who has not beenpreviously diagnosed as having an infection. For example, a subject canbe one who exhibits one or more risk factors for having an infection.

“TN” is true negative, means negative test result that accuratelyreflects the tested-for activity.

“TP” is true positive, means positive test result that accuratelyreflects the tested-for activity.

“Traditional laboratory risk factors” correspond to biomarkers isolatedor derived from subject samples and which are currently evaluated in theclinical laboratory and used in traditional global risk assessmentalgorithms.

Methods and Uses of the Invention

The methods disclosed herein are used to identify subjects with aninfection or a specific infection type. More specifically, the methodsof the invention are used to distinguish subjects having a bacterialinfection, a viral infection, a mixed infection (i.e., bacterial andviral co-infection), patients with a non-infectious disease and healthyindividuals. The methods of the present invention can also be used tomonitor or select a treatment regimen for a subject who has a aninfection, and to screen subjects who have not been previously diagnosedas having an infection, such as subjects who exhibit risk factorsdeveloping an infection. The methods of the present invention are usedto identify and/or diagnose subjects who are asymptomatic for aninfection. “Asymptomatic” means not exhibiting the traditional signs andsymptoms.

As used herein, infection is meant to include any infectious agent ofviral or bacterial origin. The bacterial infection may be the result ofgram-positive or gram-negative bacteria.

The term “Gram-positive bacteria” as used herein refers to bacteriacharacterized by having as part of their cell wall structurepeptidoglycan as well as polysaccharides and/or teichoic acids and arecharacterized by their blue-violet color reaction in the Gram-stainingprocedure.

The term “Gram-negative bacteria” as used herein refer to bacteriacharacterized by the presence of a double membrane surrounding eachbacterial cell.

A subject having an infection is identified by measuring the amounts(including the presence or absence) of an effective number (which can beone or more) of DETERMINANTS in a subject-derived sample. A clinicallysignificant alteration in the level of the DETERMINANT is determined.Alternatively, the amounts are compared to a reference value.Alterations in the amounts and patterns of expression DETERMINANTS inthe subject sample compared to the reference value are then identified.

In various embodiments, two, three, four, five, six, seven, eight, nine,ten or more DETERMINANTS are measured. For example the combination ofDETERMINANTS are selected according to any of the models enumerated inTables 1-8.

A reference value can be relative to a number or value derived frompopulation studies, including without limitation, such subjects havingthe same infection, subject having the same or similar age range,subjects in the same or similar ethnic group, or relative to thestarting sample of a subject undergoing treatment for a infection. Suchreference values can be derived from statistical analyses and/or riskprediction data of populations obtained from mathematical algorithms andcomputed indices of infection. Reference DETERMINANT indices can also beconstructed and used using algorithms and other methods of statisticaland structural classification.

In one embodiment of the present invention, the reference value is theamount (i.e. level) of DETERMINANTS in a control sample derived from oneor more subjects who do not have an infection (i.e., healthy, and or noninfectious individuals). In a further embodiment, such subjects aremonitored and/or periodically retested for a diagnostically relevantperiod of time (“longitudinal studies”) following such test to verifycontinued absence of infection. Such period of time may be one day, twodays, two to five days, five days, five to ten days, ten days, or ten ormore days from the initial testing date for determination of thereference value. Furthermore, retrospective measurement of DETERMINANTSin properly banked historical subject samples may be used inestablishing these reference values, thus shortening the study timerequired.

A reference value can also comprise the amounts of DETERMINANTS derivedfrom subjects who show an improvement as a result of treatments and/ortherapies for the infection. A reference value can also comprise theamounts of DETERMINANTS derived from subjects who have confirmedinfection by known techniques.

In another embodiment, the reference value is an index value or abaseline value. An index value or baseline value is a composite sampleof an effective amount of DETERMINANTS from one or more subjects who donot have an infection. A baseline value can also comprise the amounts ofDETERMINANTS in a sample derived from a subject who has shown animprovement in treatments or therapies for the infection. In thisembodiment, to make comparisons to the subject-derived sample, theamounts of DETERMINANTS are similarly calculated and compared to theindex value. Optionally, subjects identified as having an infection, arechosen to receive a therapeutic regimen to slow the progression oreliminate the infection.

Additionally, the amount of the DETERMINANT can be measured in a testsample and compared to the “normal control level,” utilizing techniquessuch as reference limits, discrimination limits, or risk definingthresholds to define cutoff points and abnormal values. The “normalcontrol level” means the level of one or more DETERMINANTS or combinedDETERMINANT indices typically found in a subject not suffering from aninfection. Such normal control level and cutoff points may vary based onwhether a DETERMINANT is used alone or in a formula combining with otherDETERMINANTS into an index. Alternatively, the normal control level canbe a database of DETERMINANT patterns from previously tested subjects.

The effectiveness of a treatment regimen can be monitored by detecting aDETERMINANT in an effective amount (which may be one or more) of samplesobtained from a subject over time and comparing the amount ofDETERMINANTS detected. For example, a first sample can be obtained priorto the subject receiving treatment and one or more subsequent samplesare taken after or during treatment of the subject.

For example, the methods of the invention can be used to discriminatebetween bacterial, viral and mixed infections (i.e. bacterial and viralco-infections.) This will allow patients to be stratified and treatedaccordingly.

The present invention also comprises a kit with a detection reagent thatbinds to one or more DETERMINANT polypeptides. Also provided by theinvention is an array of detection reagents, e.g., antibodies that canbind to one or more DETERMINANT polypeptides. In one embodiment, theDETERMINANTS are polypeptides and the array contains antibodies thatbind one or more DETERMINANTS selected from ABTB1, ADIPOR1, ARHGDIB,ARPC2, ATP6V0B, C1orf83, CD15, CES1, CORO1A, CRP, CSDA, EIF4B, EPSTI1,GAS7, HERC5, IF16, KIAA0082, IFIT1, IFIT3, IFITM1, IFITM3, LIPT1, IL7R,ISG20, LOC26010, LY6E, LRDD, LTA4H, MAN1C1, MBOAT2, MX1, NPM1, OAS2,PARP12, PARP9, QARS, RAB13, RAB31, RAC2, RPL34, PDIA6, PTEN, RSAD2,SART3, SDCBP, SMAD9, SOCS3, TRIM 22, UBE2N, XAF1 and ZBP1 sufficient tomeasure a statistically significant alteration in DETERMINANTexpression.

The present invention can also be used to screen patient or subjectpopulations in any number of settings. For example, a health maintenanceorganization, public health entity or school health program can screen agroup of subjects to identify those requiring interventions, asdescribed above, or for the collection of epidemiological data.Insurance companies (e.g., health, life or disability) may screenapplicants in the process of determining coverage or pricing, orexisting clients for possible intervention. Data collected in suchpopulation screens, particularly when tied to any clinical progressionto conditions like infection, will be of value in the operations of, forexample, health maintenance organizations, public health programs andinsurance companies. Such data arrays or collections can be stored inmachine-readable media and used in any number of health-related datamanagement systems to provide improved healthcare services, costeffective healthcare, improved insurance operation, etc. See, forexample, U.S. Patent Application No. 2002/0038227; U.S. PatentApplication No. US 2004/0122296; U.S. Patent Application No. US2004/0122297; and U.S. Pat. No. 5,018,067. Such systems can access thedata directly from internal data storage or remotely from one or moredata storage sites as further detailed herein.

A machine-readable storage medium can comprise a data storage materialencoded with machine readable data or data arrays which, when using amachine programmed with instructions for using said data, is capable ofuse for a variety of purposes. Measurements of effective amounts of thebiomarkers of the invention and/or the resulting evaluation of risk fromthose biomarkers can implemented in computer programs executing onprogrammable computers, comprising, inter alia, a processor, a datastorage system (including volatile and non-volatile memory and/orstorage elements), at least one input device, and at least one outputdevice. Program code can be applied to input data to perform thefunctions described above and generate output information. The outputinformation can be applied to one or more output devices, according tomethods known in the art. The computer may be, for example, a personalcomputer, microcomputer, or workstation of conventional design.

Each program can be implemented in a high level procedural or objectoriented programming language to communicate with a computer system.However, the programs can be implemented in assembly or machinelanguage, if desired. The language can be a compiled or interpretedlanguage. Each such computer program can be stored on a storage media ordevice (e.g., ROM or magnetic diskette or others as defined elsewhere inthis disclosure) readable by a general or special purpose programmablecomputer, for configuring and operating the computer when the storagemedia or device is read by the computer to perform the proceduresdescribed herein. The health-related data management system of theinvention may also be considered to be implemented as acomputer-readable storage medium, configured with a computer program,where the storage medium so configured causes a computer to operate in aspecific and predefined manner to perform various functions describedherein.

The DETERMINANTS of the present invention can be used to generate a“reference DETERMINANT profile” of those subjects who do not have aninfection. The DETERMINANTS disclosed herein can also be used togenerate a “subject DETERMINANT profile” taken from subjects who have aninfection. The subject DETERMINANT profiles can be compared to areference DETERMINANT profile to diagnose or identify subjects with aninfection. The reference and subject DETERMINANT profiles of the presentinvention can be contained in a machine-readable medium, such as but notlimited to, analog tapes like those readable by a VCR, CD-ROM. DVD-ROM,USB flash media, among others. Such machine-readable media can alsocontain additional test results, such as, without limitation,measurements of clinical parameters and traditional laboratory riskfactors. Alternatively or additionally, the machine-readable media canalso comprise subject information such as medical history and anyrelevant family history. The machine-readable media can also containinformation relating to other disease-risk algorithms and computedindices such as those described herein.

Performance and Accuracy Measures of the Invention

The performance and thus absolute and relative clinical usefulness ofthe invention may be assessed in multiple ways as noted above. Amongstthe various assessments of performance, the invention is intended toprovide accuracy in clinical diagnosis and prognosis. The accuracy of adiagnostic or prognostic test, assay, or method concerns the ability ofthe test, assay, or method to distinguish between subjects having aninfection is based on whether the subjects have, a “significantalteration” (e.g., clinically significant “diagnostically significant)in the levels of a DETERMINANT. By “effective amount” it is meant thatthe measurement of an appropriate number of DETERMINANTS (which may beone or more) to produce a “significant alteration” (e.g. level ofexpression or activity of a DETERMINANT) that is different than thepredetermined cut-off point (or threshold value) for that DETERMINANT(S)and therefore indicates that the subject has an infection for which theDETERMINANT(S) is a determinant. The difference in the level ofDETERMINANT is preferably statistically significant. As noted below, andwithout any limitation of the invention, achieving statisticalsignificance, and thus the preferred analytical, diagnostic, andclinical accuracy, generally but not always requires that combinationsof several DETERMINANTS to be used together in panels and combined withmathematical algorithms in order to achieve a statistically significantDETERMINANT index.

In the categorical diagnosis of a disease state, changing the cut pointor threshold value of a test (or assay) usually changes the sensitivityand specificity, but in a qualitatively inverse relationship. Therefore,in assessing the accuracy and usefulness of a proposed medical test,assay, or method for assessing a subject's condition, one should alwaystake both sensitivity and specificity into account and be mindful ofwhat the cut point is at which the sensitivity and specificity are beingreported because sensitivity and specificity may vary significantly overthe range of cut points. One way to achieve this is by using the MCCmetric, which depends upon both sensitivity and specificity. Use ofstatistics such as AUC, encompassing all potential cut point values, ispreferred for most categorical risk measures using the invention, whilefor continuous risk measures, statistics of goodness-of-fit andcalibration to observed results or other gold standards, are preferred.

By predetermined level of predictability it is meant that the methodprovides an acceptable level of clinical or diagnostic specificity andsensitivity.

By predetermined level of predictability it is meant that the methodprovides an acceptable level of clinical or diagnostic accuracy. Usingsuch statistics, an “acceptable degree of diagnostic accuracy”, isherein defined as a test or assay (such as the test of the invention fordetermining the clinically significant presence of DETERMINANTS, whichthereby indicates the presence a type of infection) in which the AUC(area under the ROC curve for the test or assay) is at least 0.60,desirably at least 0.65, more desirably at least 0.70, preferably atleast 0.75, more preferably at least 0.80, and most preferably at least0.85.

By a “very high degree of diagnostic accuracy”, it is meant a test orassay in which the AUC (area under the ROC curve for the test or assay)is at least 0.75, 0.80, desirably at least 0.85, more desirably at least0.875, preferably at least 0.90, more preferably at least 0.925, andmost preferably at least 0.95.

Alternatively, the methods predict the presence or absence of aninfection or response to therapy with at least 75% accuracy, morepreferably 80%, 85%, 90%, 95%, 97%, 98%, 99% or greater accuracy.

The method predicts the presence or absence of an infection or responseto therapy with an MCC>= to 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0.

The predictive value of any test depends on the sensitivity andspecificity of the test, and on the prevalence of the condition in thepopulation being tested. This notion, based on Bayes' theorem, providesthat the greater the likelihood that the condition being screened for ispresent in an individual or in the population (pre-test probability),the greater the validity of a positive test and the greater thelikelihood that the result is a true positive. Thus, the problem withusing a test in any population where there is a low likelihood of thecondition being present is that a positive result has limited value(i.e., more likely to be a false positive). Similarly, in populations atvery high risk, a negative test result is more likely to be a falsenegative.

As a result, ROC and AUC can be misleading as to the clinical utility ofa test in low disease prevalence tested populations (defined as thosewith less than 1% rate of occurrences (incidence) per annum, or lessthan 10% cumulative prevalence over a specified time horizon).

A health economic utility function is an yet another means of measuringthe performance and clinical value of a given test, consisting ofweighting the potential categorical test outcomes based on actualmeasures of clinical and economic value for each. Health economicperformance is closely related to accuracy, as a health economic utilityfunction specifically assigns an economic value for the benefits ofcorrect classification and the costs of misclassification of testedsubjects. As a performance measure, it is not unusual to require a testto achieve a level of performance which results in an increase in healtheconomic value per test (prior to testing costs) in excess of the targetprice of the test.

In general, alternative methods of determining diagnostic accuracy arecommonly used for continuous measures, when a disease category has notyet been clearly defined by the relevant medical societies and practiceof medicine, where thresholds for therapeutic use are not yetestablished, or where there is no existing gold standard for diagnosisof the pre-disease. For continuous measures of risk, measures ofdiagnostic accuracy for a calculated index are typically based on curvefit and calibration between the predicted continuous value and theactual observed values (or a historical index calculated value) andutilize measures such as R squared, Hosmer-Lemeshow P-value statisticsand confidence intervals. It is not unusual for predicted values usingsuch algorithms to be reported including a confidence interval (usually90% or 95% CI) based on a historical observed cohort's predictions, asin the test for risk of future breast cancer recurrence commercializedby Genomic Health, Inc. (Redwood City, Calif.).

In general, by defining the degree of diagnostic accuracy, i.e., cutpoints on a ROC curve, defining an acceptable AUC value, and determiningthe acceptable ranges in relative concentration of what constitutes aneffective amount of the DETERMINANTS of the invention allows for one ofskill in the art to use the DETERMINANTS to identify, diagnose, orprognose subjects with a pre-determined level of predictability andperformance.

Furthermore, other unlisted biomarkers will be very highly correlatedwith the DETRMINANTS (for the purpose of this application, any twovariables will be considered to be “very highly correlated” when theyhave a Coefficient of Determination (R²) of 0.5 or greater). The presentinvention encompasses such functional and statistical equivalents to theaforementioned DETERMINANTS. Furthermore, the statistical utility ofsuch additional DETERMINANTS is substantially dependent on thecross-correlation between multiple biomarkers and any new biomarkerswill often be required to operate within a panel in order to elaboratethe meaning of the underlying biology.

One or more, preferably two or more of the listed DETERMINANTS can bedetected in the practice of the present invention. For example, two (2),three (3), four (4), five (5), ten (10), fifteen (15), twenty (20),forty (40), or more DETERMINANTS can be detected.

In some aspects, all DETERMINANTS listed herein can be detected.Preferred ranges from which the number of DETERMINANTS can be detectedinclude ranges bounded by any minimum selected from between one and,particularly two, three, four, five, six, seven, eight, nine ten,twenty, or forty Particularly preferred ranges include two to five(2-5), two to ten (2-10), two to twenty (2-20), or two to forty (2-40).

Construction of DETERMINANT Panels

Groupings of DETERMINANTS can be included in “panels.” A “panel” withinthe context of the present invention means a group of biomarkers(whether they are DETERMINANTS, clinical parameters, or traditionallaboratory risk factors) that includes more than one DETERMINANT. Apanel can also comprise additional biomarkers, e.g., clinicalparameters, traditional laboratory risk factors, known to be present orassociated with infection, in combination with a selected group of theDETERMINANTS listed herein.

As noted above, many of the individual DETERMINANTS, clinicalparameters, and traditional laboratory risk factors listed, when usedalone and not as a member of a multi-biomarker panel of DETERMINANTS,have little or no clinical use in reliably distinguishing individualnormal subjects, subjects at risk for having an infection (e.g.,bacterial, viral or co-infection), and thus cannot reliably be usedalone in classifying any subject between those three states. Even wherethere are statistically significant differences in their meanmeasurements in each of these populations, as commonly occurs in studieswhich are sufficiently powered, such biomarkers may remain limited intheir applicability to an individual subject, and contribute little todiagnostic or prognostic predictions for that subject. A common measureof statistical significance is the p-value, which indicates theprobability that an observation has arisen by chance alone; preferably,such p-values are 0.05 or less, representing a 5% or less chance thatthe observation of interest arose by chance. Such p-values dependsignificantly on the power of the study performed.

Despite this individual DETERMINANT performance, and the generalperformance of formulas combining only the traditional clinicalparameters and few traditional laboratory risk factors, the presentinventors have noted that certain specific combinations of two or moreDETERMINANTS can also be used as multi-biomarker panels comprisingcombinations of DETERMINANTS that are known to be involved in one ormore physiological or biological pathways, and that such information canbe combined and made clinically useful through the use of variousformulae, including statistical classification algorithms and others,combining and in many cases extending the performance characteristics ofthe combination beyond that of the individual DETERMINANTS. Thesespecific combinations show an acceptable level of diagnostic accuracy,and, when sufficient information from multiple DETERMINANTS is combinedin a trained formula, often reliably achieve a high level of diagnosticaccuracy transportable from one population to another.

The general concept of how two less specific or lower performingDETERMINANTS are combined into novel and more useful combinations forthe intended indications, is a key aspect of the invention. Multiplebiomarkers can often yield better performance than the individualcomponents when proper mathematical and clinical algorithms are used;this is often evident in both sensitivity and specificity, and resultsin a greater AUC. Secondly, there is often novel unperceived informationin the existing biomarkers, as such was necessary in order to achievethrough the new formula an improved level of sensitivity or specificity.This hidden information may hold true even for biomarkers which aregenerally regarded to have suboptimal clinical performance on their own.In fact, the suboptimal performance in terms of high false positiverates on a single biomarker measured alone may very well be an indicatorthat some important additional information is contained within thebiomarker results—information which would not be elucidated absent thecombination with a second biomarker and a mathematical formula.

Several statistical and modeling algorithms known in the art can be usedto both assist in DETERMINANT selection choices and optimize thealgorithms combining these choices. Statistical tools such as factor andcross-biomarker correlation/covariance analyses allow more rationaleapproaches to panel construction. Mathematical clustering andclassification tree showing the Euclidean standardized distance betweenthe DETERMINANTS can be advantageously used. Pathway informed seeding ofsuch statistical classification techniques also may be employed, as mayrational approaches based on the selection of individual DETERMINANTSbased on their participation across in particular pathways orphysiological functions.

Ultimately, formula such as statistical classification algorithms can bedirectly used to both select DETERMINANTS and to generate and train theoptimal formula necessary to combine the results from multipleDETERMINANTS into a single index. Often, techniques such as forward(from zero potential explanatory parameters) and backwards selection(from all available potential explanatory parameters) are used, andinformation criteria, such as AIC or BIC, are used to quantify thetradeoff between the performance and diagnostic accuracy of the paneland the number of DETERMINANTS used. The position of the individualDETERMINANT on a forward or backwards selected panel can be closelyrelated to its provision of incremental information content for thealgorithm, so the order of contribution is highly dependent on the otherconstituent DETERMINANTS in the panel.

Construction of Clinical Algorithms

Any formula may be used to combine DETERMINANT results into indicesuseful in the practice of the invention. As indicated above, and withoutlimitation, such indices may indicate, among the various otherindications, the probability, likelihood, absolute or relative risk,time to or rate of conversion from one to another disease states, ormake predictions of future biomarker measurements of infection. This maybe for a specific time period or horizon, or for remaining lifetimerisk, or simply be provided as an index relative to another referencesubject population.

Although various preferred formula are described here, several othermodel and formula types beyond those mentioned herein and in thedefinitions above are well known to one skilled in the art. The actualmodel type or formula used may itself be selected from the field ofpotential models based on the performance and diagnostic accuracycharacteristics of its results in a training population. The specificsof the formula itself may commonly be derived from DETERMINANT resultsin the relevant training population. Amongst other uses, such formulamay be intended to map the feature space derived from one or moreDETERMINANT inputs to a set of subject classes (e.g. useful inpredicting class membership of subjects as normal, having an infection),to derive an estimation of a probability function of risk using aBayesian approach, or to estimate the class-conditional probabilities,then use Bayes' rule to produce the class probability function as in theprevious case.

Preferred formulas include the broad class of statistical classificationalgorithms, and in particular the use of discriminant analysis. The goalof discriminant analysis is to predict class membership from apreviously identified set of features. In the case of lineardiscriminant analysis (LDA), the linear combination of features isidentified that maximizes the separation among groups by some criteria.Features can be identified for LDA using an eigengene based approachwith different thresholds (ELDA) or a stepping algorithm based on amultivariate analysis of variance (MANOVA). Forward, backward, andstepwise algorithms can be performed that minimize the probability of noseparation based on the Hotelling-Lawley statistic.

Eigengene-based Linear Discriminant Analysis (ELDA) is a featureselection technique developed by Shen et al. (2006). The formula selectsfeatures (e.g. biomarkers) in a multivariate framework using a modifiedeigen analysis to identify features associated with the most importanteigenvectors. “Important” is defined as those eigenvectors that explainthe most variance in the differences among samples that are trying to beclassified relative to some threshold.

A support vector machine (SVM) is a classification formula that attemptsto find a hyperplane that separates two classes. This hyperplanecontains support vectors, data points that are exactly the margindistance away from the hyperplane. In the likely event that noseparating hyperplane exists in the current dimensions of the data, thedimensionality is expanded greatly by projecting the data into largerdimensions by taking non-linear functions of the original variables(Venables and Ripley, 2002). Although not required, filtering offeatures for SVM often improves prediction. Features (e.g., biomarkers)can be identified for a support vector machine using a non-parametricKruskal-Wallis (KW) test to select the best univariate features. Arandom forest (RF, Breiman, 2001) or recursive partitioning (RPART,Breiman et al., 1984) can also be used separately or in combination toidentify biomarker combinations that are most important. Both KW and RFrequire that a number of features be selected from the total. RPARTcreates a single classification tree using a subset of availablebiomarkers.

Other formula may be used in order to pre-process the results ofindividual DETERMINANT measurement into more valuable forms ofinformation, prior to their presentation to the predictive formula. Mostnotably, normalization of biomarker results, using either commonmathematical transformations such as logarithmic or logistic functions,as normal or other distribution positions, in reference to apopulation's mean values, etc. are all well known to those skilled inthe art. Of particular interest are a set of normalizations based onClinical Parameters such as age, gender, race, or sex, where specificformula are used solely on subjects within a class or continuouslycombining a Clinical Parameter as an input. In other cases,analyte-based biomarkers can be combined into calculated variables whichare subsequently presented to a formula.

In addition to the individual parameter values of one subjectpotentially being normalized, an overall predictive formula for allsubjects, or any known class of subjects, may itself be recalibrated orotherwise adjusted based on adjustment for a population's expectedprevalence and mean biomarker parameter values, according to thetechnique outlined in D'Agostino et al, (2001) JAMA 286:180-187, orother similar normalization and recalibration techniques. Suchepidemiological adjustment statistics may be captured, confirmed,improved and updated continuously through a registry of past datapresented to the model, which may be machine readable or otherwise, oroccasionally through the retrospective query of stored samples orreference to historical studies of such parameters and statistics.Additional examples that may be the subject of formula recalibration orother adjustments include statistics used in studies by Pepe, M. S. etal, 2004 on the limitations of odds ratios; Cook, N. R., 2007 relatingto ROC curves. Finally, the numeric result of a classifier formulaitself may be transformed post-processing by its reference to an actualclinical population and study results and observed endpoints, in orderto calibrate to absolute risk and provide confidence intervals forvarying numeric results of the classifier or risk formula.

Measurement of DETERMINANTS

The actual measurement of levels or amounts of the DETERMINANTS can bedetermined at the protein level using any method known in the art. Forexample, by measuring the levels of peptides encoded by the geneproducts described herein, or subcellular localization or activitiesthereof. Such methods are well known in the art and include, e.g.,immunoassays based on antibodies to proteins, aptamers or molecularimprints. Any biological material can be used for thedetection/quantification of the protein or its activity. Alternatively,a suitable method can be selected to determine the activity of proteinsencoded by the marker genes according to the activity of each proteinanalyzed.

The DETERMINANT proteins, polypeptides, mutations, and polymorphismsthereof can be detected in any suitable manner, but is typicallydetected by contacting a sample from the subject with an antibody whichbinds the DETERMINANT protein, polypeptide, mutation, polymorphism, orpost translational modification additions (e.g. carbohydrates) and thendetecting the presence or absence of a reaction product. The antibodymay be monoclonal, polyclonal, chimeric, or a fragment of the foregoing,as discussed in detail above, and the step of detecting the reactionproduct may be carried out with any suitable immunoassay. The samplefrom the subject is typically a biological sample as described above,and may be the same sample of biological sample used to conduct themethod described above.

Immunoassays carried out in accordance with the present invention may behomogeneous assays or heterogeneous assays. In a homogeneous assay theimmunological reaction usually involves the specific antibody (e.g.,anti-DETERMINANT protein antibody), a labeled analyte, and the sample ofinterest. The signal arising from the label is modified, directly orindirectly, upon the binding of the antibody to the labeled analyte.Both the immunological reaction and detection of the extent thereof canbe carried out in a homogeneous solution. Immunochemical labels whichmay be employed include free radicals, radioisotopes, fluorescent dyes,enzymes, bacteriophages, or coenzymes.

In a heterogeneous assay approach, the reagents are usually the sample,the antibody, and means for producing a detectable signal. Samples asdescribed above may be used. The antibody can be immobilized on asupport, such as a bead (such as protein A and protein G agarose beads),plate or slide, and contacted with the specimen suspected of containingthe antigen in a liquid phase. The support is then separated from theliquid phase and either the support phase or the liquid phase isexamined for a detectable signal employing means for producing suchsignal. The signal is related to the presence of the analyte in thesample. Means for producing a detectable signal include the use ofradioactive labels, fluorescent labels, or enzyme labels. For example,if the antigen to be detected contains a second binding site, anantibody which binds to that site can be conjugated to a detectablegroup and added to the liquid phase reaction solution before theseparation step. The presence of the detectable group on the solidsupport indicates the presence of the antigen in the test sample.Examples of suitable immunoassays are oligonucleotides, immunoblotting,immunofluorescence methods, immunoprecipitation, chemiluminescencemethods, electrochemiluminescence (ECL) or enzyme-linked immunoassays.

Those skilled in the art will be familiar with numerous specificimmunoassay formats and variations thereof which may be useful forcarrying out the method disclosed herein. See generally E. Maggio,Enzyme-Immunoassay, (1980) (CRC Press, Inc., Boca Raton, Fla.); see alsoU.S. Pat. No. 4,727,022 to Skold et al. titled “Methods for ModulatingLigand-Receptor Interactions and their Application,” U.S. Pat. No.4,659,678 to Forrest et al. titled “Immunoassay of Antigens,” U.S. Pat.No. 4,376,110 to David et al., titled “Immunometric Assays UsingMonoclonal Antibodies,” U.S. Pat. No. 4,275,149 to Litman et al., titled“Macromolecular Environment Control in Specific Receptor Assays,” U.S.Pat. No. 4,233,402 to Maggio et al., titled “Reagents and MethodEmploying Channeling,” and U.S. Pat. No. 4,230,767 to Boguslaski et al.,titled “Heterogenous Specific Binding Assay Employing a Coenzyme asLabel.” The DETERMINANT can also be detected with antibodies using flowcytometry. Those skilled in the art will be familiar with flowcytometric techniques which may be useful in carrying out the methodsdisclosed herein. (See, H. M. Shapiro, Practical Flow Cytometry, (2003))

Antibodies can be conjugated to a solid support suitable for adiagnostic assay (e.g., beads such as protein A or protein G agarose,microspheres, plates, slides or wells formed from materials such aslatex or polystyrene) in accordance with known techniques, such aspassive binding. Antibodies as described herein may likewise beconjugated to detectable labels or groups such as radiolabels (e.g.,³⁵S, ¹²⁵I, ¹³¹I) enzyme labels (e.g., horseradish peroxidase, alkalinephosphatase), and fluorescent labels (e.g., fluorescein, Alexa, greenfluorescent protein, rhodamine) in accordance with known techniques.

Antibodies can also be useful for detecting post-translationalmodifications of DETERMINANT proteins, polypeptides, mutations, andpolymorphisms, such as tyrosine phosphorylation, threoninephosphorylation, serine phosphorylation, glycosylation (e.g., O-GlcNAc).Such antibodies specifically detect the phosphorylated amino acids in aprotein or proteins of interest, and can be used in immunoblotting,immunofluorescence, and ELISA assays described herein. These antibodiesare well-known to those skilled in the art, and commercially available.Post-translational modifications can also be determined using metastableions in reflector matrix-assisted laser desorption ionization-time offlight mass spectrometry (MALDI-TOF) (Wirth, U. et al. (2002) Proteomics2(10): 1445-51).

For DETERMINANT proteins, polypeptides, mutations, and polymorphismsknown to have enzymatic activity, the activities can be determined invitro using enzyme assays known in the art. Such assays include, withoutlimitation, kinase assays, phosphatase assays, reductase assays, amongmany others. Modulation of the kinetics of enzyme activities can bedetermined by measuring the rate constant K_(M) using known algorithms,such as the Hill plot, Michaelis-Menten equation, linear regressionplots such as Lineweaver-Burk analysis, and Scatchard plot.

Kits

The invention also includes a DETERMINANT-detection reagent, orantibodies packaged together in the form of a kit. The kit may containin separate containers an antibody (either already bound to a solidmatrix or packaged separately with reagents for binding them to thematrix), control formulations (positive and/or negative), and/or adetectable label such as fluorescein, green fluorescent protein,rhodamine, cyanine dyes, Alexa dyes, luciferase, radiolabels, amongothers. Instructions (e.g., written, tape, VCR, CD-ROM, etc.) forcarrying out the assay may be included in the kit. The assay may forexample be in the form of a sandwich ELISA as known in the art.

For example, DETERMINANT detection reagents can be immobilized on asolid matrix such as a porous strip to form at least one DETERMINANTdetection site. The measurement or detection region of the porous stripmay include a plurality of sites. A test strip may also contain sitesfor negative and/or positive controls. Alternatively, control sites canbe located on a separate strip from the test strip. Optionally, thedifferent detection sites may contain different amounts of immobilizeddetection reagents, e.g., a higher amount in the first detection siteand lesser amounts in subsequent sites. Upon the addition of testsample, the number of sites displaying a detectable signal provides aquantitative indication of the amount of DETERMINANTS present in thesample. The detection sites may be configured in any suitably detectableshape and are typically in the shape of a bar or dot spanning the widthof a test strip.

Suitable sources for antibodies for the detection of DETERMINANTSinclude commercially available sources such as, for example, Abazyme,Abnova, Affinity Biologicals, AntibodyShop, Aviva bioscience,Biogenesis, Biosense Laboratories, Calbiochem, Cell Sciences, ChemiconInternational, Chemokine, Clontech, Cytolab, DAKO, DiagnosticBioSystems, eBioscience, Endocrine Technologies, Enzo Biochem,Eurogentec, Fusion Antibodies, Genesis Biotech, GloboZymes, HaematologicTechnologies, Immunodetect, lmmunodiagnostik, Immunometrics, Immunostar,Immunovision, Biogenex, Invitrogen, Jackson ImmunoResearch Laboratory,KMI Diagnostics, Koma Biotech, LabFrontier Life Science Institute, LeeLaboratories, Lifescreen, Maine Biotechnology Services, Mediclone,MicroPharm Ltd., ModiQuest, Molecular Innovations, Molecular Probes,Neoclone, Neuromics, New England Biolabs, Novocastra, Novus Biologicals,Oncogene Research Products, Orbigen, Oxford Biotechnology, Panvera,PerkinElmer Life Sciences, Pharmingen, Phoenix Pharmaceuticals, PierceChemical Company, Polymun Scientific, Polysiences, Inc., PromegaCorporation, Proteogenix, Protos Immunoresearch, QED Biosciences, Inc.,R&D Systems, Repligen, Research Diagnostics, Roboscreen, Santa CruzBiotechnology, Seikagaku America, Serologic al Corporation, Serotec,SigmaAldrich, StemCell Technologies, Synaptic Systems GmbH, Technopharm,Terra Nova Biotechnology, TiterMax, Trillium Diagnostics, UpstateBiotechnology, US Biological, Vector Laboratories, Wako Pure ChemicalIndustries, and Zeptometrix. However, the skilled artisan can routinelymake antibodies, against any of the polypeptide DETERMINANTS describedherein.

EXAMPLES Example 1: General Methods

In-Vivo Clinical Study Protocol

To screen for potential DETERMINANTS that can separate between differentsources of infection we performed a clinical study on 168 hospitalpatients. Study workflow is depicted in FIG. 2. Briefly, after signingan informed consent, 2-6 ml of peripheral venous blood was collected inEDTA containing CBC tubes. The blood was than stored in 4 degreesCelsius for 1-4 hours. Depending on the type of infection, patientspecimens were also collected (e.g. nasal swab and urine) formicrobiological analysis. The clinical history, the clinical labresults, the imaging data and the microbiological results are used toidentify the source of infection by an infectious disease expert.DETERMINANT measurements and infection source related data were sotredin a database that was used to screen and then test the differentialaccuracy of each individual DETERMINANT and the multi-DETERMINANTsignature.

Patient Inclusion & Exclusion Criteria

Patient inclusion criteria were:

-   -   i) Acute infectious disease patients with a peak fever higher        than 37.5° C. and 38.3° C. in adults and children respectively        during the last 7 days, with symptoms that began no more than 8        days prior to inclusion date or,    -   ii) Healthy individuals or,    -   iii) Patients with a non-infectious disease

Subject, or legal guardian, signed the informed consent was obtained inall cases.

Patient exclusion criteria were:

-   -   i. An acute infectious disease during the last four weeks,    -   ii. A Congenital Immune Deficiency,    -   iii, Patients under immunosuppressive regimen:        -   Active chemotherapy        -   Post-transplant drugs        -   High dose steroids >80 mg prednisone per day or equivalent        -   Active radiotherapy        -   Cytotoxic drugs (anti-TNF drugs, Cyclosporine, Tacrolimus,            Monoclonal Abs, Mycophenolate, MTX, Azathioprine, IVIG)    -   iv. Patients under immune-simulative regimen:        -   IL-2        -   G-CSF/GM-CSF        -   Interferons    -   v. Patients with an active hematological malignancy (e.g. CLL),    -   vi. Patients that had another infectious disease in the past 3        weeks,    -   vii. Patients with active malignancy of solid organ (e.g. NSCLC)    -   viii. Patients with myeloproliferative or myelodysplastic        disorder. Patients who are HIV-1 or HCV carriers.

Determining Patient Source of Infection

The following criteria were used in order to determine whether a patienthad a viral or bacterial infection:

Examples of Criteria for Bacterial Infections:

-   -   1) Bacteremia: A positive blood culture/positive blood PCR.    -   2) Urinary tract infection: A positive urine culture (>10⁵/ml        for midstream, >10⁴/ml for catheter collection, >10³ for Supra        pubic aspiration) of a pathogenic bacteria identified by culture        accompanied by urinary complains or acute infection symptoms.    -   3) Pyelonephritis: UTI with cortical defects in technetium        99M-DMSA or abdominal US.    -   4) Lobar pneumonia: consolidation in a lobar territory diagnosed        on a CXR by radiologist accompanied with clinical signs and        symptoms of LRTI.    -   5) Bacterial meningitis: cerebrospinal fluid (CSF) pleocytosis        of >10 cells/ul or positive culture or positive bacterial PCR.    -   6) Deep abscess: As assessed by CT scan or surgical exploration.    -   7) Septic arthritis: synovial fluid with >50,000 WBCs/ml        and >80% neutrophils or a positive culture/PCR/Gram stain.    -   8) Atypical Pneumonia, a positive PCR for M. pneumonia (MP)        accompanied with clinical signs and symptoms of LRTI.    -   9) Cellulites, Warmth skin, Erythema, edema, and tenderness of        the affected area and a positive bacterial culture of a        gram-positive cocci.        Examples of criteria for viral infections:    -   1) Bronchiolitis, a positive RSV antigen/PCR with clinical        findings of bronchiolitis (e.g. tachypnea, diffuse expiratory        wheezing, intercostal retractions). Disease should resolve        within five days without Abx.    -   2) Viral Pneumonia: clinical signs and symptoms of LRTI with a        positive PCR for a respiratory virus (listed in 6.1) in the        absence of radiological sign of consolidation and the presence        of two or more of the following radiographic findings:        -   a. Para-hilar/peri-bronchial infiltrates.        -   b. Hyperinflation.        -   c. Segmental/lobar atelectasis.        -   d. Hilar adenopathy.        -   e. Patchy diffuse consolidation    -   3) Croup or Laryngotracheobronchitis, a positive PCR for one of        the following: Parainfluenza/Influenza A/RSV/Adenovirus in the        presence of clinical features of croup (stridor, predominantly        inspiratory, Normal voice or laryngitis, no drooling, nocturnal        attack, self-limiting). Disease resolved within 5 days without        Abx    -   4) Infectious mononucleosis, a positive PCR/IgM serology for        Epstein-Barr virus (EBV) or Cytomegalovirus (CMV) accompanied by        at least one of the following: lymphocytosis, more than 10%        atypical lymphocytes on peripheral smear, positive blood PCR for        EBV or CMV and Lymphadenopathy.    -   5) Viral Otitis Media, positive PCR of a respiratory virus        isolated from middle ear aspirate in the absence of bacterial        pathogens and clinical symptoms of acute Otitis Media. Disease        resolved within 5 days without Abx.    -   6) Viral gastroenteritis—a positive PCR of        Adenovirus/Rotavirus/Noroviruses or Rota antigen in the stool        accompanied with clinical signs and symptoms of acute        gastroenteritis (less than 1w) and negative stool culture for        Salmonella, Shigella or Campylobacter. Disease resolve within 7        days without Abx    -   7) Aseptic meningitis, a positive PCR of CSF sample for one of        the following: Enterovirus, HSV1/2, VZV, EBV or CMV accompanied        with clinical signs and symptoms of        meningitis/meningoenchephalitis (meningismus, with benign        clinical course or resolution without Abx.    -   8) Roseola Infantum, positive HHV-6 PCR from the blood/positive        HHV-6 serology in the presence of fever,        Maculopapular/erythematous rash with/without Nagayama spots and        diarrhea.    -   9) Erythema Infectiosum, positive human parvovirus B19 PCR or        positive IgM test in the presence of clinics (slapped-cheek        appearance, macular eruption on the extremities,        polyarthropathy, self-limiting).    -   10) Hand-foot-and-mouth disease, a positive PCR for coxsackie        virus or Enterovirus 71 or HSV in the presence of vesicular        lesions on the mouth and exanthema on the hands and/or feet in        association with fever.    -   11) Varicella—positive PCR for VZV or positive sero-conversion        in the presence of different stages of the vesicular rash.

Many of the infectious disease patients do not fall into the abovementioned criteria for viral and bacterial infections. In order todiagnose the source of infection in these patients their medical recordswere examined by an infectious disease (ID) specialist. Each patient wasclassified as having either a bacterial, viral, mixed or non-infectiousdisease. To assist ID specialists in accurate diagnosis the followingpathogens were tested for:

-   -   1) Adenovirus A/B/C/D/E    -   2) Corona virus 229E    -   3) Corona virus NL63    -   4) Corona virus 0C43    -   5) Parainfluenza virus 1    -   6) Parainfluenza virus 2    -   7) Parainfluenza virus 3    -   8) Parainfluenza virus 4    -   9) Rhinovirus A/B/C    -   10) Influenza A virus    -   11) Influenza B virus    -   12) Respiratory syncytial virus A    -   13) Respiratory syncytial virus B    -   14) Boca virus 1/2/3/4    -   15) Enterovirus    -   16) Bordetella pertussis    -   17) Mycoplasma Pneumoniae    -   18) Chlamydia Pneumoniae    -   19) Legionella Pneumonia    -   20) S. Pneumoniae (in adults only (i.e., above 18 years of age))    -   21) H. Influenza (in adults only (i.e., above 18 years of age))

Patients also underwent a CRP test, complete blood count and basicchemistry. Lastly, depending on the site of infection the followingtests were also performed:

Urinary Tract Infections:

-   -   Urine culture    -   Urine test strip

Gastrointestinal Infections:

-   -   Stool culture for Salmonella, Shigella and Campylobacter    -   In pediatrics patients only—Rota Ag in stool

In Systemic Infections:

-   -   Blood culture    -   Serology for EBV and CMV

In Lower Respiratory Infections:

-   -   CXR    -   Saturation

DETERMINANT Measurements & Normalization

Whole blood was fractionated to cellular and serum fractions andsubsequantially treated with red blood cell lysing buffer (BDBioscience). White blood cells were subsequently washed three times withphosphate buffered saline pH 7.3. In order to measure the levels ofmembrane associated DETERMINANT polypeptides, the cells were incubatedwith primary antibodies for 40 minutes, washed twice and incubated withPE conjugated secondary antibody (Jackson Laboratories, emission 575 nm)for additional 20 minutes. In case of intracellular DETERMINANTpolypeptides, cells were first fixed and permeabilized with fixation andpermeabilization buffer kit (eBioscience). Following fixation andpermeabilization cells were incubated with primary antibodies for 40minutes, washed twice and incubated with PE conjugated secondaryantibody for additional 20 minutes. IgG Isotype controls were used foreach mode of staining as negative control background. Following thestaining procedure, cells were analyzed by using an LSRII flowcytometer. Granulocytes, monocytes and lymphocytes were distinguishedfrom each other by using an SSC/FSC dot plot. Background and specificstaining were determined for lymphocytes, monocytes and granulocytes foreach specific antigen. Total leukocytes mean levels was computed bysumming the DETERMINANT polypeptides levels of all the cell types anddividing by the white blood count.

DETERMINANT levels were normalized to the population mean. To avoidnumerical errors due to outlier measurements (>mean±3×std), thesemeasurements were truncated and assigned the value mean±3×std.

DETERMINANT Diagnosis Statistical Analysis

Single DETERMINANT Statistical Significance

Classification accuracy was measured in terms of sensitivity,specificity, PPV, NPV and Matthews correlation coefficient (MCC) definedas follows:

Sensitivity=TP/(TP+FN),

Specificity=TN/(TN+FP),

PPV=TP/(TP+FP),

NPV=TN/(TN+FN),

MCC=(TP*TN−FP*FN)/{(TP+FN)*(TP+FP)*(TN+FP)*(TN+FN)}{circumflex over( )}0.5,

where TP, FP, TN, FN are true-positives, false-positives,true-negatives, and false-negatives, respectively. Note that MCC valuesrange between −1 to +1, indicating completely wrong and perfectclassification, respectively. An MCC of 0 indicates randomclassification. It has been shown that the MCC is especially useful formeasuring and optimizing classification accuracy in cases of unbalancedclass sizes (Baldi, Brunak et al. 2000). The differential diagnosis ofDETERMINANTS was evaluated using a linear classification scheme, inwhich the cutoff that maximizes the MCC on the train set was computedand then used to classify the patients in the test set. To obtain theaccuracy over the entire dataset we repeated this process using aleave-10%-cross validation scheme. The differential diagnosis ofproteins was also evaluated using a Wilcoxon-Rank-Sum test.

Multi-DETERMINANT Signature Statistical Significance

The diagnostic accuracy of the multi-DETERMINANT signatures wasdetermined using a leave-10%-out cross validation scheme for trainingand testing a support vector machine (SVM) with a linear kernel (CJCBurges, 1998). Classification accuracy was measured using the samecriteria as in the single DETERMINANT. We also tested the classificationaccuracy using other multiparamteric models including: (i) an RBF kernelSVM, (ii) an artificial neural network (one hidden layer with threenodes, one output node and tansig transfer functions), (iii) a naïvebayes network and (iv) a k-nearest-neighbor classification algorithm.For most of the tested DETERMINANT combinations the linear SVM yieldedeither superior or equivalent MCC classification results compared theother models. We therefore report herein only the results of the linearSVM. To assess the improvement attained when combining multipleDETERMINANTS compared to single DETERMINANTS we used the dMCC criterioncomputed as follows: MCC_(i,j)−max(MCC_(i), MCC_(j)), where MCC_(i),MCC_(j) and MCC_(i,j) correspond to the MCC obtained for DETERMINANT iand j individually and for the pair.

Patient Cohort Characteristics

A cohort of 168 patients and healthy individuals were recruited at theBnei-Zion hospital and the Hillel Yafe medical center in Israel. Thenumber of male and female patients was roughly equal (FIG. 3A). Patientages ranged between 1 month and 93 years with average 28.3+−28.4 andmedian 17 (for details see FIGS. 3B and 3C). Each patient was classifiedas viral, bacterial or mixed infections, and an additional cohort ofnon-infectious disease and healthy individuals were added as a control(FIG. 3D). Time from initial appearance of symptoms ranged between 0 to8 days (FIG. 3E). Patients exhibited a wide range of clinical syndromesincluding bacteremia, cellulitis, lower respiratory tract infection(LRTI), upper respiratory tract infection (URTI), urinary tractinfection (UTI) (FIG. 3F). In about 50% of the patients the pathogen wasisolated exhibiting a wide distribution of over 26 disease causingagents (FIG. 3G).

Example 2: Most Determinant Polypeptides are not DifferentiallyExpressed in Different Types of Infections

We have determined that most DETERMINANT polypeptides are notdifferentially expressed in patients with different types of infections.Moreover, DETERMINAT-polypeptides that have a well-establishedmechanistic role in the immune defense against infections are often notdifferentially expressed. Thus an immunological role ofDETERMINAT-polypeptides does not necessarily imply diagnostic utility.This point is illustrated in FIG. 5, which shows examples of DETERMINANTpolypeptides with an active immunological role in the host response tobacterial or viral infections. We find that the levels of theseDETERMINANT polypeptides were not significantly differentially expressedin lymphocytes of patients with viral versus bacterial infections.

Example 3: Determinants that Differentiate Between Bacterial VersusViral Infected Patients

We identified a few DETERMINANTS that were differentially expressed inpatients with bacterial versus viral infections in a statisticallysignificant manner (Wilcoxon ranksum P<0.001). DETERMINANT names andclassification accuracies are listed in Table 1A. The distributions andindividual patient measurements for each of the DETERMINANTS aredepicted in FIG. 4A (dots corresponds to DETERMINANTS measurement inindividual patients and bars indicate group means). The abbreviationslym, gran, mono, mean and total are used to indicate whether aDETERMINANT polypeptide was differentially expressed in lymphocytes,granulocytes, monocytes, mean signal over all leukocytes or total signalof leukocytes respectively. The latter was measured in a constant volumeof 1 ul of blood. Each subplot corresponds to a different DETERMINANT.

Example 4: Determinants that Differentiate Between Mixed Versus ViralInfected Patients

Differentiating between a mixed infection (i.e. bacterial and viralco-infection) and a pure viral infection is important for deciding theappropriate treatment. To address this we identified a set ofDETERMINANTS that were differentially expressed in patients with mixedinfections versus viral infections in a statistically significant manner(Wilcoxon ranksum P<0.001). DETERMINANT names and classificationaccuracies are listed in Table 1B. The distributions and individualpatient measurements for each of the DETERMINANTS are depicted in FIG.4B.

Example 5: Determinants that Differentiate Between Viral VersusNon-Infectious Disease or Healthy Subjects

We identified a set of DETERMINANTS that were differentially expressedin patients with a viral infection versus patients with a non-infectiousdisease or healthy subjects in a statistically significant manner(Wilcoxon ranksum P<0.001). DETERMINANT names and classificationaccuracies are listed in Table 1C. The distributions and individualpatient measurements for each of the DETERMINANTS are depicted in FIG.4C.

Example 6: Determinants that Differentiate Between Bacterial VersusNon-Infectious Disease or Healthy Patients

We identified a set of DETERMINANTS that were differentially expressedin patients with a bacterial infection versus patients with anon-infections disease or healthy subjects in a statisticallysignificant manner (Wilcoxon ranksum P<0.001). DETERMINANTS names andclassification accuracies are listed in Table 1D. The distributions andindividual patient measurements for each of the DETERMINANTS aredepicted in FIG. 4D.

Example 7: Determinants that Differentiate Between Infectious DiseaseVersus Non-Infectious Disease or Healthy Patients

We identified a set of DETERMINANTS that were differentially expressedin patients with an infectious disease versus patients with anon-infections disease or healthy subjects in a statisticallysignificant manner (Wilcoxon ranksum P<0.001). DETERMINANT names andclassification accuracy are listed in Table 1E. The distributions andindividual patient measurements for each of the DETERMINANTS aredepicted in FIG. 4E.

Example 8: Multi-Determinant Signatures May Improve the Accuracy ofDifferentiation Between Different Types of Infection Bacterial VersusViral Infected Patients

We scanned the space of DETERMINANT combinations and identified pairsand triplets of DETERMINANTS whose combined signature differentiatedbetween patients with bacterial versus viral infections in a way thatsignificantly improved over the classification accuracy of thecorresponding individual DETERMINANTS (FIG. 7). The combinedclassification accuracies of pairs and triplets of total leukocytes meanlevel DETERMINANTS are depicted in Table 2 and 3 respectively. Thecombined classification accuracies of pairs of DETERMINATS measured indifferent cell types are depicted in Table 4.

Mixed Versus Viral Infected Patients

We identified pairs of DETERMINANTS whose combined signaturedifferentiated between patients with mixed versus viral infections. Thecombined classification accuracies of DETERMINANT pairs are depicted inTable 5.

Infection Versus Non-Infectious and Healthy Patients

We identified pairs of DETERMINANTS whose combined signaturedifferentiated between patients with an infectious disease versuspatients with a non-infectious disease or healthy subjects. The combinedclassification accuracies of DETERMINANT pairs used to classify patientswith a viral infection versus patients with a non-infectious disease orhealthy subjects are depicted in Table 6; patients with a bacterialinfection versus patients with a non-infectious disease or healthysubjects are depicted in Table 7; patients with an infectious diseaseversus patients with a non-infectious disease or healthy subjects aredepicted in Table 8.

Example 9: Discorrelation Between Protein and mRNA Differntial Behaviourin Bacterial Versus Viral Infections

Genes whose mRNA levels are differentially expressed between bacterialand viral infections often do not exhibit the same differential behaviorin the corresponding proteins. mRNAs whose levels were differentiallyexpressed in PBMCs of patients with viral versus bacterial infections(t-test P-value <10-6) (analyzed data from Ramilo et al 2007) werecompared to our protein measurements. Many genes that weredifferentially expressed on the mRNA level did not exhibit the samebehavior on the protein level as shown in FIG. 8 (mRNA and thecorresponding protein measurements are shown on the left and rightpanels respectively). Each dot corresponds to a patient and the barsindicate viral and bacterial group means.

Example 10: Comparison of Protein Expression in Different Cell Types

The expression levels of some proteins are not well correlated acrossdifferent cells types of the immune system. FIG. 9 depicts examples oftwo proteins (PARP12 and OAS2) whose levels on granulocytes andlymphocytes are poorly correlated. Each dot corresponds to patientswhose protein levels were measured on granulocytes (x-axis) andlymphocytes (y-axis).

TABLE 1A Bacterial versus viral infected patients Wilcoxon ranksum TotalSensitivity Specificity log2 DETERMINANT P-value MCC Accuracy % % PPV %NPV % (med1/med2) ABTB1, gran, intra 8.00E−04 0.14 55 66 49 43 71−0.4577 Absolute neutrophil count 9.00E−08 0.593 63 92 83 81 0.8719(ANC) ABTB1, mono, intra 8.00E−04 0.14 55 66 49 43 71 −0.4577 ADIPOR1,total, membrane 4.00E−04 0.3 64 69 61 53 76 1.0834 ARHGDIB, gran, intra2.00E−04 0.42 76 59 83 59 83 −0.7392 ARHGDIB, lymp, intra 3.00E−04 0.1262 41 71 37 74 −0.7871 ARHGDIB, mean, intra 4.00E−04 0.16 61 53 64 39 76−0.8076 ARPC2, lymp, intra 6.00E−04 0.17 67 35 80 43 75 −0.952 CD15,total, membrane 1.00E−05 0.31 62 79 52 51 80 0.8445 CORO1A, gran, intra9.00E−04 0.02 53 41 61 39 63 −0.5317 CORO1A, mean, intra 1.00E−04 0.1156 51 60 44 66 −0.6381 CORO1A, mono, intra 9.00E−04 0.02 53 41 61 39 63−0.5317 CRP 5.00E−11 0.51 76 79 73 65 85 2.7636 CSDA, gran, intra8.00E−04 0.28 64 68 62 51 76 −0.4731 CSDA, mono, intra 8.00E−04 0.28 6468 62 51 76 −0.4731 EIF4B, gran, intra 7.00E−07 0.38 69 73 65 64 74−0.597 EIF4B, lymp, intra 6.00E−08 0.29 65 49 78 66 64 −0.7342 EIF4B,mean, intra 3.00E−05 0.24 62 63 61 58 66 −0.5269 EIF4B, mono, intra7.00E−07 0.38 69 73 65 64 74 −0.597 EPSTI1, lymp, membrane 1.00E−04 0.2356 81 42 45 79 −0.3862 GAS7, lymp, intra 6.00E−04 0.16 52 77 38 42 74−0.6104 HERC5, gran, intra 2.00E−04 0.46 70 88 63 50 93 −0.7506 HERC5,mean, intra 2.00E−04 0.55 75 94 66 55 96 −0.818 IFI6, gran, intra8.00E−04 0.31 63 77 55 51 80 −0.5597 IFI6, gran, intra 7.00E−04 0.48 699459 59 4896 96 −0.6788 IFI6, mono, intra 8.00E−04 0.31 63 77 55 51 80−0.5597 IFIT1, gran, intra 1.00E−04 0.77 91 96 78 92 88 −1.3341 IFIT1,lymp, intra 4.00E−04 0.71 88 96 70 88 88 −1.3187 IFIT1, mean, intra4.00E−05 0.86 94 91 100 100 82 −1.2072 IFIT1, mono, intra 1.00E−04 0.7791 96 78 92 88 −1.3341 IFIT3, gran, intra 2.00E−06 0.68 86 82 88 74 92−1.6387 IFIT3, lymp, intra 7.00E−07 0.64 81 94 76 62 97 −1.8025 IFIT3,mean, intra 1.00E−05 0.49 79 65 85 65 85 −1.3629 IFITM1, gran, membrane2.00E−04 0.13 58 20 89 60 58 −0.4164 IFITM1, lymp, membrane 8.00E−090.57 78 62 92 86 75 −0.862 IFITM1, mean, membrane 2.00E−04 0.2 61 29 8865 60 −0.3102 IFITM1, mono, membrane 2.00E−07 0.23 63 45 77 61 63 −1.013IFITM3, gran, membrane 1.00E−07 0.3 66 50 78 65 66 −0.8206 IFITM3, mean,membrane 2.00E−07 0.47 73 54 89 80 70 −0.7955 IFITM3, mono, membrane1.00E−09 0.32 66 63 69 62 70 −0.9316 IL7R, total, membrane 7.00E−05 0.2161 56 65 50 70 0.6816 LOC26010, gran, intra 2.00E−04 0.26 62 73 53 57 70−0.5838 LOC26010, mean, intra 8.00E−04 0.15 56 71 43 52 63 −0.3595LOC26010, mono, intra 2.00E−04 0.26 62 73 53 57 70 −0.5838 LY6E, lymp,membrane 6.00E−04 0.08 54 58 51 49 59 −0.4506 Lym (%) 6.00E−13 0.616 8174 87 82 80 −1.2551 MAN1C1, gran, intra 1.00E−03 0.2 55 77 42 44 76−0.4912 MAN1C1, mean, intra 7.00E−04 0.4 69 77 63 56 83 −0.4595 MAN1C1,mono, intra 1.00E−03 0.2 55 77 42 44 76 −0.4912 MBOAT2, lymp, intra7.00E−04 0.06 53 53 54 32 73 −0.7531 MX1, gran, intra 2.00E−12 0.45 7283 62 65 81 −1.1395 MX1, lymp, intra 8.00E−09 0.38 66 87 49 59 82 −0.898MX1, mean, intra 1.00E−10 0.56 75 97 56 65 95 −1.0368 MX1, mono, intra2.00E−12 0.45 72 83 62 65 81 −1.1395 Neu (%) 2.00E−12 0.546 77 77 77 7481 0.4759 NPM1, gran, intra 7.00E−04 0.29 59 85 43 48 82 −0.4158 NPM1,mean, intra 6.00E−04 0.33 63 82 51 52 82 −0.3911 NPM1, mono, intra7.00E−04 0.29 59 85 43 48 82 −0.4158 OAS2, gran, intra 3.00E−08 0.52 7490 60 66 88 −0.8708 OAS2, mean, intra 1.00E−05 0.43 68 90 49 60 86−0.4718 OAS2, mono, intra 3.00E−08 0.52 74 90 60 66 88 −0.8708 PARP12,gran, intra 3.00E−05 0.19 58 67 53 46 72 −0.6208 PARP12, mean, intra6.00E−06 0.38 66 82 56 54 83 −0.7165 PARP12, mono, intra 3.00E−05 0.1958 67 53 46 72 −0.6208 PARP9, lymp, intra 3.00E−04 0.4 67 85 56 54 86−0.5272 PARP9, lymp, intra 2.00E−04 0.46 76 78 71 86 57 0.7802 PDIA6,gran, intra 9.00E−04 0.4 67 84 57 53 86 −0.7829 PDIA6, lymp, intra5.00E−04 0.37 62 90 45 49 89 −0.5593 PDIA6, mono, intra 9.00E−04 0.4 6784 57 53 86 −0.7829 PTEN, gran, intra 2.00E−05 −0.05 50 36 59 35 60−0.5881 PTEN, lymp, intra 1.00E−04 0.08 57 41 67 43 65 −0.5419 PTEN,mean, intra 2.00E−04 −0.11 48 31 58 32 57 −0.4633 PTEN, mono, intra2.00E−05 −0.05 50 36 59 35 60 −0.5881 RSAD2, gran, intra 1.00E−16 0.6382 78 85 82 82 −1.7372 RSAD2, lymp, intra 2.00E−04 0.18 57 78 39 52 67−0.412 RSAD2, mean, intra 5.00E−15 0.64 82 76 88 84 81 −1.3804 RSAD2,mono, intra 1.00E−16 0.63 82 78 85 82 82 −1.7372 RSAD2, total, intra1.00E−05 0.32 64 81 51 58 76 −0.7941 SDCBP, mean, intra 9.00E−04 0.16 5474 41 45 71 −0.424 TRIM 22, lymp, intra 1.00E−04 0.46 67 94 56 47 96−0.6477 WBC 2.00E−05 0.028 53 39 64 47 56 0.5448 *Positives andnegatives correspond to Bacterial and Viral infected patientsrespectively

TABLE 1B Mixed (bacterial and viral) versus viral infected patientsWilcoxon ranksum Total Sensitivity Specificity log2(med1/ DETERMINANTP-value MCC Accuracy % % PPV % NPV % med2) ANC 3.00E−04 0.62 89 97 56 9082 −1.2704 ARHGDIB, gran, intra 4.00E−04 0.4 83 92 44 87 58 1.1331ARHGDIB, lymp, intra 4.00E−04 0.32 79 88 44 86 47 1.2267 ARHGDIB, mean,intra 9.00E−04 0.2 76 87 31 83 38 0.9582 ARHGDIB, mono, intra 4.00E−040.4 83 92 44 87 58 1.1331 ARPC2, gran, intra 6.00E−05 0.31 76 83 50 8742 1.0578 ARPC2, lymp, intra 2.00E−04 0.22 75 84 38 84 38 0.8354 ARPC2,mean, intra 1.00E−04 0.23 73 81 44 85 37 0.9228 ARPC2, mono, intra6.00E−05 0.31 76 83 50 87 42 1.0578 ATP6V0B, mean, intra 6.00E−04 0.3673 74 69 90 41 0.7126 CD15, gran, membrane 8.00E−04 0.44 84 94 44 87 640.7065 CES1, gran, intra 2.00E−05 0.53 83 84 75 93 55 1.034 CES1, lymp,intra 5.00E−04 0.39 73 72 75 92 40 0.8815 CES1, mean, intra 3.00E−050.51 85 92 56 89 64 0.9951 CES1, mono, intra 2.00E−05 0.53 83 84 75 9355 1.034 CORO1A, gran, intra 7.00E−05 0.43 80 84 63 90 50 0.8348 CORO1A,lymp, intra 3.00E−04 0.47 79 80 75 93 48 0.709 CORO1A, mean, intra2.00E−05 0.58 86 90 69 92 65 1.031 CORO1A, mono, intra 7.00E−05 0.43 8084 63 90 50 0.8348 CRP 6.00E−06 0.55 86 92 63 90 67 −3.0326 HERC5, gran,intra 5.00E−04 0.5 83 87 67 92 56 0.7673 HERC5, mean, intra 5.00E−04 0.375 80 53 88 40 0.7926 HERC5, mono, intra 5.00E−04 0.5 83 87 67 92 560.7673 IFIT3, gran, intra 2.00E−05 0.41 79 83 63 90 48 1.3384 IFIT3,lymp, intra 7.00E−04 0.12 76 91 19 82 33 1.1029 IFIT3, mean, intra1.00E−04 0.31 72 74 63 88 38 1.1795 IFIT3, mono, intra 2.00E−05 0.41 7983 63 90 48 1.3384 LIPT1, gran, intra 7.00E−05 0.26 78 88 38 85 430.9803 LIPT1, lymp, intra 3.00E−04 0.38 83 94 38 86 60 1.0083 LIPT1,mean, intra 2.00E−04 0.3 76 82 50 86 42 0.7438 LIPT1, mono, intra7.00E−05 0.26 78 88 38 85 43 0.9803 LOC26010, gran, intra 3.00E−05 0.4784 91 56 91 56 1.092 LOC26010, lymp, intra 4.00E−05 0.41 80 84 63 91 450.8577 LOC26010, mean, intra 4.00E−05 0.35 80 86 50 89 44 0.9144LOC26010, mono, intra 3.00E−05 0.47 84 91 56 91 56 1.092 Lym (%)5.00E−06 0.35 80 87 50 89 44 1.5718 MX1, gran, intra 1.00E−06 0.65 90 9569 93 73 1.6082 MX1, lymp, intra 1.00E−06 0.47 86 93 50 90 62 1.5425MX1, mean, intra 3.00E−06 0.73 92 96 75 95 80 1.5264 MX1, mono, intra1.00E−06 0.65 90 95 69 93 73 1.6082 Neu (%) 4.00E−06 0.46 81 84 69 93 48−0.5346 OAS2, gran, intra 4.00E−05 0.44 85 92 50 90 57 1.2302 OAS2,lymp, intra 8.00E−04 0.38 76 77 69 92 39 0.9389 OAS2, mean, intra1.00E−04 0.49 81 82 75 94 48 0.9043 OAS2, mono, intra 4.00E−05 0.44 8592 50 90 57 1.2302 PARP12, gran, intra 1.00E−04 0.33 68 66 75 91 350.7337 PARP12, lymp, intra 9.00E−04 0.22 79 92 25 83 44 0.8365 PARP12,mean, intra 2.00E−05 0.34 76 81 56 88 43 0.8935 PARP12, mono, intra1.00E−04 0.33 68 66 75 91 35 0.7337 PARP9, gran, intra 3.00E−04 0.32 7580 56 88 41 0.9399 PARP9, lymp, intra 1.00E−05 0.46 80 83 69 91 501.0354 PARP9, mean, intra 7.00E−04 0.38 78 84 56 88 47 0.7744 PARP9,mono, intra 3.00E−04 0.32 75 80 56 88 41 0.9399 PTEN, gran, intra3.00E−05 0.38 76 78 67 91 42 1.0924 PTEN, lymp, intra 2.00E−04 0.37 8495 33 86 63 0.7166 PTEN, mean, intra 6.00E−05 0.15 75 87 27 83 33 0.9682PTEN, mono, intra 3.00E−05 0.38 76 78 67 91 42 1.0924 RSAD2, gran, intra1.00E−06 0.62 88 91 75 94 63 1.6165 RSAD2, lymp, intra 2.00E−05 0.3 7579 56 89 36 0.933 RSAD2, mean, intra 6.00E−06 0.47 84 90 56 90 56 1.3028RSAD2, mono, intra 1.00E−06 0.62 88 91 75 94 63 1.6165 SART3, lymp,intra 4.00E−04 0.35 79 86 50 87 47 0.8566 SOCS3, gran, intra 2.00E−040.1 65 71 40 83 25 1.0003 SOCS3, lymp, intra 1.00E−04 0.3 69 70 67 90 341.0643 SOCS3, mean, intra 9.00E−05 0.31 70 70 67 90 36 1.0804 SOCS3,mono, intra 2.00E−04 0.1 65 71 40 83 25 1.0003 UBE2N, mean, intra1.00E−03 0.34 73 74 67 90 38 0.6314 *Positives and negatives correspondto Viral and Mixed infected patients respectively

TABLE 1C Viral versus non-infectious and healthy patients Wilcoxonranksum Total DETERMINANT P-value MCC Accuracy Sensitivity % Specificity% PPV % NPV % log2(med1/med2) IFIT3, gran, intra 2.00E−06 0.52 79 78 8696 46 1.4768 IFIT3, lymp, intra 4.00E−04 0.516 78 76 89 97 44 1.4378IFIT3, mean, intra 1.00E−05 0.478 83 87 64 92 53 1.3977 IFIT3, total,intra 7.00E−06 0.447 83 89 57 90 53 1.5834 IFITM3, mono, membrane5.00E−05 0.599 91 97 54 92 78 1.409 LOC26010, gran, intra 9.00E−06 0.31774 76 64 92 33 1.0447 LOC26010, mean, intra 4.00E−05 0.245 71 74 57 9030 0.8998 LOC26010, total, intra 2.00E−05 0.508 77 74 93 98 41 0.8842MAN1C1, lymp, intra 7.00E−04 0.679 91 93 80 96 67 −0.8502 MX1, gran,intra 5.00E−08 0.762 93 95 86 97 75 1.7607 MX1, lymp, intra 3.00E−060.641 86 85 93 98 54 1.2356 MX1, mean, intra 1.00E−07 0.793 94 96 86 9780 1.5771 MX1, total, intra 5.00E−07 0.533 81 81 86 97 46 1.7951 OAS2,gran, intra 2.00E−06 0.497 85 89 64 93 53 1.3996 OAS2, mean, intra3.00E−05 0.179 76 84 36 87 29 1.0438 OAS2, total, intra 4.00E−05 0.17160 59 64 90 23 1.0833 RAB13, gran, intra 7.00E−06 0.535 86 91 64 92 600.8966 RAB13, mean, intra 4.00E−05 0.465 80 82 71 93 48 0.6475 RSAD2,gran, intra 1.00E−06 0.732 92 93 86 97 71 2.0751 RSAD2, mean, intra1.00E−06 0.471 84 88 64 93 50 1.6929 RSAD2, total, intra 7.00E−06 0.49485 89 64 93 53 1.9603 SART3, gran, intra 3.00E−05 0.279 76 81 50 88 370.9517 *Positives and negatives correspond to viral versus healthy andnon-infectious patients respectively

TABLE 1D Bacterial versus non-infectious and healthy patients Wilcoxonranksum Total DETERMINANT P-value MCC Accuracy Sensitivity % Specificity% PPV % NPV % log2(med1/med2) CRP 7.00E−04 0.795 91 94 86 94 86 5.9873HERC5, lymp, intra 6.00E−04 0.32 69 76 56 76 56 −1.1808 KIAA0082, lymp,intra 8.00E−04 0.652 85 94 67 84 86 −1.088 LOC26010, total, intra3.00E−05 0.535 78 74 93 98 45 0.9881 MX1, total, intra 2.00E−05 0.256 6768 64 89 31 1.2637 OAS2, total, intra 1.00E−04 0.214 63 63 64 89 281.0966 RAB13, total, intra 5.00E−05 0.564 81 82 79 91 61 1.312 SMAD9,lymp, intra 5.00E−04 0.741 88 94 78 89 88 −0.7465 WBC 8.00E−04 0.624 8176 89 93 67 0.7744 *Positives and negatives correspond to Bacterialversus healthy and non-infectious patients respectively

TABLE 1E Infectious versus non-infectious and healthy Wilcoxon ranksumTotal DETERMINANT P-value MCC Accuracy Sensitivity % Specificity % PPV %NPV % log2(med1/med2) CRP 5.00E−04 0.75 96 98 71 97 83 5.2216 IFIT3,total, intra 7.00E−06 0.447 83 89 57 90 53 1.5834 LOC26010, total, intra2.00E−05 0.508 77 74 93 98 41 0.8842 MAN1C1, lymp, intra 5.00E−04 0.63794 98 60 95 75 −0.9458 MX1, gran, intra 2.00E−05 0.16 69 70 57 95 151.1574 MX1, mean, intra 4.00E−05 0.289 75 75 71 97 21 0.9615 MX1, total,intra 5.00E−07 0.533 81 81 86 97 46 1.7951 OAS2, total, intra 4.00E−050.171 60 59 64 90 23 1.0833 RAB13, gran, intra 9.00E−05 0.332 80 82 6495 29 0.6433 RAB13, mean, intra 8.00E−05 0.359 79 79 71 96 29 0.5312RSAD2, total, intra 7.00E−06 0.494 85 89 64 93 53 1.9603 SMAD9, lymp,intra 5.00E−04 0.396 89 97 33 92 60 −0.6464 *Positives and negativescorrespond to Infectious versus healthy and non-infectious patientsrespectively

TABLE 2 The classification accuracy of bacterial vs. viral infectedpatients computed over pairs of features. DETERMINANT measurements weremeasured over population mean. (mean pairs) Total Sen Spe PPV NPVFeature #1 Feature #2 MCC dMCC accuracy % % % % % ANC CORO1A, mean,intra 0.41 −0.03 73 92 42 72 76 ANC CRP 0.58 0.02 80 87 70 83 76 ANCEIF4B, mean, intra 0.5 0.06 77 92 53 76 80 ANC IFIT3, mean, intra 0.50.06 77 92 53 76 80 ANC IFITM1, mean, membrane 0.43 −0.01 74 94 42 73 80ANC IFITM3, mean, membrane 0.43 −0.01 74 94 42 73 80 ANC LOC26010, mean,intra 0.43 −0.01 74 94 42 73 80 ANC Lym(%) 0.5 −0.02 77 88 61 79 74 ANCMAN1C1, mean, intra 0.36 −0.08 72 90 40 72 71 ANC MX1, mean, intra 0.570.12 80 92 61 79 82 ANC Neu(%) 0.53 −0.03 78 91 58 78 79 ANC NPM1, mean,intra 0.43 −0.01 74 92 45 73 77 ANC OAS2, mean, intra 0.4 −0.04 73 90 4573 74 ANC PARP12, mean, intra 0.48 0.04 76 90 53 76 77 ANC PTEN, mean,intra 0.43 −0.01 74 92 45 73 77 ANC RSAD2, mean, intra 0.64 0 83 85 7987 77 ANC SDCBP, mean, intra 0.45 0.01 75 90 50 74 76 ANC WBC 0.53 0.0978 95 50 76 86 CORO1A, mean, intra CRP 0.56 0 79 91 61 78 82 CORO1A,mean, intra EIF4B, mean, intra 0.31 0 68 81 49 71 61 CORO1A, mean, intraIFIT3, mean, intra 0.39 0.14 71 79 59 75 64 CORO1A, mean, intra IFITM1,mean, membrane 0.14 −0.15 60 73 41 66 48 CORO1A, mean, intra IFITM3,mean, membrane 0.16 −0.19 61 74 41 67 50 CORO1A, mean, intra LOC26010,mean, intra 0.16 −0.05 61 74 41 67 50 CORO1A, mean, intra Lym(%) 0.51−0.01 76 77 74 83 67 CORO1A, mean, intra MAN1C1, mean, intra 0.25 0.1 6679 45 71 56 CORO1A, mean, intra MX1, mean, intra 0.48 0.03 75 81 67 7968 CORO1A, mean, intra Neu(%) 0.55 −0.01 79 89 64 80 78 CORO1A, mean,intra NPM1, mean, intra 0.2 0.05 63 75 44 68 53 CORO1A, mean, intraOAS2, mean, intra 0.19 −0.11 62 73 46 68 51 CORO1A, mean, intra PARP12,mean, intra 0.28 0.03 66 76 51 71 57 CORO1A, mean, intra PTEN, mean,intra 0.18 −0.02 62 74 44 68 52 CORO1A, mean, intra RSAD2, mean, intra0.59 −0.05 80 82 77 85 73 CORO1A, mean, intra SDCBP, mean, intra 0.190.04 63 77 41 67 53 CORO1A, mean, intra WBC 0.28 0.03 67 82 44 70 61 CRPEIF4B, mean, intra 0.65 0.09 83 95 66 81 89 CRP IFIT3, mean, intra 0.690.13 85 91 76 85 85 CRP IFITM1, mean, membrane 0.58 0.02 80 91 63 79 83CRP IFITM3, mean, membrane 0.67 0.11 84 91 74 84 85 CRP LOC26010, mean,intra 0.69 0.13 85 90 79 87 83 CRP Lym(%) 0.7 0.14 86 92 76 86 85 CRPMAN1C1, mean, intra 0.61 0.05 82 90 70 83 81 CRP MX1, mean, intra 0.740.18 88 93 79 87 88 CRP Neu(%) 0.65 0.09 84 92 71 83 84 CRP NPM1, mean,intra 0.65 0.09 83 88 76 85 81 CRP OAS2, mean, intra 0.65 0.09 83 91 7183 84 CRP PARP12, mean, intra 0.76 0.2 89 95 79 87 91 CRP PTEN, mean,intra 0.69 0.13 85 93 74 84 88 CRP RSAD2, mean, intra 0.85 0.21 93 93 9295 90 CRP SDCBP, mean, intra 0.65 0.09 83 89 74 84 82 CRP WBC 0.54 −0.0279 88 63 79 77 EIF4B, mean, intra IFIT3, mean, intra 0.23 −0.08 64 76 4669 55 EIF4B, mean, intra IFITM1, mean, membrane 0.26 −0.05 63 69 56 6660 EIF4B, mean, intra IFITM3, mean, membrane 0.32 −0.03 66 68 64 70 62EIF4B, mean, intra LOC26010, mean, intra 0.3 −0.01 65 63 68 69 61 EIF4B,mean, intra Lym(%) 0.54 0.02 77 75 79 81 73 EIF4B, mean, intra MAN1C1,mean, intra 0.25 −0.06 66 79 45 71 56 EIF4B, mean, intra MX1, mean,intra 0.46 0.01 72 67 79 79 67 EIF4B, mean, intra Neu(%) 0.57 0.01 78 7879 81 75 EIF4B, mean, intra NPM1, mean, intra 0.08 −0.23 58 72 36 64 45EIF4B, mean, intra OAS2, mean, intra 0.34 0.03 67 67 68 71 64 EIF4B,mean, intra PARP12, mean, intra 0.26 −0.05 65 74 51 71 56 EIF4B, mean,intra PTEN, mean, intra 0.16 −0.15 61 74 41 67 50 EIF4B, mean, intraRSAD2, mean, intra 0.63 −0.01 81 79 84 85 78 EIF4B, mean, intra SDCBP,mean, intra 0.17 −0.14 62 77 38 66 52 EIF4B, mean, intra WBC 0.38 0.0769 79 58 69 71 IFIT3, mean, intra IFITM1, mean, membrane 0.25 −0.04 6576 49 70 56 IFIT3, mean, intra IFITM3, mean, membrane 0.26 −0.09 65 7451 71 56 IFIT3, mean, intra LOC26010, mean, intra 0.16 −0.09 60 69 46 6749 IFIT3, mean, intra Lym(%) 0.56 0.04 79 85 69 82 75 IFIT3, mean, intraMAN1C1, mean, intra 0.21 −0.04 65 83 35 68 55 IFIT3, mean, intra MX1,mean, intra 0.38 −0.07 70 74 64 77 61 IFIT3, mean, intra Neu(%) 0.620.06 82 89 72 83 80 IFIT3, mean, intra NPM1, mean, intra 0.34 0.09 69 7756 73 61 IFIT3, mean, intra OAS2, mean, intra 0.21 −0.09 63 74 46 69 53IFIT3, mean, intra PARP12, mean, intra 0.34 0.09 68 73 62 75 59 IFIT3,mean, intra PTEN, mean, intra 0.16 −0.09 60 69 46 67 49 IFIT3, mean,intra RSAD2, mean, intra 0.59 −0.05 80 81 79 86 72 IFIT3, mean, intraSDCBP, mean, intra 0.23 −0.02 63 69 54 70 53 IFIT3, mean, intra WBC 0.30.05 67 77 51 72 59 IFITM1, mean, membrane IFITM3, mean, membrane 0.33−0.02 66 64 69 72 61 IFITM1, mean, membrane LOC26010, mean, intra 0.22−0.07 61 63 59 65 56 IFITM1, mean, membrane Lym(%) 0.52 0 76 76 76 80 73IFITM1, mean, membrane MAN1C1, mean, intra 0.1 −0.19 61 83 26 65 47IFITM1, mean, membrane MX1, mean, intra 0.48 0.03 74 72 76 79 69 IFITM1,mean, membrane Neu(%) 0.53 −0.03 76 75 78 81 72 IFITM1, mean, membraneNPM1, mean, intra 0.08 −0.21 58 72 36 64 45 IFITM1, mean, membrane OAS2,mean, intra 0.31 0.01 66 65 66 70 61 IFITM1, mean, membrane PARP12,mean, intra 0.23 −0.06 64 74 49 70 54 IFITM1, mean, membrane PTEN, mean,intra 0.2 −0.09 63 77 41 68 53 IFITM1, mean, membrane RSAD2, mean, intra0.57 −0.07 79 76 81 83 74 IFITM1, mean, membrane SDCBP, mean, intra 0.04−0.25 57 75 28 62 42 IFITM1, mean, membrane WBC 0.3 0.01 66 74 56 67 63IFITM3, mean, membrane LOC26010, mean, intra 0.34 −0.01 66 63 71 73 61IFITM3, mean, membrane Lym(%) 0.48 −0.04 74 76 71 76 71 IFITM3, mean,membrane MAN1C1, mean, intra 0.08 −0.27 60 81 26 65 44 IFITM3, mean,membrane MX1, mean, intra 0.4 −0.05 70 69 71 75 66 IFITM3, mean,membrane Neu(%) 0.58 0.02 79 83 75 80 79 IFITM3, mean, membrane NPM1,mean, intra 0.21 −0.14 64 80 38 67 56 IFITM3, mean, membrane OAS2, mean,intra 0.33 −0.02 66 64 69 72 61 IFITM3, mean, membrane PARP12, mean,intra 0.23 −0.12 64 74 49 70 54 IFITM3, mean, membrane PTEN, mean, intra0.2 −0.15 63 76 44 68 53 IFITM3, mean, membrane RSAD2, mean, intra 0.63−0.01 82 81 83 85 78 IFITM3, mean, membrane SDCBP, mean, intra 0.04−0.31 57 75 28 62 42 IFITM3, mean, membrane WBC 0.37 0.02 69 74 63 71 66LOC26010, mean, intra Lym(%) 0.52 0 76 76 76 79 73 LOC26010, mean, intraMAN1C1, mean, intra 0.18 −0.03 64 81 35 68 52 LOC26010, mean, intra MX1,mean, intra 0.44 −0.01 72 68 76 77 67 LOC26010, mean, intra Neu(%) 0.49−0.07 75 75 74 77 72 LOC26010, mean, intra NPM1, mean, intra 0.14 −0.0761 77 36 65 50 LOC26010, mean, intra OAS2, mean, intra 0.26 −0.04 63 5868 68 58 LOC26010, mean, intra PARP12, mean, intra 0.26 0.01 65 74 51 7156 LOC26010, mean, intra PTEN, mean, intra 0.15 −0.06 60 71 44 67 49LOC26010, mean, intra RSAD2, mean, intra 0.64 0 82 81 84 85 79 LOC26010,mean, intra SDCBP, mean, intra 0.16 −0.05 62 79 36 66 52 LOC26010, mean,intra WBC 0.29 0.04 65 74 55 65 64 Lym(%) MAN1C1, mean, intra 0.42 −0.173 83 58 77 67 Lym(%) MX1, mean, intra 0.62 0.1 81 83 79 82 80 Lym(%)Neu(%) 0.53 −0.03 77 75 79 81 72 Lym(%) NPM1, mean, intra 0.54 0.02 7882 72 82 72 Lym(%) OAS2, mean, intra 0.55 0.03 78 78 77 80 75 Lym(%)PARP12, mean, intra 0.56 0.04 79 82 74 84 73 Lym(%) PTEN, mean, intra0.47 −0.05 74 76 72 81 65 Lym(%) RSAD2, mean, intra 0.61 −0.03 81 81 8183 78 Lym(%) SDCBP, mean, intra 0.45 −0.07 74 79 67 79 67 Lym(%) WBC0.58 0.06 79 79 79 82 75 MAN1C1, mean, intra MX1, mean, intra 0.38 −0.0771 77 61 77 61 MAN1C1, mean, intra Neu(%) 0.5 −0.06 77 88 58 78 75MAN1C1, mean, intra NPM1, mean, intra 0.19 0.06 64 79 39 68 52 MAN1C1,mean, intra OAS2, mean, intra 0.15 −0.15 63 81 32 67 50 MAN1C1, mean,intra PARP12, mean, intra 0.21 −0.04 64 75 45 70 52 MAN1C1, mean, intraPTEN, mean, intra 0.28 0.08 67 79 48 72 58 MAN1C1, mean, intra RSAD2,mean, intra 0.58 −0.06 81 87 71 83 76 MAN1C1, mean, intra SDCBP, mean,intra 0.3 0.17 69 83 45 72 61 MAN1C1, mean, intra WBC 0.22 −0.03 66 8829 68 60 MX1, mean, intra Neu(%) 0.59 0.03 80 83 76 80 80 MX1, mean,intra NPM1, mean, intra 0.36 −0.09 69 72 64 76 60 MX1, mean, intra OAS2,mean, intra 0.45 0 72 68 77 78 68 MX1, mean, intra PARP12, mean, intra0.53 0.08 77 79 74 83 69 MX1, mean, intra PTEN, mean, intra 0.37 −0.0870 76 62 76 62 MX1, mean, intra RSAD2, mean, intra 0.57 −0.07 78 75 8283 74 MX1, mean, intra SDCBP, mean, intra 0.41 −0.04 72 77 64 77 64 MX1,mean, intra WBC 0.44 −0.01 72 68 76 77 67 Neu(%) OAS2, mean, intra 0.570.01 79 78 79 81 75 Neu(%) PARP12, mean, intra 0.62 0.06 82 87 74 84 78Neu(%) PTEN, mean, intra 0.56 0 79 84 72 83 74 Neu(%) RSAD2, mean, intra0.66 0.02 83 84 82 85 81 Neu(%) SDCBP, mean, intra 0.51 −0.05 77 82 6981 71 Neu(%) WBC 0.54 −0.02 77 80 74 79 75 NPM1, mean, intra Neu(%) 0.60.04 81 87 72 83 78 NPM1, mean, intra OAS2, mean, intra 0.04 −0.26 56 7033 62 42 NPM1, mean, intra PARP12, mean, intra 0.22 −0.03 63 70 51 69 53NPM1, mean, intra PTEN, mean, intra 0.14 −0.06 60 72 41 66 48 NPM1,mean, intra RSAD2, mean, intra 0.58 −0.06 80 82 77 85 73 NPM1, mean,intra SDCBP, mean, intra 0.07 −0.06 58 75 31 63 44 NPM1, mean, intra WBC0.39 0.14 72 89 46 72 72 OAS2, mean, intra PARP12, mean, intra 0.24−0.06 64 73 51 70 54 OAS2, mean, intra PTEN, mean, intra 0.14 −0.16 6073 41 66 48 OAS2, mean, intra RSAD2, mean, intra 0.66 0.02 83 82 84 8680 OAS2, mean, intra SDCBP, mean, intra 0.03 −0.27 56 72 31 62 41 OAS2,mean, intra WBC 0.34 0.04 67 75 58 68 67 PARP12, mean, intra PTEN, mean,intra 0.25 0 65 76 49 70 56 PARP12, mean, intra RSAD2, mean, intra 0.61−0.03 81 84 77 85 75 PARP12, mean, intra SDCBP, mean, intra 0.21 −0.0463 72 49 69 53 PARP12, mean, intra WBC 0.35 0.1 70 84 49 72 66 PTEN,mean, intra RSAD2, mean, intra 0.61 −0.03 81 82 79 86 74 PTEN, mean,intra SDCBP, mean, intra 0.24 0.04 65 77 46 69 56 PTEN, mean, intra WBC0.3 0.05 68 85 41 70 64 RSAD2, mean, intra SDCBP, mean, intra 0.61 −0.0381 82 79 86 74 RSAD2, mean, intra WBC 0.63 −0.01 81 78 85 86 77 SDCBP,mean, intra WBC 0.27 0.02 67 84 41 69 62 * Positive and negativecorrespond to bacterial and viral infected patients respectively

TABLE 3 The classification accuracy of bacterial vs. viral infectedpatients computed over pairs of features. DETERMINANT measurements weremeasured over cell population mean. (mean triplets) Total Sen Spe PPVNPV Feature #1 Feature #2 Feature #3 MCC dMCC accuracy % % % % % ANCCORO1A, mean, intra CRP 0.6 0.08 83 88 76 85 80 ANC CORO1A, mean, intraEIF4B, mean, intra 0.5 0.04 76 94 47 74 82 ANC CORO1A, mean, intraIFIT3, mean, intra 0.5 0.04 76 90 53 76 77 ANC CORO1A, mean, intraIFITM1, mean, membrane 0.4 −0.01 74 92 45 73 77 ANC CORO1A, mean, intraIFITM3, mean, membrane 0.4 −0.04 73 90 45 73 74 ANC CORO1A, mean, intraLOC26010, mean, intra 0.4 −0.01 74 92 45 73 77 ANC CORO1A, mean, intraLym(%) 0.5 0 78 89 61 79 77 ANC CORO1A, mean, intra MAN1C1, mean, intra0.3 −0.14 70 88 37 71 65 ANC CORO1A, mean, intra MX1, mean, intra 0.60.14 81 92 63 80 83 ANC CORO1A, mean, intra Neu(%) 0.5 −0.06 77 90 55 7778 ANC CORO1A, mean, intra NPM1, mean, intra 0.4 −0.06 72 89 45 72 71ANC CORO1A, mean, intra OAS2, mean, intra 0.4 −0.03 73 92 42 72 76 ANCCORO1A, mean, intra PARP12, mean, intra 0.5 0.04 76 90 53 76 77 ANCCORO1A, mean, intra PTEN, mean, intra 0.4 −0.01 74 92 45 73 77 ANCCORO1A, mean, intra RSAD2, mean, intra 0.6 0 83 85 79 87 77 ANC CORO1A,mean, intra SDCBP, mean, intra 0.5 0.01 75 90 50 74 76 ANC CORO1A, mean,intra WBC 0.6 0.11 79 94 55 77 84 ANC CRP EIF4B, mean, intra 0.7 0.15 8691 78 87 85 ANC CRP IFIT3, mean, intra 0.7 0.15 86 90 81 88 83 ANC CRPIFITM1, mean, membrane 0.7 0.13 85 90 78 87 83 ANC CRP IFITM3, mean,membrane 0.6 0.08 83 90 73 84 82 ANC CRP LOC26010, mean, intra 0.7 0.1586 90 81 88 83 ANC CRP Lym(%) 0.7 0.11 85 90 76 86 82 ANC CRP MAN1C1,mean, intra 0.6 0.08 83 90 72 84 81 ANC CRP MX1, mean, intra 0.7 0.15 8691 78 87 85 ANC CRP Neu(%) 0.7 0.11 85 92 73 85 84 ANC CRP NPM1, mean,intra 0.7 0.13 85 89 78 86 83 ANC CRP OAS2, mean, intra 0.7 0.11 84 8878 86 81 ANC CRP PARP12, mean, intra 0.7 0.17 87 91 81 88 86 ANC CRPPTEN, mean, intra 0.7 0.17 87 91 81 88 86 ANC CRP RSAD2, mean, intra 0.80.2 93 97 86 92 94 ANC CRP SDCBP, mean, intra 0.8 0.19 88 91 84 90 86ANC CRP WBC 0.6 0.06 82 90 70 83 81 ANC EIF4B, mean, intra IFIT3, mean,intra 0.5 0.1 79 92 58 78 81 ANC EIF4B, mean, intra IFITM1, mean,membrane 0.5 0.01 75 92 47 74 78 ANC EIF4B, mean, intra IFITM3, mean,membrane 0.5 0.04 76 92 50 75 79 ANC EIF4B, mean, intra LOC26010, mean,intra 0.5 0.04 76 92 50 75 79 ANC EIF4B, mean, intra Lym(%) 0.6 0.09 8290 68 82 81 ANC EIF4B, mean, intra MAN1C1, mean, intra 0.4 −0.08 72 9040 72 71 ANC EIF4B, mean, intra MX1, mean, intra 0.6 0.18 83 92 68 83 84ANC EIF4B, mean, intra Neu(%) 0.7 0.1 84 92 71 84 84 ANC EIF4B, mean,intra NPM1, mean, intra 0.5 0.06 77 93 50 75 83 ANC EIF4B, mean, intraOAS2, mean, intra 0.5 0.06 77 90 55 77 78 ANC EIF4B, mean, intra PARP12,mean, intra 0.6 0.13 80 92 61 79 82 ANC EIF4B, mean, intra PTEN, mean,intra 0.5 0.01 75 92 47 74 78 ANC EIF4B, mean, intra RSAD2, mean, intra0.6 0 83 85 79 87 77 ANC EIF4B, mean, intra SDCBP, mean, intra 0.5 0.0175 90 50 74 76 ANC EIF4B, mean, intra WBC 0.6 0.15 81 92 63 80 83 ANCIFIT3, mean, intra IFITM1, mean, membrane 0.4 −0.04 73 89 47 73 72 ANCIFIT3, mean, intra IFITM3, mean, membrane 0.5 0.01 75 89 53 75 74 ANCIFIT3, mean, intra LOC26010, mean, intra 0.4 −0.01 74 89 50 74 73 ANCIFIT3, mean, intra Lym(%) 0.6 0.07 81 89 68 82 79 ANC IFIT3, mean, intraMAN1C1, mean, intra 0.4 −0.08 72 90 40 72 71 ANC IFIT3, mean, intra MX1,mean, intra 0.5 0.09 79 90 61 79 79 ANC IFIT3, mean, intra Neu(%) 0.60.01 80 89 66 81 78 ANC IFIT3, mean, intra NPM1, mean, intra 0.5 0.01 7590 50 74 76 ANC IFIT3, mean, intra OAS2, mean, intra 0.5 0.04 76 92 5075 79 ANC IFIT3, mean, intra PARP12, mean, intra 0.5 0.01 75 87 55 76 72ANC IFIT3, mean, intra PTEN, mean, intra 0.5 0.01 75 92 47 74 78 ANCIFIT3, mean, intra RSAD2, mean, intra 0.7 0.04 85 87 82 89 79 ANC IFIT3,mean, intra SDCBP, mean, intra 0.5 0.03 76 90 53 75 77 ANC IFIT3, mean,intra WBC 0.5 0.1 79 89 63 80 77 ANC IFITM1, mean, membrane IFITM3,mean, membrane 0.5 0.02 75 94 45 73 81 ANC IFITM1, mean, membraneLOC26010, mean, intra 0.4 −0.01 74 94 42 73 80 ANC IFITM1, mean,membrane Lym(%) 0.5 −0.02 77 87 61 78 74 ANC IFITM1, mean, membraneMAN1C1, mean, intra 0.4 −0.08 72 90 40 72 71 ANC IFITM1, mean, membraneMX1, mean, intra 0.6 0.14 81 92 63 80 83 ANC IFITM1, mean, membraneNeu(%) 0.5 −0.06 77 89 58 77 76 ANC IFITM1, mean, membrane NPM1, mean,intra 0.4 −0.06 72 89 45 72 71 ANC IFITM1, mean, membrane OAS2, mean,intra 0.5 0.01 75 90 50 75 76 ANC IFITM1, mean, membrane PARP12, mean,intra 0.5 0.04 76 90 53 76 77 ANC IFITM1, mean, membrane PTEN, mean,intra 0.5 0.01 75 92 47 74 78 ANC IFITM1, mean, membrane RSAD2, mean,intra 0.7 0.02 84 87 79 87 79 ANC IFITM1, mean, membrane SDCBP, mean,intra 0.5 0.01 75 90 50 74 76 ANC IFITM1, mean, membrane WBC 0.5 0.06 7794 50 75 83 ANC IFITM3, mean, membrane LOC26010, mean, intra 0.4 −0.0373 94 39 72 79 ANC IFITM3, mean, membrane Lym(%) 0.5 0 78 89 61 79 77ANC IFITM3, mean, membrane MAN1C1, mean, intra 0.4 −0.08 72 92 37 72 73ANC IFITM3, mean, membrane MX1, mean, intra 0.6 0.12 80 92 61 79 82 ANCIFITM3, mean, membrane Neu(%) 0.5 −0.06 77 89 58 77 76 ANC IFITM3, mean,membrane NPM1, mean, intra 0.4 −0.04 73 90 45 72 74 ANC IFITM3, mean,membrane OAS2, mean, intra 0.4 −0.08 71 89 42 71 70 ANC IFITM3, mean,membrane PARP12, mean, intra 0.4 −0.01 74 89 50 74 73 ANC IFITM3, mean,membrane PTEN, mean, intra 0.4 −0.04 73 90 45 73 74 ANC IFITM3, mean,membrane RSAD2, mean, intra 0.6 −0.09 79 84 71 83 73 ANC IFITM3, mean,membrane SDCBP, mean, intra 0.4 −0.04 73 90 45 72 74 ANC IFITM3, mean,membrane WBC 0.5 0.06 77 94 50 75 83 ANC LOC26010, mean, intra Lym(%)0.6 0.03 79 87 66 81 76 ANC LOC26010, mean, intra MAN1C1, mean, intra0.3 −0.11 71 90 37 71 69 ANC LOC26010, mean, intra MX1, mean, intra 0.50.09 79 89 63 80 77 ANC LOC26010, mean, intra Neu(%) 0.6 0.03 81 92 6380 83 ANC LOC26010, mean, intra NPM1, mean, intra 0.4 −0.01 74 92 45 7377 ANC LOC26010, mean, intra OAS2, mean, intra 0.4 −0.04 73 90 45 73 74ANC LOC26010, mean, intra PARP12, mean, intra 0.4 −0.01 74 87 53 75 71ANC LOC26010, mean, intra PTEN, mean, intra 0.4 −0.04 73 90 45 73 74 ANCLOC26010, mean, intra RSAD2, mean, intra 0.6 0 83 85 79 87 77 ANCLOC26010, mean, intra SDCBP, mean, intra 0.4 −0.01 74 90 47 73 75 ANCLOC26010, mean, intra WBC 0.5 0.08 78 92 55 77 81 ANC Lym(%) MAN1C1,mean, intra 0.4 −0.09 74 87 53 76 70 ANC Lym(%) MX1, mean, intra 0.60.05 80 87 68 82 76 ANC Lym(%) Neu(%) 0.5 −0.03 78 88 63 80 75 ANCLym(%) NPM1, mean, intra 0.5 0.02 79 89 63 79 77 ANC Lym(%) OAS2, mean,intra 0.6 0.03 79 87 66 81 76 ANC Lym(%) PARP12, mean, intra 0.6 0.05 8087 68 82 76 ANC Lym(%) PTEN, mean, intra 0.5 −0.02 77 85 63 79 73 ANCLym(%) RSAD2, mean, intra 0.7 0.02 84 89 76 86 81 ANC Lym(%) SDCBP,mean, intra 0.5 0 78 85 66 80 74 ANC Lym(%) WBC 0.5 −0.04 76 86 61 79 72ANC MAN1C1, mean, intra MX1, mean, intra 0.5 0.03 77 90 53 77 76 ANCMAN1C1, mean, intra Neu(%) 0.5 −0.11 76 88 53 77 73 ANC MAN1C1, mean,intra NPM1, mean, intra 0.3 −0.11 71 88 40 72 67 ANC MAN1C1, mean, intraOAS2, mean, intra 0.3 −0.11 71 90 37 71 69 ANC MAN1C1, mean, intraPARP12, mean, intra 0.3 −0.11 71 88 40 72 67 ANC MAN1C1, mean, intraPTEN, mean, intra 0.3 −0.11 71 88 40 72 67 ANC MAN1C1, mean, intraRSAD2, mean, intra 0.6 −0.06 80 85 73 85 73 ANC MAN1C1, mean, intraSDCBP, mean, intra 0.4 −0.08 72 90 40 72 71 ANC MAN1C1, mean, intra WBC0.4 −0.05 73 90 43 73 72 ANC MX1, mean, intra Neu(%) 0.6 0.07 83 92 6883 84 ANC MX1, mean, intra NPM1, mean, intra 0.6 0.12 80 92 61 79 82 ANCMX1, mean, intra OAS2, mean, intra 0.5 0.09 79 90 61 79 79 ANC MX1,mean, intra PARP12, mean, intra 0.6 0.18 83 92 68 83 84 ANC MX1, mean,intra PTEN, mean, intra 0.6 0.14 81 94 61 79 85 ANC MX1, mean, intraRSAD2, mean, intra 0.6 −0.05 81 85 74 84 76 ANC MX1, mean, intra SDCBP,mean, intra 0.6 0.12 80 92 61 79 82 ANC MX1, mean, intra WBC 0.6 0.12 8089 66 81 78 ANC Neu(%) OAS2, mean, intra 0.6 0.03 81 90 66 81 81 ANCNeu(%) PARP12, mean, intra 0.6 0.03 81 90 66 81 81 ANC Neu(%) PTEN,mean, intra 0.5 −0.02 79 89 63 80 77 ANC Neu(%) RSAD2, mean, intra 0.6−0.03 82 87 74 84 78 ANC Neu(%) SDCBP, mean, intra 0.5 −0.04 78 85 66 8074 ANC Neu(%) WBC 0.5 −0.03 78 91 58 78 79 ANC NPM1, mean, intra Neu(%)0.5 −0.02 79 89 63 79 77 ANC NPM1, mean, intra OAS2, mean, intra 0.4−0.04 73 90 45 72 74 ANC NPM1, mean, intra PARP12, mean, intra 0.4 −0.0174 89 50 74 73 ANC NPM1, mean, intra PTEN, mean, intra 0.4 −0.06 72 8945 72 71 ANC NPM1, mean, intra RSAD2, mean, intra 0.6 0 83 85 79 87 77ANC NPM1, mean, intra SDCBP, mean, intra 0.5 0.01 75 90 50 74 76 ANCNPM1, mean, intra WBC 0.5 0.08 78 92 55 77 81 ANC OAS2, mean, intraPARP12, mean, intra 0.4 −0.04 73 89 47 73 72 ANC OAS2, mean, intra PTEN,mean, intra 0.4 −0.06 72 89 45 72 71 ANC OAS2, mean, intra RSAD2, mean,intra 0.6 0 83 85 79 87 77 ANC OAS2, mean, intra SDCBP, mean, intra 0.50.03 76 92 50 75 79 ANC OAS2, mean, intra WBC 0.5 0.04 76 90 53 76 77ANC PARP12, mean, intra PTEN, mean, intra 0.5 0.04 76 90 53 76 77 ANCPARP12, mean, intra RSAD2, mean, intra 0.7 0.02 84 87 79 87 79 ANCPARP12, mean, intra SDCBP, mean, intra 0.5 0.01 75 90 50 74 76 ANCPARP12, mean, intra WBC 0.6 0.13 80 92 61 79 82 ANC PTEN, mean, intraRSAD2, mean, intra 0.6 −0.02 82 85 76 85 76 ANC PTEN, mean, intra SDCBP,mean, intra 0.4 −0.01 74 90 47 73 75 ANC PTEN, mean, intra WBC 0.5 0.0878 90 58 78 79 ANC RSAD2, mean, intra SDCBP, mean, intra 0.6 0 83 85 7987 77 ANC RSAD2, mean, intra WBC 0.6 −0.03 82 87 74 84 78 ANC SDCBP,mean, intra WBC 0.5 0.03 76 90 53 75 77 CORO1A, mean, intra CRP EIF4B,mean, intra 0.6 0.02 80 90 66 80 81 CORO1A, mean, intra CRP IFIT3, mean,intra 0.7 0.13 85 91 76 85 85 CORO1A, mean, intra CRP IFITM1, mean,membrane 0.6 0.02 80 91 63 79 83 CORO1A, mean, intra CRP IFITM3, mean,membrane 0.7 0.13 85 91 76 85 85 CORO1A, mean, intra CRP LOC26010, mean,intra 0.7 0.13 85 90 79 87 83 CORO1A, mean, intra CRP Lym(%) 0.7 0.13 8591 76 85 85 CORO1A, mean, intra CRP MAN1C1, mean, intra 0.6 0.05 82 9070 83 81 CORO1A, mean, intra CRP MX1, mean, intra 0.7 0.15 86 93 76 8688 CORO1A, mean, intra CRP Neu(%) 0.7 0.15 86 93 76 86 88 CORO1A, mean,intra CRP NPM1, mean, intra 0.6 0.06 82 88 74 83 80 CORO1A, mean, intraCRP OAS2, mean, intra 0.7 0.13 85 91 76 85 85 CORO1A, mean, intra CRPPARP12, mean, intra 0.8 0.22 90 95 82 89 91 CORO1A, mean, intra CRPPTEN, mean, intra 0.7 0.13 85 93 74 84 88 CORO1A, mean, intra CRP RSAD2,mean, intra 0.8 0.17 91 88 95 96 84 CORO1A, mean, intra CRP SDCBP, mean,intra 0.6 0.06 82 89 71 82 82 CORO1A, mean, intra CRP WBC 0.7 0.09 83 8876 85 81 CORO1A, mean, intra EIF4B, mean, intra IFIT3, mean, intra 0.30.02 68 76 56 73 59 CORO1A, mean, intra EIF4B, mean, intra IFITM1, mean,membrane 0.3 −0.02 67 81 46 70 60 CORO1A, mean, intra EIF4B, mean, intraIFITM3, mean, membrane 0.3 −0.06 67 81 46 70 60 CORO1A, mean, intraEIF4B, mean, intra LOC26010, mean, intra 0.2 −0.09 64 77 44 69 55CORO1A, mean, intra EIF4B, mean, intra Lym(%) 0.5 −0.02 76 79 72 82 68CORO1A, mean, intra EIF4B, mean, intra MAN1C1, mean, intra 0.4 0.08 7285 52 75 67 CORO1A, mean, intra EIF4B, mean, intra MX1, mean, intra 0.50.04 76 82 67 80 70 CORO1A, mean, intra EIF4B, mean, intra Neu(%) 0.60.06 82 89 72 83 80 CORO1A, mean, intra EIF4B, mean, intra NPM1, mean,intra 0.2 −0.1 64 79 41 68 55 CORO1A, mean, intra EIF4B, mean, intraOAS2, mean, intra 0.3 −0.02 67 79 49 71 59 CORO1A, mean, intra EIF4B,mean, intra PARP12, mean, intra 0.2 −0.08 64 74 49 70 54 CORO1A, mean,intra EIF4B, mean, intra PTEN, mean, intra 0.3 −0.04 66 79 46 70 58CORO1A, mean, intra EIF4B, mean, intra RSAD2, mean, intra 0.6 −0.01 8284 79 87 76 CORO1A, mean, intra EIF4B, mean, intra SDCBP, mean, intra0.3 −0.05 66 80 44 69 59 CORO1A, mean, intra EIF4B, mean, intra WBC 0.3−0.03 67 82 44 70 61 CORO1A, mean, intra IFIT3, mean, intra IFITM1,mean, membrane 0.3 0.02 68 79 51 72 61 CORO1A, mean, intra IFIT3, mean,intra IFITM3, mean, membrane 0.2 −0.11 64 73 51 70 54 CORO1A, mean,intra IFIT3, mean, intra LOC26010, mean, intra 0.4 0.12 70 77 59 75 62CORO1A, mean, intra IFIT3, mean, intra Lym(%) 0.6 0.04 79 85 69 82 75CORO1A, mean, intra IFIT3, mean, intra MAN1C1, mean, intra 0.3 0.06 6979 52 73 59 CORO1A, mean, intra IFIT3, mean, intra MX1, mean, intra 0.50.01 74 79 67 79 67 CORO1A, mean, intra IFIT3, mean, intra Neu(%) 0.60.04 81 87 72 83 78 CORO1A, mean, intra IFIT3, mean, intra NPM1, mean,intra 0.3 0.09 69 77 56 73 61 CORO1A, mean, intra IFIT3, mean, intraOAS2, mean, intra 0.3 0.03 68 76 56 73 59 CORO1A, mean, intra IFIT3,mean, intra PARP12, mean, intra 0.3 0.06 67 73 59 74 57 CORO1A, mean,intra IFIT3, mean, intra PTEN, mean, intra 0.3 0.08 68 74 59 74 59CORO1A, mean, intra IFIT3, mean, intra RSAD2, mean, intra 0.6 −0.07 7981 77 85 71 CORO1A, mean, intra IFIT3, mean, intra SDCBP, mean, intra0.4 0.11 70 79 56 74 63 CORO1A, mean, intra IFIT3, mean, intra WBC 0.2−0.02 64 76 46 69 55 CORO1A, mean, intra IFITM1, mean, membrane IFITM3,mean, membrane 0.2 −0.19 61 74 41 67 50 CORO1A, mean, intra IFITM1,mean, membrane LOC26010, mean, intra 0.1 −0.15 60 73 41 66 48 CORO1A,mean, intra IFITM1, mean, membrane Lym(%) 0.5 −0.03 75 77 72 81 67CORO1A, mean, intra IFITM1, mean, membrane MAN1C1, mean, intra 0.3 −0.0167 81 45 71 58 CORO1A, mean, intra IFITM1, mean, membrane MX1, mean,intra 0.5 0.02 75 82 64 78 69 CORO1A, mean, intra IFITM1, mean, membraneNeu(%) 0.5 −0.05 77 84 67 80 72 CORO1A, mean, intra IFITM1, mean,membrane NPM1, mean, intra 0.2 −0.12 62 75 41 67 52 CORO1A, mean, intraIFITM1, mean, membrane OAS2, mean, intra 0.2 −0.13 61 71 46 68 50CORO1A, mean, intra IFITM1, mean, membrane PARP12, mean, intra 0.3 0.0167 76 54 72 58 CORO1A, mean, intra IFITM1, mean, membrane PTEN, mean,intra 0.2 −0.06 64 76 46 69 55 CORO1A, mean, intra IFITM1, mean,membrane RSAD2, mean, intra 0.6 −0.01 82 84 79 87 76 CORO1A, mean, intraIFITM1, mean, membrane SDCBP, mean, intra 0.2 −0.14 61 75 38 66 50CORO1A, mean, intra IFITM1, mean, membrane WBC 0.3 −0.03 66 82 41 69 59CORO1A, mean, intra IFITM3, mean, membrane LOC26010, mean, intra 0.2−0.19 61 74 41 67 50 CORO1A, mean, intra IFITM3, mean, membrane Lym(%)0.4 −0.09 73 79 64 78 66 CORO1A, mean, intra IFITM3, mean, membraneMAN1C1, mean, intra 0.2 −0.12 65 77 45 70 54 CORO1A, mean, intra IFITM3,mean, membrane MX1, mean, intra 0.5 0.01 74 79 67 79 67 CORO1A, mean,intra IFITM3, mean, membrane Neu(%) 0.5 −0.03 78 89 62 79 77 CORO1A,mean, intra IFITM3, mean, membrane NPM1, mean, intra 0.2 −0.17 62 74 4467 52 CORO1A, mean, intra IFITM3, mean, membrane OAS2, mean, intra 0.2−0.19 60 69 46 67 49 CORO1A, mean, intra IFITM3, mean, membrane PARP12,mean, intra 0.3 −0.05 67 76 54 72 58 CORO1A, mean, intra IFITM3, mean,membrane PTEN, mean, intra 0.2 −0.17 62 74 44 68 52 CORO1A, mean, intraIFITM3, mean, membrane RSAD2, mean, intra 0.7 0.01 83 84 82 88 76CORO1A, mean, intra IFITM3, mean, membrane SDCBP, mean, intra 0.2 −0.1862 77 38 66 52 CORO1A, mean, intra IFITM3, mean, membrane WBC 0.2 −0.1165 81 41 68 57 CORO1A, mean, intra LOC26010, mean, intra Lym(%) 0.5−0.03 76 82 67 80 70 CORO1A, mean, intra LOC26010, mean, intra MAN1C1,mean, intra 0.3 0.07 67 81 45 71 58 CORO1A, mean, intra LOC26010, mean,intra MX1, mean, intra 0.5 0.05 76 81 69 81 69 CORO1A, mean, intraLOC26010, mean, intra Neu(%) 0.6 0.04 81 89 69 82 79 CORO1A, mean, intraLOC26010, mean, intra NPM1, mean, intra 0.2 −0.01 63 75 44 68 53 CORO1A,mean, intra LOC26010, mean, intra OAS2, mean, intra 0.2 −0.15 60 71 4467 49 CORO1A, mean, intra LOC26010, mean, intra PARP12, mean, intra 0.30 65 76 49 70 56 CORO1A, mean, intra LOC26010, mean, intra PTEN, mean,intra 0.2 −0.03 62 74 44 68 52 CORO1A, mean, intra LOC26010, mean, intraRSAD2, mean, intra 0.6 −0.01 82 84 79 87 76 CORO1A, mean, intraLOC26010, mean, intra SDCBP, mean, intra 0.2 −0.04 62 75 41 67 52CORO1A, mean, intra LOC26010, mean, intra WBC 0.3 0 65 77 46 70 56CORO1A, mean, intra Lym(%) MAN1C1, mean, intra 0.5 −0.05 76 85 61 79 70CORO1A, mean, intra Lym(%) MX1, mean, intra 0.6 0.12 83 87 77 86 79CORO1A, mean, intra Lym(%) Neu(%) 0.5 −0.03 77 79 74 83 69 CORO1A, mean,intra Lym(%) NPM1, mean, intra 0.5 −0.02 76 79 72 81 68 CORO1A, mean,intra Lym(%) OAS2, mean, intra 0.5 0.02 78 82 72 82 72 CORO1A, mean,intra Lym(%) PARP12, mean, intra 0.6 0.06 80 84 74 84 74 CORO1A, mean,intra Lym(%) PTEN, mean, intra 0.5 −0.07 73 74 72 81 64 CORO1A, mean,intra Lym(%) RSAD2, mean, intra 0.7 0.01 83 85 79 87 78 CORO1A, mean,intra Lym(%) SDCBP, mean, intra 0.4 −0.09 73 79 64 77 66 CORO1A, mean,intra Lym(%) WBC 0.5 −0.05 75 84 62 78 71 CORO1A, mean, intra MAN1C1,mean, intra MX1, mean, intra 0.4 −0.08 71 79 58 76 62 CORO1A, mean,intra MAN1C1, mean, intra Neu(%) 0.5 −0.09 76 85 61 79 70 CORO1A, mean,intra MAN1C1, mean, intra NPM1, mean, intra 0.3 0.13 67 81 45 71 58CORO1A, mean, intra MAN1C1, mean, intra OAS2, mean, intra 0.3 −0.04 6677 48 71 56 CORO1A, mean, intra MAN1C1, mean, intra PARP12, mean, intra0.3 0.01 66 77 48 71 56 CORO1A, mean, intra MAN1C1, mean, intra PTEN,mean, intra 0.3 0.14 70 79 55 75 61 CORO1A, mean, intra MAN1C1, mean,intra RSAD2, mean, intra 0.6 −0.05 81 85 74 85 74 CORO1A, mean, intraMAN1C1, mean, intra SDCBP, mean, intra 0.3 0.11 66 77 48 71 56 CORO1A,mean, intra MAN1C1, mean, intra WBC 0.2 −0.04 65 81 39 69 55 CORO1A,mean, intra MX1, mean, intra Neu(%) 0.7 0.1 84 89 77 86 81 CORO1A, mean,intra MX1, mean, intra NPM1, mean, intra 0.4 −0.02 73 79 64 77 66CORO1A, mean, intra MX1, mean, intra OAS2, mean, intra 0.4 −0.04 72 7962 77 65 CORO1A, mean, intra MX1, mean, intra PARP12, mean, intra 0.50.05 76 81 69 81 69 CORO1A, mean, intra MX1, mean, intra PTEN, mean,intra 0.5 0.02 75 82 64 78 69 CORO1A, mean, intra MX1, mean, intraRSAD2, mean, intra 0.6 −0.07 79 79 79 86 70 CORO1A, mean, intra MX1,mean, intra SDCBP, mean, intra 0.5 0 74 80 64 78 68 CORO1A, mean, intraMX1, mean, intra WBC 0.4 −0.02 73 79 64 78 66 CORO1A, mean, intra Neu(%)OAS2, mean, intra 0.6 0.04 81 89 69 82 79 CORO1A, mean, intra Neu(%)PARP12, mean, intra 0.6 0.08 83 89 74 85 81 CORO1A, mean, intra Neu(%)PTEN, mean, intra 0.5 −0.02 78 82 72 82 72 CORO1A, mean, intra Neu(%)RSAD2, mean, intra 0.7 0.02 84 89 77 86 81 CORO1A, mean, intra Neu(%)SDCBP, mean, intra 0.5 −0.03 78 84 69 81 73 CORO1A, mean, intra Neu(%)WBC 0.5 −0.05 77 89 59 77 77 CORO1A, mean, intra NPM1, mean, intraNeu(%) 0.6 −0.01 79 85 69 81 75 CORO1A, mean, intra NPM1, mean, intraOAS2, mean, intra 0.2 −0.12 62 74 44 67 52 CORO1A, mean, intra NPM1,mean, intra PARP12, mean, intra 0.3 0.01 65 72 54 71 55 CORO1A, mean,intra NPM1, mean, intra PTEN, mean, intra 0.2 −0.03 62 75 41 67 52CORO1A, mean, intra NPM1, mean, intra RSAD2, mean, intra 0.6 −0.03 81 8279 86 74 CORO1A, mean, intra NPM1, mean, intra SDCBP, mean, intra 0.20.02 62 75 41 67 52 CORO1A, mean, intra NPM1, mean, intra WBC 0.3 0.0166 80 44 69 59 CORO1A, mean, intra OAS2, mean, intra PARP12, mean, intra0.3 −0.03 65 73 54 71 55 CORO1A, mean, intra OAS2, mean, intra PTEN,mean, intra 0.2 −0.12 62 74 44 68 52 CORO1A, mean, intra OAS2, mean,intra RSAD2, mean, intra 0.6 −0.01 82 84 79 87 76 CORO1A, mean, intraOAS2, mean, intra SDCBP, mean, intra 0.1 −0.16 60 70 44 66 49 CORO1A,mean, intra OAS2, mean, intra WBC 0.3 −0.04 66 81 44 69 59 CORO1A, mean,intra PARP12, mean, intra PTEN, mean, intra 0.3 0.01 65 74 51 71 56CORO1A, mean, intra PARP12, mean, intra RSAD2, mean, intra 0.6 −0.09 7879 77 84 70 CORO1A, mean, intra PARP12, mean, intra SDCBP, mean, intra0.3 0 65 74 51 70 56 CORO1A, mean, intra PARP12, mean, intra WBC 0.30.02 66 79 46 70 58 CORO1A, mean, intra PTEN, mean, intra RSAD2, mean,intra 0.6 −0.05 80 81 79 86 72 CORO1A, mean, intra PTEN, mean, intraSDCBP, mean, intra 0.2 −0.05 61 74 41 66 50 CORO1A, mean, intra PTEN,mean, intra WBC 0.2 −0.01 65 79 44 69 57 CORO1A, mean, intra RSAD2,mean, intra SDCBP, mean, intra 0.6 −0.05 80 80 79 86 72 CORO1A, mean,intra RSAD2, mean, intra WBC 0.6 −0.05 80 82 77 85 73 CORO1A, mean,intra SDCBP, mean, intra WBC 0.3 0.03 67 80 46 70 60 CRP EIF4B, mean,intra IFIT3, mean, intra 0.7 0.11 84 91 74 84 85 CRP EIF4B, mean, intraIFITM1, mean, membrane 0.7 0.15 86 91 79 87 86 CRP EIF4B, mean, intraIFITM3, mean, membrane 0.7 0.13 85 91 76 85 85 CRP EIF4B, mean, intraLOC26010, mean, intra 0.7 0.13 85 90 79 87 83 CRP EIF4B, mean, intraLym(%) 0.8 0.2 89 93 82 89 89 CRP EIF4B, mean, intra MAN1C1, mean, intra0.6 0.05 82 90 70 83 81 CRP EIF4B, mean, intra MX1, mean, intra 0.7 0.1888 93 79 87 88 CRP EIF4B, mean, intra Neu(%) 0.7 0.18 88 95 76 86 91 CRPEIF4B, mean, intra NPM1, mean, intra 0.7 0.09 83 88 76 85 81 CRP EIF4B,mean, intra OAS2, mean, intra 0.7 0.11 84 91 74 84 85 CRP EIF4B, mean,intra PARP12, mean, intra 0.8 0.22 90 95 82 89 91 CRP EIF4B, mean, intraPTEN, mean, intra 0.7 0.15 86 93 76 86 88 CRP EIF4B, mean, intra RSAD2,mean, intra 0.9 0.25 95 95 95 96 92 CRP EIF4B, mean, intra SDCBP, mean,intra 0.6 0.06 82 88 74 83 80 CRP EIF4B, mean, intra WBC 0.7 0.15 86 9179 87 86 CRP IFIT3, mean, intra IFITM1, mean, membrane 0.7 0.15 86 93 7686 88 CRP IFIT3, mean, intra IFITM3, mean, membrane 0.7 0.13 85 91 76 8585 CRP IFIT3, mean, intra LOC26010, mean, intra 0.7 0.18 88 95 76 86 91CRP IFIT3, mean, intra Lym(%) 0.7 0.18 88 91 82 88 86 CRP IFIT3, mean,intra MAN1C1, mean, intra 0.6 0.03 81 88 70 82 78 CRP IFIT3, mean, intraMX1, mean, intra 0.8 0.2 89 93 82 89 89 CRP IFIT3, mean, intra Neu(%)0.8 0.2 89 93 82 89 89 CRP IFIT3, mean, intra NPM1, mean, intra 0.8 0.288 93 82 88 89 CRP IFIT3, mean, intra OAS2, mean, intra 0.7 0.11 84 9174 84 85 CRP IFIT3, mean, intra PARP12, mean, intra 0.7 0.11 84 91 74 8485 CRP IFIT3, mean, intra PTEN, mean, intra 0.7 0.15 86 91 79 87 86 CRPIFIT3, mean, intra RSAD2, mean, intra 0.9 0.21 93 93 92 95 90 CRP IFIT3,mean, intra SDCBP, mean, intra 0.7 0.11 84 88 79 86 81 CRP IFIT3, mean,intra WBC 0.7 0.13 85 91 76 85 85 CRP IFITM1, mean, membrane IFITM3,mean, membrane 0.7 0.11 84 91 74 84 85 CRP IFITM1, mean, membraneLOC26010, mean, intra 0.7 0.13 85 90 79 87 83 CRP IFITM1, mean, membraneLym(%) 0.8 0.26 92 95 87 92 92 CRP IFITM1, mean, membrane MAN1C1, mean,intra 0.6 0.05 82 90 70 83 81 CRP IFITM1, mean, membrane MX1, mean,intra 0.8 0.2 89 93 82 89 89 CRP IFITM1, mean, membrane Neu(%) 0.9 0.2993 97 87 92 94 CRP IFITM1, mean, membrane NPM1, mean, intra 0.7 0.15 8691 79 87 86 CRP IFITM1, mean, membrane OAS2, mean, intra 0.7 0.13 85 9374 84 88 CRP IFITM1, mean, membrane PARP12, mean, intra 0.8 0.2 89 93 8289 89 CRP IFITM1, mean, membrane PTEN, mean, intra 0.7 0.15 86 93 76 8688 CRP IFITM1, mean, membrane RSAD2, mean, intra 0.8 0.19 92 93 89 93 89CRP IFITM1, mean, membrane SDCBP, mean, intra 0.7 0.11 84 91 74 84 85CRP IFITM1, mean, membrane WBC 0.7 0.09 83 90 74 84 82 CRP IFITM3, mean,membrane LOC26010, mean, intra 0.7 0.15 86 93 76 86 88 CRP IFITM3, mean,membrane Lym(%) 0.8 0.24 91 97 82 89 94 CRP IFITM3, mean, membraneMAN1C1, mean, intra 0.6 0.03 81 90 67 81 80 CRP IFITM3, mean, membraneMX1, mean, intra 0.7 0.18 88 93 79 87 88 CRP IFITM3, mean, membraneNeu(%) 0.8 0.22 90 95 82 89 91 CRP IFITM3, mean, membrane NPM1, mean,intra 0.7 0.11 84 89 76 85 83 CRP IFITM3, mean, membrane OAS2, mean,intra 0.7 0.11 84 91 74 84 85 CRP IFITM3, mean, membrane PARP12, mean,intra 0.7 0.18 88 95 76 86 91 CRP IFITM3, mean, membrane PTEN, mean,intra 0.7 0.18 88 95 76 86 91 CRP IFITM3, mean, membrane RSAD2, mean,intra 0.8 0.19 92 90 95 96 86 CRP IFITM3, mean, membrane SDCBP, mean,intra 0.7 0.11 84 89 76 85 83 CRP IFITM3, mean, membrane WBC 0.7 0.11 8490 76 85 83 CRP LOC26010, mean, intra Lym(%) 0.8 0.24 91 95 84 90 91 CRPLOC26010, mean, intra MAN1C1, mean, intra 0.6 0.05 82 92 67 81 83 CRPLOC26010, mean, intra MX1, mean, intra 0.8 0.2 89 93 82 89 89 CRPLOC26010, mean, intra Neu(%) 0.8 0.27 92 97 84 90 94 CRP LOC26010, mean,intra NPM1, mean, intra 0.7 0.13 85 89 79 86 83 CRP LOC26010, mean,intra OAS2, mean, intra 0.7 0.13 85 91 76 85 85 CRP LOC26010, mean,intra PARP12, mean, intra 0.7 0.15 86 91 79 87 86 CRP LOC26010, mean,intra PTEN, mean, intra 0.7 0.18 88 93 79 87 88 CRP LOC26010, mean,intra RSAD2, mean, intra 0.8 0.17 91 90 92 95 85 CRP LOC26010, mean,intra SDCBP, mean, intra 0.7 0.11 84 91 74 84 85 CRP LOC26010, mean,intra WBC 0.7 0.11 84 88 79 86 81 CRP Lym(%) MAN1C1, mean, intra 0.70.14 86 92 77 86 85 CRP Lym(%) MX1, mean, intra 0.8 0.2 89 93 82 89 89CRP Lym(%) Neu(%) 0.7 0.14 86 92 76 86 85 CRP Lym(%) NPM1, mean, intra0.8 0.22 89 93 84 90 89 CRP Lym(%) OAS2, mean, intra 0.8 0.22 90 93 8490 89 CRP Lym(%) PARP12, mean, intra 0.8 0.22 90 95 82 89 91 CRP Lym(%)PTEN, mean, intra 0.8 0.22 90 95 82 89 91 CRP Lym(%) RSAD2, mean, intra0.9 0.21 93 95 89 93 92 CRP Lym(%) SDCBP, mean, intra 0.7 0.18 87 91 8288 86 CRP Lym(%) WBC 0.7 0.11 85 90 76 86 83 CRP MAN1C1, mean, intraMX1, mean, intra 0.7 0.11 85 92 73 85 85 CRP MAN1C1, mean, intra Neu(%)0.7 0.17 87 94 77 87 88 CRP MAN1C1, mean, intra NPM1, mean, intra 0.60.03 81 90 67 81 80 CRP MAN1C1, mean, intra OAS2, mean, intra 0.6 0.0582 90 70 83 81 CRP MAN1C1, mean, intra PARP12, mean, intra 0.6 0.05 8290 70 83 81 CRP MAN1C1, mean, intra PTEN, mean, intra 0.6 0.05 82 90 7083 81 CRP MAN1C1, mean, intra RSAD2, mean, intra 0.9 0.22 94 96 90 94 93CRP MAN1C1, mean, intra SDCBP, mean, intra 0.6 0.03 81 90 67 81 80 CRPMAN1C1, mean, intra WBC 0.6 0.08 83 90 73 84 81 CRP MX1, mean, intraNeu(%) 0.7 0.18 88 93 79 87 88 CRP MX1, mean, intra NPM1, mean, intra0.7 0.15 86 91 79 87 86 CRP MX1, mean, intra OAS2, mean, intra 0.8 0.289 93 82 89 89 CRP MX1, mean, intra PARP12, mean, intra 0.8 0.24 91 9584 90 91 CRP MX1, mean, intra PTEN, mean, intra 0.8 0.22 90 95 82 89 91CRP MX1, mean, intra RSAD2, mean, intra 0.9 0.21 93 93 92 95 90 CRP MX1,mean, intra SDCBP, mean, intra 0.7 0.15 86 91 79 87 86 CRP MX1, mean,intra WBC 0.7 0.13 85 91 76 85 85 CRP Neu(%) OAS2, mean, intra 0.8 0.2290 93 84 90 89 CRP Neu(%) PARP12, mean, intra 0.8 0.24 91 97 82 89 94CRP Neu(%) PTEN, mean, intra 0.8 0.22 90 95 82 89 91 CRP Neu(%) RSAD2,mean, intra 0.9 0.25 95 97 92 95 95 CRP Neu(%) SDCBP, mean, intra 0.70.18 87 91 82 88 86 CRP Neu(%) WBC 0.7 0.11 85 92 74 85 85 CRP NPM1,mean, intra Neu(%) 0.8 0.2 88 93 82 88 89 CRP NPM1, mean, intra OAS2,mean, intra 0.6 0.06 82 88 74 83 80 CRP NPM1, mean, intra PARP12, mean,intra 0.7 0.13 85 91 76 85 85 CRP NPM1, mean, intra PTEN, mean, intra0.7 0.11 84 89 76 85 83 CRP NPM1, mean, intra RSAD2, mean, intra 0.80.17 91 88 95 96 84 CRP NPM1, mean, intra SDCBP, mean, intra 0.6 0.06 8289 71 82 82 CRP NPM1, mean, intra WBC 0.7 0.09 83 88 76 85 81 CRP OAS2,mean, intra PARP12, mean, intra 0.7 0.18 88 93 79 87 88 CRP OAS2, mean,intra PTEN, mean, intra 0.7 0.15 86 93 76 86 88 CRP OAS2, mean, intraRSAD2, mean, intra 0.8 0.19 92 91 92 95 88 CRP OAS2, mean, intra SDCBP,mean, intra 0.7 0.09 83 88 76 85 81 CRP OAS2, mean, intra WBC 0.7 0.1385 90 79 87 83 CRP PARP12, mean, intra PTEN, mean, intra 0.8 0.2 89 9382 89 89 CRP PARP12, mean, intra RSAD2, mean, intra 0.8 0.19 92 93 89 9389 CRP PARP12, mean, intra SDCBP, mean, intra 0.7 0.13 85 88 82 88 82CRP PARP12, mean, intra WBC 0.7 0.15 86 91 79 87 86 CRP PTEN, mean,intra RSAD2, mean, intra 0.8 0.19 92 91 92 95 88 CRP PTEN, mean, intraSDCBP, mean, intra 0.7 0.11 84 88 79 86 81 CRP PTEN, mean, intra WBC 0.80.2 89 93 82 89 89 CRP RSAD2, mean, intra SDCBP, mean, intra 0.8 0.19 9289 95 96 86 CRP RSAD2, mean, intra WBC 0.9 0.25 95 97 92 95 95 CRPSDCBP, mean, intra WBC 0.7 0.11 84 88 79 86 81 EIF4B, mean, intra IFIT3,mean, intra IFITM1, mean, membrane 0.2 −0.1 63 74 46 69 53 EIF4B, mean,intra IFIT3, mean, intra IFITM3, mean, membrane 0.2 −0.12 64 76 46 69 55EIF4B, mean, intra IFIT3, mean, intra LOC26010, mean, intra 0.2 −0.09 6373 49 69 53 EIF4B, mean, intra IFIT3, mean, intra Lym(%) 0.6 0.08 81 8969 82 79 EIF4B, mean, intra IFIT3, mean, intra MAN1C1, mean, intra 0.3 069 81 48 72 60 EIF4B, mean, intra IFIT3, mean, intra MX1, mean, intra0.4 −0.07 70 74 64 77 61 EIF4B, mean, intra IFIT3, mean, intra Neu(%)0.6 0.02 80 85 72 83 76 EIF4B, mean, intra IFIT3, mean, intra NPM1,mean, intra 0.3 0.02 69 79 54 73 62 EIF4B, mean, intra IFIT3, mean,intra OAS2, mean, intra 0.2 −0.08 64 76 46 69 55 EIF4B, mean, intraIFIT3, mean, intra PARP12, mean, intra 0.3 0.03 68 73 62 75 59 EIF4B,mean, intra IFIT3, mean, intra PTEN, mean, intra 0.2 −0.14 61 71 46 6850 EIF4B, mean, intra IFIT3, mean, intra RSAD2, mean, intra 0.6 −0.01 8284 79 87 76 EIF4B, mean, intra IFIT3, mean, intra SDCBP, mean, intra 0.2−0.07 64 72 51 70 54 EIF4B, mean, intra IFIT3, mean, intra WBC 0.3 −0.0366 76 51 71 57 EIF4B, mean, intra IFITM1, mean, membrane IFITM3, mean,membrane 0.3 −0.04 66 67 64 70 61 EIF4B, mean, intra IFITM1, mean,membrane LOC26010, mean, intra 0.2 −0.07 62 61 63 67 57 EIF4B, mean,intra IFITM1, mean, membrane Lym(%) 0.6 0.05 79 76 81 83 74 EIF4B, mean,intra IFITM1, mean, membrane MAN1C1, mean, intra 0.3 −0.03 67 81 45 7158 EIF4B, mean, intra IFITM1, mean, membrane MX1, mean, intra 0.4 −0.0569 65 75 76 64 EIF4B, mean, intra IFITM1, mean, membrane Neu(%) 0.6 0.0681 82 80 83 78 EIF4B, mean, intra IFITM1, mean, membrane NPM1, mean,intra 0.1 −0.24 57 70 36 63 44 EIF4B, mean, intra IFITM1, mean, membraneOAS2, mean, intra 0.3 −0.03 64 63 66 69 59 EIF4B, mean, intra IFITM1,mean, membrane PARP12, mean, intra 0.2 −0.09 63 73 49 69 53 EIF4B, mean,intra IFITM1, mean, membrane PTEN, mean, intra 0.1 −0.17 60 73 41 66 48EIF4B, mean, intra IFITM1, mean, membrane RSAD2, mean, intra 0.6 −0.0878 76 80 82 73 EIF4B, mean, intra IFITM1, mean, membrane SDCBP, mean,intra 0.1 −0.19 60 75 36 65 48 EIF4B, mean, intra IFITM1, mean, membraneWBC 0.3 0.01 66 75 56 68 65 EIF4B, mean, intra IFITM3, mean, membraneLOC26010, mean, intra 0.3 −0.02 66 65 68 71 62 EIF4B, mean, intraIFITM3, mean, membrane Lym(%) 0.6 0.06 79 81 78 82 77 EIF4B, mean, intraIFITM3, mean, membrane MAN1C1, mean, intra 0.3 −0.1 66 79 45 71 56EIF4B, mean, intra IFITM3, mean, membrane MX1, mean, intra 0.5 0 72 6778 79 66 EIF4B, mean, intra IFITM3, mean, membrane Neu(%) 0.6 0.05 81 8576 81 80 EIF4B, mean, intra IFITM3, mean, membrane NPM1, mean, intra 0.1−0.21 60 72 41 66 48 EIF4B, mean, intra IFITM3, mean, membrane OAS2,mean, intra 0.4 0.05 70 72 68 73 67 EIF4B, mean, intra IFITM3, mean,membrane PARP12, mean, intra 0.2 −0.12 64 74 49 70 54 EIF4B, mean, intraIFITM3, mean, membrane PTEN, mean, intra 0.2 −0.15 63 76 44 68 53 EIF4B,mean, intra IFITM3, mean, membrane RSAD2, mean, intra 0.6 −0.01 82 81 8385 78 EIF4B, mean, intra IFITM3, mean, membrane SDCBP, mean, intra 0.2−0.18 62 77 38 66 52 EIF4B, mean, intra IFITM3, mean, membrane WBC 0.40.01 69 75 61 70 67 EIF4B, mean, intra LOC26010, mean, intra Lym(%) 0.50.02 77 78 76 79 75 EIF4B, mean, intra LOC26010, mean, intra MAN1C1,mean, intra 0.3 −0.03 67 79 48 72 58 EIF4B, mean, intra LOC26010, mean,intra MX1, mean, intra 0.5 0.06 75 67 84 83 68 EIF4B, mean, intraLOC26010, mean, intra Neu(%) 0.5 −0.04 76 79 73 77 75 EIF4B, mean, intraLOC26010, mean, intra NPM1, mean, intra 0.2 −0.12 63 79 38 67 54 EIF4B,mean, intra LOC26010, mean, intra OAS2, mean, intra 0.3 −0.02 64 61 6869 60 EIF4B, mean, intra LOC26010, mean, intra PARP12, mean, intra 0.3−0.03 66 74 54 72 57 EIF4B, mean, intra LOC26010, mean, intra PTEN,mean, intra 0.2 −0.13 62 74 44 68 52 EIF4B, mean, intra LOC26010, mean,intra RSAD2, mean, intra 0.6 −0.01 81 79 84 85 78 EIF4B, mean, intraLOC26010, mean, intra SDCBP, mean, intra 0.2 −0.14 62 77 38 66 52 EIF4B,mean, intra LOC26010, mean, intra WBC 0.3 0 66 74 56 66 65 EIF4B, mean,intra Lym(%) MAN1C1, mean, intra 0.6 0.03 80 88 65 81 77 EIF4B, mean,intra Lym(%) MX1, mean, intra 0.6 0.09 81 81 81 83 78 EIF4B, mean, intraLym(%) Neu(%) 0.5 −0.02 77 75 79 81 73 EIF4B, mean, intra Lym(%) NPM1,mean, intra 0.5 0 77 79 74 83 69 EIF4B, mean, intra Lym(%) OAS2, mean,intra 0.6 0.05 78 78 79 81 75 EIF4B, mean, intra Lym(%) PARP12, mean,intra 0.5 0.01 77 79 74 83 69 EIF4B, mean, intra Lym(%) PTEN, mean,intra 0.5 −0.03 75 77 72 81 67 EIF4B, mean, intra Lym(%) RSAD2, mean,intra 0.6 0 82 82 82 84 80 EIF4B, mean, intra Lym(%) SDCBP, mean, intra0.5 −0.06 74 77 69 80 66 EIF4B, mean, intra Lym(%) WBC 0.6 0.03 78 76 7981 74 EIF4B, mean, intra MAN1C1, mean, intra MX1, mean, intra 0.4 −0.0572 81 58 76 64 EIF4B, mean, intra MAN1C1, mean, intra Neu(%) 0.5 −0.0478 90 58 78 78 EIF4B, mean, intra MAN1C1, mean, intra NPM1, mean, intra0.3 0 69 79 52 73 59 EIF4B, mean, intra MAN1C1, mean, intra OAS2, mean,intra 0.3 −0.03 67 81 45 71 58 EIF4B, mean, intra MAN1C1, mean, intraPARP12, mean, intra 0.2 −0.09 64 73 48 70 52 EIF4B, mean, intra MAN1C1,mean, intra PTEN, mean, intra 0.3 0.02 70 83 48 73 63 EIF4B, mean, intraMAN1C1, mean, intra RSAD2, mean, intra 0.6 −0.08 80 85 71 83 73 EIF4B,mean, intra MAN1C1, mean, intra SDCBP, mean, intra 0.3 −0.05 66 77 48 7156 EIF4B, mean, intra MAN1C1, mean, intra WBC 0.3 −0.04 67 83 42 70 59EIF4B, mean, intra MX1, mean, intra Neu(%) 0.6 0.03 80 82 77 81 79EIF4B, mean, intra MX1, mean, intra NPM1, mean, intra 0.4 −0.09 69 72 6476 60 EIF4B, mean, intra MX1, mean, intra OAS2, mean, intra 0.5 0 72 6481 79 66 EIF4B, mean, intra MX1, mean, intra PARP12, mean, intra 0.50.07 77 81 72 82 70 EIF4B, mean, intra MX1, mean, intra PTEN, mean,intra 0.4 −0.08 70 76 62 76 62 EIF4B, mean, intra MX1, mean, intraRSAD2, mean, intra 0.6 −0.07 78 75 82 83 74 EIF4B, mean, intra MX1,mean, intra SDCBP, mean, intra 0.4 −0.07 70 74 64 76 61 EIF4B, mean,intra MX1, mean, intra WBC 0.5 0.04 75 74 76 78 71 EIF4B, mean, intraNeu(%) OAS2, mean, intra 0.6 0.02 79 79 79 81 77 EIF4B, mean, intraNeu(%) PARP12, mean, intra 0.7 0.1 84 89 77 86 81 EIF4B, mean, intraNeu(%) PTEN, mean, intra 0.5 −0.02 78 84 69 81 73 EIF4B, mean, intraNeu(%) RSAD2, mean, intra 0.7 0.05 84 85 84 86 83 EIF4B, mean, intraNeu(%) SDCBP, mean, intra 0.5 −0.05 77 82 69 81 71 EIF4B, mean, intraNeu(%) WBC 0.6 0.06 81 85 77 81 81 EIF4B, mean, intra NPM1, mean, intraNeu(%) 0.6 0.03 81 89 69 82 79 EIF4B, mean, intra NPM1, mean, intraOAS2, mean, intra 0.1 −0.2 59 72 38 65 47 EIF4B, mean, intra NPM1, mean,intra PARP12, mean, intra 0.3 −0.04 65 70 56 72 55 EIF4B, mean, intraNPM1, mean, intra PTEN, mean, intra 0.2 −0.16 61 74 41 66 50 EIF4B,mean, intra NPM1, mean, intra RSAD2, mean, intra 0.6 −0.06 80 82 77 8573 EIF4B, mean, intra NPM1, mean, intra SDCBP, mean, intra 0.2 −0.13 6274 44 67 52 EIF4B, mean, intra NPM1, mean, intra WBC 0.3 −0.01 68 85 4169 64 EIF4B, mean, intra OAS2, mean, intra PARP12, mean, intra 0.3 −0.0266 73 56 73 56 EIF4B, mean, intra OAS2, mean, intra PTEN, mean, intra0.1 −0.21 58 71 38 65 45 EIF4B, mean, intra OAS2, mean, intra RSAD2,mean, intra 0.6 −0.01 81 79 84 85 78 EIF4B, mean, intra OAS2, mean,intra SDCBP, mean, intra 0.2 −0.16 61 75 38 66 50 EIF4B, mean, intraOAS2, mean, intra WBC 0.4 0.04 68 75 60 68 67 EIF4B, mean, intra PARP12,mean, intra PTEN, mean, intra 0.3 −0.03 66 74 54 72 57 EIF4B, mean,intra PARP12, mean, intra RSAD2, mean, intra 0.7 0.03 84 85 82 88 78EIF4B, mean, intra PARP12, mean, intra SDCBP, mean, intra 0.2 −0.07 6472 51 70 54 EIF4B, mean, intra PARP12, mean, intra WBC 0.3 0.02 69 84 4671 64 EIF4B, mean, intra PTEN, mean, intra RSAD2, mean, intra 0.6 −0.0281 81 82 88 73 EIF4B, mean, intra PTEN, mean, intra SDCBP, mean, intra0.2 −0.07 65 77 46 69 56 EIF4B, mean, intra PTEN, mean, intra WBC 0.30.01 69 87 41 70 67 EIF4B, mean, intra RSAD2, mean, intra SDCBP, mean,intra 0.6 −0.07 79 80 77 84 71 EIF4B, mean, intra RSAD2, mean, intra WBC0.6 0 82 79 85 86 78 EIF4B, mean, intra SDCBP, mean, intra WBC 0.2 −0.164 80 38 67 56 IFIT3, mean, intra IFITM1, mean, membrane IFITM3, mean,membrane 0.2 −0.12 64 74 49 70 54 IFIT3, mean, intra IFITM1, mean,membrane LOC26010, mean, intra 0.1 −0.15 59 68 46 67 47 IFIT3, mean,intra IFITM1, mean, membrane Lym(%) 0.5 0.02 78 82 72 82 72 IFIT3, mean,intra IFITM1, mean, membrane MAN1C1, mean, intra 0.2 −0.06 66 85 35 6958 IFIT3, mean, intra IFITM1, mean, membrane MX1, mean, intra 0.4 −0.0571 76 64 77 63 IFIT3, mean, intra IFITM1, mean, membrane Neu(%) 0.6 0.0481 89 69 82 79 IFIT3, mean, intra IFITM1, mean, membrane NPM1, mean,intra 0.3 0.01 67 75 54 72 58 IFIT3, mean, intra IFITM1, mean, membraneOAS2, mean, intra 0.2 −0.1 62 71 49 69 51 IFIT3, mean, intra IFITM1,mean, membrane PARP12, mean, intra 0.4 0.13 72 76 67 78 63 IFIT3, mean,intra IFITM1, mean, membrane PTEN, mean, intra 0.2 −0.08 62 69 51 69 51IFIT3, mean, intra IFITM1, mean, membrane RSAD2, mean, intra 0.6 −0.0580 81 79 86 72 IFIT3, mean, intra IFITM1, mean, membrane SDCBP, mean,intra 0.2 −0.12 61 70 46 67 50 IFIT3, mean, intra IFITM1, mean, membraneWBC 0.2 −0.09 63 76 44 68 53 IFIT3, mean, intra IFITM3, mean, membraneLOC26010, mean, intra 0.2 −0.17 61 69 49 68 50 IFIT3, mean, intraIFITM3, mean, membrane Lym(%) 0.6 0.04 79 84 72 83 74 IFIT3, mean, intraIFITM3, mean, membrane MAN1C1, mean, intra 0.3 −0.09 67 85 39 70 60IFIT3, mean, intra IFITM3, mean, membrane MX1, mean, intra 0.4 −0.06 7073 67 78 60 IFIT3, mean, intra IFITM3, mean, membrane Neu(%) 0.6 0.02 8085 72 83 76 IFIT3, mean, intra IFITM3, mean, membrane NPM1, mean, intra0.3 −0.05 67 75 54 72 58 IFIT3, mean, intra IFITM3, mean, membrane OAS2,mean, intra 0.2 −0.12 64 74 49 70 54 IFIT3, mean, intra IFITM3, mean,membrane PARP12, mean, intra 0.4 0.09 73 76 69 80 64 IFIT3, mean, intraIFITM3, mean, membrane PTEN, mean, intra 0.2 −0.14 62 69 51 69 51 IFIT3,mean, intra IFITM3, mean, membrane RSAD2, mean, intra 0.6 −0.03 81 82 7986 74 IFIT3, mean, intra IFITM3, mean, membrane SDCBP, mean, intra 0.2−0.14 63 72 49 69 53 IFIT3, mean, intra IFITM3, mean, membrane WBC 0.3−0.07 66 76 51 71 57 IFIT3, mean, intra LOC26010, mean, intra Lym(%) 0.60.04 79 85 69 82 75 IFIT3, mean, intra LOC26010, mean, intra MAN1C1,mean, intra 0.2 −0.04 65 83 35 68 55 IFIT3, mean, intra LOC26010, mean,intra MX1, mean, intra 0.4 −0.04 71 73 69 79 61 IFIT3, mean, intraLOC26010, mean, intra Neu(%) 0.6 0.06 82 89 72 83 80 IFIT3, mean, intraLOC26010, mean, intra NPM1, mean, intra 0.4 0.1 69 75 59 74 61 IFIT3,mean, intra LOC26010, mean, intra OAS2, mean, intra 0.2 −0.14 60 69 4667 49 IFIT3, mean, intra LOC26010, mean, intra PARP12, mean, intra 0.30.09 68 73 62 75 59 IFIT3, mean, intra LOC26010, mean, intra PTEN, mean,intra 0.2 −0.09 60 69 46 67 49 IFIT3, mean, intra LOC26010, mean, intraRSAD2, mean, intra 0.6 −0.05 80 81 79 86 72 IFIT3, mean, intra LOC26010,mean, intra SDCBP, mean, intra 0.2 −0.07 61 69 49 68 50 IFIT3, mean,intra LOC26010, mean, intra WBC 0.3 0.03 66 76 51 71 57 IFIT3, mean,intra Lym(%) MAN1C1, mean, intra 0.5 −0.02 77 88 58 78 75 IFIT3, mean,intra Lym(%) MX1, mean, intra 0.6 0.1 82 87 74 84 78 IFIT3, mean, intraLym(%) Neu(%) 0.6 0 79 85 69 82 75 IFIT3, mean, intra Lym(%) NPM1, mean,intra 0.6 0.05 80 87 69 82 77 IFIT3, mean, intra Lym(%) OAS2, mean,intra 0.5 0.02 78 84 69 81 73 IFIT3, mean, intra Lym(%) PARP12, mean,intra 0.6 0.06 80 85 72 83 76 IFIT3, mean, intra Lym(%) PTEN, mean,intra 0.5 0.02 78 84 69 81 73 IFIT3, mean, intra Lym(%) RSAD2, mean,intra 0.7 0.01 83 85 79 87 78 IFIT3, mean, intra Lym(%) SDCBP, mean,intra 0.6 0.03 79 85 69 81 75 IFIT3, mean, intra Lym(%) WBC 0.6 0.05 8089 67 81 79 IFIT3, mean, intra MAN1C1, mean, intra MX1, mean, intra 0.4−0.02 73 79 65 79 65 IFIT3, mean, intra MAN1C1, mean, intra Neu(%) 0.5−0.06 77 88 58 78 75 IFIT3, mean, intra MAN1C1, mean, intra NPM1, mean,intra 0.3 0.03 67 79 48 72 58 IFIT3, mean, intra MAN1C1, mean, intraOAS2, mean, intra 0.1 −0.17 61 77 35 67 48 IFIT3, mean, intra MAN1C1,mean, intra PARP12, mean, intra 0.2 −0.04 64 75 45 70 52 IFIT3, mean,intra MAN1C1, mean, intra PTEN, mean, intra 0.3 0.06 69 81 48 72 60IFIT3, mean, intra MAN1C1, mean, intra RSAD2, mean, intra 0.5 −0.11 7885 68 81 72 IFIT3, mean, intra MAN1C1, mean, intra SDCBP, mean, intra0.4 0.11 71 85 48 73 65 IFIT3, mean, intra MAN1C1, mean, intra WBC 0.30.01 67 87 35 69 61 IFIT3, mean, intra MX1, mean, intra Neu(%) 0.6 0.0481 85 74 84 76 IFIT3, mean, intra MX1, mean, intra NPM1, mean, intra 0.4−0.09 69 72 64 76 60 IFIT3, mean, intra MX1, mean, intra OAS2, mean,intra 0.4 −0.05 71 76 64 77 63 IFIT3, mean, intra MX1, mean, intraPARP12, mean, intra 0.5 0.08 77 79 74 83 69 IFIT3, mean, intra MX1,mean, intra PTEN, mean, intra 0.4 −0.09 69 74 62 75 60 IFIT3, mean,intra MX1, mean, intra RSAD2, mean, intra 0.6 −0.01 82 84 79 87 76IFIT3, mean, intra MX1, mean, intra SDCBP, mean, intra 0.4 −0.07 70 7464 76 61 IFIT3, mean, intra MX1, mean, intra WBC 0.5 0.02 75 82 64 78 69IFIT3, mean, intra Neu(%) OAS2, mean, intra 0.6 0.04 81 87 72 83 78IFIT3, mean, intra Neu(%) PARP12, mean, intra 0.6 0.02 80 85 72 83 76IFIT3, mean, intra Neu(%) PTEN, mean, intra 0.6 0.06 82 89 72 83 80IFIT3, mean, intra Neu(%) RSAD2, mean, intra 0.6 0 83 87 77 86 79 IFIT3,mean, intra Neu(%) SDCBP, mean, intra 0.5 −0.03 78 84 69 81 73 IFIT3,mean, intra Neu(%) WBC 0.6 0.01 80 89 67 81 79 IFIT3, mean, intra NPM1,mean, intra Neu(%) 0.6 0.06 82 89 72 83 80 IFIT3, mean, intra NPM1,mean, intra OAS2, mean, intra 0.2 −0.07 64 74 49 69 54 IFIT3, mean,intra NPM1, mean, intra PARP12, mean, intra 0.4 0.13 70 74 64 76 61IFIT3, mean, intra NPM1, mean, intra PTEN, mean, intra 0.3 0 65 74 51 7056 IFIT3, mean, intra NPM1, mean, intra RSAD2, mean, intra 0.6 −0.05 8080 79 86 72 IFIT3, mean, intra NPM1, mean, intra SDCBP, mean, intra 0.30.09 69 77 56 73 61 IFIT3, mean, intra NPM1, mean, intra WBC 0.4 0.14 7285 51 73 69 IFIT3, mean, intra OAS2, mean, intra PARP12, mean, intra 0.40.06 69 74 62 75 60 IFIT3, mean, intra OAS2, mean, intra PTEN, mean,intra 0.2 −0.08 63 71 51 70 53 IFIT3, mean, intra OAS2, mean, intraRSAD2, mean, intra 0.6 −0.03 81 82 79 86 74 IFIT3, mean, intra OAS2,mean, intra SDCBP, mean, intra 0.2 −0.14 61 72 44 67 50 IFIT3, mean,intra OAS2, mean, intra WBC 0.3 0 67 77 51 72 59 IFIT3, mean, intraPARP12, mean, intra PTEN, mean, intra 0.3 0.01 64 69 56 72 54 IFIT3,mean, intra PARP12, mean, intra RSAD2, mean, intra 0.6 −0.02 82 85 77 8577 IFIT3, mean, intra PARP12, mean, intra SDCBP, mean, intra 0.3 0.05 6774 56 73 58 IFIT3, mean, intra PARP12, mean, intra WBC 0.4 0.11 70 79 5674 63 IFIT3, mean, intra PTEN, mean, intra RSAD2, mean, intra 0.6 −0.0580 81 79 86 72 IFIT3, mean, intra PTEN, mean, intra SDCBP, mean, intra0.3 0.02 66 75 51 71 57 IFIT3, mean, intra PTEN, mean, intra WBC 0.30.04 67 79 49 71 59 IFIT3, mean, intra RSAD2, mean, intra SDCBP, mean,intra 0.6 −0.05 80 80 79 86 72 IFIT3, mean, intra RSAD2, mean, intra WBC0.6 −0.03 81 82 79 86 74 IFIT3, mean, intra SDCBP, mean, intra WBC 0.30.01 66 79 46 70 58 IFITM1, mean, membrane IFITM3, mean, membraneLOC26010, mean, intra 0.3 −0.06 64 60 69 70 59 IFITM1, mean, membraneIFITM3, mean, membrane Lym(%) 0.5 −0.06 73 75 71 76 70 IFITM1, mean,membrane IFITM3, mean, membrane MAN1C1, mean, intra 0.1 −0.25 61 83 2665 47 IFITM1, mean, membrane IFITM3, mean, membrane MX1, mean, intra 0.4−0.03 71 69 73 76 66 IFITM1, mean, membrane IFITM3, mean, membraneNeu(%) 0.6 0.01 79 81 76 81 76 IFITM1, mean, membrane IFITM3, mean,membrane NPM1, mean, intra 0.1 −0.22 60 74 38 65 48 IFITM1, mean,membrane IFITM3, mean, membrane OAS2, mean, intra 0.4 0 67 65 69 72 62IFITM1, mean, membrane IFITM3, mean, membrane PARP12, mean, intra 0.2−0.14 63 74 46 69 53 IFITM1, mean, membrane IFITM3, mean, membrane PTEN,mean, intra 0.2 −0.19 61 74 41 67 50 IFITM1, mean, membrane IFITM3,mean, membrane RSAD2, mean, intra 0.5 −0.11 76 75 78 81 72 IFITM1, mean,membrane IFITM3, mean, membrane SDCBP, mean, intra 0 −0.31 57 75 28 6242 IFITM1, mean, membrane IFITM3, mean, membrane WBC 0.4 0.04 70 78 6171 69 IFITM1, mean, membrane LOC26010, mean, intra Lym(%) 0.6 0.05 79 8176 81 76 IFITM1, mean, membrane LOC26010, mean, intra MAN1C1, mean,intra 0.2 −0.11 64 81 35 68 52 IFITM1, mean, membrane LOC26010, mean,intra MX1, mean, intra 0.5 0.04 74 71 78 80 69 IFITM1, mean, membraneLOC26010, mean, intra Neu(%) 0.5 −0.02 77 78 76 80 74 IFITM1, mean,membrane LOC26010, mean, intra NPM1, mean, intra 0.1 −0.19 59 74 36 6447 IFITM1, mean, membrane LOC26010, mean, intra OAS2, mean, intra 0.3 065 64 66 70 60 IFITM1, mean, membrane LOC26010, mean, intra PARP12,mean, intra 0.2 −0.09 63 76 44 68 53 IFITM1, mean, membrane LOC26010,mean, intra PTEN, mean, intra 0.1 −0.17 59 73 38 65 47 IFITM1, mean,membrane LOC26010, mean, intra RSAD2, mean, intra 0.6 −0.07 79 78 80 8275 IFITM1, mean, membrane LOC26010, mean, intra SDCBP, mean, intra 0.2−0.1 63 79 38 67 54 IFITM1, mean, membrane LOC26010, mean, intra WBC 0.3−0.03 63 69 56 66 60 IFITM1, mean, membrane Lym(%) MAN1C1, mean, intra0.4 −0.1 73 83 58 77 67 IFITM1, mean, membrane Lym(%) MX1, mean, intra0.7 0.17 85 88 81 85 84 IFITM1, mean, membrane Lym(%) Neu(%) 0.5 −0.0277 78 76 80 74 IFITM1, mean, membrane Lym(%) NPM1, mean, intra 0.5 −0.0276 79 72 81 68 IFITM1, mean, membrane Lym(%) OAS2, mean, intra 0.6 0.0579 79 78 81 75 IFITM1, mean, membrane Lym(%) PARP12, mean, intra 0.60.04 79 82 74 84 73 IFITM1, mean, membrane Lym(%) PTEN, mean, intra 0.5−0.05 74 76 72 81 65 IFITM1, mean, membrane Lym(%) RSAD2, mean, intra0.6 −0.02 81 82 80 83 78 IFITM1, mean, membrane Lym(%) SDCBP, mean,intra 0.4 −0.08 73 77 67 78 65 IFITM1, mean, membrane Lym(%) WBC 0.60.05 79 82 75 80 77 IFITM1, mean, membrane MAN1C1, mean, intra MX1,mean, intra 0.3 −0.13 69 77 55 74 59 IFITM1, mean, membrane MAN1C1,mean, intra Neu(%) 0.5 −0.11 75 85 58 77 69 IFITM1, mean, membraneMAN1C1, mean, intra NPM1, mean, intra 0.2 −0.12 63 77 39 68 50 IFITM1,mean, membrane MAN1C1, mean, intra OAS2, mean, intra 0.1 −0.18 61 79 3266 48 IFITM1, mean, membrane MAN1C1, mean, intra PARP12, mean, intra 0.2−0.12 63 77 39 68 50 IFITM1, mean, membrane MAN1C1, mean, intra PTEN,mean, intra 0.3 0.02 69 81 48 72 60 IFITM1, mean, membrane MAN1C1, mean,intra RSAD2, mean, intra 0.6 0 83 87 77 87 77 IFITM1, mean, membraneMAN1C1, mean, intra SDCBP, mean, intra 0.3 0.01 69 83 45 72 61 IFITM1,mean, membrane MAN1C1, mean, intra WBC 0.2 −0.1 65 87 29 67 56 IFITM1,mean, membrane MX1, mean, intra Neu(%) 0.6 0.07 82 85 78 82 81 IFITM1,mean, membrane MX1, mean, intra NPM1, mean, intra 0.3 −0.12 68 72 62 7559 IFITM1, mean, membrane MX1, mean, intra OAS2, mean, intra 0.4 −0.0271 67 76 77 65 IFITM1, mean, membrane MX1, mean, intra PARP12, mean,intra 0.5 0.03 75 81 67 79 68 IFITM1, mean, membrane MX1, mean, intraPTEN, mean, intra 0.4 −0.04 72 81 59 76 66 IFITM1, mean, membrane MX1,mean, intra RSAD2, mean, intra 0.5 −0.11 76 74 80 82 71 IFITM1, mean,membrane MX1, mean, intra SDCBP, mean, intra 0.4 −0.08 70 75 62 75 62IFITM1, mean, membrane MX1, mean, intra WBC 0.5 0.01 73 69 76 78 67IFITM1, mean, membrane Neu(%) OAS2, mean, intra 0.5 −0.04 76 78 75 79 73IFITM1, mean, membrane Neu(%) PARP12, mean, intra 0.6 0.02 80 85 72 8376 IFITM1, mean, membrane Neu(%) PTEN, mean, intra 0.5 −0.02 78 82 72 8272 IFITM1, mean, membrane Neu(%) RSAD2, mean, intra 0.7 0.01 82 83 81 8580 IFITM1, mean, membrane Neu(%) SDCBP, mean, intra 0.5 −0.09 75 80 6779 68 IFITM1, mean, membrane Neu(%) WBC 0.6 0.01 79 81 76 81 76 IFITM1,mean, membrane NPM1, mean, intra Neu(%) 0.6 −0.01 79 85 69 81 75 IFITM1,mean, membrane NPM1, mean, intra OAS2, mean, intra 0 −0.28 55 69 33 6241 IFITM1, mean, membrane NPM1, mean, intra PARP12, mean, intra 0.2−0.07 63 70 51 69 53 IFITM1, mean, membrane NPM1, mean, intra PTEN,mean, intra 0.2 −0.14 61 74 41 66 50 IFITM1, mean, membrane NPM1, mean,intra RSAD2, mean, intra 0.6 −0.01 82 82 82 88 74 IFITM1, mean, membraneNPM1, mean, intra SDCBP, mean, intra 0.1 −0.2 59 75 33 64 46 IFITM1,mean, membrane NPM1, mean, intra WBC 0.3 0.03 69 85 44 70 65 IFITM1,mean, membrane OAS2, mean, intra PARP12, mean, intra 0.2 −0.08 63 73 4969 53 IFITM1, mean, membrane OAS2, mean, intra PTEN, mean, intra 0.1−0.16 60 73 41 66 48 IFITM1, mean, membrane OAS2, mean, intra RSAD2,mean, intra 0.6 −0.02 81 81 81 84 77 IFITM1, mean, membrane OAS2, mean,intra SDCBP, mean, intra 0.1 −0.25 57 74 31 63 43 IFITM1, mean, membraneOAS2, mean, intra WBC 0.3 −0.01 65 72 56 67 62 IFITM1, mean, membranePARP12, mean, intra PTEN, mean, intra 0.2 −0.09 62 71 49 69 51 IFITM1,mean, membrane PARP12, mean, intra RSAD2, mean, intra 0.7 0.03 84 87 7987 79 IFITM1, mean, membrane PARP12, mean, intra SDCBP, mean, intra 0.1−0.15 60 70 44 66 49 IFITM1, mean, membrane PARP12, mean, intra WBC 0.30.02 68 82 46 71 62 IFITM1, mean, membrane PTEN, mean, intra RSAD2,mean, intra 0.6 −0.03 81 82 79 86 74 IFITM1, mean, membrane PTEN, mean,intra SDCBP, mean, intra 0.3 −0.04 65 75 49 70 56 IFITM1, mean, membranePTEN, mean, intra WBC 0.3 0.03 69 87 41 70 67 IFITM1, mean, membraneRSAD2, mean, intra SDCBP, mean, intra 0.6 −0.03 81 82 79 86 74 IFITM1,mean, membrane RSAD2, mean, intra WBC 0.6 −0.05 79 76 83 85 74 IFITM1,mean, membrane SDCBP, mean, intra WBC 0.3 −0.02 67 84 41 69 62 IFITM3,mean, membrane LOC26010, mean, intra Lym(%) 0.5 −0.05 74 78 69 76 72IFITM3, mean, membrane LOC26010, mean, intra MAN1C1, mean, intra 0.2−0.14 65 83 35 68 55 IFITM3, mean, membrane LOC26010, mean, intra MX1,mean, intra 0.5 0.01 73 69 76 78 67 IFITM3, mean, membrane LOC26010,mean, intra Neu(%) 0.6 −0.01 78 82 73 79 77 IFITM3, mean, membraneLOC26010, mean, intra NPM1, mean, intra 0.1 −0.23 60 75 36 65 48 IFITM3,mean, membrane LOC26010, mean, intra OAS2, mean, intra 0.4 0.01 68 65 7173 63 IFITM3, mean, membrane LOC26010, mean, intra PARP12, mean, intra0.2 −0.14 63 74 46 69 53 IFITM3, mean, membrane LOC26010, mean, intraPTEN, mean, intra 0.1 −0.23 59 71 41 66 47 IFITM3, mean, membraneLOC26010, mean, intra RSAD2, mean, intra 0.6 −0.02 81 79 83 85 77IFITM3, mean, membrane LOC26010, mean, intra SDCBP, mean, intra 0.2−0.17 63 80 36 66 54 IFITM3, mean, membrane LOC26010, mean, intra WBC0.3 −0.06 65 69 59 68 61 IFITM3, mean, membrane Lym(%) MAN1C1, mean,intra 0.4 −0.1 73 83 58 77 67 IFITM3, mean, membrane Lym(%) MX1, mean,intra 0.6 0.11 82 83 80 83 80 IFITM3, mean, membrane Lym(%) Neu(%) 0.5−0.08 74 76 71 76 71 IFITM3, mean, membrane Lym(%) NPM1, mean, intra 0.5−0.05 75 80 67 79 68 IFITM3, mean, membrane Lym(%) OAS2, mean, intra 0.60.05 79 79 78 81 75 IFITM3, mean, membrane Lym(%) PARP12, mean, intra0.5 0 77 82 69 81 71 IFITM3, mean, membrane Lym(%) PTEN, mean, intra 0.4−0.12 71 74 67 78 62 IFITM3, mean, membrane Lym(%) RSAD2, mean, intra0.6 −0.02 81 81 81 84 77 IFITM3, mean, membrane Lym(%) SDCBP, mean,intra 0.5 −0.04 75 79 69 80 68 IFITM3, mean, membrane Lym(%) WBC 0.5−0.03 75 78 71 77 72 IFITM3, mean, membrane MAN1C1, mean, intra MX1,mean, intra 0.4 −0.09 70 75 61 76 59 IFITM3, mean, membrane MAN1C1,mean, intra Neu(%) 0.5 −0.06 77 88 58 78 75 IFITM3, mean, membraneMAN1C1, mean, intra NPM1, mean, intra 0.1 −0.21 61 75 39 67 48 IFITM3,mean, membrane MAN1C1, mean, intra OAS2, mean, intra 0.2 −0.19 63 79 3567 50 IFITM3, mean, membrane MAN1C1, mean, intra PARP12, mean, intra 0.1−0.24 59 69 42 67 45 IFITM3, mean, membrane MAN1C1, mean, intra PTEN,mean, intra 0.3 −0.07 67 79 48 72 58 IFITM3, mean, membrane MAN1C1,mean, intra RSAD2, mean, intra 0.6 −0.05 81 85 74 85 74 IFITM3, mean,membrane MAN1C1, mean, intra SDCBP, mean, intra 0.3 −0.1 66 81 42 70 57IFITM3, mean, membrane MAN1C1, mean, intra WBC 0.2 −0.13 66 88 29 68 60IFITM3, mean, membrane MX1, mean, intra Neu(%) 0.6 0.02 79 83 75 80 79IFITM3, mean, membrane MX1, mean, intra NPM1, mean, intra 0.4 −0.03 7274 69 79 63 IFITM3, mean, membrane MX1, mean, intra OAS2, mean, intra0.4 −0.06 69 67 73 75 64 IFITM3, mean, membrane MX1, mean, intra PARP12,mean, intra 0.5 0.01 74 77 69 80 66 IFITM3, mean, membrane MX1, mean,intra PTEN, mean, intra 0.4 −0.07 70 74 64 77 61 IFITM3, mean, membraneMX1, mean, intra RSAD2, mean, intra 0.6 −0.05 79 78 81 84 75 IFITM3,mean, membrane MX1, mean, intra SDCBP, mean, intra 0.5 0.02 74 75 72 8165 IFITM3, mean, membrane MX1, mean, intra WBC 0.4 −0.05 70 69 71 75 66IFITM3, mean, membrane Neu(%) OAS2, mean, intra 0.5 −0.02 77 79 75 79 75IFITM3, mean, membrane Neu(%) PARP12, mean, intra 0.6 0.04 81 87 72 8378 IFITM3, mean, membrane Neu(%) PTEN, mean, intra 0.5 −0.03 78 85 67 8074 IFITM3, mean, membrane Neu(%) RSAD2, mean, intra 0.6 0 82 85 80 84 81IFITM3, mean, membrane Neu(%) SDCBP, mean, intra 0.5 −0.05 77 82 69 8171 IFITM3, mean, membrane Neu(%) WBC 0.6 0.01 79 83 73 79 78 IFITM3,mean, membrane NPM1, mean, intra Neu(%) 0.6 0.01 80 89 67 81 79 IFITM3,mean, membrane NPM1, mean, intra OAS2, mean, intra 0.1 −0.29 57 72 33 6343 IFITM3, mean, membrane NPM1, mean, intra PARP12, mean, intra 0.2−0.17 61 67 51 68 50 IFITM3, mean, membrane NPM1, mean, intra PTEN,mean, intra 0.1 −0.23 59 70 41 65 47 IFITM3, mean, membrane NPM1, mean,intra RSAD2, mean, intra 0.6 −0.01 82 84 79 86 76 IFITM3, mean, membraneNPM1, mean, intra SDCBP, mean, intra 0.1 −0.23 60 75 36 65 48 IFITM3,mean, membrane NPM1, mean, intra WBC 0.3 −0.03 69 84 46 71 64 IFITM3,mean, membrane OAS2, mean, intra PARP12, mean, intra 0.2 −0.15 62 71 4969 51 IFITM3, mean, membrane OAS2, mean, intra PTEN, mean, intra 0.1−0.21 60 73 41 66 48 IFITM3, mean, membrane OAS2, mean, intra RSAD2,mean, intra 0.6 −0.02 81 79 83 85 77 IFITM3, mean, membrane OAS2, mean,intra SDCBP, mean, intra 0 −0.34 55 70 31 61 40 IFITM3, mean, membraneOAS2, mean, intra WBC 0.3 −0.02 67 74 59 69 65 IFITM3, mean, membranePARP12, mean, intra PTEN, mean, intra 0.2 −0.14 63 74 46 69 53 IFITM3,mean, membrane PARP12, mean, intra RSAD2, mean, intra 0.7 0.01 83 85 7987 78 IFITM3, mean, membrane PARP12, mean, intra SDCBP, mean, intra 0.1−0.22 59 67 46 66 47 IFITM3, mean, membrane PARP12, mean, intra WBC 0.3−0.04 68 81 49 71 61 IFITM3, mean, membrane PTEN, mean, intra RSAD2,mean, intra 0.7 0.01 83 85 79 87 78 IFITM3, mean, membrane PTEN, mean,intra SDCBP, mean, intra 0.2 −0.14 63 74 46 68 53 IFITM3, mean, membranePTEN, mean, intra WBC 0.3 −0.07 67 82 44 70 61 IFITM3, mean, membraneRSAD2, mean, intra SDCBP, mean, intra 0.6 −0.01 82 84 79 86 76 IFITM3,mean, membrane RSAD2, mean, intra WBC 0.6 0 82 79 85 86 77 IFITM3, mean,membrane SDCBP, mean, intra WBC 0.2 −0.12 65 80 41 68 57 LOC26010, mean,intra Lym(%) MAN1C1, mean, intra 0.4 −0.1 73 83 58 77 67 LOC26010, mean,intra Lym(%) MX1, mean, intra 0.6 0.11 81 82 81 83 79 LOC26010, mean,intra Lym(%) Neu(%) 0.5 −0.05 75 74 77 79 72 LOC26010, mean, intraLym(%) NPM1, mean, intra 0.5 0.01 78 84 69 81 73 LOC26010, mean, intraLym(%) OAS2, mean, intra 0.6 0.03 78 76 79 81 74 LOC26010, mean, intraLym(%) PARP12, mean, intra 0.6 0.06 80 85 72 83 76 LOC26010, mean, intraLym(%) PTEN, mean, intra 0.5 −0.03 75 77 72 81 67 LOC26010, mean, intraLym(%) RSAD2, mean, intra 0.6 0 82 83 81 83 81 LOC26010, mean, intraLym(%) SDCBP, mean, intra 0.5 −0.07 74 79 67 79 67 LOC26010, mean, intraLym(%) WBC 0.5 0 76 78 74 78 74 LOC26010, mean, intra MAN1C1, mean,intra MX1, mean, intra 0.4 −0.1 70 77 58 75 60 LOC26010, mean, intraMAN1C1, mean, intra Neu(%) 0.5 −0.06 77 87 61 79 73 LOC26010, mean,intra MAN1C1, mean, intra NPM1, mean, intra 0.2 −0.04 63 77 39 68 50LOC26010, mean, intra MAN1C1, mean, intra OAS2, mean, intra 0.2 −0.12 6481 35 68 52 LOC26010, mean, intra MAN1C1, mean, intra PARP12, mean,intra 0.2 −0.09 61 73 42 68 48 LOC26010, mean, intra MAN1C1, mean, intraPTEN, mean, intra 0.2 0.02 65 77 45 70 54 LOC26010, mean, intra MAN1C1,mean, intra RSAD2, mean, intra 0.6 −0.06 81 87 71 83 76 LOC26010, mean,intra MAN1C1, mean, intra SDCBP, mean, intra 0.2 0 65 81 39 69 55LOC26010, mean, intra MAN1C1, mean, intra WBC 0.3 0.04 69 87 39 70 63LOC26010, mean, intra MX1, mean, intra Neu(%) 0.6 0.02 79 81 77 81 77LOC26010, mean, intra MX1, mean, intra NPM1, mean, intra 0.4 −0.08 69 7067 77 59 LOC26010, mean, intra MX1, mean, intra OAS2, mean, intra 0.5 072 68 77 78 68 LOC26010, mean, intra MX1, mean, intra PARP12, mean,intra 0.5 0.08 77 79 74 83 69 LOC26010, mean, intra MX1, mean, intraPTEN, mean, intra 0.4 −0.03 72 76 67 78 63 LOC26010, mean, intra MX1,mean, intra RSAD2, mean, intra 0.6 −0.04 80 76 84 85 75 LOC26010, mean,intra MX1, mean, intra SDCBP, mean, intra 0.4 −0.05 71 74 67 78 62LOC26010, mean, intra MX1, mean, intra WBC 0.4 −0.04 70 68 73 74 66LOC26010, mean, intra Neu(%) OAS2, mean, intra 0.6 0.01 78 78 79 81 75LOC26010, mean, intra Neu(%) PARP12, mean, intra 0.6 0.06 82 87 74 84 78LOC26010, mean, intra Neu(%) PTEN, mean, intra 0.6 0.02 80 87 69 82 77LOC26010, mean, intra Neu(%) RSAD2, mean, intra 0.7 0.03 84 85 82 85 82LOC26010, mean, intra Neu(%) SDCBP, mean, intra 0.5 −0.05 77 82 69 81 71LOC26010, mean, intra Neu(%) WBC 0.6 −0.01 78 82 73 78 78 LOC26010,mean, intra NPM1, mean, intra Neu(%) 0.6 −0.01 79 85 69 81 75 LOC26010,mean, intra NPM1, mean, intra OAS2, mean, intra 0.1 −0.2 59 74 36 64 47LOC26010, mean, intra NPM1, mean, intra PARP12, mean, intra 0.2 −0.07 6167 51 68 50 LOC26010, mean, intra NPM1, mean, intra PTEN, mean, intra0.1 −0.07 60 72 41 66 48 LOC26010, mean, intra NPM1, mean, intra RSAD2,mean, intra 0.6 −0.06 80 82 77 85 73 LOC26010, mean, intra NPM1, mean,intra SDCBP, mean, intra 0.1 −0.1 60 77 33 64 48 LOC26010, mean, intraNPM1, mean, intra WBC 0.4 0.12 71 85 49 72 68 LOC26010, mean, intraOAS2, mean, intra PARP12, mean, intra 0.2 −0.1 62 71 49 69 51 LOC26010,mean, intra OAS2, mean, intra PTEN, mean, intra 0.1 −0.17 59 69 44 66 47LOC26010, mean, intra OAS2, mean, intra RSAD2, mean, intra 0.6 0 82 8184 85 79 LOC26010, mean, intra OAS2, mean, intra SDCBP, mean, intra 0.1−0.21 59 75 33 64 46 LOC26010, mean, intra OAS2, mean, intra WBC 0.30.02 66 75 56 67 66 LOC26010, mean, intra PARP12, mean, intra PTEN,mean, intra 0.2 −0.02 64 76 46 69 55 LOC26010, mean, intra PARP12, mean,intra RSAD2, mean, intra 0.6 −0.02 82 85 77 85 77 LOC26010, mean, intraPARP12, mean, intra SDCBP, mean, intra 0.2 −0.08 61 70 46 67 50LOC26010, mean, intra PARP12, mean, intra WBC 0.3 0.08 69 82 49 72 63LOC26010, mean, intra PTEN, mean, intra RSAD2, mean, intra 0.6 −0.05 8082 77 85 73 LOC26010, mean, intra PTEN, mean, intra SDCBP, mean, intra0.3 0.08 67 79 49 71 59 LOC26010, mean, intra PTEN, mean, intra WBC 0.30.08 69 84 46 71 64 LOC26010, mean, intra RSAD2, mean, intra SDCBP,mean, intra 0.6 −0.03 81 82 79 86 74 LOC26010, mean, intra RSAD2, mean,intra WBC 0.7 0.02 83 82 84 86 80 LOC26010, mean, intra SDCBP, mean,intra WBC 0.3 0 66 82 41 68 59 Lym(%) MAN1C1, mean, intra MX1, mean,intra 0.7 0.14 84 90 74 85 82 Lym(%) MAN1C1, mean, intra Neu(%) 0.4−0.14 73 83 58 77 67 Lym(%) MAN1C1, mean, intra NPM1, mean, intra 0.5−0.07 75 83 61 78 68 Lym(%) MAN1C1, mean, intra OAS2, mean, intra 0.4−0.09 73 81 61 78 66 Lym(%) MAN1C1, mean, intra PARP12, mean, intra 0.4−0.1 73 83 58 77 67 Lym(%) MAN1C1, mean, intra PTEN, mean, intra 0.5−0.07 75 85 58 77 69 Lym(%) MAN1C1, mean, intra RSAD2, mean, intra 0.6−0.02 82 85 77 86 75 Lym(%) MAN1C1, mean, intra SDCBP, mean, intra 0.50.01 78 87 65 80 74 Lym(%) MAN1C1, mean, intra WBC 0.4 −0.11 73 87 52 7570 Lym(%) MX1, mean, intra Neu(%) 0.6 0.06 81 85 77 81 81 Lym(%) MX1,mean, intra NPM1, mean, intra 0.6 0.06 80 84 74 84 74 Lym(%) MX1, mean,intra OAS2, mean, intra 0.6 0.1 81 83 79 82 80 Lym(%) MX1, mean, intraPARP12, mean, intra 0.6 0.1 82 87 74 84 78 Lym(%) MX1, mean, intra PTEN,mean, intra 0.6 0.06 80 85 72 83 76 Lym(%) MX1, mean, intra RSAD2, mean,intra 0.6 0 82 82 82 84 80 Lym(%) MX1, mean, intra SDCBP, mean, intra0.6 0.12 83 87 77 85 79 Lym(%) MX1, mean, intra WBC 0.7 0.15 84 86 81 8483 Lym(%) Neu(%) OAS2, mean, intra 0.6 −0.01 78 78 77 80 75 Lym(%)Neu(%) PARP12, mean, intra 0.6 −0.01 78 81 74 83 71 Lym(%) Neu(%) PTEN,mean, intra 0.5 −0.11 73 74 72 81 64 Lym(%) Neu(%) RSAD2, mean, intra0.6 −0.03 81 81 81 83 78 Lym(%) Neu(%) SDCBP, mean, intra 0.5 −0.08 7579 69 80 68 Lym(%) Neu(%) WBC 0.6 0 78 77 79 82 74 Lym(%) NPM1, mean,intra Neu(%) 0.6 0 79 84 72 82 74 Lym(%) NPM1, mean, intra OAS2, mean,intra 0.5 0.02 78 80 74 83 71 Lym(%) NPM1, mean, intra PARP12, mean,intra 0.6 0.04 79 82 74 83 73 Lym(%) NPM1, mean, intra PTEN, mean, intra0.5 0.02 78 82 72 82 72 Lym(%) NPM1, mean, intra RSAD2, mean, intra 0.70.02 84 87 79 87 79 Lym(%) NPM1, mean, intra SDCBP, mean, intra 0.5−0.06 74 77 69 80 66 Lym(%) NPM1, mean, intra WBC 0.5 0.01 78 87 64 7976 Lym(%) OAS2, mean, intra PARP12, mean, intra 0.5 0 77 81 72 82 70Lym(%) OAS2, mean, intra PTEN, mean, intra 0.6 0.03 78 81 74 83 71Lym(%) OAS2, mean, intra RSAD2, mean, intra 0.6 −0.01 81 81 82 84 78Lym(%) OAS2, mean, intra SDCBP, mean, intra 0.4 −0.08 73 75 69 79 64Lym(%) OAS2, mean, intra WBC 0.6 0.06 79 81 77 81 77 Lym(%) PARP12,mean, intra PTEN, mean, intra 0.6 0.03 78 81 74 83 71 Lym(%) PARP12,mean, intra RSAD2, mean, intra 0.7 0.03 84 87 79 87 79 Lym(%) PARP12,mean, intra SDCBP, mean, intra 0.5 −0.06 74 77 69 80 66 Lym(%) PARP12,mean, intra WBC 0.6 0.08 81 89 69 82 79 Lym(%) PTEN, mean, intra RSAD2,mean, intra 0.7 0.05 85 89 79 87 82 Lym(%) PTEN, mean, intra SDCBP,mean, intra 0.5 −0.06 74 77 69 80 66 Lym(%) PTEN, mean, intra WBC 0.5−0.01 77 85 64 79 74 Lym(%) RSAD2, mean, intra SDCBP, mean, intra 0.6−0.01 82 84 79 86 76 Lym(%) RSAD2, mean, intra WBC 0.6 −0.03 81 84 77 8180 Lym(%) SDCBP, mean, intra WBC 0.5 −0.03 76 84 64 78 71 MAN1C1, mean,intra MX1, mean, intra Neu(%) 0.7 0.1 84 90 74 85 82 MAN1C1, mean, intraMX1, mean, intra NPM1, mean, intra 0.3 −0.12 69 75 58 75 58 MAN1C1,mean, intra MX1, mean, intra OAS2, mean, intra 0.3 −0.12 69 75 58 75 58MAN1C1, mean, intra MX1, mean, intra PARP12, mean, intra 0.5 0.03 76 8365 80 69 MAN1C1, mean, intra MX1, mean, intra PTEN, mean, intra 0.4−0.08 71 81 55 75 63 MAN1C1, mean, intra MX1, mean, intra RSAD2, mean,intra 0.6 −0.05 81 85 74 85 74 MAN1C1, mean, intra MX1, mean, intraSDCBP, mean, intra 0.3 −0.14 67 73 58 75 56 MAN1C1, mean, intra MX1,mean, intra WBC 0.3 −0.11 70 79 55 75 61 MAN1C1, mean, intra Neu(%)OAS2, mean, intra 0.5 −0.09 76 85 61 79 70 MAN1C1, mean, intra Neu(%)PARP12, mean, intra 0.5 −0.09 76 85 61 79 70 MAN1C1, mean, intra Neu(%)PTEN, mean, intra 0.5 −0.09 76 85 61 79 70 MAN1C1, mean, intra Neu(%)RSAD2, mean, intra 0.6 −0.05 81 85 74 85 74 MAN1C1, mean, intra Neu(%)SDCBP, mean, intra 0.6 −0.01 80 88 65 81 77 MAN1C1, mean, intra Neu(%)WBC 0.4 −0.15 73 87 52 75 70 MAN1C1, mean, intra NPM1, mean, intraNeu(%) 0.5 −0.09 76 85 61 79 70 MAN1C1, mean, intra NPM1, mean, intraOAS2, mean, intra 0.2 −0.1 64 77 42 69 52 MAN1C1, mean, intra NPM1,mean, intra PARP12, mean, intra 0.3 0.03 66 73 55 73 55 MAN1C1, mean,intra NPM1, mean, intra PTEN, mean, intra 0.3 0.09 67 77 52 73 57MAN1C1, mean, intra NPM1, mean, intra RSAD2, mean, intra 0.6 −0.05 81 8574 85 74 MAN1C1, mean, intra NPM1, mean, intra SDCBP, mean, intra 0.40.24 71 81 55 75 63 MAN1C1, mean, intra NPM1, mean, intra WBC 0.3 0.0167 85 39 70 60 MAN1C1, mean, intra OAS2, mean, intra PARP12, mean, intra0.2 −0.11 63 73 45 69 50 MAN1C1, mean, intra OAS2, mean, intra PTEN,mean, intra 0.3 −0.04 66 77 48 71 56 MAN1C1, mean, intra OAS2, mean,intra RSAD2, mean, intra 0.6 −0.08 80 85 71 83 73 MAN1C1, mean, intraOAS2, mean, intra SDCBP, mean, intra 0.3 −0.02 67 81 45 71 58 MAN1C1,mean, intra OAS2, mean, intra WBC 0.2 −0.13 64 83 32 67 53 MAN1C1, mean,intra PARP12, mean, intra PTEN, mean, intra 0.2 −0.07 63 75 42 68 50MAN1C1, mean, intra PARP12, mean, intra RSAD2, mean, intra 0.6 −0.07 8081 77 86 71 MAN1C1, mean, intra PARP12, mean, intra SDCBP, mean, intra0.3 0.02 66 75 52 72 55 MAN1C1, mean, intra PARP12, mean, intra WBC 0.2−0.09 63 79 35 67 50 MAN1C1, mean, intra PTEN, mean, intra RSAD2, mean,intra 0.6 −0.05 81 85 74 85 74 MAN1C1, mean, intra PTEN, mean, intraSDCBP, mean, intra 0.2 0.03 65 77 45 70 54 MAN1C1, mean, intra PTEN,mean, intra WBC 0.3 0.04 69 87 39 70 63 MAN1C1, mean, intra RSAD2, mean,intra SDCBP, mean, intra 0.6 −0.03 82 87 74 85 77 MAN1C1, mean, intraRSAD2, mean, intra WBC 0.6 −0.08 80 85 71 83 73 MAN1C1, mean, intraSDCBP, mean, intra WBC 0.2 −0.08 64 83 32 67 53 MX1, mean, intra Neu(%)OAS2, mean, intra 0.6 0.03 80 83 76 80 80 MX1, mean, intra Neu(%)PARP12, mean, intra 0.6 0.04 81 85 74 84 76 MX1, mean, intra Neu(%)PTEN, mean, intra 0.6 0.06 82 87 74 84 78 MX1, mean, intra Neu(%) RSAD2,mean, intra 0.6 −0.03 81 81 81 83 78 MX1, mean, intra Neu(%) SDCBP,mean, intra 0.7 0.1 84 87 79 87 79 MX1, mean, intra Neu(%) WBC 0.6 0.0882 85 79 82 82 MX1, mean, intra NPM1, mean, intra Neu(%) 0.6 0.06 82 8577 85 77 MX1, mean, intra NPM1, mean, intra OAS2, mean, intra 0.3 −0.1168 70 64 75 58 MX1, mean, intra NPM1, mean, intra PARP12, mean, intra0.5 0.03 75 77 72 81 67 MX1, mean, intra NPM1, mean, intra PTEN, mean,intra 0.3 −0.13 67 70 62 74 57 MX1, mean, intra NPM1, mean, intra RSAD2,mean, intra 0.6 −0.01 82 84 79 86 76 MX1, mean, intra NPM1, mean, intraSDCBP, mean, intra 0.4 −0.09 69 72 64 76 60 MX1, mean, intra NPM1, mean,intra WBC 0.5 0.02 75 82 64 78 69 MX1, mean, intra OAS2, mean, intraPARP12, mean, intra 0.5 0.02 74 76 72 81 65 MX1, mean, intra OAS2, mean,intra PTEN, mean, intra 0.4 −0.02 73 81 62 77 67 MX1, mean, intra OAS2,mean, intra RSAD2, mean, intra 0.6 −0.06 79 76 82 83 75 MX1, mean, intraOAS2, mean, intra SDCBP, mean, intra 0.4 −0.04 72 77 64 77 64 MX1, mean,intra OAS2, mean, intra WBC 0.4 −0.01 72 68 76 77 67 MX1, mean, intraPARP12, mean, intra PTEN, mean, intra 0.5 0.03 75 79 69 80 68 MX1, mean,intra PARP12, mean, intra RSAD2, mean, intra 0.6 −0.03 81 82 79 86 74MX1, mean, intra PARP12, mean, intra SDCBP, mean, intra 0.5 0.07 77 7974 83 69 MX1, mean, intra PARP12, mean, intra WBC 0.4 −0.02 73 79 64 7866 MX1, mean, intra PTEN, mean, intra RSAD2, mean, intra 0.6 −0.03 81 8279 86 74 MX1, mean, intra PTEN, mean, intra SDCBP, mean, intra 0.4 −0.0671 77 62 76 63 MX1, mean, intra PTEN, mean, intra WBC 0.4 −0.02 73 79 6478 66 MX1, mean, intra RSAD2, mean, intra SDCBP, mean, intra 0.6 −0.0182 84 79 86 76 MX1, mean, intra RSAD2, mean, intra WBC 0.6 −0.06 79 7881 82 76 MX1, mean, intra SDCBP, mean, intra WBC 0.5 0.02 75 82 64 78 69Neu(%) OAS2, mean, intra PARP12, mean, intra 0.6 0.08 83 87 77 86 79Neu(%) OAS2, mean, intra PTEN, mean, intra 0.6 0.08 83 89 74 85 81Neu(%) OAS2, mean, intra RSAD2, mean, intra 0.7 0.05 84 85 84 86 83Neu(%) OAS2, mean, intra SDCBP, mean, intra 0.5 −0.08 75 79 69 80 68Neu(%) OAS2, mean, intra WBC 0.5 −0.04 76 78 74 78 74 Neu(%) PARP12,mean, intra PTEN, mean, intra 0.6 0.06 82 89 72 83 80 Neu(%) PARP12,mean, intra RSAD2, mean, intra 0.6 0 83 87 77 86 79 Neu(%) PARP12, mean,intra SDCBP, mean, intra 0.5 −0.04 77 80 72 82 70 Neu(%) PARP12, mean,intra WBC 0.6 0.01 80 89 67 81 79 Neu(%) PTEN, mean, intra RSAD2, mean,intra 0.7 0.02 84 89 77 86 81 Neu(%) PTEN, mean, intra SDCBP, mean,intra 0.5 −0.03 78 84 69 81 73 Neu(%) PTEN, mean, intra WBC 0.5 −0.03 7887 64 79 76 Neu(%) RSAD2, mean, intra SDCBP, mean, intra 0.6 0 83 87 7785 79 Neu(%) RSAD2, mean, intra WBC 0.7 0.02 83 82 84 86 80 Neu(%)SDCBP, mean, intra WBC 0.5 −0.07 76 84 64 78 71 NPM1, mean, intra Neu(%)OAS2, mean, intra 0.6 −0.01 79 85 69 81 75 NPM1, mean, intra Neu(%)PARP12, mean, intra 0.6 0 79 84 72 82 74 NPM1, mean, intra Neu(%) PTEN,mean, intra 0.6 −0.01 79 85 69 81 75 NPM1, mean, intra Neu(%) RSAD2,mean, intra 0.6 0 83 87 77 85 79 NPM1, mean, intra Neu(%) SDCBP, mean,intra 0.5 −0.05 77 82 69 81 71 NPM1, mean, intra Neu(%) WBC 0.5 −0.03 7889 62 78 77 NPM1, mean, intra OAS2, mean, intra PARP12, mean, intra 0.2−0.08 63 70 51 69 53 NPM1, mean, intra OAS2, mean, intra PTEN, mean,intra 0.1 −0.2 58 69 41 65 46 NPM1, mean, intra OAS2, mean, intra RSAD2,mean, intra 0.6 −0.01 82 84 79 86 76 NPM1, mean, intra OAS2, mean, intraSDCBP, mean, intra 0.1 −0.23 58 75 31 63 44 NPM1, mean, intra OAS2,mean, intra WBC 0.3 0 68 82 46 70 62 NPM1, mean, intra PARP12, mean,intra PTEN, mean, intra 0.2 −0.04 63 72 49 69 53 NPM1, mean, intraPARP12, mean, intra RSAD2, mean, intra 0.6 −0.07 79 80 77 84 71 NPM1,mean, intra PARP12, mean, intra SDCBP, mean, intra 0.2 −0.05 62 69 51 6951 NPM1, mean, intra PARP12, mean, intra WBC 0.3 0.06 68 80 49 71 61NPM1, mean, intra PTEN, mean, intra RSAD2, mean, intra 0.6 −0.06 80 8277 85 73 NPM1, mean, intra PTEN, mean, intra SDCBP, mean, intra 0.2−0.05 61 74 41 66 50 NPM1, mean, intra PTEN, mean, intra WBC 0.3 0.05 6884 44 70 63 NPM1, mean, intra RSAD2, mean, intra SDCBP, mean, intra 0.6−0.06 80 82 77 85 73 NPM1, mean, intra RSAD2, mean, intra WBC 0.6 −0.0481 84 77 85 75 NPM1, mean, intra SDCBP, mean, intra WBC 0.3 0.07 69 8446 71 64 OAS2, mean, intra PARP12, mean, intra PTEN, mean, intra 0.2−0.11 62 73 46 68 51 OAS2, mean, intra PARP12, mean, intra RSAD2, mean,intra 0.7 0.03 84 87 79 87 79 OAS2, mean, intra PARP12, mean, intraSDCBP, mean, intra 0.2 −0.11 62 70 49 68 51 OAS2, mean, intra PARP12,mean, intra WBC 0.3 0.01 68 82 46 71 62 OAS2, mean, intra PTEN, mean,intra RSAD2, mean, intra 0.6 −0.01 82 84 79 87 76 OAS2, mean, intraPTEN, mean, intra SDCBP, mean, intra 0.2 −0.09 63 74 46 68 53 OAS2,mean, intra PTEN, mean, intra WBC 0.3 0 68 85 41 70 64 OAS2, mean, intraRSAD2, mean, intra SDCBP, mean, intra 0.6 −0.04 81 84 77 85 75 OAS2,mean, intra RSAD2, mean, intra WBC 0.6 −0.01 81 79 84 85 78 OAS2, mean,intra SDCBP, mean, intra WBC 0.2 −0.07 65 80 41 68 57 PARP12, mean,intra PTEN, mean, intra RSAD2, mean, intra 0.6 −0.01 82 84 79 87 76PARP12, mean, intra PTEN, mean, intra SDCBP, mean, intra 0.2 −0.04 63 7446 68 53 PARP12, mean, intra PTEN, mean, intra WBC 0.3 0.04 67 81 46 7060 PARP12, mean, intra RSAD2, mean, intra SDCBP, mean, intra 0.6 −0.0779 80 77 84 71 PARP12, mean, intra RSAD2, mean, intra WBC 0.6 −0.05 8082 77 85 73 PARP12, mean, intra SDCBP, mean, intra WBC 0.3 0.05 68 84 4470 63 PTEN, mean, intra RSAD2, mean, intra SDCBP, mean, intra 0.6 −0.0381 82 79 86 74 PTEN, mean, intra RSAD2, mean, intra WBC 0.6 −0.07 79 7979 86 70 PTEN, mean, intra SDCBP, mean, intra WBC 0.3 0.03 67 82 44 6961 RSAD2, mean, intra SDCBP, mean, intra WBC 0.6 −0.05 80 80 79 86 72 *Positive and negative correspond to bacterial and viral infectedpatients respectively *dMCC is the improvement of the MCC of a tripletover the maximal MCC attained in any of the corresponding individualfeatures.

TABLE 4 The classification accuracy of bacterial vs. viral infectedpatients computed over pairs of features. DETERMINANT measurements weremeasured over different cell types. Total Sen Spe PPV NPV Feature #1Feature #2 MCC dMCC accuracy % % % % % ABTB1, gran, intra ABTB1, mono,intra 0.12 0 63 87 22 66 50 ABTB1, gran, intra ANC 0.42 −0.02 74 95 3973 80 ABTB1, gran, intra CORO1A, gran, intra 0.25 0.09 67 80 44 71 56ABTB1, gran, intra CORO1A, mean, intra 0.29 0.14 68 78 50 73 57 ABTB1,gran, intra CORO1A, mono, intra 0.25 0.09 67 80 44 71 56 ABTB1, gran,intra CRP 0.74 0.18 88 96 74 86 92 ABTB1, gran, intra CSDA, gran, intra0.34 0.22 70 79 55 75 61 ABTB1, gran, intra CSDA, mono, intra 0.34 0.2270 79 55 75 61 ABTB1, gran, intra EIF4B, gran, intra 0.26 −0.12 67 78 4772 56 ABTB1, gran, intra EIF4B, lymp, intra 0.36 −0.04 71 82 53 75 63ABTB1, gran, intra EIF4B, mean, intra 0.25 −0.06 67 82 41 70 57 ABTB1,gran, intra EIF4B, mono, intra 0.26 −0.12 67 78 47 72 56 ABTB1, gran,intra EPSTI1, lymp, membrane 0.32 0.13 69 79 52 74 59 ABTB1, gran, intraGAS7, lymp, intra 0.27 0.15 67 77 48 72 56 ABTB1, gran, intra IFI6,gran, intra 0.07 −0.05 61 84 22 65 44 ABTB1, gran, intra IFI6, mono,intra 0.07 −0.05 61 84 22 65 44 ABTB1, gran, intra IFIT3, gran, intra0.28 −0.11 68 82 44 71 58 ABTB1, gran, intra IFIT3, lymp, intra 0.25−0.18 66 75 50 72 53 ABTB1, gran, intra IFIT3, mean, intra 0.13 −0.12 6175 38 67 46 ABTB1, gran, intra IFIT3, mono, intra 0.28 −0.11 68 82 44 7158 ABTB1, gran, intra IFITM1, gran, membrane 0.04 −0.22 61 87 16 64 42ABTB1, gran, intra IFITM1, lymp, membrane 0.31 −0.07 69 82 47 73 60ABTB1, gran, intra IFITM1, mean, membrane 0.04 −0.25 61 87 16 64 42ABTB1, gran, intra IFITM1, mono, membrane 0.02 −0.29 57 76 25 64 38ABTB1, gran, intra IFITM3, gran, membrane 0.06 −0.29 61 85 19 64 43ABTB1, gran, intra IFITM3, mean, membrane 0.06 −0.29 61 85 19 64 43ABTB1, gran, intra IFITM3, mono, membrane 0.23 −0.18 66 78 44 70 54ABTB1, gran, intra LOC26010, gran, intra 0.11 −0.12 62 84 25 66 47ABTB1, gran, intra LOC26010, mean, intra 0.07 −0.14 61 84 22 65 44ABTB1, gran, intra LOC26010, mono, intra 0.11 −0.12 62 84 25 66 47ABTB1, gran, intra LY6E, lymp, membrane 0.3 0.07 69 85 42 71 62 ABTB1,gran, intra Lym(%) 0.55 0.03 79 85 69 82 73 ABTB1, gran, intra MAN1C1,gran, intra 0.27 0.15 67 83 42 70 59 ABTB1, gran, intra MAN1C1, mean,intra 0.24 0.11 66 83 39 69 57 ABTB1, gran, intra MAN1C1, mono, intra0.27 0.15 67 83 42 70 59 ABTB1, gran, intra MX1, gran, intra 0.42 −0.1274 82 59 78 66 ABTB1, gran, intra MX1, lymp, intra 0.29 −0.06 68 78 5073 57 ABTB1, gran, intra MX1, mean, intra 0.4 −0.05 72 80 59 77 63ABTB1, gran, intra MX1, mono, intra 0.42 −0.12 74 82 59 78 66 ABTB1,gran, intra Neu(%) 0.58 0.02 80 85 72 84 74 ABTB1, gran, intra NPM1,gran, intra 0.12 0 62 80 31 66 48 ABTB1, gran, intra NPM1, mean, intra0.18 0.05 64 81 34 68 52 ABTB1, gran, intra NPM1, mono, intra 0.12 0 6280 31 66 48 ABTB1, gran, intra OAS2, gran, intra 0.1 −0.26 61 78 31 6645 ABTB1, gran, intra OAS2, mean, intra 0.06 −0.24 61 85 19 64 43 ABTB1,gran, intra OAS2, mono, intra 0.1 −0.26 61 78 31 66 45 ABTB1, gran,intra PARP12, gran, intra 0.08 −0.11 60 76 31 66 43 ABTB1, gran, intraPARP12, mean, intra 0.21 −0.04 64 76 44 70 52 ABTB1, gran, intra PARP12,mono, intra 0.08 −0.11 60 76 31 66 43 ABTB1, gran, intra PARP9, lymp,intra 0.12 −0.02 63 87 22 66 50 ABTB1, gran, intra PDIA6, gran, intra0.23 0.1 65 79 42 70 54 ABTB1, gran, intra PDIA6, lymp, intra 0.27 0.1567 77 48 72 56 ABTB1, gran, intra PDIA6, mono, intra 0.23 0.1 65 79 4270 54 ABTB1, gran, intra PTEN, gran, intra 0.18 −0.04 63 76 41 69 50ABTB1, gran, intra PTEN, lymp, intra 0.19 0.07 64 80 38 69 52 ABTB1,gran, intra PTEN, mean, intra 0.16 −0.04 63 80 34 68 50 ABTB1, gran,intra PTEN, mono, intra 0.18 −0.04 63 76 41 69 50 ABTB1, gran, intraRSAD2, gran, intra 0.68 0.05 85 89 78 88 81 ABTB1, gran, intra RSAD2,lymp, intra 0.23 0 66 78 44 70 54 ABTB1, gran, intra RSAD2, mean, intra0.63 −0.01 83 87 75 86 77 ABTB1, gran, intra RSAD2, mono, intra 0.680.05 85 89 78 88 81 ABTB1, gran, intra SDCBP, mean, intra 0.18 0.06 6481 34 68 52 ABTB1, gran, intra WBC 0.32 0.07 70 89 38 71 67 ABTB1, mono,intra ANC 0.42 −0.02 74 95 39 73 80 ABTB1, mono, intra CORO1A, gran,intra 0.25 0.09 67 80 44 71 56 ABTB1, mono, intra CORO1A, mean, intra0.29 0.14 68 78 50 73 57 ABTB1, mono, intra CORO1A, mono, intra 0.250.09 67 80 44 71 56 ABTB1, mono, intra CRP 0.74 0.18 88 96 74 86 92ABTB1, mono, intra CSDA, gran, intra 0.34 0.22 70 79 55 75 61 ABTB1,mono, intra CSDA, mono, intra 0.34 0.22 70 79 55 75 61 ABTB1, mono,intra EIF4B, gran, intra 0.26 −0.12 67 78 47 72 56 ABTB1, mono, intraEIF4B, lymp, intra 0.36 −0.04 71 82 53 75 63 ABTB1, mono, intra EIF4B,mean, intra 0.25 −0.06 67 82 41 70 57 ABTB1, mono, intra EIF4B, mono,intra 0.26 −0.12 67 78 47 72 56 ABTB1, mono, intra EPSTI1, lymp,membrane 0.32 0.13 69 79 52 74 59 ABTB1, mono, intra GAS7, lymp, intra0.27 0.15 67 77 48 72 56 ABTB1, mono, intra IFI6, gran, intra 0.07 −0.0561 84 22 65 44 ABTB1, mono, intra IFI6, mono, intra 0.07 −0.05 61 84 2265 44 ABTB1, mono, intra IFIT3, gran, intra 0.28 −0.11 68 82 44 71 58ABTB1, mono, intra IFIT3, lymp, intra 0.25 −0.18 66 75 50 72 53 ABTB1,mono, intra IFIT3, mean, intra 0.13 −0.12 61 75 38 67 46 ABTB1, mono,intra IFIT3, mono, intra 0.28 −0.11 68 82 44 71 58 ABTB1, mono, intraIFITM1, gran, membrane 0.04 −0.22 61 87 16 64 42 ABTB1, mono, intraIFITM1, lymp, membrane 0.31 −0.07 69 82 47 73 60 ABTB1, mono, intraIFITM1, mean, membrane 0.04 −0.25 61 87 16 64 42 ABTB1, mono, intraIFITM1, mono, membrane 0.02 −0.29 57 76 25 64 38 ABTB1, mono, intraIFITM3, gran, membrane 0.06 −0.29 61 85 19 64 43 ABTB1, mono, intraIFITM3, mean, membrane 0.06 −0.29 61 85 19 64 43 ABTB1, mono, intraIFITM3, mono, membrane 0.23 −0.18 66 78 44 70 54 ABTB1, mono, intraLOC26010, gran, intra 0.11 −0.12 62 84 25 66 47 ABTB1, mono, intraLOC26010, mean, intra 0.07 −0.14 61 84 22 65 44 ABTB1, mono, intraLOC26010, mono, intra 0.11 −0.12 62 84 25 66 47 ABTB1, mono, intra LY6E,lymp, membrane 0.3 0.07 69 85 42 71 62 ABTB1, mono, intra Lym(%) 0.550.03 79 85 69 82 73 ABTB1, mono, intra MAN1C1, gran, intra 0.27 0.15 6783 42 70 59 ABTB1, mono, intra MAN1C1, mean, intra 0.24 0.11 66 83 39 6957 ABTB1, mono, intra MAN1C1, mono, intra 0.27 0.15 67 83 42 70 59ABTB1, mono, intra MX1, gran, intra 0.42 −0.12 74 82 59 78 66 ABTB1,mono, intra MX1, lymp, intra 0.29 −0.06 68 78 50 73 57 ABTB1, mono,intra MX1, mean, intra 0.4 −0.05 72 80 59 77 63 ABTB1, mono, intra MX1,mono, intra 0.42 −0.12 74 82 59 78 66 ABTB1, mono, intra Neu(%) 0.580.02 80 85 72 84 74 ABTB1, mono, intra NPM1, gran, intra 0.12 0 62 80 3166 48 ABTB1, mono, intra NPM1, mean, intra 0.18 0.05 64 81 34 68 52ABTB1, mono, intra NPM1, mono, intra 0.12 0 62 80 31 66 48 ABTB1, mono,intra OAS2, gran, intra 0.1 −0.26 61 78 31 66 45 ABTB1, mono, intraOAS2, mean, intra 0.06 −0.24 61 85 19 64 43 ABTB1, mono, intra OAS2,mono, intra 0.1 −0.26 61 78 31 66 45 ABTB1, mono, intra PARP12, gran,intra 0.08 −0.11 60 76 31 66 43 ABTB1, mono, intra PARP12, mean, intra0.21 −0.04 64 76 44 70 52 ABTB1, mono, intra PARP12, mono, intra 0.08−0.11 60 76 31 66 43 ABTB1, mono, intra PARP9, lymp, intra 0.12 −0.02 6387 22 66 50 ABTB1, mono, intra PDIA6, gran, intra 0.23 0.1 65 79 42 7054 ABTB1, mono, intra PDIA6, lymp, intra 0.27 0.15 67 77 48 72 56 ABTB1,mono, intra PDIA6, mono, intra 0.23 0.1 65 79 42 70 54 ABTB1, mono,intra PTEN, gran, intra 0.18 −0.04 63 76 41 69 50 ABTB1, mono, intraPTEN, lymp, intra 0.19 0.07 64 80 38 69 52 ABTB1, mono, intra PTEN,mean, intra 0.16 −0.04 63 80 34 68 50 ABTB1, mono, intra PTEN, mono,intra 0.18 −0.04 63 76 41 69 50 ABTB1, mono, intra RSAD2, gran, intra0.68 0.05 85 89 78 88 81 ABTB1, mono, intra RSAD2, lymp, intra 0.23 0 6678 44 70 54 ABTB1, mono, intra RSAD2, mean, intra 0.63 −0.01 83 87 75 8677 ABTB1, mono, intra RSAD2, mono, intra 0.68 0.05 85 89 78 88 81 ABTB1,mono, intra SDCBP, mean, intra 0.18 0.06 64 81 34 68 52 ABTB1, mono,intra WBC 0.32 0.07 70 89 38 71 67 ANC CORO1A, gran, intra 0.41 −0.03 7492 42 73 76 ANC CORO1A, mean, intra 0.41 −0.03 73 92 42 72 76 ANCCORO1A, mono, intra 0.41 −0.03 74 92 42 73 76 ANC CRP 0.58 0.02 80 87 7083 76 ANC CSDA, gran, intra 0.39 −0.05 73 90 43 73 72 ANC CSDA, mono,intra 0.39 −0.05 73 90 43 73 72 ANC EIF4B, gran, intra 0.53 0.09 78 9158 78 79 ANC EIF4B, lymp, intra 0.5 0.06 77 92 53 77 80 ANC EIF4B, mean,intra 0.5 0.06 77 92 53 76 80 ANC EIF4B, mono, intra 0.53 0.09 78 91 5878 79 ANC EPSTI1, lymp, membrane 0.37 −0.07 72 87 47 74 67 ANC GAS7,lymp, intra 0.4 −0.04 73 91 43 74 72 ANC IFI6, gran, intra 0.38 −0.06 7391 42 73 73 ANC IFI6, mono, intra 0.38 −0.06 73 91 42 73 73 ANC IFIT3,gran, intra 0.48 0.04 76 91 53 76 77 ANC IFIT3, lymp, intra 0.46 0.02 7586 58 77 71 ANC IFIT3, mean, intra 0.5 0.06 77 92 53 76 80 ANC IFIT3,mono, intra 0.48 0.04 76 91 53 76 77 ANC IFITM1, gran, membrane 0.41−0.03 74 94 39 72 79 ANC IFITM1, lymp, membrane 0.46 0.02 75 91 50 75 76ANC IFITM1, mean, membrane 0.43 −0.01 74 94 42 73 80 ANC IFITM1, mono,membrane 0.48 0.04 76 89 55 77 75 ANC IFITM3, gran, membrane 0.44 0 7594 42 73 80 ANC IFITM3, mean, membrane 0.43 −0.01 74 94 42 73 80 ANCIFITM3, mono, membrane 0.48 0.04 76 91 53 76 77 ANC LOC26010, gran,intra 0.46 0.02 75 94 45 74 81 ANC LOC26010, mean, intra 0.43 −0.01 7494 42 73 80 ANC LOC26010, mono, intra 0.46 0.02 75 94 45 74 81 ANC LY6E,lymp, membrane 0.36 −0.08 72 92 37 72 73 ANC Lym(%) 0.5 −0.02 77 88 6179 74 ANC MAN1C1, gran, intra 0.39 −0.05 73 92 40 73 75 ANC MAN1C1,mean, intra 0.36 −0.08 72 90 40 72 71 ANC MAN1C1, mono, intra 0.39 −0.0573 92 40 73 75 ANC MX1, gran, intra 0.62 0.08 82 89 71 84 79 ANC MX1,lymp, intra 0.53 0.09 78 94 53 77 83 ANC MX1, mean, intra 0.57 0.12 8092 61 79 82 ANC MX1, mono, intra 0.62 0.08 82 89 71 84 79 ANC Neu(%)0.53 −0.03 78 91 58 78 79 ANC NPM1, gran, intra 0.48 0.04 76 94 47 75 82ANC NPM1, mean, intra 0.43 −0.01 74 92 45 73 77 ANC NPM1, mono, intra0.48 0.04 76 94 47 75 82 ANC OAS2, gran, intra 0.43 −0.01 75 89 50 75 73ANC OAS2, mean, intra 0.4 −0.04 73 90 45 73 74 ANC OAS2, mono, intra0.43 −0.01 75 89 50 75 73 ANC PARP12, gran, intra 0.5 0.06 77 91 55 7778 ANC PARP12, mean, intra 0.48 0.04 76 90 53 76 77 ANC PARP12, mono,intra 0.5 0.06 77 91 55 77 78 ANC PARP9, lymp, intra 0.46 0.02 75 91 5075 76 ANC PDIA6, gran, intra 0.34 −0.1 71 87 43 73 65 ANC PDIA6, lymp,intra 0.43 −0.01 75 94 40 74 80 ANC PDIA6, mono, intra 0.34 −0.1 71 8743 73 65 ANC PTEN, gran, intra 0.41 −0.03 74 89 47 74 72 ANC PTEN, lymp,intra 0.46 0.02 75 91 50 75 76 ANC PTEN, mean, intra 0.43 −0.01 74 92 4573 77 ANC PTEN, mono, intra 0.41 −0.03 74 89 47 74 72 ANC RSAD2, gran,intra 0.66 0.03 84 88 79 88 79 ANC RSAD2, lymp, intra 0.41 −0.03 74 8850 75 70 ANC RSAD2, mean, intra 0.64 0 83 85 79 87 77 ANC RSAD2, mono,intra 0.66 0.03 84 88 79 88 79 ANC SDCBP, mean, intra 0.45 0.01 75 90 5074 76 ANC WBC 0.53 0.09 78 95 50 76 86 CORO1A, gran, intra CORO1A, mean,intra 0.13 −0.03 60 74 38 66 48 CORO1A, gran, intra CORO1A, mono, intra0.16 0 63 81 33 67 52 CORO1A, gran, intra CRP 0.54 −0.02 79 90 61 78 79CORO1A, gran, intra CSDA, gran, intra 0.17 0.01 63 77 39 68 50 CORO1A,gran, intra CSDA, mono, intra 0.17 0.01 63 77 39 68 50 CORO1A, gran,intra EIF4B, gran, intra 0.27 −0.11 67 81 44 70 59 CORO1A, gran, intraEIF4B, lymp, intra 0.16 −0.24 63 81 33 67 52 CORO1A, gran, intra EIF4B,mean, intra 0.23 −0.08 65 82 38 68 58 CORO1A, gran, intra EIF4B, mono,intra 0.27 −0.11 67 81 44 70 59 CORO1A, gran, intra EPSTI1, lymp,membrane 0.13 −0.06 62 79 32 67 48 CORO1A, gran, intra GAS7, lymp, intra0.18 0.02 63 75 42 69 50 CORO1A, gran, intra IFI6, gran, intra 0.17 0.0162 75 41 68 50 CORO1A, gran, intra IFI6, mono, intra 0.17 0.01 62 75 4168 50 CORO1A, gran, intra IFIT3, gran, intra 0.35 −0.04 69 72 64 77 58CORO1A, gran, intra IFIT3, lymp, intra 0.35 −0.08 69 73 62 76 59 CORO1A,gran, intra IFIT3, mean, intra 0.27 0.02 65 73 54 71 55 CORO1A, gran,intra IFIT3, mono, intra 0.35 −0.04 69 72 64 77 58 CORO1A, gran, intraIFITM1, gran, membrane 0.14 −0.12 62 81 31 66 50 CORO1A, gran, intraIFITM1, lymp, membrane 0.3 −0.08 67 73 56 73 56 CORO1A, gran, intraIFITM1, mean, membrane 0.1 −0.19 59 76 33 64 46 CORO1A, gran, intraIFITM1, mono, membrane 0.27 −0.04 67 80 46 71 58 CORO1A, gran, intraIFITM3, gran, membrane 0.12 −0.23 61 80 31 65 48 CORO1A, gran, intraIFITM3, mean, membrane 0.21 −0.14 64 81 38 68 56 CORO1A, gran, intraIFITM3, mono, membrane 0.32 −0.09 68 75 56 74 58 CORO1A, gran, intraLOC26010, gran, intra 0.17 −0.06 62 75 41 68 50 CORO1A, gran, intraLOC26010, mean, intra 0.2 −0.01 63 76 44 68 53 CORO1A, gran, intraLOC26010, mono, intra 0.17 −0.06 62 75 41 68 50 CORO1A, gran, intraLY6E, lymp, membrane 0.11 −0.12 61 77 32 66 45 CORO1A, gran, intraLym(%) 0.49 −0.03 76 78 72 82 67 CORO1A, gran, intra MAN1C1, gran, intra0.25 0.09 66 79 45 71 56 CORO1A, gran, intra MAN1C1, mean, intra 0.280.12 67 81 45 71 58 CORO1A, gran, intra MAN1C1, mono, intra 0.25 0.09 6679 45 71 56 CORO1A, gran, intra MX1, gran, intra 0.49 −0.05 76 80 69 8168 CORO1A, gran, intra MX1, lymp, intra 0.37 0.02 71 80 56 75 63 CORO1A,gran, intra MX1, mean, intra 0.38 −0.07 70 74 64 77 61 CORO1A, gran,intra MX1, mono, intra 0.49 −0.05 76 80 69 81 68 CORO1A, gran, intraNeu(%) 0.58 0.02 81 89 67 81 79 CORO1A, gran, intra NPM1, gran, intra0.17 0.01 63 78 38 67 52 CORO1A, gran, intra NPM1, mean, intra 0.15−0.01 61 75 38 66 50 CORO1A, gran, intra NPM1, mono, intra 0.17 0.01 6378 38 67 52 CORO1A, gran, intra OAS2, gran, intra 0.18 −0.18 62 72 46 6950 CORO1A, gran, intra OAS2, mean, intra 0.12 −0.18 59 71 41 66 47CORO1A, gran, intra OAS2, mono, intra 0.18 −0.18 62 72 46 69 50 CORO1A,gran, intra PARP12, gran, intra 0.21 0.02 64 77 44 69 53 CORO1A, gran,intra PARP12, mean, intra 0.26 0.01 65 74 51 71 56 CORO1A, gran, intraPARP12, mono, intra 0.21 0.02 64 77 44 69 53 CORO1A, gran, intra PARP9,lymp, intra 0.15 −0.01 62 80 33 66 50 CORO1A, gran, intra PDIA6, gran,intra 0.32 0.16 69 79 52 74 59 CORO1A, gran, intra PDIA6, lymp, intra0.24 0.08 65 75 48 71 54 CORO1A, gran, intra PDIA6, mono, intra 0.320.16 69 79 52 74 59 CORO1A, gran, intra PTEN, gran, intra 0.15 −0.07 6173 41 67 48 CORO1A, gran, intra PTEN, lymp, intra 0.08 −0.08 58 72 36 6544 CORO1A, gran, intra PTEN, mean, intra 0.14 −0.06 60 73 41 66 48CORO1A, gran, intra PTEN, mono, intra 0.15 −0.07 61 73 41 67 48 CORO1A,gran, intra RSAD2, gran, intra 0.66 0.03 83 84 82 89 76 CORO1A, gran,intra RSAD2, lymp, intra 0.14 −0.09 62 81 31 66 50 CORO1A, gran, intraRSAD2, mean, intra 0.57 −0.07 79 81 77 85 71 CORO1A, gran, intra RSAD2,mono, intra 0.66 0.03 83 84 82 89 76 CORO1A, gran, intra SDCBP, mean,intra 0.14 −0.02 61 77 36 65 50 CORO1A, gran, intra WBC 0.35 0.1 71 8941 71 70 CORO1A, mean, intra CORO1A, mono, intra 0.13 −0.03 60 74 38 6648 CORO1A, mean, intra CRP 0.56 0 79 91 61 78 82 CORO1A, mean, intraCSDA, gran, intra 0.31 0.16 69 79 52 73 59 CORO1A, mean, intra CSDA,mono, intra 0.31 0.16 69 79 52 73 59 CORO1A, mean, intra EIF4B, gran,intra 0.31 −0.07 68 81 49 71 61 CORO1A, mean, intra EIF4B, lymp, intra0.22 −0.18 64 77 44 69 55 CORO1A, mean, intra EIF4B, mean, intra 0.31 068 81 49 71 61 CORO1A, mean, intra EIF4B, mono, intra 0.31 −0.07 68 8149 71 61 CORO1A, mean, intra EPSTI1, lymp, membrane 0.38 0.19 71 79 5876 62 CORO1A, mean, intra GAS7, lymp, intra 0.2 0.05 64 77 42 69 52CORO1A, mean, intra IFI6, gran, intra 0.18 0.03 62 74 44 68 52 CORO1A,mean, intra IFI6, mono, intra 0.18 0.03 62 74 44 68 52 CORO1A, mean,intra IFIT3, gran, intra 0.38 −0.01 70 74 64 77 61 CORO1A, mean, intraIFIT3, lymp, intra 0.4 −0.03 71 76 64 77 63 CORO1A, mean, intra IFIT3,mean, intra 0.39 0.14 71 79 59 75 64 CORO1A, mean, intra IFIT3, mono,intra 0.38 −0.01 70 74 64 77 61 CORO1A, mean, intra IFITM1, gran,membrane 0.12 −0.14 59 73 38 65 47 CORO1A, mean, intra IFITM1, lymp,membrane 0.37 −0.01 70 77 59 75 62 CORO1A, mean, intra IFITM1, mean,membrane 0.14 −0.15 60 73 41 66 48 CORO1A, mean, intra IFITM1, mono,membrane 0.29 −0.02 67 79 49 71 59 CORO1A, mean, intra IFITM3, gran,membrane 0.18 −0.17 62 76 41 67 52 CORO1A, mean, intra IFITM3, mean,membrane 0.16 −0.19 61 74 41 67 50 CORO1A, mean, intra IFITM3, mono,membrane 0.37 −0.04 70 77 59 75 62 CORO1A, mean, intra LOC26010, gran,intra 0.18 −0.05 62 74 44 68 52 CORO1A, mean, intra LOC26010, mean,intra 0.16 −0.05 61 74 41 67 50 CORO1A, mean, intra LOC26010, mono,intra 0.18 −0.05 62 74 44 68 52 CORO1A, mean, intra LY6E, lymp, membrane0.18 −0.05 63 75 42 69 50 CORO1A, mean, intra Lym(%) 0.51 −0.01 76 77 7483 67 CORO1A, mean, intra MAN1C1, gran, intra 0.26 0.11 66 77 48 71 56CORO1A, mean, intra MAN1C1, mean, intra 0.25 0.1 66 79 45 71 56 CORO1A,mean, intra MAN1C1, mono, intra 0.26 0.11 66 77 48 71 56 CORO1A, mean,intra MX1, gran, intra 0.5 −0.04 76 81 69 81 69 CORO1A, mean, intra MX1,lymp, intra 0.41 0.06 72 81 59 76 66 CORO1A, mean, intra MX1, mean,intra 0.48 0.03 75 81 67 79 68 CORO1A, mean, intra MX1, mono, intra 0.5−0.04 76 81 69 81 69 CORO1A, mean, intra Neu(%) 0.55 −0.01 79 89 64 8078 CORO1A, mean, intra NPM1, gran, intra 0.24 0.09 65 79 44 69 57CORO1A, mean, intra NPM1, mean, intra 0.2 0.05 63 75 44 68 53 CORO1A,mean, intra NPM1, mono, intra 0.24 0.09 65 79 44 69 57 CORO1A, mean,intra OAS2, gran, intra 0.2 −0.16 62 71 49 69 51 CORO1A, mean, intraOAS2, mean, intra 0.19 −0.11 62 73 46 68 51 CORO1A, mean, intra OAS2,mono, intra 0.2 −0.16 62 71 49 69 51 CORO1A, mean, intra PARP12, gran,intra 0.25 0.06 65 77 46 70 56 CORO1A, mean, intra PARP12, mean, intra0.28 0.03 66 76 51 71 57 CORO1A, mean, intra PARP12, mono, intra 0.250.06 65 77 46 70 56 CORO1A, mean, intra PARP9, lymp, intra 0.14 −0.01 6177 36 66 50 CORO1A, mean, intra PDIA6, gran, intra 0.31 0.16 69 81 48 7360 CORO1A, mean, intra PDIA6, lymp, intra 0.21 0.06 64 75 45 70 52CORO1A, mean, intra PDIA6, mono, intra 0.31 0.16 69 81 48 73 60 CORO1A,mean, intra PTEN, gran, intra 0.21 −0.01 63 74 46 69 53 CORO1A, mean,intra PTEN, lymp, intra 0.07 −0.08 57 71 36 64 44 CORO1A, mean, intraPTEN, mean, intra 0.18 −0.02 62 74 44 68 52 CORO1A, mean, intra PTEN,mono, intra 0.21 −0.01 63 74 46 69 53 CORO1A, mean, intra RSAD2, gran,intra 0.62 −0.01 81 81 82 88 73 CORO1A, mean, intra RSAD2, lymp, intra0.16 −0.07 62 79 36 66 52 CORO1A, mean, intra RSAD2, mean, intra 0.59−0.05 80 82 77 85 73 CORO1A, mean, intra RSAD2, mono, intra 0.62 −0.0181 81 82 88 73 CORO1A, mean, intra SDCBP, mean, intra 0.19 0.04 63 77 4167 53 CORO1A, mean, intra WBC 0.28 0.03 67 82 44 70 61 CORO1A, mono,intra CRP 0.54 −0.02 79 90 61 78 79 CORO1A, mono, intra CSDA, gran,intra 0.17 0.01 63 77 39 68 50 CORO1A, mono, intra CSDA, mono, intra0.17 0.01 63 77 39 68 50 CORO1A, mono, intra EIF4B, gran, intra 0.27−0.11 67 81 44 70 59 CORO1A, mono, intra EIF4B, lymp, intra 0.16 −0.2463 81 33 67 52 CORO1A, mono, intra EIF4B, mean, intra 0.23 −0.08 65 8238 68 58 CORO1A, mono, intra EIF4B, mono, intra 0.27 −0.11 67 81 44 7059 CORO1A, mono, intra EPSTI1, lymp, membrane 0.13 −0.06 62 79 32 67 48CORO1A, mono, intra GAS7, lymp, intra 0.18 0.02 63 75 42 69 50 CORO1A,mono, intra IFI6, gran, intra 0.17 0.01 62 75 41 68 50 CORO1A, mono,intra IFI6, mono, intra 0.17 0.01 62 75 41 68 50 CORO1A, mono, intraIFIT3, gran, intra 0.35 −0.04 69 72 64 77 58 CORO1A, mono, intra IFIT3,lymp, intra 0.35 −0.08 69 73 62 76 59 CORO1A, mono, intra IFIT3, mean,intra 0.27 0.02 65 73 54 71 55 CORO1A, mono, intra IFIT3, mono, intra0.35 −0.04 69 72 64 77 58 CORO1A, mono, intra IFITM1, gran, membrane0.14 −0.12 62 81 31 66 50 CORO1A, mono, intra IFITM1, lymp, membrane 0.3−0.08 67 73 56 73 56 CORO1A, mono, intra IFITM1, mean, membrane 0.1−0.19 59 76 33 64 46 CORO1A, mono, intra IFITM1, mono, membrane 0.27−0.04 67 80 46 71 58 CORO1A, mono, intra IFITM3, gran, membrane 0.12−0.23 61 80 31 65 48 CORO1A, mono, intra IFITM3, mean, membrane 0.21−0.14 64 81 38 68 56 CORO1A, mono, intra IFITM3, mono, membrane 0.32−0.09 68 75 56 74 58 CORO1A, mono, intra LOC26010, gran, intra 0.17−0.06 62 75 41 68 50 CORO1A, mono, intra LOC26010, mean, intra 0.2 −0.0163 76 44 68 53 CORO1A, mono, intra LOC26010, mono, intra 0.17 −0.06 6275 41 68 50 CORO1A, mono, intra LY6E, lymp, membrane 0.11 −0.12 61 77 3266 45 CORO1A, mono, intra Lym(%) 0.49 −0.03 76 78 72 82 67 CORO1A, mono,intra MAN1C1, gran, intra 0.25 0.09 66 79 45 71 56 CORO1A, mono, intraMAN1C1, mean, intra 0.28 0.12 67 81 45 71 58 CORO1A, mono, intra MAN1C1,mono, intra 0.25 0.09 66 79 45 71 56 CORO1A, mono, intra MX1, gran,intra 0.49 −0.05 76 80 69 81 68 CORO1A, mono, intra MX1, lymp, intra0.37 0.02 71 80 56 75 63 CORO1A, mono, intra MX1, mean, intra 0.38 −0.0770 74 64 77 61 CORO1A, mono, intra MX1, mono, intra 0.49 −0.05 76 80 6981 68 CORO1A, mono, intra Neu(%) 0.58 0.02 81 89 67 81 79 CORO1A, mono,intra NPM1, gran, intra 0.17 0.01 63 78 38 67 52 CORO1A, mono, intraNPM1, mean, intra 0.15 −0.01 61 75 38 66 50 CORO1A, mono, intra NPM1,mono, intra 0.17 0.01 63 78 38 67 52 CORO1A, mono, intra OAS2, gran,intra 0.18 −0.18 62 72 46 69 50 CORO1A, mono, intra OAS2, mean, intra0.12 −0.18 59 71 41 66 47 CORO1A, mono, intra OAS2, mono, intra 0.18−0.18 62 72 46 69 50 CORO1A, mono, intra PARP12, gran, intra 0.21 0.0264 77 44 69 53 CORO1A, mono, intra PARP12, mean, intra 0.26 0.01 65 7451 71 56 CORO1A, mono, intra PARP12, mono, intra 0.21 0.02 64 77 44 6953 CORO1A, mono, intra PARP9, lymp, intra 0.15 −0.01 62 80 33 66 50CORO1A, mono, intra PDIA6, gran, intra 0.32 0.16 69 79 52 74 59 CORO1A,mono, intra PDIA6, lymp, intra 0.24 0.08 65 75 48 71 54 CORO1A, mono,intra PDIA6, mono, intra 0.32 0.16 69 79 52 74 59 CORO1A, mono, intraPTEN, gran, intra 0.15 −0.07 61 73 41 67 48 CORO1A, mono, intra PTEN,lymp, intra 0.08 −0.08 58 72 36 65 44 CORO1A, mono, intra PTEN, mean,intra 0.14 −0.06 60 73 41 66 48 CORO1A, mono, intra PTEN, mono, intra0.15 −0.07 61 73 41 67 48 CORO1A, mono, intra RSAD2, gran, intra 0.660.03 83 84 82 89 76 CORO1A, mono, intra RSAD2, lymp, intra 0.14 −0.09 6281 31 66 50 CORO1A, mono, intra RSAD2, mean, intra 0.57 −0.07 79 81 7785 71 CORO1A, mono, intra RSAD2, mono, intra 0.66 0.03 83 84 82 89 76CORO1A, mono, intra SDCBP, mean, intra 0.14 −0.02 61 77 36 65 50 CORO1A,mono, intra WBC 0.35 0.1 71 89 41 71 70 CRP CSDA, gran, intra 0.59 0.0381 90 67 81 80 CRP CSDA, mono, intra 0.59 0.03 81 90 67 81 80 CRP EIF4B,gran, intra 0.65 0.09 84 93 68 82 87 CRP EIF4B, lymp, intra 0.61 0.05 8293 63 80 86 CRP EIF4B, mean, intra 0.65 0.09 83 95 66 81 89 CRP EIF4B,mono, intra 0.65 0.09 84 93 68 82 87 CRP EPSTI1, lymp, membrane 0.590.03 81 90 67 81 80 CRP GAS7, lymp, intra 0.59 0.03 81 90 67 81 80 CRPIFI6, gran, intra 0.74 0.18 88 93 79 88 88 CRP IFI6, mono, intra 0.740.18 88 93 79 88 88 CRP IFIT3, gran, intra 0.7 0.14 86 92 76 86 85 CRPIFIT3, lymp, intra 0.61 0.05 82 88 71 83 79 CRP IFIT3, mean, intra 0.690.13 85 91 76 85 85 CRP IFIT3, mono, intra 0.7 0.14 86 92 76 86 85 CRPIFITM1, gran, membrane 0.63 0.07 83 95 63 80 89 CRP IFITM1, lymp,membrane 0.63 0.07 83 92 68 82 84 CRP IFITM1, mean, membrane 0.58 0.0280 91 63 79 83 CRP IFITM1, mono, membrane 0.7 0.14 86 92 76 86 85 CRPIFITM3, gran, membrane 0.63 0.07 83 92 68 82 84 CRP IFITM3, mean,membrane 0.67 0.11 84 91 74 84 85 CRP IFITM3, mono, membrane 0.81 0.2591 95 84 90 91 CRP LOC26010, gran, intra 0.72 0.16 87 92 79 87 86 CRPLOC26010, mean, intra 0.69 0.13 85 90 79 87 83 CRP LOC26010, mono, intra0.72 0.16 87 92 79 87 86 CRP LY6E, lymp, membrane 0.59 0.03 81 92 63 8083 CRP Lym(%) 0.7 0.14 86 92 76 86 85 CRP MAN1C1, gran, intra 0.61 0.0582 90 70 83 81 CRP MAN1C1, mean, intra 0.61 0.05 82 90 70 83 81 CRPMAN1C1, mono, intra 0.61 0.05 82 90 70 83 81 CRP MX1, gran, intra 0.780.22 90 93 84 90 89 CRP MX1, lymp, intra 0.72 0.16 87 93 76 86 88 CRPMX1, mean, intra 0.74 0.18 88 93 79 87 88 CRP MX1, mono, intra 0.78 0.2290 93 84 90 89 CRP Neu(%) 0.65 0.09 84 92 71 83 84 CRP NPM1, gran, intra0.67 0.11 85 90 76 85 83 CRP NPM1, mean, intra 0.65 0.09 83 88 76 85 81CRP NPM1, mono, intra 0.67 0.11 85 90 76 85 83 CRP OAS2, gran, intra0.65 0.09 84 92 71 83 84 CRP OAS2, mean, intra 0.65 0.09 83 91 71 83 84CRP OAS2, mono, intra 0.65 0.09 84 92 71 83 84 CRP PARP12, gran, intra0.79 0.23 90 97 79 88 94 CRP PARP12, mean, intra 0.76 0.2 89 95 79 87 91CRP PARP12, mono, intra 0.79 0.23 90 97 79 88 94 CRP PARP9, lymp, intra0.7 0.14 86 93 74 85 88 CRP PDIA6, gran, intra 0.73 0.17 87 96 73 85 92CRP PDIA6, lymp, intra 0.62 0.06 82 92 67 82 83 CRP PDIA6, mono, intra0.73 0.17 87 96 73 85 92 CRP PTEN, gran, intra 0.78 0.22 90 95 82 89 91CRP PTEN, lymp, intra 0.65 0.09 84 92 71 83 84 CRP PTEN, mean, intra0.69 0.13 85 93 74 84 88 CRP PTEN, mono, intra 0.78 0.22 90 95 82 89 91CRP RSAD2, gran, intra 0.89 0.26 95 95 95 97 92 CRP RSAD2, lymp, intra0.61 0.05 82 90 68 82 81 CRP RSAD2, mean, intra 0.85 0.21 93 93 92 95 90CRP RSAD2, mono, intra 0.89 0.26 95 95 95 97 92 CRP SDCBP, mean, intra0.65 0.09 83 89 74 84 82 CRP WBC 0.54 −0.02 79 88 63 79 77 CSDA, gran,intra CSDA, mono, intra 0.08 −0.01 60 81 26 65 44 CSDA, gran, intraEIF4B, gran, intra 0.34 −0.04 70 79 55 75 61 CSDA, gran, intra EIF4B,lymp, intra 0.2 −0.2 64 77 42 69 52 CSDA, gran, intra EIF4B, mean, intra0.36 0.05 71 85 48 73 65 CSDA, gran, intra EIF4B, mono, intra 0.34 −0.0470 79 55 75 61 CSDA, gran, intra EPSTI1, lymp, membrane 0.28 0.09 67 8145 71 58 CSDA, gran, intra GAS7, lymp, intra 0.14 0.04 61 75 39 67 48CSDA, gran, intra IFI6, gran, intra 0.09 0 60 79 29 65 45 CSDA, gran,intra IFI6, mono, intra 0.09 0 60 79 29 65 45 CSDA, gran, intra IFIT3,gran, intra 0.33 −0.06 70 83 48 73 63 CSDA, gran, intra IFIT3, lymp,intra 0.26 −0.17 66 77 48 71 56 CSDA, gran, intra IFIT3, mean, intra0.23 −0.02 65 77 45 70 54 CSDA, gran, intra IFIT3, mono, intra 0.33−0.06 70 83 48 73 63 CSDA, gran, intra IFITM1, gran, membrane 0.07 −0.1959 77 29 65 43 CSDA, gran, intra IFITM1, lymp, membrane 0.28 −0.1 67 7948 72 58 CSDA, gran, intra IFITM1, mean, membrane 0.1 −0.19 60 77 32 6645 CSDA, gran, intra IFITM1, mono, membrane 0.39 0.08 72 83 55 75 65CSDA, gran, intra IFITM3, gran, membrane 0.1 −0.25 61 83 26 65 47 CSDA,gran, intra IFITM3, mean, membrane 0.09 −0.26 60 79 29 65 45 CSDA, gran,intra IFITM3, mono, membrane 0.43 0.02 73 81 61 78 66 CSDA, gran, intraLOC26010, gran, intra 0.22 −0.01 65 79 42 69 54 CSDA, gran, intraLOC26010, mean, intra 0.22 0.01 65 79 42 69 54 CSDA, gran, intraLOC26010, mono, intra 0.22 −0.01 65 79 42 69 54 CSDA, gran, intra LY6E,lymp, membrane −0.06 −0.29 55 79 16 61 31 CSDA, gran, intra Lym(%) 0.520 77 79 74 84 68 CSDA, gran, intra MAN1C1, gran, intra 0.34 0.23 70 7955 75 61 CSDA, gran, intra MAN1C1, mean, intra 0.31 0.18 69 81 48 72 60CSDA, gran, intra MAN1C1, mono, intra 0.34 0.23 70 79 55 75 61 CSDA,gran, intra MX1, gran, intra 0.46 −0.08 75 79 68 80 66 CSDA, gran, intraMX1, lymp, intra 0.21 −0.14 64 75 45 70 52 CSDA, gran, intra MX1, mean,intra 0.42 −0.03 71 69 74 82 59 CSDA, gran, intra MX1, mono, intra 0.46−0.08 75 79 68 80 66 CSDA, gran, intra Neu(%) 0.59 0.03 81 85 74 85 74CSDA, gran, intra NPM1, gran, intra 0.13 0.03 61 77 35 67 48 CSDA, gran,intra NPM1, mean, intra 0.13 0 61 77 35 67 48 CSDA, gran, intra NPM1,mono, intra 0.13 0.03 61 77 35 67 48 CSDA, gran, intra OAS2, gran, intra0.22 −0.14 65 79 42 69 54 CSDA, gran, intra OAS2, mean, intra 0.09 −0.2160 79 29 65 45 CSDA, gran, intra OAS2, mono, intra 0.22 −0.14 65 79 4269 54 CSDA, gran, intra PARP12, gran, intra 0.18 −0.01 63 75 42 68 50CSDA, gran, intra PARP12, mean, intra 0.3 0.05 67 75 55 74 57 CSDA,gran, intra PARP12, mono, intra 0.18 −0.01 63 75 42 68 50 CSDA, gran,intra PARP9, lymp, intra 0.13 −0.01 61 77 35 67 48 CSDA, gran, intraPDIA6, gran, intra 0.18 0.05 63 75 42 68 50 CSDA, gran, intra PDIA6,lymp, intra 0.06 −0.03 58 73 32 64 42 CSDA, gran, intra PDIA6, mono,intra 0.18 0.05 63 75 42 68 50 CSDA, gran, intra PTEN, gran, intra 0.21−0.01 64 75 45 70 52 CSDA, gran, intra PTEN, lymp, intra 0.18 0.09 63 7542 68 50 CSDA, gran, intra PTEN, mean, intra 0.18 −0.02 63 75 42 68 50CSDA, gran, intra PTEN, mono, intra 0.21 −0.01 64 75 45 70 52 CSDA,gran, intra RSAD2, gran, intra 0.62 −0.01 82 85 77 86 75 CSDA, gran,intra RSAD2, lymp, intra 0.11 −0.12 61 81 29 66 47 CSDA, gran, intraRSAD2, mean, intra 0.64 0 83 87 77 87 77 CSDA, gran, intra RSAD2, mono,intra 0.62 −0.01 82 85 77 86 75 CSDA, gran, intra SDCBP, mean, intra0.34 0.25 70 79 55 75 61 CSDA, gran, intra WBC 0.25 0 67 88 32 69 63CSDA, mono, intra EIF4B, gran, intra 0.34 −0.04 70 79 55 75 61 CSDA,mono, intra EIF4B, lymp, intra 0.2 −0.2 64 77 42 69 52 CSDA, mono, intraEIF4B, mean, intra 0.36 0.05 71 85 48 73 65 CSDA, mono, intra EIF4B,mono, intra 0.34 −0.04 70 79 55 75 61 CSDA, mono, intra EPSTI1, lymp,membrane 0.28 0.09 67 81 45 71 58 CSDA, mono, intra GAS7, lymp, intra0.14 0.04 61 75 39 67 48 CSDA, mono, intra IFI6, gran, intra 0.09 0 6079 29 65 45 CSDA, mono, intra IFI6, mono, intra 0.09 0 60 79 29 65 45CSDA, mono, intra IFIT3, gran, intra 0.33 −0.06 70 83 48 73 63 CSDA,mono, intra IFIT3, lymp, intra 0.26 −0.17 66 77 48 71 56 CSDA, mono,intra IFIT3, mean, intra 0.23 −0.02 65 77 45 70 54 CSDA, mono, intraIFIT3, mono, intra 0.33 −0.06 70 83 48 73 63 CSDA, mono, intra IFITM1,gran, membrane 0.07 −0.19 59 77 29 65 43 CSDA, mono, intra IFITM1, lymp,membrane 0.28 −0.1 67 79 48 72 58 CSDA, mono, intra IFITM1, mean,membrane 0.1 −0.19 60 77 32 66 45 CSDA, mono, intra IFITM1, mono,membrane 0.39 0.08 72 83 55 75 65 CSDA, mono, intra IFITM3, gran,membrane 0.1 −0.25 61 83 26 65 47 CSDA, mono, intra IFITM3, mean,membrane 0.09 −0.26 60 79 29 65 45 CSDA, mono, intra IFITM3, mono,membrane 0.43 0.02 73 81 61 78 66 CSDA, mono, intra LOC26010, gran,intra 0.22 −0.01 65 79 42 69 54 CSDA, mono, intra LOC26010, mean, intra0.22 0.01 65 79 42 69 54 CSDA, mono, intra LOC26010, mono, intra 0.22−0.01 65 79 42 69 54 CSDA, mono, intra LY6E, lymp, membrane −0.06 −0.2955 79 16 61 31 CSDA, mono, intra Lym(%) 0.52 0 77 79 74 84 68 CSDA,mono, intra MAN1C1, gran, intra 0.34 0.23 70 79 55 75 61 CSDA, mono,intra MAN1C1, mean, intra 0.31 0.18 69 81 48 72 60 CSDA, mono, intraMAN1C1, mono, intra 0.34 0.23 70 79 55 75 61 CSDA, mono, intra MX1,gran, intra 0.46 −0.08 75 79 68 80 66 CSDA, mono, intra MX1, lymp, intra0.21 −0.14 64 75 45 70 52 CSDA, mono, intra MX1, mean, intra 0.42 −0.0371 69 74 82 59 CSDA, mono, intra MX1, mono, intra 0.46 −0.08 75 79 68 8066 CSDA, mono, intra Neu(%) 0.59 0.03 81 85 74 85 74 CSDA, mono, intraNPM1, gran, intra 0.13 0.03 61 77 35 67 48 CSDA, mono, intra NPM1, mean,intra 0.13 0 61 77 35 67 48 CSDA, mono, intra NPM1, mono, intra 0.130.03 61 77 35 67 48 CSDA, mono, intra OAS2, gran, intra 0.22 −0.14 65 7942 69 54 CSDA, mono, intra OAS2, mean, intra 0.09 −0.21 60 79 29 65 45CSDA, mono, intra OAS2, mono, intra 0.22 −0.14 65 79 42 69 54 CSDA,mono, intra PARP12, gran, intra 0.18 −0.01 63 75 42 68 50 CSDA, mono,intra PARP12, mean, intra 0.3 0.05 67 75 55 74 57 CSDA, mono, intraPARP12, mono, intra 0.18 −0.01 63 75 42 68 50 CSDA, mono, intra PARP9,lymp, intra 0.13 −0.01 61 77 35 67 48 CSDA, mono, intra PDIA6, gran,intra 0.18 0.05 63 75 42 68 50 CSDA, mono, intra PDIA6, lymp, intra 0.06−0.03 58 73 32 64 42 CSDA, mono, intra PDIA6, mono, intra 0.18 0.05 6375 42 68 50 CSDA, mono, intra PTEN, gran, intra 0.21 −0.01 64 75 45 7052 CSDA, mono, intra PTEN, lymp, intra 0.18 0.09 63 75 42 68 50 CSDA,mono, intra PTEN, mean, intra 0.18 −0.02 63 75 42 68 50 CSDA, mono,intra PTEN, mono, intra 0.21 −0.01 64 75 45 70 52 CSDA, mono, intraRSAD2, gran, intra 0.62 −0.01 82 85 77 86 75 CSDA, mono, intra RSAD2,lymp, intra 0.11 −0.12 61 81 29 66 47 CSDA, mono, intra RSAD2, mean,intra 0.64 0 83 87 77 87 77 CSDA, mono, intra RSAD2, mono, intra 0.62−0.01 82 85 77 86 75 CSDA, mono, intra SDCBP, mean, intra 0.34 0.25 7079 55 75 61 CSDA, mono, intra WBC 0.25 0 67 88 32 69 63 EIF4B, gran,intra EIF4B, lymp, intra 0.43 0.03 72 69 75 76 67 EIF4B, gran, intraEIF4B, mean, intra 0.38 0 69 63 76 75 64 EIF4B, gran, intra EIF4B, mono,intra 0.38 0 69 62 76 75 63 EIF4B, gran, intra EPSTI1, lymp, membrane0.37 −0.01 70 74 65 78 59 EIF4B, gran, intra GAS7, lymp, intra 0.34−0.04 69 74 61 76 58 EIF4B, gran, intra IFI6, gran, intra 0.19 −0.19 6377 41 68 52 EIF4B, gran, intra IFI6, mono, intra 0.19 −0.19 63 77 41 6852 EIF4B, gran, intra IFIT3, gran, intra 0.38 −0.01 71 78 59 76 62EIF4B, gran, intra IFIT3, lymp, intra 0.35 −0.08 70 78 56 75 61 EIF4B,gran, intra IFIT3, mean, intra 0.33 −0.05 68 76 56 73 59 EIF4B, gran,intra IFIT3, mono, intra 0.38 −0.01 71 78 59 76 62 EIF4B, gran, intraIFITM1, gran, membrane 0.28 −0.1 64 65 63 69 59 EIF4B, gran, intraIFITM1, lymp, membrane 0.43 0.05 72 72 72 76 67 EIF4B, gran, intraIFITM1, mean, membrane 0.28 −0.1 64 65 63 68 60 EIF4B, gran, intraIFITM1, mono, membrane 0.32 −0.06 66 69 63 70 62 EIF4B, gran, intraIFITM3, gran, membrane 0.34 −0.04 67 68 67 71 63 EIF4B, gran, intraIFITM3, mean, membrane 0.33 −0.05 66 65 68 71 62 EIF4B, gran, intraIFITM3, mono, membrane 0.45 0.04 72 70 75 78 67 EIF4B, gran, intraLOC26010, gran, intra 0.39 0.01 69 65 75 75 64 EIF4B, gran, intraLOC26010, mean, intra 0.38 0 69 63 76 75 64 EIF4B, gran, intra LOC26010,mono, intra 0.39 0.01 69 65 75 75 64 EIF4B, gran, intra LY6E, lymp,membrane 0.41 0.03 70 68 73 75 66 EIF4B, gran, intra Lym(%) 0.55 0.03 7776 79 81 73 EIF4B, gran, intra MAN1C1, gran, intra 0.36 −0.02 71 83 5274 64 EIF4B, gran, intra MAN1C1, mean, intra 0.39 0.01 72 83 55 75 65EIF4B, gran, intra MAN1C1, mono, intra 0.36 −0.02 71 83 52 74 64 EIF4B,gran, intra MX1, gran, intra 0.57 0.03 78 73 84 84 73 EIF4B, gran, intraMX1, lymp, intra 0.54 0.16 77 73 81 82 72 EIF4B, gran, intra MX1, mean,intra 0.58 0.13 78 72 85 85 73 EIF4B, gran, intra MX1, mono, intra 0.570.03 78 73 84 84 73 EIF4B, gran, intra Neu(%) 0.53 −0.03 76 76 77 80 73EIF4B, gran, intra NPM1, gran, intra 0.16 −0.22 62 75 41 67 50 EIF4B,gran, intra NPM1, mean, intra 0.27 −0.11 66 75 51 71 57 EIF4B, gran,intra NPM1, mono, intra 0.16 −0.22 62 75 41 67 50 EIF4B, gran, intraOAS2, gran, intra 0.4 0.02 69 64 76 76 64 EIF4B, gran, intra OAS2, mean,intra 0.38 0 69 65 73 73 64 EIF4B, gran, intra OAS2, mono, intra 0.40.02 69 64 76 76 64 EIF4B, gran, intra PARP12, gran, intra 0.24 −0.14 6577 46 70 55 EIF4B, gran, intra PARP12, mean, intra 0.27 −0.11 65 71 5672 55 EIF4B, gran, intra PARP12, mono, intra 0.24 −0.14 65 77 46 70 55EIF4B, gran, intra PARP9, lymp, intra 0.3 −0.08 68 80 49 72 59 EIF4B,gran, intra PDIA6, gran, intra 0.24 −0.14 65 77 45 71 54 EIF4B, gran,intra PDIA6, lymp, intra 0.31 −0.07 68 74 58 75 56 EIF4B, gran, intraPDIA6, mono, intra 0.24 −0.14 65 77 45 71 54 EIF4B, gran, intra PTEN,gran, intra 0.26 −0.12 66 77 49 71 56 EIF4B, gran, intra PTEN, lymp,intra 0.33 −0.05 69 78 54 74 60 EIF4B, gran, intra PTEN, mean, intra 0.2−0.18 63 77 41 68 53 EIF4B, gran, intra PTEN, mono, intra 0.26 −0.12 6677 49 71 56 EIF4B, gran, intra RSAD2, gran, intra 0.62 −0.01 81 78 84 8577 EIF4B, gran, intra RSAD2, lymp, intra 0.45 0.07 72 70 75 76 68 EIF4B,gran, intra RSAD2, mean, intra 0.6 −0.04 80 78 82 84 76 EIF4B, gran,intra RSAD2, mono, intra 0.62 −0.01 81 78 84 85 77 EIF4B, gran, intraSDCBP, mean, intra 0.2 −0.18 63 75 44 68 53 EIF4B, gran, intra WBC 0.510.13 76 84 66 75 77 EIF4B, lymp, intra EIF4B, mean, intra 0.39 −0.01 6969 69 72 66 EIF4B, lymp, intra EIF4B, mono, intra 0.43 0.03 72 69 75 7667 EIF4B, lymp, intra EPSTI1, lymp, membrane 0.32 −0.08 69 79 52 74 59EIF4B, lymp, intra GAS7, lymp, intra 0.27 −0.13 67 75 52 73 55 EIF4B,lymp, intra IFI6, gran, intra 0.16 −0.24 62 77 38 67 50 EIF4B, lymp,intra IFI6, mono, intra 0.16 −0.24 62 77 38 67 50 EIF4B, lymp, intraIFIT3, gran, intra 0.37 −0.03 71 80 56 75 63 EIF4B, lymp, intra IFIT3,lymp, intra 0.33 −0.1 69 78 54 74 60 EIF4B, lymp, intra IFIT3, mean,intra 0.34 −0.06 69 79 54 73 62 EIF4B, lymp, intra IFIT3, mono, intra0.37 −0.03 71 80 56 75 63 EIF4B, lymp, intra IFITM1, gran, membrane 0.38−0.02 69 73 65 72 66 EIF4B, lymp, intra IFITM1, lymp, membrane 0.4 0 7070 70 74 66 EIF4B, lymp, intra IFITM1, mean, membrane 0.37 −0.03 69 7463 71 66 EIF4B, lymp, intra IFITM1, mono, membrane 0.36 −0.04 69 73 6371 66 EIF4B, lymp, intra IFITM3, gran, membrane 0.41 0.01 71 73 68 74 67EIF4B, lymp, intra IFITM3, mean, membrane 0.4 0 70 72 68 73 67 EIF4B,lymp, intra IFITM3, mono, membrane 0.46 0.05 73 73 73 77 69 EIF4B, lymp,intra LOC26010, gran, intra 0.43 0.03 72 74 68 73 69 EIF4B, lymp, intraLOC26010, mean, intra 0.4 0 70 74 66 72 68 EIF4B, lymp, intra LOC26010,mono, intra 0.43 0.03 72 74 68 73 69 EIF4B, lymp, intra LY6E, lymp,membrane 0.37 −0.03 69 70 67 72 65 EIF4B, lymp, intra Lym(%) 0.66 0.1483 82 84 86 80 EIF4B, lymp, intra MAN1C1, gran, intra 0.2 −0.2 64 77 4269 52 EIF4B, lymp, intra MAN1C1, mean, intra 0.19 −0.21 64 79 39 68 52EIF4B, lymp, intra MAN1C1, mono, intra 0.2 −0.2 64 77 42 69 52 EIF4B,lymp, intra MX1, gran, intra 0.56 0.02 78 76 81 82 74 EIF4B, lymp, intraMX1, lymp, intra 0.47 0.07 74 73 75 77 70 EIF4B, lymp, intra MX1, mean,intra 0.52 0.07 76 75 77 79 73 EIF4B, lymp, intra MX1, mono, intra 0.560.02 78 76 81 82 74 EIF4B, lymp, intra Neu(%) 0.67 0.11 84 85 82 85 82EIF4B, lymp, intra NPM1, gran, intra 0.31 −0.09 69 83 46 71 62 EIF4B,lymp, intra NPM1, mean, intra 0.2 −0.2 63 75 44 68 53 EIF4B, lymp, intraNPM1, mono, intra 0.31 −0.09 69 83 46 71 62 EIF4B, lymp, intra OAS2,gran, intra 0.49 0.09 74 76 73 77 72 EIF4B, lymp, intra OAS2, mean,intra 0.46 0.06 73 76 69 74 72 EIF4B, lymp, intra OAS2, mono, intra 0.490.09 74 76 73 77 72 EIF4B, lymp, intra PARP12, gran, intra 0.28 −0.12 6778 49 71 58 EIF4B, lymp, intra PARP12, mean, intra 0.32 −0.08 68 77 5473 60 EIF4B, lymp, intra PARP12, mono, intra 0.28 −0.12 67 78 49 71 58EIF4B, lymp, intra PARP9, lymp, intra 0.24 −0.16 66 83 38 69 58 EIF4B,lymp, intra PDIA6, gran, intra 0.35 −0.05 70 79 55 75 61 EIF4B, lymp,intra PDIA6, lymp, intra 0.25 −0.15 65 74 52 72 53 EIF4B, lymp, intraPDIA6, mono, intra 0.35 −0.05 70 79 55 75 61 EIF4B, lymp, intra PTEN,gran, intra 0.21 −0.19 64 77 44 69 53 EIF4B, lymp, intra PTEN, lymp,intra 0.17 −0.23 62 75 41 68 50 EIF4B, lymp, intra PTEN, mean, intra0.22 −0.18 64 77 44 69 55 EIF4B, lymp, intra PTEN, mono, intra 0.21−0.19 64 77 44 69 53 EIF4B, lymp, intra RSAD2, gran, intra 0.61 −0.02 8078 83 84 76 EIF4B, lymp, intra RSAD2, lymp, intra 0.37 −0.03 69 72 65 7166 EIF4B, lymp, intra RSAD2, mean, intra 0.63 −0.01 81 82 81 83 79EIF4B, lymp, intra RSAD2, mono, intra 0.61 −0.02 80 78 83 84 76 EIF4B,lymp, intra SDCBP, mean, intra 0.19 −0.21 63 79 38 67 54 EIF4B, lymp,intra WBC 0.46 0.06 74 78 68 74 72 EIF4B, mean, intra EIF4B, mono, intra0.38 0 69 63 76 75 64 EIF4B, mean, intra EPSTI1, lymp, membrane 0.31 068 75 55 74 57 EIF4B, mean, intra GAS7, lymp, intra 0.27 −0.04 67 75 5273 55 EIF4B, mean, intra IFI6, gran, intra 0.15 −0.16 61 76 38 66 50EIF4B, mean, intra IFI6, mono, intra 0.15 −0.16 61 76 38 66 50 EIF4B,mean, intra IFIT3, gran, intra 0.33 −0.06 68 76 56 73 59 EIF4B, mean,intra IFIT3, lymp, intra 0.3 −0.13 67 76 54 72 58 EIF4B, mean, intraIFIT3, mean, intra 0.23 −0.08 64 76 46 69 55 EIF4B, mean, intra IFIT3,mono, intra 0.33 −0.06 68 76 56 73 59 EIF4B, mean, intra IFITM1, gran,membrane 0.26 −0.05 63 68 58 66 60 EIF4B, mean, intra IFITM1, lymp,membrane 0.39 0.01 69 71 68 73 66 EIF4B, mean, intra IFITM1, mean,membrane 0.26 −0.05 63 69 56 66 60 EIF4B, mean, intra IFITM1, mono,membrane 0.28 −0.03 64 65 63 68 60 EIF4B, mean, intra IFITM3, gran,membrane 0.31 −0.04 66 65 66 70 61 EIF4B, mean, intra IFITM3, mean,membrane 0.32 −0.03 66 68 64 70 62 EIF4B, mean, intra IFITM3, mono,membrane 0.4 −0.01 70 71 69 74 66 EIF4B, mean, intra LOC26010, gran,intra 0.33 0.02 66 65 68 70 63 EIF4B, mean, intra LOC26010, mean, intra0.3 −0.01 65 63 68 69 61 EIF4B, mean, intra LOC26010, mono, intra 0.330.02 66 65 68 70 63 EIF4B, mean, intra LY6E, lymp, membrane 0.36 0.05 6870 67 72 64 EIF4B, mean, intra Lym(%) 0.54 0.02 77 75 79 81 73 EIF4B,mean, intra MAN1C1, gran, intra 0.27 −0.04 67 83 42 70 59 EIF4B, mean,intra MAN1C1, mean, intra 0.25 −0.06 66 79 45 71 56 EIF4B, mean, intraMAN1C1, mono, intra 0.27 −0.04 67 83 42 70 59 EIF4B, mean, intra MX1,gran, intra 0.53 −0.01 76 69 84 83 70 EIF4B, mean, intra MX1, lymp,intra 0.42 0.07 71 67 76 76 66 EIF4B, mean, intra MX1, mean, intra 0.460.01 72 67 79 79 67 EIF4B, mean, intra MX1, mono, intra 0.53 −0.01 76 6984 83 70 EIF4B, mean, intra Neu(%) 0.57 0.01 78 78 79 81 75 EIF4B, mean,intra NPM1, gran, intra 0.08 −0.23 58 74 33 63 45 EIF4B, mean, intraNPM1, mean, intra 0.08 −0.23 58 72 36 64 45 EIF4B, mean, intra NPM1,mono, intra 0.08 −0.23 58 74 33 63 45 EIF4B, mean, intra OAS2, gran,intra 0.4 0.04 69 63 77 76 64 EIF4B, mean, intra OAS2, mean, intra 0.340.03 67 67 68 71 64 EIF4B, mean, intra OAS2, mono, intra 0.4 0.04 69 6377 76 64 EIF4B, mean, intra PARP12, gran, intra 0.16 −0.15 61 74 41 6750 EIF4B, mean, intra PARP12, mean, intra 0.26 −0.05 65 74 51 71 56EIF4B, mean, intra PARP12, mono, intra 0.16 −0.15 61 74 41 67 50 EIF4B,mean, intra PARP9, lymp, intra 0.19 −0.12 63 79 38 67 54 EIF4B, mean,intra PDIA6, gran, intra 0.26 −0.05 67 79 45 71 56 EIF4B, mean, intraPDIA6, lymp, intra 0.27 −0.04 67 77 48 72 56 EIF4B, mean, intra PDIA6,mono, intra 0.26 −0.05 67 79 45 71 56 EIF4B, mean, intra PTEN, gran,intra 0.2 −0.11 63 76 44 68 53 EIF4B, mean, intra PTEN, lymp, intra 0.310 68 79 51 72 61 EIF4B, mean, intra PTEN, mean, intra 0.16 −0.15 61 7441 67 50 EIF4B, mean, intra PTEN, mono, intra 0.2 −0.11 63 76 44 68 53EIF4B, mean, intra RSAD2, gran, intra 0.63 0 81 79 84 85 78 EIF4B, mean,intra RSAD2, lymp, intra 0.41 0.1 70 68 73 74 66 EIF4B, mean, intraRSAD2, mean, intra 0.63 −0.01 81 79 84 85 78 EIF4B, mean, intra RSAD2,mono, intra 0.63 0 81 79 84 85 78 EIF4B, mean, intra SDCBP, mean, intra0.17 −0.14 62 77 38 66 52 EIF4B, mean, intra WBC 0.38 0.07 69 79 58 6971 EIF4B, mono, intra EPSTI1, lymp, membrane 0.37 −0.01 70 74 65 78 59EIF4B, mono, intra GAS7, lymp, intra 0.34 −0.04 69 74 61 76 58 EIF4B,mono, intra IFI6, gran, intra 0.19 −0.19 63 77 41 68 52 EIF4B, mono,intra IFI6, mono, intra 0.19 −0.19 63 77 41 68 52 EIF4B, mono, intraIFIT3, gran, intra 0.38 −0.01 71 78 59 76 62 EIF4B, mono, intra IFIT3,lymp, intra 0.35 −0.08 70 78 56 75 61 EIF4B, mono, intra IFIT3, mean,intra 0.33 −0.05 68 76 56 73 59 EIF4B, mono, intra IFIT3, mono, intra0.38 −0.01 71 78 59 76 62 EIF4B, mono, intra IFITM1, gran, membrane 0.28−0.1 64 65 63 69 59 EIF4B, mono, intra IFITM1, lymp, membrane 0.43 0.0572 72 72 76 67 EIF4B, mono, intra IFITM1, mean, membrane 0.28 −0.1 64 6563 68 60 EIF4B, mono, intra IFITM1, mono, membrane 0.32 −0.06 66 69 6370 62 EIF4B, mono, intra IFITM3, gran, membrane 0.34 −0.04 67 68 67 7163 EIF4B, mono, intra IFITM3, mean, membrane 0.33 −0.05 66 65 68 71 62EIF4B, mono, intra IFITM3, mono, membrane 0.45 0.04 72 70 75 78 67EIF4B, mono, intra LOC26010, gran, intra 0.39 0.01 69 65 75 75 64 EIF4B,mono, intra LOC26010, mean, intra 0.38 0 69 63 76 75 64 EIF4B, mono,intra LOC26010, mono, intra 0.39 0.01 69 65 75 75 64 EIF4B, mono, intraLY6E, lymp, membrane 0.41 0.03 70 68 73 75 66 EIF4B, mono, intra Lym(%)0.55 0.03 77 76 79 81 73 EIF4B, mono, intra MAN1C1, gran, intra 0.36−0.02 71 83 52 74 64 EIF4B, mono, intra MAN1C1, mean, intra 0.39 0.01 7283 55 75 65 EIF4B, mono, intra MAN1C1, mono, intra 0.36 −0.02 71 83 5274 64 EIF4B, mono, intra MX1, gran, intra 0.57 0.03 78 73 84 84 73EIF4B, mono, intra MX1, lymp, intra 0.54 0.16 77 73 81 82 72 EIF4B,mono, intra MX1, mean, intra 0.58 0.13 78 72 85 85 73 EIF4B, mono, intraMX1, mono, intra 0.57 0.03 78 73 84 84 73 EIF4B, mono, intra Neu(%) 0.53−0.03 76 76 77 80 73 EIF4B, mono, intra NPM1, gran, intra 0.16 −0.22 6275 41 67 50 EIF4B, mono, intra NPM1, mean, intra 0.27 −0.11 66 75 51 7157 EIF4B, mono, intra NPM1, mono, intra 0.16 −0.22 62 75 41 67 50 EIF4B,mono, intra OAS2, gran, intra 0.4 0.02 69 64 76 76 64 EIF4B, mono, intraOAS2, mean, intra 0.38 0 69 65 73 73 64 EIF4B, mono, intra OAS2, mono,intra 0.4 0.02 69 64 76 76 64 EIF4B, mono, intra PARP12, gran, intra0.24 −0.14 65 77 46 70 55 EIF4B, mono, intra PARP12, mean, intra 0.27−0.11 65 71 56 72 55 EIF4B, mono, intra PARP12, mono, intra 0.24 −0.1465 77 46 70 55 EIF4B, mono, intra PARP9, lymp, intra 0.3 −0.08 68 80 4972 59 EIF4B, mono, intra PDIA6, gran, intra 0.24 −0.14 65 77 45 71 54EIF4B, mono, intra PDIA6, lymp, intra 0.31 −0.07 68 74 58 75 56 EIF4B,mono, intra PDIA6, mono, intra 0.24 −0.14 65 77 45 71 54 EIF4B, mono,intra PTEN, gran, intra 0.26 −0.12 66 77 49 71 56 EIF4B, mono, intraPTEN, lymp, intra 0.33 −0.05 69 78 54 74 60 EIF4B, mono, intra PTEN,mean, intra 0.2 −0.18 63 77 41 68 53 EIF4B, mono, intra PTEN, mono,intra 0.26 −0.12 66 77 49 71 56 EIF4B, mono, intra RSAD2, gran, intra0.62 −0.01 81 78 84 85 77 EIF4B, mono, intra RSAD2, lymp, intra 0.450.07 72 70 75 76 68 EIF4B, mono, intra RSAD2, mean, intra 0.6 −0.04 8078 82 84 76 EIF4B, mono, intra RSAD2, mono, intra 0.62 −0.01 81 78 84 8577 EIF4B, mono, intra SDCBP, mean, intra 0.2 −0.18 63 75 44 68 53 EIF4B,mono, intra WBC 0.51 0.13 76 84 66 75 77 EPSTI1, lymp, membrane GAS7,lymp, intra 0.14 −0.05 62 77 35 67 48 EPSTI1, lymp, membrane IFI6, gran,intra 0.24 0.05 65 77 45 71 54 EPSTI1, lymp, membrane IFI6, mono, intra0.24 0.05 65 77 45 71 54 EPSTI1, lymp, membrane IFIT3, gran, intra 0.21−0.18 64 75 45 70 52 EPSTI1, lymp, membrane IFIT3, lymp, intra 0.2 −0.2364 77 42 69 52 EPSTI1, lymp, membrane IFIT3, mean, intra 0.26 0.01 67 7945 71 56 EPSTI1, lymp, membrane IFIT3, mono, intra 0.21 −0.18 64 75 4570 52 EPSTI1, lymp, membrane IFITM1, gran, membrane 0.12 −0.14 62 81 2966 47 EPSTI1, lymp, membrane IFITM1, lymp, membrane 0.15 −0.23 62 75 3968 48 EPSTI1, lymp, membrane IFITM1, mean, membrane 0.15 −0.14 63 81 3267 50 EPSTI1, lymp, membrane IFITM1, mono, membrane 0.28 −0.03 68 81 4572 58 EPSTI1, lymp, membrane IFITM3, gran, membrane 0.08 −0.27 61 81 2665 44 EPSTI1, lymp, membrane IFITM3, mean, membrane 0.06 −0.29 60 79 2665 42 EPSTI1, lymp, membrane IFITM3, mono, membrane 0.27 −0.14 67 75 5273 55 EPSTI1, lymp, membrane LOC26010, gran, intra 0.26 0.03 67 79 45 7156 EPSTI1, lymp, membrane LOC26010, mean, intra 0.24 0.03 67 83 39 70 57EPSTI1, lymp, membrane LOC26010, mono, intra 0.26 0.03 67 79 45 71 56EPSTI1, lymp, membrane LY6E, lymp, membrane 0.21 −0.02 65 83 35 69 55EPSTI1, lymp, membrane Lym(%) 0.48 −0.04 76 85 61 79 70 EPSTI1, lymp,membrane MAN1C1, gran, intra 0.28 0.09 67 81 45 71 58 EPSTI1, lymp,membrane MAN1C1, mean, intra 0.3 0.11 69 83 45 72 61 EPSTI1, lymp,membrane MAN1C1, mono, intra 0.28 0.09 67 81 45 71 58 EPSTI1, lymp,membrane MX1, gran, intra 0.48 −0.06 76 83 65 80 69 EPSTI1, lymp,membrane MX1, lymp, intra 0.27 −0.08 67 75 52 73 55 EPSTI1, lymp,membrane MX1, mean, intra 0.43 −0.02 74 81 61 78 66 EPSTI1, lymp,membrane MX1, mono, intra 0.48 −0.06 76 83 65 80 69 EPSTI1, lymp,membrane Neu(%) 0.48 −0.08 76 83 65 80 69 EPSTI1, lymp, membrane NPM1,gran, intra 0.34 0.15 70 81 52 74 62 EPSTI1, lymp, membrane NPM1, mean,intra 0.39 0.2 72 83 55 75 65 EPSTI1, lymp, membrane NPM1, mono, intra0.34 0.15 70 81 52 74 62 EPSTI1, lymp, membrane OAS2, gran, intra 0.21−0.15 64 75 45 70 52 EPSTI1, lymp, membrane OAS2, mean, intra 0.16 −0.1463 79 35 68 50 EPSTI1, lymp, membrane OAS2, mono, intra 0.21 −0.15 64 7545 70 52 EPSTI1, lymp, membrane PARP12, gran, intra 0.41 0.22 73 79 6178 63 EPSTI1, lymp, membrane PARP12, mean, intra 0.41 0.16 73 79 61 7863 EPSTI1, lymp, membrane PARP12, mono, intra 0.41 0.22 73 79 61 78 63EPSTI1, lymp, membrane PARP9, lymp, intra 0.21 0.02 65 83 35 69 55EPSTI1, lymp, membrane PDIA6, gran, intra 0.27 0.08 67 75 52 73 55EPSTI1, lymp, membrane PDIA6, lymp, intra 0.32 0.13 69 79 52 74 59EPSTI1, lymp, membrane PDIA6, mono, intra 0.27 0.08 67 75 52 73 55EPSTI1, lymp, membrane PTEN, gran, intra 0.4 0.18 71 75 65 78 61 EPSTI1,lymp, membrane PTEN, lymp, intra 0.27 0.08 67 77 48 72 56 EPSTI1, lymp,membrane PTEN, mean, intra 0.36 0.16 70 77 58 76 60 EPSTI1, lymp,membrane PTEN, mono, intra 0.4 0.18 71 75 65 78 61 EPSTI1, lymp,membrane RSAD2, gran, intra 0.62 −0.01 82 85 77 87 75 EPSTI1, lymp,membrane RSAD2, lymp, intra 0.19 −0.04 64 79 39 69 52 EPSTI1, lymp,membrane RSAD2, mean, intra 0.54 −0.1 79 83 71 83 71 EPSTI1, lymp,membrane RSAD2, mono, intra 0.62 −0.01 82 85 77 87 75 EPSTI1, lymp,membrane SDCBP, mean, intra 0.36 0.17 71 83 52 74 64 EPSTI1, lymp,membrane WBC 0.26 0.01 68 87 35 70 61 GAS7, lymp, intra IFI6, gran,intra 0 −0.1 55 68 32 63 37 GAS7, lymp, intra IFI6, mono, intra 0 −0.155 68 32 63 37 GAS7, lymp, intra IFIT3, gran, intra 0.2 −0.19 63 72 4870 50 GAS7, lymp, intra IFIT3, lymp, intra 0.27 −0.16 67 77 48 72 56GAS7, lymp, intra IFIT3, mean, intra 0.17 −0.08 62 72 45 69 48 GAS7,lymp, intra IFIT3, mono, intra 0.2 −0.19 63 72 48 70 50 GAS7, lymp,intra IFITM1, gran, membrane 0.07 −0.19 58 72 35 66 42 GAS7, lymp, intraIFITM1, lymp, membrane 0.14 −0.24 61 72 42 68 46 GAS7, lymp, intraIFITM1, mean, membrane 0.02 −0.27 56 70 32 64 38 GAS7, lymp, intraIFITM1, mono, membrane 0.3 −0.01 68 77 52 73 57 GAS7, lymp, intraIFITM3, gran, membrane 0.05 −0.3 57 70 35 65 41 GAS7, lymp, intraIFITM3, mean, membrane 0.05 −0.3 57 70 35 65 41 GAS7, lymp, intraIFITM3, mono, membrane 0.34 −0.07 69 75 58 75 58 GAS7, lymp, intraLOC26010, gran, intra 0.17 −0.06 63 77 39 68 50 GAS7, lymp, intraLOC26010, mean, intra 0.14 −0.07 62 77 35 67 48 GAS7, lymp, intraLOC26010, mono, intra 0.17 −0.06 63 77 39 68 50 GAS7, lymp, intra LY6E,lymp, membrane 0.06 −0.17 58 74 32 65 42 GAS7, lymp, intra Lym(%) 0.49−0.03 76 81 68 81 68 GAS7, lymp, intra MAN1C1, gran, intra 0.2 0.09 6477 42 69 52 GAS7, lymp, intra MAN1C1, mean, intra 0.11 −0.02 60 75 35 6646 GAS7, lymp, intra MAN1C1, mono, intra 0.2 0.09 64 77 42 69 52 GAS7,lymp, intra MX1, gran, intra 0.51 −0.03 77 83 68 81 70 GAS7, lymp, intraMX1, lymp, intra 0.31 −0.04 69 81 48 73 60 GAS7, lymp, intra MX1, mean,intra 0.45 0 74 77 68 80 64 GAS7, lymp, intra MX1, mono, intra 0.51−0.03 77 83 68 81 70 GAS7, lymp, intra Neu(%) 0.45 −0.11 75 83 61 79 68GAS7, lymp, intra NPM1, gran, intra 0.2 0.1 64 77 42 69 52 GAS7, lymp,intra NPM1, mean, intra 0.17 0.04 63 77 39 68 50 GAS7, lymp, intra NPM1,mono, intra 0.2 0.1 64 77 42 69 52 GAS7, lymp, intra OAS2, gran, intra0.15 −0.21 61 70 45 69 47 GAS7, lymp, intra OAS2, mean, intra −0.01−0.31 55 70 29 63 36 GAS7, lymp, intra OAS2, mono, intra 0.15 −0.21 6170 45 69 47 GAS7, lymp, intra PARP12, gran, intra 0.24 0.05 65 75 48 7154 GAS7, lymp, intra PARP12, mean, intra 0.2 −0.05 63 72 48 70 50 GAS7,lymp, intra PARP12, mono, intra 0.24 0.05 65 75 48 71 54 GAS7, lymp,intra PARP9, lymp, intra 0.07 −0.07 58 72 35 66 42 GAS7, lymp, intraPDIA6, gran, intra 0.16 0.03 62 74 42 68 48 GAS7, lymp, intra PDIA6,lymp, intra 0.11 0.01 60 72 39 67 44 GAS7, lymp, intra PDIA6, mono,intra 0.16 0.03 62 74 42 68 48 GAS7, lymp, intra PTEN, gran, intra 0.18−0.04 62 70 48 70 48 GAS7, lymp, intra PTEN, lymp, intra 0.15 0.05 62 7539 68 48 GAS7, lymp, intra PTEN, mean, intra 0.12 −0.08 60 70 42 67 45GAS7, lymp, intra PTEN, mono, intra 0.18 −0.04 62 70 48 70 48 GAS7,lymp, intra RSAD2, gran, intra 0.62 −0.01 82 85 77 87 75 GAS7, lymp,intra RSAD2, lymp, intra 0.06 −0.17 58 74 32 65 42 GAS7, lymp, intraRSAD2, mean, intra 0.61 −0.03 82 87 74 85 77 GAS7, lymp, intra RSAD2,mono, intra 0.62 −0.01 82 85 77 87 75 GAS7, lymp, intra SDCBP, mean,intra 0.25 0.15 66 79 45 71 56 GAS7, lymp, intra WBC 0.19 −0.06 64 81 3568 52 IFI6, gran, intra IFI6, mono, intra 0.06 −0.02 59 80 26 64 43IFI6, gran, intra IFIT3, gran, intra 0.33 −0.06 69 77 56 74 59 IFI6,gran, intra IFIT3, lymp, intra 0.4 −0.03 72 78 62 77 63 IFI6, gran,intra IFIT3, mean, intra 0.34 0.09 69 77 56 74 61 IFI6, gran, intraIFIT3, mono, intra 0.33 −0.06 69 77 56 74 59 IFI6, gran, intra IFITM1,gran, membrane 0.05 −0.21 59 81 23 63 43 IFI6, gran, intra IFITM1, lymp,membrane 0.35 −0.03 70 78 56 75 61 IFI6, gran, intra IFITM1, mean,membrane 0 −0.29 55 74 26 61 38 IFI6, gran, intra IFITM1, mono, membrane0.23 −0.08 64 72 51 71 53 IFI6, gran, intra IFITM3, gran, membrane 0.09−0.26 60 80 28 65 46 IFI6, gran, intra IFITM3, mean, membrane 0.05 −0.357 74 31 63 43 IFI6, gran, intra IFITM3, mono, membrane 0.26 −0.15 65 7056 73 54 IFI6, gran, intra LOC26010, gran, intra 0.09 −0.14 59 75 33 6545 IFI6, gran, intra LOC26010, mean, intra −0.01 −0.22 54 71 28 61 38IFI6, gran, intra LOC26010, mono, intra 0.09 −0.14 59 75 33 65 45 IFI6,gran, intra LY6E, lymp, membrane −0.02 −0.25 57 79 19 63 35 IFI6, gran,intra Lym(%) 0.49 −0.03 76 78 72 82 67 IFI6, gran, intra MAN1C1, gran,intra 0.13 0.02 61 77 35 67 48 IFI6, gran, intra MAN1C1, mean, intra0.13 0 61 77 35 67 48 IFI6, gran, intra MAN1C1, mono, intra 0.13 0.02 6177 35 67 48 IFI6, gran, intra MX1, gran, intra 0.47 −0.07 75 78 69 81 66IFI6, gran, intra MX1, lymp, intra 0.32 −0.03 68 73 59 75 57 IFI6, gran,intra MX1, mean, intra 0.43 −0.02 73 79 64 78 66 IFI6, gran, intra MX1,mono, intra 0.47 −0.07 75 78 69 81 66 IFI6, gran, intra Neu(%) 0.53−0.03 78 81 72 83 70 IFI6, gran, intra NPM1, gran, intra 0.14 0.04 61 7538 66 48 IFI6, gran, intra NPM1, mean, intra 0.05 −0.08 56 69 36 63 42IFI6, gran, intra NPM1, mono, intra 0.14 0.04 61 75 38 66 48 IFI6, gran,intra OAS2, gran, intra 0.15 −0.21 61 73 41 67 48 IFI6, gran, intraOAS2, mean, intra 0.09 −0.21 59 77 31 64 46 IFI6, gran, intra OAS2,mono, intra 0.15 −0.21 61 73 41 67 48 IFI6, gran, intra PARP12, gran,intra 0.17 −0.02 61 70 46 68 49 IFI6, gran, intra PARP12, mean, intra0.19 −0.06 62 73 46 68 51 IFI6, gran, intra PARP12, mono, intra 0.17−0.02 61 70 46 68 49 IFI6, gran, intra PARP9, lymp, intra 0.18 0.04 6273 44 68 50 IFI6, gran, intra PDIA6, gran, intra 0.01 −0.12 57 75 26 6338 IFI6, gran, intra PDIA6, lymp, intra 0.03 −0.05 57 74 29 64 39 IFI6,gran, intra PDIA6, mono, intra 0.01 −0.12 57 75 26 63 38 IFI6, gran,intra PTEN, gran, intra 0.18 −0.04 62 72 46 69 50 IFI6, gran, intraPTEN, lymp, intra 0.05 −0.03 56 69 36 64 41 IFI6, gran, intra PTEN,mean, intra 0.12 −0.08 59 71 41 66 47 IFI6, gran, intra PTEN, mono,intra 0.18 −0.04 62 72 46 69 50 IFI6, gran, intra RSAD2, gran, intra0.69 0.06 85 88 82 89 80 IFI6, gran, intra RSAD2, lymp, intra 0.24 0.0166 81 41 69 57 IFI6, gran, intra RSAD2, mean, intra 0.61 −0.03 81 82 7986 74 IFI6, gran, intra RSAD2, mono, intra 0.69 0.06 85 88 82 89 80IFI6, gran, intra SDCBP, mean, intra 0.1 0.02 59 74 36 64 47 IFI6, gran,intra WBC 0.26 0.01 67 83 41 70 59 IFI6, mono, intra IFIT3, gran, intra0.33 −0.06 69 77 56 74 59 IFI6, mono, intra IFIT3, lymp, intra 0.4 −0.0372 78 62 77 63 IFI6, mono, intra IFIT3, mean, intra 0.34 0.09 69 77 5674 61 IFI6, mono, intra IFIT3, mono, intra 0.33 −0.06 69 77 56 74 59IFI6, mono, intra IFITM1, gran, membrane 0.05 −0.21 59 81 23 63 43 IFI6,mono, intra IFITM1, lymp, membrane 0.35 −0.03 70 78 56 75 61 IFI6, mono,intra IFITM1, mean, membrane 0 −0.29 55 74 26 61 38 IFI6, mono, intraIFITM1, mono, membrane 0.23 −0.08 64 72 51 71 53 IFI6, mono, intraIFITM3, gran, membrane 0.09 −0.26 60 80 28 65 46 IFI6, mono, intraIFITM3, mean, membrane 0.05 −0.3 57 74 31 63 43 IFI6, mono, intraIFITM3, mono, membrane 0.26 −0.15 65 70 56 73 54 IFI6, mono, intraLOC26010, gran, intra 0.09 −0.14 59 75 33 65 45 IFI6, mono, intraLOC26010, mean, intra −0.01 −0.22 54 71 28 61 38 IFI6, mono, intraLOC26010, mono, intra 0.09 −0.14 59 75 33 65 45 IFI6, mono, intra LY6E,lymp, membrane −0.02 −0.25 57 79 19 63 35 IFI6, mono, intra Lym(%) 0.49−0.03 76 78 72 82 67 IFI6, mono, intra MAN1C1, gran, intra 0.13 0.02 6177 35 67 48 IFI6, mono, intra MAN1C1, mean, intra 0.13 0 61 77 35 67 48IFI6, mono, intra MAN1C1, mono, intra 0.13 0.02 61 77 35 67 48 IFI6,mono, intra MX1, gran, intra 0.47 −0.07 75 78 69 81 66 IFI6, mono, intraMX1, lymp, intra 0.32 −0.03 68 73 59 75 57 IFI6, mono, intra MX1, mean,intra 0.43 −0.02 73 79 64 78 66 IFI6, mono, intra MX1, mono, intra 0.47−0.07 75 78 69 81 66 IFI6, mono, intra Neu(%) 0.53 −0.03 78 81 72 83 70IFI6, mono, intra NPM1, gran, intra 0.14 0.04 61 75 38 66 48 IFI6, mono,intra NPM1, mean, intra 0.05 −0.08 56 69 36 63 42 IFI6, mono, intraNPM1, mono, intra 0.14 0.04 61 75 38 66 48 IFI6, mono, intra OAS2, gran,intra 0.15 −0.21 61 73 41 67 48 IFI6, mono, intra OAS2, mean, intra 0.09−0.21 59 77 31 64 46 IFI6, mono, intra OAS2, mono, intra 0.15 −0.21 6173 41 67 48 IFI6, mono, intra PARP12, gran, intra 0.17 −0.02 61 70 46 6849 IFI6, mono, intra PARP12, mean, intra 0.19 −0.06 62 73 46 68 51 IFI6,mono, intra PARP12, mono, intra 0.17 −0.02 61 70 46 68 49 IFI6, mono,intra PARP9, lymp, intra 0.18 0.04 62 73 44 68 50 IFI6, mono, intraPDIA6, gran, intra 0.01 −0.12 57 75 26 63 38 IFI6, mono, intra PDIA6,lymp, intra 0.03 −0.05 57 74 29 64 39 IFI6, mono, intra PDIA6, mono,intra 0.01 −0.12 57 75 26 63 38 IFI6, mono, intra PTEN, gran, intra 0.18−0.04 62 72 46 69 50 IFI6, mono, intra PTEN, lymp, intra 0.05 −0.03 5669 36 64 41 IFI6, mono, intra PTEN, mean, intra 0.12 −0.08 59 71 41 6647 IFI6, mono, intra PTEN, mono, intra 0.18 −0.04 62 72 46 69 50 IFI6,mono, intra RSAD2, gran, intra 0.69 0.06 85 88 82 89 80 IFI6, mono,intra RSAD2, lymp, intra 0.24 0.01 66 81 41 69 57 IFI6, mono, intraRSAD2, mean, intra 0.61 −0.03 81 82 79 86 74 IFI6, mono, intra RSAD2,mono, intra 0.69 0.06 85 88 82 89 80 IFI6, mono, intra SDCBP, mean,intra 0.1 0.02 59 74 36 64 47 IFI6, mono, intra WBC 0.26 0.01 67 83 4170 59 IFIT3, gran, intra IFIT3, lymp, intra 0.36 −0.07 70 75 62 76 60IFIT3, gran, intra IFIT3, mean, intra 0.36 −0.03 70 79 56 74 63 IFIT3,gran, intra IFIT3, mono, intra 0.38 −0.01 71 78 59 76 62 IFIT3, gran,intra IFITM1, gran, membrane 0.35 −0.04 70 78 56 75 61 IFIT3, gran,intra IFITM1, lymp, membrane 0.35 −0.04 69 73 62 76 59 IFIT3, gran,intra IFITM1, mean, membrane 0.33 −0.06 68 76 56 73 59 IFIT3, gran,intra IFITM1, mono, membrane 0.38 −0.01 71 78 59 76 62 IFIT3, gran,intra IFITM3, gran, membrane 0.35 −0.04 70 78 56 75 61 IFIT3, gran,intra IFITM3, mean, membrane 0.34 −0.05 69 77 56 74 61 IFIT3, gran,intra IFITM3, mono, membrane 0.42 0.01 73 78 64 78 64 IFIT3, gran, intraLOC26010, gran, intra 0.3 −0.09 67 73 56 73 56 IFIT3, gran, intraLOC26010, mean, intra 0.27 −0.12 65 73 54 71 55 IFIT3, gran, intraLOC26010, mono, intra 0.3 −0.09 67 73 56 73 56 IFIT3, gran, intra LY6E,lymp, membrane 0.19 −0.2 64 79 39 69 52 IFIT3, gran, intra Lym(%) 0.560.04 80 86 69 82 75 IFIT3, gran, intra MAN1C1, gran, intra 0.35 −0.04 7187 45 73 67 IFIT3, gran, intra MAN1C1, mean, intra 0.3 −0.09 69 85 42 7162 IFIT3, gran, intra MAN1C1, mono, intra 0.35 −0.04 71 87 45 73 67IFIT3, gran, intra MX1, gran, intra 0.46 −0.08 75 80 67 80 67 IFIT3,gran, intra MX1, lymp, intra 0.42 0.03 73 78 64 78 64 IFIT3, gran, intraMX1, mean, intra 0.4 −0.05 71 74 67 78 62 IFIT3, gran, intra MX1, mono,intra 0.46 −0.08 75 80 67 80 67 IFIT3, gran, intra Neu(%) 0.62 0.06 8389 72 84 80 IFIT3, gran, intra NPM1, gran, intra 0.4 0.01 72 78 62 77 63IFIT3, gran, intra NPM1, mean, intra 0.39 0 71 77 62 76 63 IFIT3, gran,intra NPM1, mono, intra 0.4 0.01 72 78 62 77 63 IFIT3, gran, intra OAS2,gran, intra 0.38 −0.01 71 78 59 76 62 IFIT3, gran, intra OAS2, mean,intra 0.33 −0.06 68 76 56 73 59 IFIT3, gran, intra OAS2, mono, intra0.38 −0.01 71 78 59 76 62 IFIT3, gran, intra PARP12, gran, intra 0.38−0.01 71 78 59 76 62 IFIT3, gran, intra PARP12, mean, intra 0.38 −0.0170 74 64 77 61 IFIT3, gran, intra PARP12, mono, intra 0.38 −0.01 71 7859 76 62 IFIT3, gran, intra PARP9, lymp, intra 0.34 −0.05 69 75 59 75 59IFIT3, gran, intra PDIA6, gran, intra 0.25 −0.14 67 81 42 70 57 IFIT3,gran, intra PDIA6, lymp, intra 0.4 0.01 73 81 58 77 64 IFIT3, gran,intra PDIA6, mono, intra 0.25 −0.14 67 81 42 70 57 IFIT3, gran, intraPTEN, gran, intra 0.37 −0.02 70 73 64 77 60 IFIT3, gran, intra PTEN,lymp, intra 0.32 −0.07 68 73 59 75 57 IFIT3, gran, intra PTEN, mean,intra 0.29 −0.1 66 73 56 73 56 IFIT3, gran, intra PTEN, mono, intra 0.37−0.02 70 73 64 77 60 IFIT3, gran, intra RSAD2, gran, intra 0.67 0.04 8486 82 89 78 IFIT3, gran, intra RSAD2, lymp, intra 0.36 −0.03 70 77 59 7561 IFIT3, gran, intra RSAD2, mean, intra 0.61 −0.03 81 82 79 86 74IFIT3, gran, intra RSAD2, mono, intra 0.67 0.04 84 86 82 89 78 IFIT3,gran, intra SDCBP, mean, intra 0.35 −0.04 69 75 59 74 61 IFIT3, gran,intra WBC 0.38 −0.01 72 83 54 75 66 IFIT3, lymp, intra IFIT3, mean,intra 0.38 −0.05 70 74 64 77 61 IFIT3, lymp, intra IFIT3, mono, intra0.36 −0.07 70 75 62 76 60 IFIT3, lymp, intra IFITM1, gran, membrane 0.35−0.08 69 73 62 76 59 IFIT3, lymp, intra IFITM1, lymp, membrane 0.3 −0.1367 73 56 73 56 IFIT3, lymp, intra IFITM1, mean, membrane 0.34 −0.09 6873 62 75 59 IFIT3, lymp, intra IFITM1, mono, membrane 0.42 −0.01 73 7864 78 64 IFIT3, lymp, intra IFITM3, gran, membrane 0.39 −0.04 71 73 6778 60 IFIT3, lymp, intra IFITM3, mean, membrane 0.36 −0.07 69 73 64 7660 IFIT3, lymp, intra IFITM3, mono, membrane 0.36 −0.07 70 75 62 76 60IFIT3, lymp, intra LOC26010, gran, intra 0.35 −0.08 69 73 62 76 59IFIT3, lymp, intra LOC26010, mean, intra 0.32 −0.11 67 71 62 75 57IFIT3, lymp, intra LOC26010, mono, intra 0.35 −0.08 69 73 62 76 59IFIT3, lymp, intra LY6E, lymp, membrane 0.22 −0.21 64 74 48 71 52 IFIT3,lymp, intra Lym(%) 0.59 0.07 81 83 77 85 73 IFIT3, lymp, intra MAN1C1,gran, intra 0.29 −0.14 67 77 52 73 57 IFIT3, lymp, intra MAN1C1, mean,intra 0.29 −0.14 67 77 52 73 57 IFIT3, lymp, intra MAN1C1, mono, intra0.29 −0.14 67 77 52 73 57 IFIT3, lymp, intra MX1, gran, intra 0.43 −0.1173 77 67 79 63 IFIT3, lymp, intra MX1, lymp, intra 0.4 −0.03 72 77 64 7863 IFIT3, lymp, intra MX1, mean, intra 0.36 −0.09 69 73 64 76 60 IFIT3,lymp, intra MX1, mono, intra 0.43 −0.11 73 77 67 79 63 IFIT3, lymp,intra Neu(%) 0.61 0.05 82 84 77 86 75 IFIT3, lymp, intra NPM1, gran,intra 0.34 −0.09 69 73 62 75 59 IFIT3, lymp, intra NPM1, mean, intra0.39 −0.04 71 75 64 77 63 IFIT3, lymp, intra NPM1, mono, intra 0.34−0.09 69 73 62 75 59 IFIT3, lymp, intra OAS2, gran, intra 0.39 −0.04 7175 64 77 61 IFIT3, lymp, intra OAS2, mean, intra 0.36 −0.07 69 73 64 7660 IFIT3, lymp, intra OAS2, mono, intra 0.39 −0.04 71 75 64 77 61 IFIT3,lymp, intra PARP12, gran, intra 0.4 −0.03 72 78 62 77 63 IFIT3, lymp,intra PARP12, mean, intra 0.38 −0.05 70 74 64 77 61 IFIT3, lymp, intraPARP12, mono, intra 0.4 −0.03 72 78 62 77 63 IFIT3, lymp, intra PARP9,lymp, intra 0.43 0 73 77 67 79 63 IFIT3, lymp, intra PDIA6, gran, intra0.29 −0.14 68 79 48 72 58 IFIT3, lymp, intra PDIA6, lymp, intra 0.35−0.08 70 79 55 75 61 IFIT3, lymp, intra PDIA6, mono, intra 0.29 −0.14 6879 48 72 58 IFIT3, lymp, intra PTEN, gran, intra 0.42 −0.01 73 78 64 7864 IFIT3, lymp, intra PTEN, lymp, intra 0.32 −0.11 68 73 59 75 57 IFIT3,lymp, intra PTEN, mean, intra 0.33 −0.1 68 76 56 73 59 IFIT3, lymp,intra PTEN, mono, intra 0.42 −0.01 73 78 64 78 64 IFIT3, lymp, intraRSAD2, gran, intra 0.67 0.04 84 86 82 89 78 IFIT3, lymp, intra RSAD2,lymp, intra 0.33 −0.1 68 72 62 75 57 IFIT3, lymp, intra RSAD2, mean,intra 0.61 −0.03 81 82 79 86 74 IFIT3, lymp, intra RSAD2, mono, intra0.67 0.04 84 86 82 89 78 IFIT3, lymp, intra SDCBP, mean, intra 0.37−0.06 70 75 62 75 62 IFIT3, lymp, intra WBC 0.33 −0.1 69 78 54 74 60IFIT3, mean, intra IFIT3, mono, intra 0.36 −0.03 70 79 56 74 63 IFIT3,mean, intra IFITM1, gran, membrane 0.21 −0.05 63 74 46 69 53 IFIT3,mean, intra IFITM1, lymp, membrane 0.31 −0.07 67 73 59 74 57 IFIT3,mean, intra IFITM1, mean, membrane 0.25 −0.04 65 76 49 70 56 IFIT3,mean, intra IFITM1, mono, membrane 0.32 0.01 68 77 54 73 60 IFIT3, mean,intra IFITM3, gran, membrane 0.24 −0.11 64 73 51 70 54 IFIT3, mean,intra IFITM3, mean, membrane 0.26 −0.09 65 74 51 71 56 IFIT3, mean,intra IFITM3, mono, membrane 0.35 −0.06 69 76 59 75 61 IFIT3, mean,intra LOC26010, gran, intra 0.22 −0.03 63 71 51 70 53 IFIT3, mean, intraLOC26010, mean, intra 0.16 −0.09 60 69 46 67 49 IFIT3, mean, intraLOC26010, mono, intra 0.22 −0.03 63 71 51 70 53 IFIT3, mean, intra LY6E,lymp, membrane 0.13 −0.12 62 79 32 67 48 IFIT3, mean, intra Lym(%) 0.560.04 79 85 69 82 75 IFIT3, mean, intra MAN1C1, gran, intra 0.2 −0.05 6585 32 68 56 IFIT3, mean, intra MAN1C1, mean, intra 0.21 −0.04 65 83 3568 55 IFIT3, mean, intra MAN1C1, mono, intra 0.2 −0.05 65 85 32 68 56IFIT3, mean, intra MX1, gran, intra 0.44 −0.1 73 77 67 79 65 IFIT3,mean, intra MX1, lymp, intra 0.27 −0.08 65 71 56 72 55 IFIT3, mean,intra MX1, mean, intra 0.38 −0.07 70 74 64 77 61 IFIT3, mean, intra MX1,mono, intra 0.44 −0.1 73 77 67 79 65 IFIT3, mean, intra Neu(%) 0.62 0.0682 89 72 83 80 IFIT3, mean, intra NPM1, gran, intra 0.36 0.11 70 77 5975 62 IFIT3, mean, intra NPM1, mean, intra 0.34 0.09 69 77 56 73 61IFIT3, mean, intra NPM1, mono, intra 0.36 0.11 70 77 59 75 62 IFIT3,mean, intra OAS2, gran, intra 0.28 −0.08 66 76 51 71 57 IFIT3, mean,intra OAS2, mean, intra 0.21 −0.09 63 74 46 69 53 IFIT3, mean, intraOAS2, mono, intra 0.28 −0.08 66 76 51 71 57 IFIT3, mean, intra PARP12,gran, intra 0.31 0.06 67 73 59 74 57 IFIT3, mean, intra PARP12, mean,intra 0.34 0.09 68 73 62 75 59 IFIT3, mean, intra PARP12, mono, intra0.31 0.06 67 73 59 74 57 IFIT3, mean, intra PARP9, lymp, intra 0.22−0.03 63 71 51 70 53 IFIT3, mean, intra PDIA6, gran, intra 0.2 −0.05 6477 42 69 52 IFIT3, mean, intra PDIA6, lymp, intra 0.22 −0.03 64 74 48 7152 IFIT3, mean, intra PDIA6, mono, intra 0.2 −0.05 64 77 42 69 52 IFIT3,mean, intra PTEN, gran, intra 0.31 0.06 67 74 56 73 58 IFIT3, mean,intra PTEN, lymp, intra 0.21 −0.04 62 69 51 69 51 IFIT3, mean, intraPTEN, mean, intra 0.16 −0.09 60 69 46 67 49 IFIT3, mean, intra PTEN,mono, intra 0.31 0.06 67 74 56 73 58 IFIT3, mean, intra RSAD2, gran,intra 0.69 0.06 85 87 82 89 80 IFIT3, mean, intra RSAD2, lymp, intra0.18 −0.07 61 69 49 68 50 IFIT3, mean, intra RSAD2, mean, intra 0.59−0.05 80 81 79 86 72 IFIT3, mean, intra RSAD2, mono, intra 0.69 0.06 8587 82 89 80 IFIT3, mean, intra SDCBP, mean, intra 0.23 −0.02 63 69 54 7053 IFIT3, mean, intra WBC 0.3 0.05 67 77 51 72 59 IFIT3, mono, intraIFITM1, gran, membrane 0.35 −0.04 70 78 56 75 61 IFIT3, mono, intraIFITM1, lymp, membrane 0.35 −0.04 69 73 62 76 59 IFIT3, mono, intraIFITM1, mean, membrane 0.33 −0.06 68 76 56 73 59 IFIT3, mono, intraIFITM1, mono, membrane 0.38 −0.01 71 78 59 76 62 IFIT3, mono, intraIFITM3, gran, membrane 0.35 −0.04 70 78 56 75 61 IFIT3, mono, intraIFITM3, mean, membrane 0.34 −0.05 69 77 56 74 61 IFIT3, mono, intraIFITM3, mono, membrane 0.42 0.01 73 78 64 78 64 IFIT3, mono, intraLOC26010, gran, intra 0.3 −0.09 67 73 56 73 56 IFIT3, mono, intraLOC26010, mean, intra 0.27 −0.12 65 73 54 71 55 IFIT3, mono, intraLOC26010, mono, intra 0.3 −0.09 67 73 56 73 56 IFIT3, mono, intra LY6E,lymp, membrane 0.19 −0.2 64 79 39 69 52 IFIT3, mono, intra Lym(%) 0.560.04 80 86 69 82 75 IFIT3, mono, intra MAN1C1, gran, intra 0.35 −0.04 7187 45 73 67 IFIT3, mono, intra MAN1C1, mean, intra 0.3 −0.09 69 85 42 7162 IFIT3, mono, intra MAN1C1, mono, intra 0.35 −0.04 71 87 45 73 67IFIT3, mono, intra MX1, gran, intra 0.46 −0.08 75 80 67 80 67 IFIT3,mono, intra MX1, lymp, intra 0.42 0.03 73 78 64 78 64 IFIT3, mono, intraMX1, mean, intra 0.4 −0.05 71 74 67 78 62 IFIT3, mono, intra MX1, mono,intra 0.46 −0.08 75 80 67 80 67 IFIT3, mono, intra Neu(%) 0.62 0.06 8389 72 84 80 IFIT3, mono, intra NPM1, gran, intra 0.4 0.01 72 78 62 77 63IFIT3, mono, intra NPM1, mean, intra 0.39 0 71 77 62 76 63 IFIT3, mono,intra NPM1, mono, intra 0.4 0.01 72 78 62 77 63 IFIT3, mono, intra OAS2,gran, intra 0.38 −0.01 71 78 59 76 62 IFIT3, mono, intra OAS2, mean,intra 0.33 −0.06 68 76 56 73 59 IFIT3, mono, intra OAS2, mono, intra0.38 −0.01 71 78 59 76 62 IFIT3, mono, intra PARP12, gran, intra 0.38−0.01 71 78 59 76 62 IFIT3, mono, intra PARP12, mean, intra 0.38 −0.0170 74 64 77 61 IFIT3, mono, intra PARP12, mono, intra 0.38 −0.01 71 7859 76 62 IFIT3, mono, intra PARP9, lymp, intra 0.34 −0.05 69 75 59 75 59IFIT3, mono, intra PDIA6, gran, intra 0.25 −0.14 67 81 42 70 57 IFIT3,mono, intra PDIA6, lymp, intra 0.4 0.01 73 81 58 77 64 IFIT3, mono,intra PDIA6, mono, intra 0.25 −0.14 67 81 42 70 57 IFIT3, mono, intraPTEN, gran, intra 0.37 −0.02 70 73 64 77 60 IFIT3, mono, intra PTEN,lymp, intra 0.32 −0.07 68 73 59 75 57 IFIT3, mono, intra PTEN, mean,intra 0.29 −0.1 66 73 56 73 56 IFIT3, mono, intra PTEN, mono, intra 0.37−0.02 70 73 64 77 60 IFIT3, mono, intra RSAD2, gran, intra 0.67 0.04 8486 82 89 78 IFIT3, mono, intra RSAD2, lymp, intra 0.36 −0.03 70 77 59 7561 IFIT3, mono, intra RSAD2, mean, intra 0.61 −0.03 81 82 79 86 74IFIT3, mono, intra RSAD2, mono, intra 0.67 0.04 84 86 82 89 78 IFIT3,mono, intra SDCBP, mean, intra 0.35 −0.04 69 75 59 74 61 IFIT3, mono,intra WBC 0.38 −0.01 72 83 54 75 66 IFITM1, gran, membrane IFITM1, lymp,membrane 0.38 0 69 65 73 75 63 IFITM1, gran, membrane IFITM1, mean,membrane 0.3 0.01 66 71 59 68 63 IFITM1, gran, membrane IFITM1, mono,membrane 0.28 −0.03 64 64 65 69 59 IFITM1, gran, membrane IFITM3, gran,membrane 0.34 −0.01 67 66 68 72 62 IFITM1, gran, membrane IFITM3, mean,membrane 0.35 0 67 64 71 73 62 IFITM1, gran, membrane IFITM3, mono,membrane 0.41 0 70 66 75 77 64 IFITM1, gran, membrane LOC26010, gran,intra 0.26 0 63 65 62 68 59 IFITM1, gran, membrane LOC26010, mean, intra0.23 −0.03 62 63 61 66 57 IFITM1, gran, membrane LOC26010, mono, intra0.26 0 63 65 62 68 59 IFITM1, gran, membrane LY6E, lymp, membrane 0.24−0.02 62 60 63 67 57 IFITM1, gran, membrane Lym(%) 0.56 0.04 78 78 78 8274 IFITM1, gran, membrane MAN1C1, gran, intra 0.05 −0.21 59 79 26 64 42IFITM1, gran, membrane MAN1C1, mean, intra 0.1 −0.16 61 83 26 65 47IFITM1, gran, membrane MAN1C1, mono, intra 0.05 −0.21 59 79 26 64 42IFITM1, gran, membrane MX1, gran, intra 0.52 −0.02 76 77 75 79 73IFITM1, gran, membrane MX1, lymp, intra 0.4 0.05 70 70 70 74 66 IFITM1,gran, membrane MX1, mean, intra 0.5 0.05 75 72 78 80 70 IFITM1, gran,membrane MX1, mono, intra 0.52 −0.02 76 77 75 79 73 IFITM1, gran,membrane Neu(%) 0.53 −0.03 77 77 76 80 73 IFITM1, gran, membrane NPM1,gran, intra 0.04 −0.22 58 78 26 63 42 IFITM1, gran, membrane NPM1, mean,intra 0.09 −0.17 59 75 33 64 46 IFITM1, gran, membrane NPM1, mono, intra0.04 −0.22 58 78 26 63 42 IFITM1, gran, membrane OAS2, gran, intra 0.32−0.04 66 62 70 72 60 IFITM1, gran, membrane OAS2, mean, intra 0.32 0.0266 64 68 71 61 IFITM1, gran, membrane OAS2, mono, intra 0.32 −0.04 66 6270 72 60 IFITM1, gran, membrane PARP12, gran, intra 0.14 −0.12 61 75 3867 48 IFITM1, gran, membrane PARP12, mean, intra 0.21 −0.05 63 74 46 6953 IFITM1, gran, membrane PARP12, mono, intra 0.14 −0.12 61 75 38 67 48IFITM1, gran, membrane PARP9, lymp, intra 0.19 −0.07 64 83 33 67 54IFITM1, gran, membrane PDIA6, gran, intra 0.04 −0.22 58 77 26 64 40IFITM1, gran, membrane PDIA6, lymp, intra 0.04 −0.22 58 77 26 64 40IFITM1, gran, membrane PDIA6, mono, intra 0.04 −0.22 58 77 26 64 40IFITM1, gran, membrane PTEN, gran, intra 0.29 0.03 67 77 51 72 57IFITM1, gran, membrane PTEN, lymp, intra 0.02 −0.24 55 69 33 63 39IFITM1, gran, membrane PTEN, mean, intra 0.17 −0.09 62 77 38 67 52IFITM1, gran, membrane PTEN, mono, intra 0.29 0.03 67 77 51 72 57IFITM1, gran, membrane RSAD2, gran, intra 0.6 −0.03 80 77 83 85 75IFITM1, gran, membrane RSAD2, lymp, intra 0.27 0.01 64 69 58 67 60IFITM1, gran, membrane RSAD2, mean, intra 0.59 −0.05 79 79 80 83 76IFITM1, gran, membrane RSAD2, mono, intra 0.6 −0.03 80 77 83 85 75IFITM1, gran, membrane SDCBP, mean, intra 0.04 −0.22 57 75 28 62 42IFITM1, gran, membrane WBC 0.32 0.06 67 80 51 67 67 IFITM1, lymp,membrane IFITM1, mean, membrane 0.35 −0.03 67 63 73 74 61 IFITM1, lymp,membrane IFITM1, mono, membrane 0.34 −0.04 67 66 68 72 62 IFITM1, lymp,membrane IFITM3, gran, membrane 0.42 0.04 71 70 72 75 66 IFITM1, lymp,membrane IFITM3, mean, membrane 0.39 0.01 69 68 71 74 65 IFITM1, lymp,membrane IFITM3, mono, membrane 0.41 0 70 68 73 76 65 IFITM1, lymp,membrane LOC26010, gran, intra 0.4 0.02 70 70 70 74 66 IFITM1, lymp,membrane LOC26010, mean, intra 0.35 −0.03 67 64 71 73 62 IFITM1, lymp,membrane LOC26010, mono, intra 0.4 0.02 70 70 70 74 66 IFITM1, lymp,membrane LY6E, lymp, membrane 0.21 −0.17 60 57 63 65 55 IFITM1, lymp,membrane Lym(%) 0.51 −0.01 76 77 75 79 72 IFITM1, lymp, membrane MAN1C1,gran, intra 0.3 −0.08 69 85 42 71 62 IFITM1, lymp, membrane MAN1C1,mean, intra 0.26 −0.12 67 85 39 70 60 IFITM1, lymp, membrane MAN1C1,mono, intra 0.3 −0.08 69 85 42 71 62 IFITM1, lymp, membrane MX1, gran,intra 0.55 0.01 78 76 80 82 73 IFITM1, lymp, membrane MX1, lymp, intra0.48 0.1 74 73 75 78 69 IFITM1, lymp, membrane MX1, mean, intra 0.540.09 77 75 80 82 72 IFITM1, lymp, membrane MX1, mono, intra 0.55 0.01 7876 80 82 73 IFITM1, lymp, membrane Neu(%) 0.53 −0.03 77 78 75 79 73IFITM1, lymp, membrane NPM1, gran, intra 0.45 0.07 75 84 59 77 70IFITM1, lymp, membrane NPM1, mean, intra 0.4 0.02 72 80 59 75 66 IFITM1,lymp, membrane NPM1, mono, intra 0.45 0.07 75 84 59 77 70 IFITM1, lymp,membrane OAS2, gran, intra 0.45 0.07 72 69 77 78 67 IFITM1, lymp,membrane OAS2, mean, intra 0.39 0.01 69 67 73 75 64 IFITM1, lymp,membrane OAS2, mono, intra 0.45 0.07 72 69 77 78 67 IFITM1, lymp,membrane PARP12, gran, intra 0.44 0.06 74 81 62 78 67 IFITM1, lymp,membrane PARP12, mean, intra 0.37 −0.01 70 76 62 76 62 IFITM1, lymp,membrane PARP12, mono, intra 0.44 0.06 74 81 62 78 67 IFITM1, lymp,membrane PARP9, lymp, intra 0.32 −0.06 68 75 56 74 58 IFITM1, lymp,membrane PDIA6, gran, intra 0.4 0.02 73 83 55 76 65 IFITM1, lymp,membrane PDIA6, lymp, intra 0.23 −0.15 64 72 52 72 52 IFITM1, lymp,membrane PDIA6, mono, intra 0.4 0.02 73 83 55 76 65 IFITM1, lymp,membrane PTEN, gran, intra 0.33 −0.05 68 72 62 75 57 IFITM1, lymp,membrane PTEN, lymp, intra 0.26 −0.12 65 70 56 73 54 IFITM1, lymp,membrane PTEN, mean, intra 0.31 −0.07 67 74 56 73 58 IFITM1, lymp,membrane PTEN, mono, intra 0.33 −0.05 68 72 62 75 57 IFITM1, lymp,membrane RSAD2, gran, intra 0.63 0 81 81 82 85 78 IFITM1, lymp, membraneRSAD2, lymp, intra 0.38 0 69 65 73 75 63 IFITM1, lymp, membrane RSAD2,mean, intra 0.62 −0.02 81 81 81 84 77 IFITM1, lymp, membrane RSAD2,mono, intra 0.63 0 81 81 82 85 78 IFITM1, lymp, membrane SDCBP, mean,intra 0.29 −0.09 67 79 49 71 59 IFITM1, lymp, membrane WBC 0.37 −0.01 6973 64 72 66 IFITM1, mean, membrane IFITM1, mono, membrane 0.32 0.01 6664 68 71 61 IFITM1, mean, membrane IFITM3, gran, membrane 0.36 0.01 6867 69 73 63 IFITM1, mean, membrane IFITM3, mean, membrane 0.33 −0.02 6664 69 72 61 IFITM1, mean, membrane IFITM3, mono, membrane 0.42 0.01 7064 78 78 64 IFITM1, mean, membrane LOC26010, gran, intra 0.22 −0.07 6161 61 66 56 IFITM1, mean, membrane LOC26010, mean, intra 0.22 −0.07 6163 59 65 56 IFITM1, mean, membrane LOC26010, mono, intra 0.22 −0.07 6161 61 66 56 IFITM1, mean, membrane LY6E, lymp, membrane 0.23 −0.06 61 6261 66 56 IFITM1, mean, membrane Lym(%) 0.52 0 76 76 76 80 73 IFITM1,mean, membrane MAN1C1, gran, intra 0.05 −0.24 59 79 26 64 42 IFITM1,mean, membrane MAN1C1, mean, intra 0.1 −0.19 61 83 26 65 47 IFITM1,mean, membrane MAN1C1, mono, intra 0.05 −0.24 59 79 26 64 42 IFITM1,mean, membrane MX1, gran, intra 0.5 −0.04 75 74 76 79 70 IFITM1, mean,membrane MX1, lymp, intra 0.39 0.04 69 67 73 75 64 IFITM1, mean,membrane MX1, mean, intra 0.48 0.03 74 72 76 79 69 IFITM1, mean,membrane MX1, mono, intra 0.5 −0.04 75 74 76 79 70 IFITM1, mean,membrane Neu(%) 0.53 −0.03 76 75 78 81 72 IFITM1, mean, membrane NPM1,gran, intra 0.07 −0.22 58 75 31 63 44 IFITM1, mean, membrane NPM1, mean,intra 0.08 −0.21 58 72 36 64 45 IFITM1, mean, membrane NPM1, mono, intra0.07 −0.22 58 75 31 63 44 IFITM1, mean, membrane OAS2, gran, intra 0.32−0.04 66 61 71 72 60 IFITM1, mean, membrane OAS2, mean, intra 0.31 0.0166 65 66 70 61 IFITM1, mean, membrane OAS2, mono, intra 0.32 −0.04 66 6171 72 60 IFITM1, mean, membrane PARP12, gran, intra 0.15 −0.14 61 76 3866 50 IFITM1, mean, membrane PARP12, mean, intra 0.23 −0.06 64 74 49 7054 IFITM1, mean, membrane PARP12, mono, intra 0.15 −0.14 61 76 38 66 50IFITM1, mean, membrane PARP9, lymp, intra 0.18 −0.11 63 81 36 67 54IFITM1, mean, membrane PDIA6, gran, intra −0.02 −0.31 56 75 23 63 35IFITM1, mean, membrane PDIA6, lymp, intra 0.11 −0.18 61 77 32 66 45IFITM1, mean, membrane PDIA6, mono, intra −0.02 −0.31 56 75 23 63 35IFITM1, mean, membrane PTEN, gran, intra 0.22 −0.07 63 73 49 69 53IFITM1, mean, membrane PTEN, lymp, intra 0.01 −0.28 54 68 33 62 39IFITM1, mean, membrane PTEN, mean, intra 0.2 −0.09 63 77 41 68 53IFITM1, mean, membrane PTEN, mono, intra 0.22 −0.07 63 73 49 69 53IFITM1, mean, membrane RSAD2, gran, intra 0.59 −0.04 79 78 81 84 75IFITM1, mean, membrane RSAD2, lymp, intra 0.27 −0.02 64 69 58 67 61IFITM1, mean, membrane RSAD2, mean, intra 0.57 −0.07 79 76 81 83 74IFITM1, mean, membrane RSAD2, mono, intra 0.59 −0.04 79 78 81 84 75IFITM1, mean, membrane SDCBP, mean, intra 0.04 −0.25 57 75 28 62 42IFITM1, mean, membrane WBC 0.3 0.01 66 74 56 67 63 IFITM1, mono,membrane IFITM3, gran, membrane 0.36 0.01 68 68 68 72 63 IFITM1, mono,membrane IFITM3, mean, membrane 0.36 0.01 68 68 68 72 63 IFITM1, mono,membrane IFITM3, mono, membrane 0.37 −0.04 69 69 68 73 64 IFITM1, mono,membrane LOC26010, gran, intra 0.37 0.06 69 68 70 74 64 IFITM1, mono,membrane LOC26010, mean, intra 0.41 0.1 70 68 73 75 65 IFITM1, mono,membrane LOC26010, mono, intra 0.37 0.06 69 68 70 74 64 IFITM1, mono,membrane LY6E, lymp, membrane 0.32 0.01 66 65 67 71 61 IFITM1, mono,membrane Lym(%) 0.62 0.1 81 81 81 85 77 IFITM1, mono, membrane MAN1C1,gran, intra 0.22 −0.09 65 79 42 69 54 IFITM1, mono, membrane MAN1C1,mean, intra 0.22 −0.09 65 79 42 69 54 IFITM1, mono, membrane MAN1C1,mono, intra 0.22 −0.09 65 79 42 69 54 IFITM1, mono, membrane MX1, gran,intra 0.62 0.08 81 76 87 88 74 IFITM1, mono, membrane MX1, lymp, intra0.5 0.15 75 76 75 79 71 IFITM1, mono, membrane MX1, mean, intra 0.520.07 76 72 80 81 70 IFITM1, mono, membrane MX1, mono, intra 0.62 0.08 8176 87 88 74 IFITM1, mono, membrane Neu(%) 0.61 0.05 80 80 81 84 76IFITM1, mono, membrane NPM1, gran, intra 0.32 0.01 69 78 54 73 60IFITM1, mono, membrane NPM1, mean, intra 0.34 0.03 69 77 56 73 61IFITM1, mono, membrane NPM1, mono, intra 0.32 0.01 69 78 54 73 60IFITM1, mono, membrane OAS2, gran, intra 0.44 0.08 72 68 77 78 66IFITM1, mono, membrane OAS2, mean, intra 0.4 0.09 70 69 71 75 66 IFITM1,mono, membrane OAS2, mono, intra 0.44 0.08 72 68 77 78 66 IFITM1, mono,membrane PARP12, gran, intra 0.31 0 68 77 54 73 58 IFITM1, mono,membrane PARP12, mean, intra 0.37 0.06 70 77 59 75 62 IFITM1, mono,membrane PARP12, mono, intra 0.31 0 68 77 54 73 58 IFITM1, mono,membrane PARP9, lymp, intra 0.31 0 68 77 54 73 58 IFITM1, mono, membranePDIA6, gran, intra 0.25 −0.06 65 74 52 72 53 IFITM1, mono, membranePDIA6, lymp, intra 0.3 −0.01 68 77 52 73 57 IFITM1, mono, membranePDIA6, mono, intra 0.25 −0.06 65 74 52 72 53 IFITM1, mono, membranePTEN, gran, intra 0.32 0.01 69 80 51 73 61 IFITM1, mono, membrane PTEN,lymp, intra 0.42 0.11 73 80 62 77 65 IFITM1, mono, membrane PTEN, mean,intra 0.27 −0.04 66 77 49 71 58 IFITM1, mono, membrane PTEN, mono, intra0.32 0.01 69 80 51 73 61 IFITM1, mono, membrane RSAD2, gran, intra 0.660.03 83 81 85 87 78 IFITM1, mono, membrane RSAD2, lymp, intra 0.44 0.1372 68 77 78 66 IFITM1, mono, membrane RSAD2, mean, intra 0.56 −0.08 7875 81 83 73 IFITM1, mono, membrane RSAD2, mono, intra 0.66 0.03 83 81 8587 78 IFITM1, mono, membrane SDCBP, mean, intra 0.21 −0.1 63 74 46 68 53IFITM1, mono, membrane WBC 0.39 0.08 70 73 66 73 66 IFITM3, gran,membrane IFITM3, mean, membrane 0.34 −0.01 66 63 71 73 61 IFITM3, gran,membrane IFITM3, mono, membrane 0.39 −0.02 69 66 73 75 64 IFITM3, gran,membrane LOC26010, gran, intra 0.26 −0.09 63 58 68 69 57 IFITM3, gran,membrane LOC26010, mean, intra 0.31 −0.04 65 60 71 72 59 IFITM3, gran,membrane LOC26010, mono, intra 0.26 −0.09 63 58 68 69 57 IFITM3, gran,membrane LY6E, lymp, membrane 0.35 0 68 68 67 72 64 IFITM3, gran,membrane Lym(%) 0.48 −0.04 74 76 73 78 70 IFITM3, gran, membrane MAN1C1,gran, intra 0.09 −0.26 60 79 29 65 45 IFITM3, gran, membrane MAN1C1,mean, intra 0.08 −0.27 60 81 26 65 44 IFITM3, gran, membrane MAN1C1,mono, intra 0.09 −0.26 60 79 29 65 45 IFITM3, gran, membrane MX1, gran,intra 0.49 −0.05 75 76 73 78 71 IFITM3, gran, membrane MX1, lymp, intra0.39 0.04 69 66 73 75 64 IFITM3, gran, membrane MX1, mean, intra 0.42−0.03 71 69 73 76 66 IFITM3, gran, membrane MX1, mono, intra 0.49 −0.0575 76 73 78 71 IFITM3, gran, membrane Neu(%) 0.56 0 78 81 75 80 76IFITM3, gran, membrane NPM1, gran, intra 0.17 −0.18 63 79 36 67 52IFITM3, gran, membrane NPM1, mean, intra 0.12 −0.23 60 75 36 65 48IFITM3, gran, membrane NPM1, mono, intra 0.17 −0.18 63 79 36 67 52IFITM3, gran, membrane OAS2, gran, intra 0.33 −0.03 66 64 70 72 61IFITM3, gran, membrane OAS2, mean, intra 0.3 −0.05 65 63 68 70 60IFITM3, gran, membrane OAS2, mono, intra 0.33 −0.03 66 64 70 72 61IFITM3, gran, membrane PARP12, gran, intra 0.19 −0.16 63 75 44 69 52IFITM3, gran, membrane PARP12, mean, intra 0.21 −0.14 63 74 46 69 53IFITM3, gran, membrane PARP12, mono, intra 0.19 −0.16 63 75 44 69 52IFITM3, gran, membrane PARP9, lymp, intra 0.26 −0.09 67 83 41 70 59IFITM3, gran, membrane PDIA6, gran, intra 0.06 −0.29 60 79 26 65 42IFITM3, gran, membrane PDIA6, lymp, intra 0.13 −0.22 62 79 32 67 48IFITM3, gran, membrane PDIA6, mono, intra 0.06 −0.29 60 79 26 65 42IFITM3, gran, membrane PTEN, gran, intra 0.2 −0.15 63 73 46 69 51IFITM3, gran, membrane PTEN, lymp, intra 0.12 −0.23 60 73 38 66 47IFITM3, gran, membrane PTEN, mean, intra 0.21 −0.14 63 74 46 69 53IFITM3, gran, membrane PTEN, mono, intra 0.2 −0.15 63 73 46 69 51IFITM3, gran, membrane RSAD2, gran, intra 0.61 −0.02 81 78 83 85 76IFITM3, gran, membrane RSAD2, lymp, intra 0.38 0.03 69 65 73 75 63IFITM3, gran, membrane RSAD2, mean, intra 0.62 −0.02 81 79 83 85 77IFITM3, gran, membrane RSAD2, mono, intra 0.61 −0.02 81 78 83 85 76IFITM3, gran, membrane SDCBP, mean, intra 0.04 −0.31 57 75 28 62 42IFITM3, gran, membrane WBC 0.37 0.02 69 74 63 71 66 IFITM3, mean,membrane IFITM3, mono, membrane 0.38 −0.03 69 67 71 74 64 IFITM3, mean,membrane LOC26010, gran, intra 0.32 −0.03 66 63 69 71 60 IFITM3, mean,membrane LOC26010, mean, intra 0.34 −0.01 66 63 71 73 61 IFITM3, mean,membrane LOC26010, mono, intra 0.32 −0.03 66 63 69 71 60 IFITM3, mean,membrane LY6E, lymp, membrane 0.35 0 68 68 67 72 63 IFITM3, mean,membrane Lym(%) 0.48 −0.04 74 76 71 76 71 IFITM3, mean, membrane MAN1C1,gran, intra 0.07 −0.28 59 77 29 65 43 IFITM3, mean, membrane MAN1C1,mean, intra 0.08 −0.27 60 81 26 65 44 IFITM3, mean, membrane MAN1C1,mono, intra 0.07 −0.28 59 77 29 65 43 IFITM3, mean, membrane MX1, gran,intra 0.47 −0.07 73 72 75 78 69 IFITM3, mean, membrane MX1, lymp, intra0.4 0.05 69 65 75 76 64 IFITM3, mean, membrane MX1, mean, intra 0.4−0.05 70 69 71 75 66 IFITM3, mean, membrane MX1, mono, intra 0.47 −0.0773 72 75 78 69 IFITM3, mean, membrane Neu(%) 0.58 0.02 79 83 75 80 79IFITM3, mean, membrane NPM1, gran, intra 0.17 −0.18 62 77 38 66 52IFITM3, mean, membrane NPM1, mean, intra 0.21 −0.14 64 80 38 67 56IFITM3, mean, membrane NPM1, mono, intra 0.17 −0.18 62 77 38 66 52IFITM3, mean, membrane OAS2, gran, intra 0.37 0.01 68 64 73 74 62IFITM3, mean, membrane OAS2, mean, intra 0.33 −0.02 66 64 69 72 61IFITM3, mean, membrane OAS2, mono, intra 0.37 0.01 68 64 73 74 62IFITM3, mean, membrane PARP12, gran, intra 0.16 −0.19 60 69 46 67 49IFITM3, mean, membrane PARP12, mean, intra 0.23 −0.12 64 74 49 70 54IFITM3, mean, membrane PARP12, mono, intra 0.16 −0.19 60 69 46 67 49IFITM3, mean, membrane PARP9, lymp, intra 0.24 −0.11 65 81 41 68 57IFITM3, mean, membrane PDIA6, gran, intra 0.1 −0.25 60 74 35 66 44IFITM3, mean, membrane PDIA6, lymp, intra 0.14 −0.21 62 77 35 67 48IFITM3, mean, membrane PDIA6, mono, intra 0.1 −0.25 60 74 35 66 44IFITM3, mean, membrane PTEN, gran, intra 0.19 −0.16 62 73 46 68 51IFITM3, mean, membrane PTEN, lymp, intra 0.11 −0.24 58 69 41 65 46IFITM3, mean, membrane PTEN, mean, intra 0.2 −0.15 63 76 44 68 53IFITM3, mean, membrane PTEN, mono, intra 0.19 −0.16 62 73 46 68 51IFITM3, mean, membrane RSAD2, gran, intra 0.62 −0.01 81 79 83 85 77IFITM3, mean, membrane RSAD2, lymp, intra 0.35 0 68 69 66 71 64 IFITM3,mean, membrane RSAD2, mean, intra 0.63 −0.01 82 81 83 85 78 IFITM3,mean, membrane RSAD2, mono, intra 0.62 −0.01 81 79 83 85 77 IFITM3,mean, membrane SDCBP, mean, intra 0.04 −0.31 57 75 28 62 42 IFITM3,mean, membrane WBC 0.37 0.02 69 74 63 71 66 IFITM3, mono, membraneLOC26010, gran, intra 0.44 0.03 72 69 75 77 66 IFITM3, mono, membraneLOC26010, mean, intra 0.41 0 70 67 75 76 65 IFITM3, mono, membraneLOC26010, mono, intra 0.44 0.03 72 69 75 77 66 IFITM3, mono, membraneLY6E, lymp, membrane 0.35 −0.06 67 63 71 73 62 IFITM3, mono, membraneLym(%) 0.53 0.01 77 80 73 79 74 IFITM3, mono, membrane MAN1C1, gran,intra 0.31 −0.1 69 79 52 73 59 IFITM3, mono, membrane MAN1C1, mean,intra 0.28 −0.13 67 79 48 72 58 IFITM3, mono, membrane MAN1C1, mono,intra 0.31 −0.1 69 79 52 73 59 IFITM3, mono, membrane MX1, gran, intra0.61 0.07 81 78 83 85 76 IFITM3, mono, membrane MX1, lymp, intra 0.480.07 74 72 77 79 69 IFITM3, mono, membrane MX1, mean, intra 0.57 0.12 7976 81 83 74 IFITM3, mono, membrane MX1, mono, intra 0.61 0.07 81 78 8385 76 IFITM3, mono, membrane Neu(%) 0.59 0.03 80 84 75 81 79 IFITM3,mono, membrane NPM1, gran, intra 0.4 −0.01 72 76 64 77 63 IFITM3, mono,membrane NPM1, mean, intra 0.36 −0.05 70 77 59 75 62 IFITM3, mono,membrane NPM1, mono, intra 0.4 −0.01 72 76 64 77 63 IFITM3, mono,membrane OAS2, gran, intra 0.46 0.05 73 72 75 78 68 IFITM3, mono,membrane OAS2, mean, intra 0.45 0.04 73 71 75 77 68 IFITM3, mono,membrane OAS2, mono, intra 0.46 0.05 73 72 75 78 68 IFITM3, mono,membrane PARP12, gran, intra 0.33 −0.08 69 77 56 74 59 IFITM3, mono,membrane PARP12, mean, intra 0.36 −0.05 69 74 62 75 60 IFITM3, mono,membrane PARP12, mono, intra 0.33 −0.08 69 77 56 74 59 IFITM3, mono,membrane PARP9, lymp, intra 0.3 −0.11 67 73 56 73 56 IFITM3, mono,membrane PDIA6, gran, intra 0.27 −0.14 67 75 52 73 55 IFITM3, mono,membrane PDIA6, lymp, intra 0.49 0.08 76 81 68 81 68 IFITM3, mono,membrane PDIA6, mono, intra 0.27 −0.14 67 75 52 73 55 IFITM3, mono,membrane PTEN, gran, intra 0.34 −0.07 69 75 59 75 59 IFITM3, mono,membrane PTEN, lymp, intra 0.39 −0.02 71 75 64 77 61 IFITM3, mono,membrane PTEN, mean, intra 0.35 −0.06 69 76 59 75 61 IFITM3, mono,membrane PTEN, mono, intra 0.34 −0.07 69 75 59 75 59 IFITM3, mono,membrane RSAD2, gran, intra 0.63 0 81 80 83 86 77 IFITM3, mono, membraneRSAD2, lymp, intra 0.5 0.09 75 72 78 80 69 IFITM3, mono, membrane RSAD2,mean, intra 0.62 −0.02 81 82 80 83 78 IFITM3, mono, membrane RSAD2,mono, intra 0.63 0 81 80 83 86 77 IFITM3, mono, membrane SDCBP, mean,intra 0.27 −0.14 66 75 51 71 57 IFITM3, mono, membrane WBC 0.5 0.09 7578 71 77 72 LOC26010, gran, intra LOC26010, mean, intra 0.24 0.01 62 6065 66 58 LOC26010, gran, intra LOC26010, mono, intra 0.23 0 61 61 62 6557 LOC26010, gran, intra LY6E, lymp, membrane 0.23 0 62 63 60 66 57LOC26010, gran, intra Lym(%) 0.5 −0.02 75 76 74 78 72 LOC26010, gran,intra MAN1C1, gran, intra 0.12 −0.11 61 79 32 66 48 LOC26010, gran,intra MAN1C1, mean, intra 0.16 −0.07 63 79 35 67 50 LOC26010, gran,intra MAN1C1, mono, intra 0.12 −0.11 61 79 32 66 48 LOC26010, gran,intra MX1, gran, intra 0.55 0.01 77 74 81 82 73 LOC26010, gran, intraMX1, lymp, intra 0.37 0.02 69 68 70 72 65 LOC26010, gran, intra MX1,mean, intra 0.42 −0.03 71 68 74 75 67 LOC26010, gran, intra MX1, mono,intra 0.55 0.01 77 74 81 82 73 LOC26010, gran, intra Neu(%) 0.48 −0.0874 76 73 77 71 LOC26010, gran, intra NPM1, gran, intra 0.09 −0.14 59 7533 64 45 LOC26010, gran, intra NPM1, mean, intra 0.15 −0.08 61 75 38 6650 LOC26010, gran, intra NPM1, mono, intra 0.09 −0.14 59 75 33 64 45LOC26010, gran, intra OAS2, gran, intra 0.34 −0.02 66 61 73 73 61LOC26010, gran, intra OAS2, mean, intra 0.23 −0.07 61 57 66 66 57LOC26010, gran, intra OAS2, mono, intra 0.34 −0.02 66 61 73 73 61LOC26010, gran, intra PARP12, gran, intra 0.14 −0.09 61 75 38 67 48LOC26010, gran, intra PARP12, mean, intra 0.3 0.05 67 76 54 72 58LOC26010, gran, intra PARP12, mono, intra 0.14 −0.09 61 75 38 67 48LOC26010, gran, intra PARP9, lymp, intra 0.25 0.02 66 78 46 70 56LOC26010, gran, intra PDIA6, gran, intra 0.11 −0.12 61 77 32 66 45LOC26010, gran, intra PDIA6, lymp, intra 0.24 0.01 65 77 45 71 54LOC26010, gran, intra PDIA6, mono, intra 0.11 −0.12 61 77 32 66 45LOC26010, gran, intra PTEN, gran, intra 0.17 −0.06 61 70 46 68 49LOC26010, gran, intra PTEN, lymp, intra 0.21 −0.02 63 72 49 70 51LOC26010, gran, intra PTEN, mean, intra 0.15 −0.08 60 71 44 67 49LOC26010, gran, intra PTEN, mono, intra 0.17 −0.06 61 70 46 68 49LOC26010, gran, intra RSAD2, gran, intra 0.67 0.04 83 80 87 88 79LOC26010, gran, intra RSAD2, lymp, intra 0.3 0.07 65 66 63 68 62LOC26010, gran, intra RSAD2, mean, intra 0.64 0 82 81 84 85 79 LOC26010,gran, intra RSAD2, mono, intra 0.67 0.04 83 80 87 88 79 LOC26010, gran,intra SDCBP, mean, intra 0.17 −0.06 62 77 38 66 52 LOC26010, gran, intraWBC 0.37 0.12 69 80 56 69 70 LOC26010, mean, intra LOC26010, mono, intra0.24 0.01 62 60 65 66 58 LOC26010, mean, intra LY6E, lymp, membrane 0.22−0.01 61 65 57 65 57 LOC26010, mean, intra Lym(%) 0.52 0 76 76 76 79 73LOC26010, mean, intra MAN1C1, gran, intra 0.19 −0.02 64 79 39 68 52LOC26010, mean, intra MAN1C1, mean, intra 0.18 −0.03 64 81 35 68 52LOC26010, mean, intra MAN1C1, mono, intra 0.19 −0.02 64 79 39 68 52LOC26010, mean, intra MX1, gran, intra 0.51 −0.03 75 71 81 81 70LOC26010, mean, intra MX1, lymp, intra 0.33 −0.02 66 64 69 71 62LOC26010, mean, intra MX1, mean, intra 0.44 −0.01 72 68 76 77 67LOC26010, mean, intra MX1, mono, intra 0.51 −0.03 75 71 81 81 70LOC26010, mean, intra Neu(%) 0.49 −0.07 75 75 74 77 72 LOC26010, mean,intra NPM1, gran, intra 0.17 −0.04 62 77 38 66 52 LOC26010, mean, intraNPM1, mean, intra 0.14 −0.07 61 77 36 65 50 LOC26010, mean, intra NPM1,mono, intra 0.17 −0.04 62 77 38 66 52 LOC26010, mean, intra OAS2, gran,intra 0.32 −0.04 66 60 73 72 61 LOC26010, mean, intra OAS2, mean, intra0.26 −0.04 63 58 68 68 58 LOC26010, mean, intra OAS2, mono, intra 0.32−0.04 66 60 73 72 61 LOC26010, mean, intra PARP12, gran, intra 0.18−0.03 62 74 44 68 52 LOC26010, mean, intra PARP12, mean, intra 0.26 0.0165 74 51 71 56 LOC26010, mean, intra PARP12, mono, intra 0.18 −0.03 6274 44 68 52 LOC26010, mean, intra PARP9, lymp, intra 0.21 0 64 81 38 6856 LOC26010, mean, intra PDIA6, gran, intra 0.15 −0.06 62 75 39 68 48LOC26010, mean, intra PDIA6, lymp, intra 0.18 −0.03 63 75 42 69 50LOC26010, mean, intra PDIA6, mono, intra 0.15 −0.06 62 75 39 68 48LOC26010, mean, intra PTEN, gran, intra 0.17 −0.05 61 71 46 68 50LOC26010, mean, intra PTEN, lymp, intra 0.17 −0.04 61 71 46 68 50LOC26010, mean, intra PTEN, mean, intra 0.15 −0.06 60 71 44 67 49LOC26010, mean, intra PTEN, mono, intra 0.17 −0.05 61 71 46 68 50LOC26010, mean, intra RSAD2, gran, intra 0.66 0.03 83 79 87 88 78LOC26010, mean, intra RSAD2, lymp, intra 0.32 0.09 66 64 68 70 62LOC26010, mean, intra RSAD2, mean, intra 0.64 0 82 81 84 85 79 LOC26010,mean, intra RSAD2, mono, intra 0.66 0.03 83 79 87 88 78 LOC26010, mean,intra SDCBP, mean, intra 0.16 −0.05 62 79 36 66 52 LOC26010, mean, intraWBC 0.29 0.04 65 74 55 65 64 LOC26010, mono, intra LY6E, lymp, membrane0.23 0 62 63 60 66 57 LOC26010, mono, intra Lym(%) 0.5 −0.02 75 76 74 7872 LOC26010, mono, intra MAN1C1, gran, intra 0.12 −0.11 61 79 32 66 48LOC26010, mono, intra MAN1C1, mean, intra 0.16 −0.07 63 79 35 67 50LOC26010, mono, intra MAN1C1, mono, intra 0.12 −0.11 61 79 32 66 48LOC26010, mono, intra MX1, gran, intra 0.55 0.01 77 74 81 82 73LOC26010, mono, intra MX1, lymp, intra 0.37 0.02 69 68 70 72 65LOC26010, mono, intra MX1, mean, intra 0.42 −0.03 71 68 74 75 67LOC26010, mono, intra MX1, mono, intra 0.55 0.01 77 74 81 82 73LOC26010, mono, intra Neu(%) 0.48 −0.08 74 76 73 77 71 LOC26010, mono,intra NPM1, gran, intra 0.09 −0.14 59 75 33 64 45 LOC26010, mono, intraNPM1, mean, intra 0.15 −0.08 61 75 38 66 50 LOC26010, mono, intra NPM1,mono, intra 0.09 −0.14 59 75 33 64 45 LOC26010, mono, intra OAS2, gran,intra 0.34 −0.02 66 61 73 73 61 LOC26010, mono, intra OAS2, mean, intra0.23 −0.07 61 57 66 66 57 LOC26010, mono, intra OAS2, mono, intra 0.34−0.02 66 61 73 73 61 LOC26010, mono, intra PARP12, gran, intra 0.14−0.09 61 75 38 67 48 LOC26010, mono, intra PARP12, mean, intra 0.3 0.0567 76 54 72 58 LOC26010, mono, intra PARP12, mono, intra 0.14 −0.09 6175 38 67 48 LOC26010, mono, intra PARP9, lymp, intra 0.25 0.02 66 78 4670 56 LOC26010, mono, intra PDIA6, gran, intra 0.11 −0.12 61 77 32 66 45LOC26010, mono, intra PDIA6, lymp, intra 0.24 0.01 65 77 45 71 54LOC26010, mono, intra PDIA6, mono, intra 0.11 −0.12 61 77 32 66 45LOC26010, mono, intra PTEN, gran, intra 0.17 −0.06 61 70 46 68 49LOC26010, mono, intra PTEN, lymp, intra 0.21 −0.02 63 72 49 70 51LOC26010, mono, intra PTEN, mean, intra 0.15 −0.08 60 71 44 67 49LOC26010, mono, intra PTEN, mono, intra 0.17 −0.06 61 70 46 68 49LOC26010, mono, intra RSAD2, gran, intra 0.67 0.04 83 80 87 88 79LOC26010, mono, intra RSAD2, lymp, intra 0.3 0.07 65 66 63 68 62LOC26010, mono, intra RSAD2, mean, intra 0.64 0 82 81 84 85 79 LOC26010,mono, intra RSAD2, mono, intra 0.67 0.04 83 80 87 88 79 LOC26010, mono,intra SDCBP, mean, intra 0.17 −0.06 62 77 38 66 52 LOC26010, mono, intraWBC 0.37 0.12 69 80 56 69 70 LY6E, lymp, membrane Lym(%) 0.52 0 76 78 7579 73 LY6E, lymp, membrane MAN1C1, gran, intra 0.17 −0.06 64 83 32 67 53LY6E, lymp, membrane MAN1C1, mean, intra 0.2 −0.03 65 85 32 68 56 LY6E,lymp, membrane MAN1C1, mono, intra 0.17 −0.06 64 83 32 67 53 LY6E, lymp,membrane MX1, gran, intra 0.5 −0.04 75 70 81 81 69 LY6E, lymp, membraneMX1, lymp, intra 0.38 0.03 69 65 73 75 63 LY6E, lymp, membrane MX1,mean, intra 0.45 0 72 68 76 78 66 LY6E, lymp, membrane MX1, mono, intra0.5 −0.04 75 70 81 81 69 LY6E, lymp, membrane Neu(%) 0.54 −0.02 77 79 7579 75 LY6E, lymp, membrane NPM1, gran, intra 0.22 −0.01 65 79 42 69 54LY6E, lymp, membrane NPM1, mean, intra 0.18 −0.05 64 81 35 68 52 LY6E,lymp, membrane NPM1, mono, intra 0.22 −0.01 65 79 42 69 54 LY6E, lymp,membrane OAS2, gran, intra 0.41 0.05 70 62 79 78 63 LY6E, lymp, membraneOAS2, mean, intra 0.36 0.06 68 63 73 74 62 LY6E, lymp, membrane OAS2,mono, intra 0.41 0.05 70 62 79 78 63 LY6E, lymp, membrane PARP12, gran,intra 0.09 −0.14 61 79 29 66 45 LY6E, lymp, membrane PARP12, mean, intra0.16 −0.09 62 74 42 68 48 LY6E, lymp, membrane PARP12, mono, intra 0.09−0.14 61 79 29 66 45 LY6E, lymp, membrane PARP9, lymp, intra 0.08 −0.1561 81 26 65 44 LY6E, lymp, membrane PDIA6, gran, intra 0.01 −0.22 57 7526 63 38 LY6E, lymp, membrane PDIA6, lymp, intra 0.07 −0.16 60 77 29 6543 LY6E, lymp, membrane PDIA6, mono, intra 0.01 −0.22 57 75 26 63 38LY6E, lymp, membrane PTEN, gran, intra 0.12 −0.11 61 75 35 67 46 LY6E,lymp, membrane PTEN, lymp, intra −0.03 −0.26 55 72 26 62 35 LY6E, lymp,membrane PTEN, mean, intra 0.08 −0.15 60 75 32 66 43 LY6E, lymp,membrane PTEN, mono, intra 0.12 −0.11 61 75 35 67 46 LY6E, lymp,membrane RSAD2, gran, intra 0.63 0 82 83 81 84 79 LY6E, lymp, membraneRSAD2, lymp, intra 0.3 0.07 65 65 65 69 61 LY6E, lymp, membrane RSAD2,mean, intra 0.6 −0.04 80 79 80 83 76 LY6E, lymp, membrane RSAD2, mono,intra 0.63 0 82 83 81 84 79 LY6E, lymp, membrane SDCBP, mean, intra 0.330.1 70 83 48 73 63 LY6E, lymp, membrane WBC 0.37 0.12 69 79 57 69 69Lym(%) MAN1C1, gran, intra 0.45 −0.07 75 83 61 78 68 Lym(%) MAN1C1,mean, intra 0.42 −0.1 73 83 58 77 67 Lym(%) MAN1C1, mono, intra 0.45−0.07 75 83 61 78 68 Lym(%) MX1, gran, intra 0.57 0.03 79 80 77 81 76Lym(%) MX1, lymp, intra 0.63 0.11 82 82 81 84 79 Lym(%) MX1, mean, intra0.62 0.1 81 83 79 82 80 Lym(%) MX1, mono, intra 0.57 0.03 79 80 77 81 76Lym(%) Neu(%) 0.53 −0.03 77 75 79 81 72 Lym(%) NPM1, gran, intra 0.580.06 80 84 74 84 74 Lym(%) NPM1, mean, intra 0.54 0.02 78 82 72 82 72Lym(%) NPM1, mono, intra 0.58 0.06 80 84 74 84 74 Lym(%) OAS2, gran,intra 0.58 0.06 79 79 79 82 75 Lym(%) OAS2, mean, intra 0.55 0.03 78 7877 80 75 Lym(%) OAS2, mono, intra 0.58 0.06 79 79 79 82 75 Lym(%)PARP12, gran, intra 0.52 0 77 78 74 83 67 Lym(%) PARP12, mean, intra0.56 0.04 79 82 74 84 73 Lym(%) PARP12, mono, intra 0.52 0 77 78 74 8367 Lym(%) PARP9, lymp, intra 0.5 −0.02 77 83 67 80 70 Lym(%) PDIA6,gran, intra 0.44 −0.08 74 79 65 79 65 Lym(%) PDIA6, lymp, intra 0.49−0.03 76 81 68 81 68 Lym(%) PDIA6, mono, intra 0.44 −0.08 74 79 65 79 65Lym(%) PTEN, gran, intra 0.48 −0.04 75 77 72 82 65 Lym(%) PTEN, lymp,intra 0.51 −0.01 77 80 72 82 68 Lym(%) PTEN, mean, intra 0.47 −0.05 7476 72 81 65 Lym(%) PTEN, mono, intra 0.48 −0.04 75 77 72 82 65 Lym(%)RSAD2, gran, intra 0.62 −0.01 81 81 81 84 78 Lym(%) RSAD2, lymp, intra0.56 0.04 78 77 79 82 74 Lym(%) RSAD2, mean, intra 0.61 −0.03 81 81 8183 78 Lym(%) RSAD2, mono, intra 0.62 −0.01 81 81 81 84 78 Lym(%) SDCBP,mean, intra 0.45 −0.07 74 79 67 79 67 Lym(%) WBC 0.58 0.06 79 79 79 8275 MAN1C1, gran, intra MAN1C1, mean, intra 0.17 0.04 64 83 32 67 53MAN1C1, gran, intra MAN1C1, mono, intra 0.15 0.04 63 81 32 67 50 MAN1C1,gran, intra MX1, gran, intra 0.48 −0.06 76 83 65 80 69 MAN1C1, gran,intra MX1, lymp, intra 0.31 −0.04 69 79 52 73 59 MAN1C1, gran, intraMX1, mean, intra 0.43 −0.02 73 81 61 78 66 MAN1C1, gran, intra MX1,mono, intra 0.48 −0.06 76 83 65 80 69 MAN1C1, gran, intra Neu(%) 0.5−0.06 77 87 61 79 73 MAN1C1, gran, intra NPM1, gran, intra 0.2 0.09 6477 42 69 52 MAN1C1, gran, intra NPM1, mean, intra 0.2 0.07 64 77 42 6952 MAN1C1, gran, intra NPM1, mono, intra 0.2 0.09 64 77 42 69 52 MAN1C1,gran, intra OAS2, gran, intra 0.17 −0.19 63 77 39 68 50 MAN1C1, gran,intra OAS2, mean, intra 0.08 −0.22 59 75 32 65 43 MAN1C1, gran, intraOAS2, mono, intra 0.17 −0.19 63 77 39 68 50 MAN1C1, gran, intra PARP12,gran, intra 0.18 −0.01 63 75 42 68 50 MAN1C1, gran, intra PARP12, mean,intra 0.26 0.01 66 77 48 71 56 MAN1C1, gran, intra PARP12, mono, intra0.18 −0.01 63 75 42 68 50 MAN1C1, gran, intra PARP9, lymp, intra 0.170.03 64 83 32 67 53 MAN1C1, gran, intra PDIA6, gran, intra 0.25 0.12 6679 45 71 56 MAN1C1, gran, intra PDIA6, lymp, intra 0.16 0.05 61 73 42 6848 MAN1C1, gran, intra PDIA6, mono, intra 0.25 0.12 66 79 45 71 56MAN1C1, gran, intra PTEN, gran, intra 0.25 0.03 66 79 45 71 56 MAN1C1,gran, intra PTEN, lymp, intra 0.28 0.17 67 81 45 71 58 MAN1C1, gran,intra PTEN, mean, intra 0.28 0.08 67 81 45 71 58 MAN1C1, gran, intraPTEN, mono, intra 0.25 0.03 66 79 45 71 56 MAN1C1, gran, intra RSAD2,gran, intra 0.62 −0.01 82 85 77 86 75 MAN1C1, gran, intra RSAD2, lymp,intra 0.18 −0.05 64 81 35 68 52 MAN1C1, gran, intra RSAD2, mean, intra0.53 −0.11 78 85 68 81 72 MAN1C1, gran, intra RSAD2, mono, intra 0.62−0.01 82 85 77 86 75 MAN1C1, gran, intra SDCBP, mean, intra 0.21 0.1 6581 39 69 55 MAN1C1, gran, intra WBC 0.26 0.01 67 87 35 69 61 MAN1C1,mean, intra MAN1C1, mono, intra 0.17 0.04 64 83 32 67 53 MAN1C1, mean,intra MX1, gran, intra 0.48 −0.06 76 83 65 80 69 MAN1C1, mean, intraMX1, lymp, intra 0.26 −0.09 66 77 48 71 56 MAN1C1, mean, intra MX1,mean, intra 0.38 −0.07 71 77 61 77 61 MAN1C1, mean, intra MX1, mono,intra 0.48 −0.06 76 83 65 80 69 MAN1C1, mean, intra Neu(%) 0.5 −0.06 7788 58 78 75 MAN1C1, mean, intra NPM1, gran, intra 0.28 0.15 67 81 45 7158 MAN1C1, mean, intra NPM1, mean, intra 0.19 0.06 64 79 39 68 52MAN1C1, mean, intra NPM1, mono, intra 0.28 0.15 67 81 45 71 58 MAN1C1,mean, intra OAS2, gran, intra 0.18 −0.18 63 75 42 68 50 MAN1C1, mean,intra OAS2, mean, intra 0.15 −0.15 63 81 32 67 50 MAN1C1, mean, intraOAS2, mono, intra 0.18 −0.18 63 75 42 68 50 MAN1C1, mean, intra PARP12,gran, intra 0.14 −0.05 61 75 39 67 48 MAN1C1, mean, intra PARP12, mean,intra 0.21 −0.04 64 75 45 70 52 MAN1C1, mean, intra PARP12, mono, intra0.14 −0.05 61 75 39 67 48 MAN1C1, mean, intra PARP9, lymp, intra 0.14 063 83 29 66 50 MAN1C1, mean, intra PDIA6, gran, intra 0.2 0.07 64 77 4269 52 MAN1C1, mean, intra PDIA6, lymp, intra 0.12 −0.01 60 73 39 67 46MAN1C1, mean, intra PDIA6, mono, intra 0.2 0.07 64 77 42 69 52 MAN1C1,mean, intra PTEN, gran, intra 0.31 0.09 69 81 48 72 60 MAN1C1, mean,intra PTEN, lymp, intra 0.25 0.12 66 81 42 70 57 MAN1C1, mean, intraPTEN, mean, intra 0.28 0.08 67 79 48 72 58 MAN1C1, mean, intra PTEN,mono, intra 0.31 0.09 69 81 48 72 60 MAN1C1, mean, intra RSAD2, gran,intra 0.62 −0.01 82 85 77 86 75 MAN1C1, mean, intra RSAD2, lymp, intra0.17 −0.06 64 83 32 67 53 MAN1C1, mean, intra RSAD2, mean, intra 0.58−0.06 81 87 71 83 76 MAN1C1, mean, intra RSAD2, mono, intra 0.62 −0.0182 85 77 86 75 MAN1C1, mean, intra SDCBP, mean, intra 0.3 0.17 69 83 4572 61 MAN1C1, mean, intra WBC 0.22 −0.03 66 88 29 68 60 MAN1C1, mono,intra MX1, gran, intra 0.48 −0.06 76 83 65 80 69 MAN1C1, mono, intraMX1, lymp, intra 0.31 −0.04 69 79 52 73 59 MAN1C1, mono, intra MX1,mean, intra 0.43 −0.02 73 81 61 78 66 MAN1C1, mono, intra MX1, mono,intra 0.48 −0.06 76 83 65 80 69 MAN1C1, mono, intra Neu(%) 0.5 −0.06 7787 61 79 73 MAN1C1, mono, intra NPM1, gran, intra 0.2 0.09 64 77 42 6952 MAN1C1, mono, intra NPM1, mean, intra 0.2 0.07 64 77 42 69 52 MAN1C1,mono, intra NPM1, mono, intra 0.2 0.09 64 77 42 69 52 MAN1C1, mono,intra OAS2, gran, intra 0.17 −0.19 63 77 39 68 50 MAN1C1, mono, intraOAS2, mean, intra 0.08 −0.22 59 75 32 65 43 MAN1C1, mono, intra OAS2,mono, intra 0.17 −0.19 63 77 39 68 50 MAN1C1, mono, intra PARP12, gran,intra 0.18 −0.01 63 75 42 68 50 MAN1C1, mono, intra PARP12, mean, intra0.26 0.01 66 77 48 71 56 MAN1C1, mono, intra PARP12, mono, intra 0.18−0.01 63 75 42 68 50 MAN1C1, mono, intra PARP9, lymp, intra 0.17 0.03 6483 32 67 53 MAN1C1, mono, intra PDIA6, gran, intra 0.25 0.12 66 79 45 7156 MAN1C1, mono, intra PDIA6, lymp, intra 0.16 0.05 61 73 42 68 48MAN1C1, mono, intra PDIA6, mono, intra 0.25 0.12 66 79 45 71 56 MAN1C1,mono, intra PTEN, gran, intra 0.25 0.03 66 79 45 71 56 MAN1C1, mono,intra PTEN, lymp, intra 0.28 0.17 67 81 45 71 58 MAN1C1, mono, intraPTEN, mean, intra 0.28 0.08 67 81 45 71 58 MAN1C1, mono, intra PTEN,mono, intra 0.25 0.03 66 79 45 71 56 MAN1C1, mono, intra RSAD2, gran,intra 0.62 −0.01 82 85 77 86 75 MAN1C1, mono, intra RSAD2, lymp, intra0.18 −0.05 64 81 35 68 52 MAN1C1, mono, intra RSAD2, mean, intra 0.53−0.11 78 85 68 81 72 MAN1C1, mono, intra RSAD2, mono, intra 0.62 −0.0182 85 77 86 75 MAN1C1, mono, intra SDCBP, mean, intra 0.21 0.1 65 81 3969 55 MAN1C1, mono, intra WBC 0.26 0.01 67 87 35 69 61 MX1, gran, intraMX1, lymp, intra 0.51 −0.03 75 73 78 79 71 MX1, gran, intra MX1, mean,intra 0.51 −0.03 75 71 81 81 70 MX1, gran, intra MX1, mono, intra 0.54 077 73 81 82 72 MX1, gran, intra Neu(%) 0.59 0.03 79 81 77 81 77 MX1,gran, intra NPM1, gran, intra 0.46 −0.08 75 79 67 79 67 MX1, gran, intraNPM1, mean, intra 0.48 −0.06 75 79 69 80 68 MX1, gran, intra NPM1, mono,intra 0.46 −0.08 75 79 67 79 67 MX1, gran, intra OAS2, gran, intra 0.51−0.03 75 72 79 80 70 MX1, gran, intra OAS2, mean, intra 0.51 −0.03 75 7181 81 70 MX1, gran, intra OAS2, mono, intra 0.51 −0.03 75 72 79 80 70MX1, gran, intra PARP12, gran, intra 0.5 −0.04 77 81 69 81 69 MX1, gran,intra PARP12, mean, intra 0.54 0 78 82 72 82 72 MX1, gran, intra PARP12,mono, intra 0.5 −0.04 77 81 69 81 69 MX1, gran, intra PARP9, lymp, intra0.45 −0.09 74 78 67 79 65 MX1, gran, intra PDIA6, gran, intra 0.45 −0.0975 83 61 79 68 MX1, gran, intra PDIA6, lymp, intra 0.5 −0.04 76 79 71 8267 MX1, gran, intra PDIA6, mono, intra 0.45 −0.09 75 83 61 79 68 MX1,gran, intra PTEN, gran, intra 0.5 −0.04 77 81 69 81 69 MX1, gran, intraPTEN, lymp, intra 0.53 −0.01 78 81 72 83 70 MX1, gran, intra PTEN, mean,intra 0.46 −0.08 74 77 69 80 66 MX1, gran, intra PTEN, mono, intra 0.5−0.04 77 81 69 81 69 MX1, gran, intra RSAD2, gran, intra 0.61 −0.02 8077 84 85 76 MX1, gran, intra RSAD2, lymp, intra 0.51 −0.03 75 72 79 8070 MX1, gran, intra RSAD2, mean, intra 0.58 −0.06 79 76 82 83 75 MX1,gran, intra RSAD2, mono, intra 0.61 −0.02 80 77 84 85 76 MX1, gran,intra SDCBP, mean, intra 0.45 −0.09 74 79 67 79 67 MX1, gran, intra WBC0.48 −0.06 74 74 74 77 71 MX1, lymp, intra MX1, mean, intra 0.45 0 72 6976 77 68 MX1, lymp, intra MX1, mono, intra 0.51 −0.03 75 73 78 79 71MX1, lymp, intra Neu(%) 0.64 0.08 82 84 81 84 81 MX1, lymp, intra NPM1,gran, intra 0.37 0.02 71 78 59 75 62 MX1, lymp, intra NPM1, mean, intra0.35 0 69 75 59 74 61 MX1, lymp, intra NPM1, mono, intra 0.37 0.02 71 7859 75 62 MX1, lymp, intra OAS2, gran, intra 0.48 0.12 74 70 78 79 69MX1, lymp, intra OAS2, mean, intra 0.44 0.09 72 68 76 77 67 MX1, lymp,intra OAS2, mono, intra 0.48 0.12 74 70 78 79 69 MX1, lymp, intraPARP12, gran, intra 0.46 0.11 75 81 64 79 68 MX1, lymp, intra PARP12,mean, intra 0.39 0.04 71 79 59 75 64 MX1, lymp, intra PARP12, mono,intra 0.46 0.11 75 81 64 79 68 MX1, lymp, intra PARP9, lymp, intra 0.390.04 72 80 59 76 64 MX1, lymp, intra PDIA6, gran, intra 0.33 −0.02 69 7755 75 59 MX1, lymp, intra PDIA6, lymp, intra 0.28 −0.07 67 74 55 74 55MX1, lymp, intra PDIA6, mono, intra 0.33 −0.02 69 77 55 75 59 MX1, lymp,intra PTEN, gran, intra 0.37 0.02 71 80 56 75 63 MX1, lymp, intra PTEN,lymp, intra 0.38 0.03 71 78 59 76 62 MX1, lymp, intra PTEN, mean, intra0.31 −0.04 67 74 56 73 58 MX1, lymp, intra PTEN, mono, intra 0.37 0.0271 80 56 75 63 MX1, lymp, intra RSAD2, gran, intra 0.62 −0.01 81 80 8384 78 MX1, lymp, intra RSAD2, lymp, intra 0.35 0 67 65 70 72 63 MX1,lymp, intra RSAD2, mean, intra 0.58 −0.06 79 76 82 83 75 MX1, lymp,intra RSAD2, mono, intra 0.62 −0.01 81 80 83 84 78 MX1, lymp, intraSDCBP, mean, intra 0.33 −0.02 68 74 59 74 59 MX1, lymp, intra WBC 0.450.1 73 74 71 75 70 MX1, mean, intra MX1, mono, intra 0.51 −0.03 75 71 8181 70 MX1, mean, intra Neu(%) 0.59 0.03 80 83 76 80 80 MX1, mean, intraNPM1, gran, intra 0.36 −0.09 69 72 64 76 60 MX1, mean, intra NPM1, mean,intra 0.36 −0.09 69 72 64 76 60 MX1, mean, intra NPM1, mono, intra 0.36−0.09 69 72 64 76 60 MX1, mean, intra OAS2, gran, intra 0.47 0.02 73 6879 79 68 MX1, mean, intra OAS2, mean, intra 0.45 0 72 68 77 78 68 MX1,mean, intra OAS2, mono, intra 0.47 0.02 73 68 79 79 68 MX1, mean, intraPARP12, gran, intra 0.48 0.03 75 79 69 80 68 MX1, mean, intra PARP12,mean, intra 0.53 0.08 77 79 74 83 69 MX1, mean, intra PARP12, mono,intra 0.48 0.03 75 79 69 80 68 MX1, mean, intra PARP9, lymp, intra 0.42−0.03 72 77 64 77 64 MX1, mean, intra PDIA6, gran, intra 0.41 −0.04 7379 61 78 63 MX1, mean, intra PDIA6, lymp, intra 0.45 0 74 77 68 80 64MX1, mean, intra PDIA6, mono, intra 0.41 −0.04 73 79 61 78 63 MX1, mean,intra PTEN, gran, intra 0.48 0.03 75 81 67 79 68 MX1, mean, intra PTEN,lymp, intra 0.44 −0.01 73 77 67 79 65 MX1, mean, intra PTEN, mean, intra0.37 −0.08 70 76 62 76 62 MX1, mean, intra PTEN, mono, intra 0.48 0.0375 81 67 79 68 MX1, mean, intra RSAD2, gran, intra 0.64 0.01 82 79 85 8678 MX1, mean, intra RSAD2, lymp, intra 0.44 −0.01 72 69 74 76 68 MX1,mean, intra RSAD2, mean, intra 0.57 −0.07 78 75 82 83 74 MX1, mean,intra RSAD2, mono, intra 0.64 0.01 82 79 85 86 78 MX1, mean, intraSDCBP, mean, intra 0.41 −0.04 72 77 64 77 64 MX1, mean, intra WBC 0.44−0.01 72 68 76 77 67 MX1, mono, intra Neu(%) 0.59 0.03 79 81 77 81 77MX1, mono, intra NPM1, gran, intra 0.46 −0.08 75 79 67 79 67 MX1, mono,intra NPM1, mean, intra 0.48 −0.06 75 79 69 80 68 MX1, mono, intra NPM1,mono, intra 0.46 −0.08 75 79 67 79 67 MX1, mono, intra OAS2, gran, intra0.51 −0.03 75 72 79 80 70 MX1, mono, intra OAS2, mean, intra 0.51 −0.0375 71 81 81 70 MX1, mono, intra OAS2, mono, intra 0.51 −0.03 75 72 79 8070 MX1, mono, intra PARP12, gran, intra 0.5 −0.04 77 81 69 81 69 MX1,mono, intra PARP12, mean, intra 0.54 0 78 82 72 82 72 MX1, mono, intraPARP12, mono, intra 0.5 −0.04 77 81 69 81 69 MX1, mono, intra PARP9,lymp, intra 0.45 −0.09 74 78 67 79 65 MX1, mono, intra PDIA6, gran,intra 0.45 −0.09 75 83 61 79 68 MX1, mono, intra PDIA6, lymp, intra 0.5−0.04 76 79 71 82 67 MX1, mono, intra PDIA6, mono, intra 0.45 −0.09 7583 61 79 68 MX1, mono, intra PTEN, gran, intra 0.5 −0.04 77 81 69 81 69MX1, mono, intra PTEN, lymp, intra 0.53 −0.01 78 81 72 83 70 MX1, mono,intra PTEN, mean, intra 0.46 −0.08 74 77 69 80 66 MX1, mono, intra PTEN,mono, intra 0.5 −0.04 77 81 69 81 69 MX1, mono, intra RSAD2, gran, intra0.61 −0.02 80 77 84 85 76 MX1, mono, intra RSAD2, lymp, intra 0.51 −0.0375 72 79 80 70 MX1, mono, intra RSAD2, mean, intra 0.58 −0.06 79 76 8283 75 MX1, mono, intra RSAD2, mono, intra 0.61 −0.02 80 77 84 85 76 MX1,mono, intra SDCBP, mean, intra 0.45 −0.09 74 79 67 79 67 MX1, mono,intra WBC 0.48 −0.06 74 74 74 77 71 Neu(%) OAS2, gran, intra 0.59 0.0380 79 81 83 76 Neu(%) OAS2, mean, intra 0.57 0.01 79 78 79 81 75 Neu(%)OAS2, mono, intra 0.59 0.03 80 79 81 83 76 Neu(%) PARP12, gran, intra0.65 0.09 83 86 79 87 78 Neu(%) PARP12, mean, intra 0.62 0.06 82 87 7484 78 Neu(%) PARP12, mono, intra 0.65 0.09 83 86 79 87 78 Neu(%) PARP9,lymp, intra 0.52 −0.04 78 86 64 80 74 Neu(%) PDIA6, gran, intra 0.640.08 83 89 74 85 79 Neu(%) PDIA6, lymp, intra 0.51 −0.05 77 83 68 81 70Neu(%) PDIA6, mono, intra 0.64 0.08 83 89 74 85 79 Neu(%) PTEN, gran,intra 0.55 −0.01 79 83 72 83 72 Neu(%) PTEN, lymp, intra 0.58 0.02 81 8672 83 76 Neu(%) PTEN, mean, intra 0.56 0 79 84 72 83 74 Neu(%) PTEN,mono, intra 0.55 −0.01 79 83 72 83 72 Neu(%) RSAD2, gran, intra 0.660.03 83 83 84 86 80 Neu(%) RSAD2, lymp, intra 0.58 0.02 79 79 79 82 75Neu(%) RSAD2, mean, intra 0.66 0.02 83 84 82 85 81 Neu(%) RSAD2, mono,intra 0.66 0.03 83 83 84 86 80 Neu(%) SDCBP, mean, intra 0.51 −0.05 7782 69 81 71 Neu(%) WBC 0.54 −0.02 77 80 74 79 75 NPM1, gran, intraNeu(%) 0.62 0.06 82 89 72 84 80 NPM1, gran, intra NPM1, mean, intra 0.09−0.04 59 75 33 64 46 NPM1, gran, intra NPM1, mono, intra 0.1 0 60 78 3164 46 NPM1, gran, intra OAS2, gran, intra 0.11 −0.25 59 70 41 66 46NPM1, gran, intra OAS2, mean, intra 0.08 −0.22 58 74 33 63 45 NPM1,gran, intra OAS2, mono, intra 0.11 −0.25 59 70 41 66 46 NPM1, gran,intra PARP12, gran, intra 0.06 −0.13 57 70 36 64 42 NPM1, gran, intraPARP12, mean, intra 0.23 −0.02 63 69 54 70 53 NPM1, gran, intra PARP12,mono, intra 0.06 −0.13 57 70 36 64 42 NPM1, gran, intra PARP9, lymp,intra 0.17 0.03 63 79 36 67 52 NPM1, gran, intra PDIA6, gran, intra 0.190.06 63 73 45 69 50 NPM1, gran, intra PDIA6, lymp, intra 0.17 0.07 61 7145 69 48 NPM1, gran, intra PDIA6, mono, intra 0.19 0.06 63 73 45 69 50NPM1, gran, intra PTEN, gran, intra 0.21 −0.01 64 76 44 69 53 NPM1,gran, intra PTEN, lymp, intra 0.14 0.04 61 75 38 66 48 NPM1, gran, intraPTEN, mean, intra 0.15 −0.05 61 75 38 66 50 NPM1, gran, intra PTEN,mono, intra 0.21 −0.01 64 76 44 69 53 NPM1, gran, intra RSAD2, gran,intra 0.67 0.04 84 86 82 89 78 NPM1, gran, intra RSAD2, lymp, intra 0.21−0.02 65 81 38 68 56 NPM1, gran, intra RSAD2, mean, intra 0.61 −0.03 8182 79 86 74 NPM1, gran, intra RSAD2, mono, intra 0.67 0.04 84 86 82 8978 NPM1, gran, intra SDCBP, mean, intra 0.11 0.01 60 77 33 64 48 NPM1,gran, intra WBC 0.37 0.12 72 89 44 72 71 NPM1, mean, intra Neu(%) 0.60.04 81 87 72 83 78 NPM1, mean, intra NPM1, mono, intra 0.09 −0.04 59 7533 64 46 NPM1, mean, intra OAS2, gran, intra 0.11 −0.25 58 67 44 65 46NPM1, mean, intra OAS2, mean, intra 0.04 −0.26 56 70 33 62 42 NPM1,mean, intra OAS2, mono, intra 0.11 −0.25 58 67 44 65 46 NPM1, mean,intra PARP12, gran, intra 0.11 −0.08 59 72 38 65 47 NPM1, mean, intraPARP12, mean, intra 0.22 −0.03 63 70 51 69 53 NPM1, mean, intra PARP12,mono, intra 0.11 −0.08 59 72 38 65 47 NPM1, mean, intra PARP9, lymp,intra 0.12 −0.02 60 75 36 65 48 NPM1, mean, intra PDIA6, gran, intra0.22 0.09 64 73 48 70 52 NPM1, mean, intra PDIA6, lymp, intra 0.19 0.0663 73 45 69 50 NPM1, mean, intra PDIA6, mono, intra 0.22 0.09 64 73 4870 52 NPM1, mean, intra PTEN, gran, intra 0.16 −0.06 61 72 44 67 50NPM1, mean, intra PTEN, lymp, intra 0.15 0.02 61 75 38 66 50 NPM1, mean,intra PTEN, mean, intra 0.14 −0.06 60 72 41 66 48 NPM1, mean, intraPTEN, mono, intra 0.16 −0.06 61 72 44 67 50 NPM1, mean, intra RSAD2,gran, intra 0.67 0.04 84 85 82 88 78 NPM1, mean, intra RSAD2, lymp,intra 0.19 −0.04 63 79 38 67 54 NPM1, mean, intra RSAD2, mean, intra0.58 −0.06 80 82 77 85 73 NPM1, mean, intra RSAD2, mono, intra 0.67 0.0484 85 82 88 78 NPM1, mean, intra SDCBP, mean, intra 0.07 −0.06 58 75 3163 44 NPM1, mean, intra WBC 0.39 0.14 72 89 46 72 72 NPM1, mono, intraNeu(%) 0.62 0.06 82 89 72 84 80 NPM1, mono, intra OAS2, gran, intra 0.11−0.25 59 70 41 66 46 NPM1, mono, intra OAS2, mean, intra 0.08 −0.22 5874 33 63 45 NPM1, mono, intra OAS2, mono, intra 0.11 −0.25 59 70 41 6646 NPM1, mono, intra PARP12, gran, intra 0.06 −0.13 57 70 36 64 42 NPM1,mono, intra PARP12, mean, intra 0.23 −0.02 63 69 54 70 53 NPM1, mono,intra PARP12, mono, intra 0.06 −0.13 57 70 36 64 42 NPM1, mono, intraPARP9, lymp, intra 0.17 0.03 63 79 36 67 52 NPM1, mono, intra PDIA6,gran, intra 0.19 0.06 63 73 45 69 50 NPM1, mono, intra PDIA6, lymp,intra 0.17 0.07 61 71 45 69 48 NPM1, mono, intra PDIA6, mono, intra 0.190.06 63 73 45 69 50 NPM1, mono, intra PTEN, gran, intra 0.21 −0.01 64 7644 69 53 NPM1, mono, intra PTEN, lymp, intra 0.14 0.04 61 75 38 66 48NPM1, mono, intra PTEN, mean, intra 0.15 −0.05 61 75 38 66 50 NPM1,mono, intra PTEN, mono, intra 0.21 −0.01 64 76 44 69 53 NPM1, mono,intra RSAD2, gran, intra 0.67 0.04 84 86 82 89 78 NPM1, mono, intraRSAD2, lymp, intra 0.21 −0.02 65 81 38 68 56 NPM1, mono, intra RSAD2,mean, intra 0.61 −0.03 81 82 79 86 74 NPM1, mono, intra RSAD2, mono,intra 0.67 0.04 84 86 82 89 78 NPM1, mono, intra SDCBP, mean, intra 0.110.01 60 77 33 64 48 NPM1, mono, intra WBC 0.37 0.12 72 89 44 72 71 OAS2,gran, intra OAS2, mean, intra 0.38 0.02 68 60 77 76 62 OAS2, gran, intraOAS2, mono, intra 0.36 0 67 61 75 74 62 OAS2, gran, intra PARP12, gran,intra 0.18 −0.18 62 72 46 69 50 OAS2, gran, intra PARP12, mean, intra0.28 −0.08 66 74 54 72 57 OAS2, gran, intra PARP12, mono, intra 0.18−0.18 62 72 46 69 50 OAS2, gran, intra PARP9, lymp, intra 0.22 −0.14 6475 46 70 53 OAS2, gran, intra PDIA6, gran, intra 0.06 −0.3 58 74 32 6542 OAS2, gran, intra PDIA6, lymp, intra 0.18 −0.18 63 75 42 69 50 OAS2,gran, intra PDIA6, mono, intra 0.06 −0.3 58 74 32 65 42 OAS2, gran,intra PTEN, gran, intra 0.14 −0.22 60 70 44 67 47 OAS2, gran, intraPTEN, lymp, intra 0.25 −0.11 64 69 56 72 52 OAS2, gran, intra PTEN,mean, intra 0.11 −0.25 58 68 44 66 46 OAS2, gran, intra PTEN, mono,intra 0.14 −0.22 60 70 44 67 47 OAS2, gran, intra RSAD2, gran, intra0.64 0.01 82 80 84 86 78 OAS2, gran, intra RSAD2, lymp, intra 0.43 0.0771 65 78 78 65 OAS2, gran, intra RSAD2, mean, intra 0.6 −0.04 80 78 8284 76 OAS2, gran, intra RSAD2, mono, intra 0.64 0.01 82 80 84 86 78OAS2, gran, intra SDCBP, mean, intra 0.21 −0.15 63 74 46 68 53 OAS2,gran, intra WBC 0.43 0.07 72 71 73 76 67 OAS2, mean, intra OAS2, mono,intra 0.38 0.02 68 60 77 76 62 OAS2, mean, intra PARP12, gran, intra0.17 −0.13 61 73 44 67 50 OAS2, mean, intra PARP12, mean, intra 0.24−0.06 64 73 51 70 54 OAS2, mean, intra PARP12, mono, intra 0.17 −0.13 6173 44 67 50 OAS2, mean, intra PARP9, lymp, intra 0.12 −0.18 59 73 38 6547 OAS2, mean, intra PDIA6, gran, intra 0.04 −0.26 58 77 26 64 40 OAS2,mean, intra PDIA6, lymp, intra 0.05 −0.25 58 75 29 65 41 OAS2, mean,intra PDIA6, mono, intra 0.04 −0.26 58 77 26 64 40 OAS2, mean, intraPTEN, gran, intra 0.17 −0.13 61 71 46 68 50 OAS2, mean, intra PTEN,lymp, intra 0.08 −0.22 57 69 38 64 44 OAS2, mean, intra PTEN, mean,intra 0.14 −0.16 60 73 41 66 48 OAS2, mean, intra PTEN, mono, intra 0.17−0.13 61 71 46 68 50 OAS2, mean, intra RSAD2, gran, intra 0.64 0.01 8281 84 86 79 OAS2, mean, intra RSAD2, lymp, intra 0.29 −0.01 64 62 68 6960 OAS2, mean, intra RSAD2, mean, intra 0.66 0.02 83 82 84 86 80 OAS2,mean, intra RSAD2, mono, intra 0.64 0.01 82 81 84 86 79 OAS2, mean,intra SDCBP, mean, intra 0.03 −0.27 56 72 31 62 41 OAS2, mean, intra WBC0.34 0.04 67 75 58 68 67 OAS2, mono, intra PARP12, gran, intra 0.18−0.18 62 72 46 69 50 OAS2, mono, intra PARP12, mean, intra 0.28 −0.08 6674 54 72 57 OAS2, mono, intra PARP12, mono, intra 0.18 −0.18 62 72 46 6950 OAS2, mono, intra PARP9, lymp, intra 0.22 −0.14 64 75 46 70 53 OAS2,mono, intra PDIA6, gran, intra 0.06 −0.3 58 74 32 65 42 OAS2, mono,intra PDIA6, lymp, intra 0.18 −0.18 63 75 42 69 50 OAS2, mono, intraPDIA6, mono, intra 0.06 −0.3 58 74 32 65 42 OAS2, mono, intra PTEN,gran, intra 0.14 −0.22 60 70 44 67 47 OAS2, mono, intra PTEN, lymp,intra 0.25 −0.11 64 69 56 72 52 OAS2, mono, intra PTEN, mean, intra 0.11−0.25 58 68 44 66 46 OAS2, mono, intra PTEN, mono, intra 0.14 −0.22 6070 44 67 47 OAS2, mono, intra RSAD2, gran, intra 0.64 0.01 82 80 84 8678 OAS2, mono, intra RSAD2, lymp, intra 0.43 0.07 71 65 78 78 65 OAS2,mono, intra RSAD2, mean, intra 0.6 −0.04 80 78 82 84 76 OAS2, mono,intra RSAD2, mono, intra 0.64 0.01 82 80 84 86 78 OAS2, mono, intraSDCBP, mean, intra 0.21 −0.15 63 74 46 68 53 OAS2, mono, intra WBC 0.430.07 72 71 73 76 67 PARP12, gran, intra PARP12, mean, intra 0.25 0 65 7649 70 56 PARP12, gran, intra PARP12, mono, intra 0.24 0.05 65 75 49 7154 PARP12, gran, intra PARP9, lymp, intra 0.25 0.06 66 78 46 70 56PARP12, gran, intra PDIA6, gran, intra 0.19 0 64 79 39 69 52 PARP12,gran, intra PDIA6, lymp, intra 0.24 0.05 65 75 48 71 54 PARP12, gran,intra PDIA6, mono, intra 0.19 0 64 79 39 69 52 PARP12, gran, intra PTEN,gran, intra 0.19 −0.03 63 75 44 69 52 PARP12, gran, intra PTEN, lymp,intra 0.27 0.08 66 73 54 72 55 PARP12, gran, intra PTEN, mean, intra0.13 −0.07 60 74 38 66 48 PARP12, gran, intra PTEN, mono, intra 0.19−0.03 63 75 44 69 52 PARP12, gran, intra RSAD2, gran, intra 0.66 0.03 8384 82 89 76 PARP12, gran, intra RSAD2, lymp, intra 0.26 0.03 66 77 49 7156 PARP12, gran, intra RSAD2, mean, intra 0.61 −0.03 81 84 77 85 75PARP12, gran, intra RSAD2, mono, intra 0.66 0.03 83 84 82 89 76 PARP12,gran, intra SDCBP, mean, intra 0.12 −0.07 59 70 41 65 47 PARP12, gran,intra WBC 0.42 0.17 74 91 46 73 75 PARP12, mean, intra PARP12, mono,intra 0.25 0 65 76 49 70 56 PARP12, mean, intra PARP9, lymp, intra 0.250 65 77 46 70 56 PARP12, mean, intra PDIA6, gran, intra 0.25 0 65 74 5272 53 PARP12, mean, intra PDIA6, lymp, intra 0.27 0.02 67 75 52 73 55PARP12, mean, intra PDIA6, mono, intra 0.25 0 65 74 52 72 53 PARP12,mean, intra PTEN, gran, intra 0.24 −0.01 64 73 51 70 54 PARP12, mean,intra PTEN, lymp, intra 0.26 0.01 65 74 51 71 56 PARP12, mean, intraPTEN, mean, intra 0.25 0 65 76 49 70 56 PARP12, mean, intra PTEN, mono,intra 0.24 −0.01 64 73 51 70 54 PARP12, mean, intra RSAD2, gran, intra0.65 0.02 83 84 82 88 76 PARP12, mean, intra RSAD2, lymp, intra 0.340.09 69 77 56 74 61 PARP12, mean, intra RSAD2, mean, intra 0.61 −0.03 8184 77 85 75 PARP12, mean, intra RSAD2, mono, intra 0.65 0.02 83 84 82 8876 PARP12, mean, intra SDCBP, mean, intra 0.21 −0.04 63 72 49 69 53PARP12, mean, intra WBC 0.35 0.1 70 84 49 72 66 PARP12, mono, intraPARP9, lymp, intra 0.25 0.06 66 78 46 70 56 PARP12, mono, intra PDIA6,gran, intra 0.19 0 64 79 39 69 52 PARP12, mono, intra PDIA6, lymp, intra0.24 0.05 65 75 48 71 54 PARP12, mono, intra PDIA6, mono, intra 0.19 064 79 39 69 52 PARP12, mono, intra PTEN, gran, intra 0.19 −0.03 63 75 4469 52 PARP12, mono, intra PTEN, lymp, intra 0.27 0.08 66 73 54 72 55PARP12, mono, intra PTEN, mean, intra 0.13 −0.07 60 74 38 66 48 PARP12,mono, intra PTEN, mono, intra 0.19 −0.03 63 75 44 69 52 PARP12, mono,intra RSAD2, gran, intra 0.66 0.03 83 84 82 89 76 PARP12, mono, intraRSAD2, lymp, intra 0.26 0.03 66 77 49 71 56 PARP12, mono, intra RSAD2,mean, intra 0.61 −0.03 81 84 77 85 75 PARP12, mono, intra RSAD2, mono,intra 0.66 0.03 83 84 82 89 76 PARP12, mono, intra SDCBP, mean, intra0.12 −0.07 59 70 41 65 47 PARP12, mono, intra WBC 0.42 0.17 74 91 46 7375 PARP9, lymp, intra PDIA6, gran, intra 0.18 0.04 63 75 42 69 50 PARP9,lymp, intra PDIA6, lymp, intra 0.17 0.03 63 77 39 68 50 PARP9, lymp,intra PDIA6, mono, intra 0.18 0.04 63 75 42 69 50 PARP9, lymp, intraPTEN, gran, intra 0.16 −0.06 61 72 44 68 49 PARP9, lymp, intra PTEN,lymp, intra 0.16 0.02 62 77 38 67 50 PARP9, lymp, intra PTEN, mean,intra 0.18 −0.02 62 74 44 68 52 PARP9, lymp, intra PTEN, mono, intra0.16 −0.06 61 72 44 68 49 PARP9, lymp, intra RSAD2, gran, intra 0.650.02 83 86 79 87 78 PARP9, lymp, intra RSAD2, lymp, intra 0.19 −0.04 6481 36 68 54 PARP9, lymp, intra RSAD2, mean, intra 0.59 −0.05 80 82 77 8573 PARP9, lymp, intra RSAD2, mono, intra 0.65 0.02 83 86 79 87 78 PARP9,lymp, intra SDCBP, mean, intra 0.12 −0.02 60 75 36 65 48 PARP9, lymp,intra WBC 0.3 0.05 69 89 36 70 67 PDIA6, gran, intra PDIA6, lymp, intra0.14 0.01 62 77 35 67 48 PDIA6, gran, intra PDIA6, mono, intra 0.13 0 6279 32 67 48 PDIA6, gran, intra PTEN, gran, intra 0.18 −0.04 63 75 42 6950 PDIA6, gran, intra PTEN, lymp, intra 0.13 0 61 74 39 67 46 PDIA6,gran, intra PTEN, mean, intra 0.17 −0.03 63 77 39 68 50 PDIA6, gran,intra PTEN, mono, intra 0.18 −0.04 63 75 42 69 50 PDIA6, gran, intraRSAD2, gran, intra 0.62 −0.01 82 85 77 87 75 PDIA6, gran, intra RSAD2,lymp, intra 0.31 0.08 69 81 48 73 60 PDIA6, gran, intra RSAD2, mean,intra 0.57 −0.07 80 83 74 85 72 PDIA6, gran, intra RSAD2, mono, intra0.62 −0.01 82 85 77 87 75 PDIA6, gran, intra SDCBP, mean, intra 0.210.08 64 75 45 70 52 PDIA6, gran, intra WBC 0.29 0.04 69 87 39 71 63PDIA6, lymp, intra PDIA6, mono, intra 0.14 0.01 62 77 35 67 48 PDIA6,lymp, intra PTEN, gran, intra 0.14 −0.08 61 72 42 68 46 PDIA6, lymp,intra PTEN, lymp, intra 0.18 0.14 63 75 42 69 50 PDIA6, lymp, intraPTEN, mean, intra 0.07 −0.13 57 68 39 65 41 PDIA6, lymp, intra PTEN,mono, intra 0.14 −0.08 61 72 42 68 46 PDIA6, lymp, intra RSAD2, gran,intra 0.64 0.01 83 87 77 87 77 PDIA6, lymp, intra RSAD2, lymp, intra0.19 −0.04 63 74 45 70 50 PDIA6, lymp, intra RSAD2, mean, intra 0.62−0.02 82 85 77 87 75 PDIA6, lymp, intra RSAD2, mono, intra 0.64 0.01 8387 77 87 77 PDIA6, lymp, intra SDCBP, mean, intra 0.23 0.19 65 77 45 7054 PDIA6, lymp, intra WBC 0.27 0.02 68 85 39 70 60 PDIA6, mono, intraPTEN, gran, intra 0.18 −0.04 63 75 42 69 50 PDIA6, mono, intra PTEN,lymp, intra 0.13 0 61 74 39 67 46 PDIA6, mono, intra PTEN, mean, intra0.17 −0.03 63 77 39 68 50 PDIA6, mono, intra PTEN, mono, intra 0.18−0.04 63 75 42 69 50 PDIA6, mono, intra RSAD2, gran, intra 0.62 −0.01 8285 77 87 75 PDIA6, mono, intra RSAD2, lymp, intra 0.31 0.08 69 81 48 7360 PDIA6, mono, intra RSAD2, mean, intra 0.57 −0.07 80 83 74 85 72PDIA6, mono, intra RSAD2, mono, intra 0.62 −0.01 82 85 77 87 75 PDIA6,mono, intra SDCBP, mean, intra 0.21 0.08 64 75 45 70 52 PDIA6, mono,intra WBC 0.29 0.04 69 87 39 71 63 PTEN, gran, intra PTEN, lymp, intra0.16 −0.06 61 72 44 68 49 PTEN, gran, intra PTEN, mean, intra 0.23 0.0164 74 49 70 54 PTEN, gran, intra PTEN, mono, intra 0.23 0.01 64 73 49 7053 PTEN, gran, intra RSAD2, gran, intra 0.66 0.03 83 84 82 89 76 PTEN,gran, intra RSAD2, lymp, intra 0.22 −0.01 64 75 46 70 53 PTEN, gran,intra RSAD2, mean, intra 0.63 −0.01 82 84 79 87 76 PTEN, gran, intraRSAD2, mono, intra 0.66 0.03 83 84 82 89 76 PTEN, gran, intra SDCBP,mean, intra 0.27 0.05 66 77 49 70 58 PTEN, gran, intra WBC 0.33 0.08 7086 44 71 65 PTEN, lymp, intra PTEN, mean, intra 0.08 −0.12 57 69 38 6444 PTEN, lymp, intra PTEN, mono, intra 0.16 −0.06 61 72 44 68 49 PTEN,lymp, intra RSAD2, gran, intra 0.67 0.04 84 88 79 88 79 PTEN, lymp,intra RSAD2, lymp, intra 0.18 −0.05 63 78 38 68 52 PTEN, lymp, intraRSAD2, mean, intra 0.59 −0.05 80 82 77 85 73 PTEN, lymp, intra RSAD2,mono, intra 0.67 0.04 84 88 79 88 79 PTEN, lymp, intra SDCBP, mean,intra 0.22 0.18 64 75 46 69 55 PTEN, lymp, intra WBC 0.28 0.03 68 84 4170 62 PTEN, mean, intra PTEN, mono, intra 0.23 0.01 64 74 49 70 54 PTEN,mean, intra RSAD2, gran, intra 0.67 0.04 84 85 82 88 78 PTEN, mean,intra RSAD2, lymp, intra 0.23 0 64 76 46 69 55 PTEN, mean, intra RSAD2,mean, intra 0.61 −0.03 81 82 79 86 74 PTEN, mean, intra RSAD2, mono,intra 0.67 0.04 84 85 82 88 78 PTEN, mean, intra SDCBP, mean, intra 0.240.04 65 77 46 69 56 PTEN, mean, intra WBC 0.3 0.05 68 85 41 70 64 PTEN,mono, intra RSAD2, gran, intra 0.66 0.03 83 84 82 89 76 PTEN, mono,intra RSAD2, lymp, intra 0.22 −0.01 64 75 46 70 53 PTEN, mono, intraRSAD2, mean, intra 0.63 −0.01 82 84 79 87 76 PTEN, mono, intra RSAD2,mono, intra 0.66 0.03 83 84 82 89 76 PTEN, mono, intra SDCBP, mean,intra 0.27 0.05 66 77 49 70 58 PTEN, mono, intra WBC 0.33 0.08 70 86 4471 65 RSAD2, gran, intra RSAD2, lymp, intra 0.61 −0.02 80 77 84 85 76RSAD2, gran, intra RSAD2, mean, intra 0.63 −0.01 81 79 84 85 78 RSAD2,gran, intra RSAD2, mono, intra 0.63 0 81 79 84 86 77 RSAD2, gran, intraSDCBP, mean, intra 0.65 0.02 83 84 82 88 76 RSAD2, gran, intra WBC 0.630 81 77 85 87 76 RSAD2, lymp, intra RSAD2, mean, intra 0.64 0 82 81 8486 79 RSAD2, lymp, intra RSAD2, mono, intra 0.61 −0.02 80 77 84 85 76RSAD2, lymp, intra SDCBP, mean, intra 0.19 −0.04 63 77 41 67 53 RSAD2,lymp, intra WBC 0.29 0.04 65 72 56 67 63 RSAD2, mean, intra RSAD2, mono,intra 0.63 −0.01 81 79 84 85 78 RSAD2, mean, intra SDCBP, mean, intra0.61 −0.03 81 82 79 86 74 RSAD2, mean, intra WBC 0.63 −0.01 81 78 85 8677 RSAD2, mono, intra SDCBP, mean, intra 0.65 0.02 83 84 82 88 76 RSAD2,mono, intra WBC 0.63 0 81 77 85 87 76 SDCBP, mean, intra WBC 0.27 0.0267 84 41 69 62 * Positive and negative correspond to bacterial and viralinfected patients respectively

TABLE 5 The classification accuracy of viral vs. mixed infected patientscomputed over pairs of DETERMINANTS. DETERMINANT #1 DETERMINANT #2 MCCTotal accuracy % Sen % Spe % ANC UBE2N, mean, intra 0.78 89 84 93 CES1,mean, intra CRP 0.75 88 84 90 ANC SOCS3, mean, intra 0.73 86 72 97 CRPMX1, mean, intra 0.73 87 84 89 CRP LIPT1, mean, intra 0.7 86 81 89 CRPPARP12, mean, intra 0.7 86 81 89 IFIT3, mean, intra Lym(%) 0.7 85 77 91IFIT3, mean, intra Neu(%) 0.7 85 79 90 ANC PARP12, mean, intra 0.69 8573 94 ATP6V0B, mean, intra CRP 0.69 85 81 88 CRP Lym(%) 0.68 84 83 85CRP PARP9, mean, intra 0.68 84 86 83 MX1, mean, intra SOCS3, mean, intra0.68 84 72 93 ANC CRP 0.67 84 87 81 ANC LOC26010, mean, intra 0.67 84 7690 HERC5, mean, intra Neu(%) 0.67 84 80 87 MX1, mean, intra Neu(%) 0.6784 85 83 ARHGDIB, mean, intra CRP 0.66 83 84 83 ARPC2, mean, intra CRP0.66 83 78 88 CRP RSAD2, mean, intra 0.66 83 79 86 HERC5, mean, intraLym(%) 0.66 83 79 87 Neu(%) RSAD2, mean, intra 0.66 83 84 83 CRP Neu(%)0.65 82 87 79 ANC HERC5, mean, intra 0.64 82 80 84 ARPC2, mean, intraSOCS3, mean, intra 0.64 82 67 93 CES1, mean, intra Neu(%) 0.64 82 79 85CORO1A, mean, intra MX1, mean, intra 0.64 82 76 88 ANC ARPC2, mean,intra 0.63 82 79 84 ANC MX1, mean, intra 0.63 82 82 81 ANC RSAD2, mean,intra 0.63 82 81 83 ARPC2, mean, intra UBE2N, mean, intra 0.63 81 66 93CRP LOC26010, mean, intra 0.63 82 83 81 CRP OAS2, mean, intra 0.63 81 8876 CRP SOCS3, mean, intra 0.63 82 81 83 Lym(%) MX1, mean, intra 0.63 8282 81 ANC LIPT1, mean, intra 0.62 81 81 81 ANC Neu(%) 0.62 81 73 88CORO1A, mean, intra SOCS3, mean, intra 0.62 81 66 93 Lym(%) RSAD2, mean,intra 0.62 81 81 81 PARP12, mean, intra SOCS3, mean, intra 0.62 81 66 93ANC IFIT3, mean, intra 0.61 81 71 89 ATP6V0B, mean, intra SOCS3, mean,intra 0.61 80 64 93 CORO1A, mean, intra Neu(%) 0.61 81 73 88 CRP HERC5,mean, intra 0.61 80 82 79 CRP UBE2N, mean, intra 0.61 80 81 80 HERC5,mean, intra PARP12, mean, intra 0.61 80 66 92 IFIT3, mean, intra SOCS3,mean, intra 0.61 80 64 93 ANC CES1, mean, intra 0.6 80 73 86 ARHGDIB,mean, intra Lym(%) 0.6 80 79 81 ARPC2, mean, intra Neu(%) 0.6 80 79 81ARPC2, mean, intra PARP12, mean, intra 0.6 80 65 93 ATP6V0B, mean, intraUBE2N, mean, intra 0.6 80 63 93 CES1, mean, intra Lym(%) 0.6 80 79 81CRP IFIT3, mean, intra 0.6 80 79 81 CRP PTEN, mean, intra 0.6 80 86 75MX1, mean, intra PARP12, mean, intra 0.6 80 71 88 MX1, mean, intraUBE2N, mean, intra 0.6 80 71 88 PARP12, mean, intra RSAD2, mean, intra0.6 80 71 88 PTEN, mean, intra SOCS3, mean, intra 0.6 79 64 93 RSAD2,mean, intra SOCS3, mean, intra 0.6 80 72 87 IFIT3, mean, intra UBE2N,mean, intra 0.59 79 61 93 LOC26010, mean, intra Neu(%) 0.59 80 78 81 ANCLym(%) 0.58 79 69 88 CORO1A, mean, intra CRP 0.58 79 81 78 CORO1A, mean,intra IFIT3, mean, intra 0.58 80 69 88 CORO1A, mean, intra PARP12, mean,intra 0.58 80 69 88 CORO1A, mean, intra RSAD2, mean, intra 0.58 80 73 85LOC26010, mean, intra MX1, mean, intra 0.58 79 69 88 Neu(%) SOCS3, mean,intra 0.58 79 72 85 OAS2, mean, intra SOCS3, mean, intra 0.58 79 61 93PARP9, mean, intra SOCS3, mean, intra 0.58 79 61 93 PTEN, mean, intraUBE2N, mean, intra 0.58 78 61 93 SOCS3, mean, intra UBE2N, mean, intra0.58 79 61 93 ANC CORO1A, mean, intra 0.57 79 69 86 ANC OAS2, mean,intra 0.57 79 76 81 ANC PARP9, mean, intra 0.57 79 76 81 ANC PTEN, mean,intra 0.57 79 73 84 ARHGDIB, mean, intra Neu(%) 0.57 79 76 81 ARPC2,mean, intra CORO1A, mean, intra 0.57 79 68 88 CORO1A, mean, intra UBE2N,mean, intra 0.57 79 69 87 HERC5, mean, intra RSAD2, mean, intra 0.57 7969 87 LOC26010, mean, intra SOCS3, mean, intra 0.57 78 59 93 ARPC2,mean, intra Lym(%) 0.56 78 74 81 HERC5, mean, intra PTEN, mean, intra0.56 78 69 86 LIPT1, mean, intra Neu(%) 0.56 78 74 81 LOC26010, mean,intra PTEN, mean, intra 0.56 77 58 93 CES1, mean, intra PARP12, mean,intra 0.55 78 66 88 CES1, mean, intra SOCS3, mean, intra 0.55 78 67 87CORO1A, mean, intra LOC26010, mean, intra 0.55 78 66 88 CORO1A, mean,intra Lym(%) 0.55 78 73 83 IFIT3, mean, intra PARP12, mean, intra 0.5578 66 88 LOC26010, mean, intra Lym(%) 0.55 78 79 76 ATP6V0B, mean, intraMX1, mean, intra 0.54 77 65 88 CORO1A, mean, intra HERC5, mean, intra0.54 77 66 87 CORO1A, mean, intra OAS2, mean, intra 0.54 77 65 88CORO1A, mean, intra PARP9, mean, intra 0.54 77 65 88 CORO1A, mean, intraPTEN, mean, intra 0.54 77 66 87 LIPT1, mean, intra Lym(%) 0.54 77 73 81LOC26010, mean, intra RSAD2, mean, intra 0.54 77 69 84 Lym(%) SOCS3,mean, intra 0.54 77 72 81 Neu(%) PARP12, mean, intra 0.54 77 71 83 OAS2,mean, intra PARP12, mean, intra 0.54 77 65 88 PTEN, mean, intra RSAD2,mean, intra 0.54 77 66 87 ARHGDIB, mean, intra ARPC2, mean, intra 0.5377 63 88 ARPC2, mean, intra IFIT3, mean, intra 0.53 77 63 88 ARPC2,mean, intra LOC26010, mean, intra 0.53 77 63 88 ARPC2, mean, intra MX1,mean, intra 0.53 77 63 88 ARPC2, mean, intra OAS2, mean, intra 0.53 7763 88 ARPC2, mean, intr3 PARP9, mean, intra 0.53 77 63 88 CES1, mean,intra MX1, mean, intra 0.53 77 63 88 CES1, mean, intra PTEN, mean, intra0.53 77 65 87 CES1, mean, intra UBE2N, mean, intra 0.53 77 65 87LOC26010, mean, intra PARP12, mean, intra 0.53 77 63 88 Lym(%) OAS2,mean, intra 0.53 76 75 78 Neu(%) OAS2, mean, intra 0.53 76 71 81 HERC5,mean, intra IFIT3, mean, intra 0.52 76 64 87 HERC5, mean, intra MX1,mean, intra 0.52 76 64 87 Lym(%) Neu(%) 0.52 76 71 81 Neu(%) PARP9,mean, intra 0.52 76 77 75 PARP12, mean, intra PARP9, mean, intra 0.52 7766 85 ARHGDIB, mean, intra CES1, mean, intra 0.51 76 61 88 ARPC2, mean,intra ATP6V0B, mean, intra 0.51 76 61 88 ARPC2, mean, intra PTEN, mean,intra 0.51 76 63 87 ARPC2, mean, intra RSAD2, mean, intra 0.51 76 68 83ATP6V0B, mean, intra CORO1A, mean, intra 0.51 76 66 84 ATP6V0B, mean,intra Neu(%) 0.51 76 69 81 ATP6V0B, mean, intra PTEN, mean, intra 0.5176 63 87 HERC5, mean, intra SOCS3, mean, intra 0.51 75 63 86 HERC5,mean, intra UBE2N, mean, intra 0.51 76 64 86 IFIT3, mean, intraLOC26010, mean, intra 0.51 76 61 88 LIPT1, mean, intra PARP12, mean,intra 0.51 76 63 86 LIPT1, mean, intra PTEN, mean, intra 0.51 76 63 87Lym(%) PTEN, mean, intra 0.51 76 71 80 Neu(%) PTEN, mean, intra 0.51 7671 80 Neu(%) UBE2N, mean, intra 0.51 76 71 80 PARP12, mean, intra PTEN,mean, intra 0.51 76 63 87 ANC ATP6V0B, mean, intra 0.5 75 66 83 ARHGDIB,mean, intra SOCS3, mean, intra 0.5 75 59 88 ARPC2, mean, intra CES1,mean, intra 0.5 75 60 88 ATP6V0B, mean, intra Lym(%) 0.5 75 68 81 CES1,mean, intra IFIT3, mean, intra 0.5 75 60 88 LIPT1, mean, intra MX1,mean, intra 0.5 75 60 88 PARP12, mean, intra UBE2N, mean, intra 0.5 7565 84 ARHGDIB, mean, intra PARP12, mean, intra 0.49 75 65 84 ARHGDIB,mean, intra PTEN, mean, intra 0.49 74 60 87 ATP6V0B, mean, intra PARP12,mean, intra 0.49 75 65 84 LIPT1, mean, intra SOCS3, mean, intra 0.49 7561 87 MX1, mean, intra PTEN, mean, intra 0.49 74 60 87 MX1, mean, intraRSAD2, mean, intra 0.49 74 67 81 ATP6V0B, mean, intra IFIT3, mean, intra0.48 75 58 88 CORO1A, mean, intra LIPT1, mean, intra 0.48 75 66 81IFIT3, mean, intra LIPT1, mean, intra 0.48 75 58 88 LIPT1, mean, intraRSAD2, mean, intra 0.48 75 66 81 ANC ARHGDIB, mean, intra 0.47 74 69 78ARPC2, mean, intra LIPT1, mean, intra 0.47 74 56 88 ATP6V0B, mean, intraLOC26010, mean, intra 0.47 74 56 88 CES1, mean, intra CORO1A, mean,intra 0.47 74 63 83 IFIT3, mean, intra MX1, mean, intra 0.47 74 61 84IFIT3, mean, intra PTEN, mean, intra 0.47 74 58 87 LIPT1, mean, intraUBE2N, mean, intra 0.47 74 58 87 LOC26010, mean, intra UBE2N, mean,intra 0.47 74 58 87 RSAD2, mean, intra UBE2N, mean, intra 0.47 74 63 83ARPC2, mean, intra HERC5, mean, intra 0.46 74 66 80 Lym(%) PARP9, mean,intra 0.46 73 71 75 MX1, mean, intra OAS2, mean, intra 0.46 73 64 81PARP9, mean, intra PTEN, mean, intra 0.46 73 56 87 PARP9, mean, intraUBE2N, mean, intra 0.46 73 56 87 ARHGDIB, mean, intra CORO1A, mean,intra 0.45 73 63 81 HERC5, mean, intra LOC26010, mean, intra 0.45 73 6281 HERC5, mean, intra PARP9, mean, intra 0.45 73 64 80 ARHGDIB, mean,intra MX1, mean, intra 0.44 73 61 81 ATP6V0B, mean, intra CES1, mean,intra 0.44 73 50 90 ATP6V0B, mean, intra LIPT1, mean, intra 0.44 73 5388 ATP6V0B, mean, intra PARP9, mean, intra 0.44 73 53 88 ATP6V0B, mean,intra RSAD2, mean, intra 0.44 73 61 81 Lym(%) UBE2N, mean, intra 0.44 7271 73 OAS2, mean, intra PTEN, mean, intra 0.44 72 55 87 ARHGDIB, mean,intra ATP6V0B, mean, intra 0.43 72 52 88 ATP6V0B, mean, intra HERC5,mean, intra 0.43 72 62 80 HERC5, mean, intra OAS2, mean, intra 0.43 7262 80 CES1, mean, intra LOC26010, mean, intra 0.42 72 55 85 LC26010,mean, intra OAS2, mean, intra 0.42 71 60 81 MX1, mean, intra PARP9,mean, intra 0.42 72 60 81 OAS2, mean, intra RSAD2, mean, intra 0.42 7166 76 CES1, mean, intra PARP9, mean, intra 0.41 71 50 88 CES1, mean,intra RSAD2, mean, intra 0.41 71 58 81 Lym(%) PARP12, mean, intra 0.4171 66 75 ARHGDIB, mean, intra HERC5, mean, intra 0.4 71 59 80 ATP6V0B,mean, intra OAS2, mean, intra 0.4 70 48 88 HERC5, mean, intra LIPT1,mean, intra 0.4 71 59 80 OAS2, mean, intra UBE2N, mean, intra 0.4 70 5087 ARHGDIB, mean, intra IFIT3, mean, intra 0.39 70 56 81 CES1, mean,intra HERC5, mean, intra 0.39 70 57 80 CES1, mean, intra LIPT1, mean,intra 0.39 70 52 85 IFIT3, mean, intra PARP9, mean, intra 0.39 70 56 81IFIT3, mean, intra RSAD2, mean, intra 0.39 70 58 80 LOC26010, mean,intra PARP9, mean, intra 0.39 70 53 84 ARHGDIB, mean, intra UBE2N, mean,intra 0.38 69 55 81 IFIT3, mean, intra OAS2, mean, intra 0.38 70 55 81LIPT1, mean, intra LOC26010, mean, intra 0.38 70 55 81 ARHGDIB, mean,intra LOC26010, mean, intra 0.36 69 52 83 LIPT1, mean, intra PARP9,mean, intra 0.36 69 52 83 ARHGDIB, mean, intra LIPT1, mean, intra 0.3568 52 81 ARHGDIB, mean, intra RSAD2, mean, intra 0.35 68 60 75 CES1,mean, intra OAS2, mean, intra 0.35 68 47 85 LIPT1, mean, intra OAS2,mean, intra 0.35 68 50 83 PARP9, mean, intra RSAD2, mean, intra 0.35 6858 76 ARHGDIB, mean, intra PARP9, mean, intra 0.32 67 40 88 OAS2, mean,intra PARP9, mean, intra 0.29 65 40 85 ARHGDIB, mean, intra OAS2, mean,intra 0.27 65 39 85 *Positive and negative correspond to viral and mixedinfected patients respectively

TABLE 6 The classification accuracy of viral vs. non-infected patientscomputed over pairs of DETERMINANTS. Total DETERMINANT #1 DETERMINANT #2MCC accuracy % Sen % Spe % MX1, mean, intra MX1, total, intra 0.87 93 85100 LOC26010, mean, intra MX1, mean, intra 0.85 92 83 100 LOC26010,total, intra MX1, mean, intra 0.85 92 83 100 LRDD, total, intra MX1,mean, intra 0.85 92 83 100 LRDD, total, intra MX1, total, intra 0.85 9283 100 MX1, mean, intra PTEN, total, intra 0.85 92 82 100 IFIT3, total,intra MX1, total, intr3 0.84 92 81 100 MX1, mean, intra RAB13, mean,intra 0.84 92 81 100 MX1, mean, intra RSAD2, total, intra 0.84 92 82 100C1orf83, total, intra MX1, mean, intra 0.83 91 81 100 C1orf83, total,intra MX1, total, intra 0.83 91 81 100 IFIT3, total, intra MX1, mean,intra 0.83 91 79 100 IFITM3, total, membrane MX1, total, intra 0.83 9181 100 LOC26010, mean, intra MX1, total, intra 0.83 91 81 100 LOC26010,total, intra MX1, total, intra 0.83 91 81 100 MX1, mean, intra RAB13,total, intra 0.83 91 79 100 MX1, mean, intra RPL34, total, intra 0.83 9181 100 MX1, mean, intra RSAD2, mean, intra 0.83 91 81 100 MX1, mean,intra SART3, mean, intra 0.83 91 79 100 MX1, total, intra Maximaltemperature 0.83 91 80 100 MX1, total, intra RSAD2, total, intra 0.83 9181 100 MX1, total, intra SART3, mean, intra 0.83 91 79 100 MX1, total,intra OAS2, mean, intra 0.82 90 79 100 MX1, mean, intra OAS2, total,intra 0.81 90 83 96 MX1, total, intra OAS2, total, intra 0.81 90 78 100MX1, total, intra PTEN, total, intra 0.81 90 77 100 MX1, total, intraSART3, total, intra 0.81 90 77 100 IFIT3, mean, intra MX1, total, intra0.8 90 76 100 IFIT3, total, intra LRDD, total, intra 0.8 89 77 100IFIT3, mean, intra LOC26010, total, intra 0.79 89 74 100 MX1, total,intra RPL34, total, intra 0.79 89 83 95 IFIT3, mean, intra PTEN, total,intra 0.78 88 73 100 IFIT3, mean, intra RAB13, mean, intra 0.78 88 73100 IFIT3, total, intra Maximal temperature 0.78 88 76 98 IFIT3, total,intra SART3, total, intra 0.78 88 73 100 Maximal temperature RSAD2,mean, intra 0.78 89 87 91 MX1, mean, intra Maximal temperature 0.77 8880 95 MX1, mean, intra OAS2, mean, intra 0.77 88 83 93 MX1, total, intraRSAD2, mean, intra 0.77 88 83 93 IFIT3, mean, intra MX1, mean, intra0.76 88 79 95 MX1, total, intra RAB13, total, intra 0.76 88 79 95IFITM3, total, membrane MX1, mean, intra 0.75 87 82 92 MX1, mean, intraSART3, total, intra 0.75 88 81 93 MX1, total, intra RAB13, mean, intra0.75 88 77 95 C1orf83, total, intra LOC26010, total, intra 0.74 87 75 97IFIT3, mean, intra LRDD, total, intra 0.74 86 70 100 IFIT3, total, intraRAB13, mean, intra 0.73 86 73 96 Maximal temperature RSAD2, total, intra0.73 87 82 91 C1orf83, total, intra IFIT3, mean, intra 0.72 86 75 95C1orf83, total, intra IFIT3, total, intra 0.72 86 77 93 C1orf83, total,intra OAS2, mean, intra 0.72 85 67 100 C1orf83, total, intra OAS2,total, intra 0.72 85 67 100 IFIT3, mean, intra OAS2, total, intra 0.7286 76 94 IFIT3, total, intra SART3, mean, intra 0.72 86 68 99 IFIT3,total, intra LOC26010, mean, intra 0.71 86 74 94 IFIT3, total, intraLOC26010, total, intra 0.71 86 76 93 IFIT3, mean, intra RAB13, total,intra 0.7 85 71 95 LOC26010, total, intra LRDD, total, intra 0.7 85 7990 LOC26010, total, intra PTEN, total, intra 0.7 85 71 95 LOC26010,total, intra RSAD2, mean, intra 0.7 85 75 93 LRDD, total, intra OAS2,total, intra 0.7 83 64 100 IFIT3, total, intra OAS2, total, intra 0.6985 74 93 LOC26010, total, intra Maximal temperature 0.69 84 73 94LOC26010, total, intra RPL34, total, intra 0.69 84 74 93 OAS2, total,intra RSAD2, mean, intra 0.69 84 74 93 IFIT3, total, intra IFITM3,total, membrane 0.68 84 74 92 LOC26010, total, intra RSAD2, total, intra0.68 84 74 93 RSAD2, mean, intra SART3, total, intra 0.68 84 73 93LOC26010, total, intra OAS2, total, intra 0.67 83 72 93 LRDD, total,intra RAB13, total, intra 0.67 83 75 90 LRDD, total, intra RSAD2, mean,intra 0.67 83 75 90 OAS2, total, intra PTEN, total, intra 0.67 84 68 95PTEN, total, intra RPL34, total, intra 0.67 83 75 90 IFIT3, total, intraRSAD2, mean, intra 0.66 84 71 93 IFIT3, total, intra RSAD2, total, intra0.66 84 71 93 IFITM3, total, membrane LOC26010, total, intra 0.66 83 7590 RSAD2, mean, intra RSAD2, total, intra 0.66 83 71 93 IFIT3, mean,intra Maximal temperature 0.65 83 73 91 IFIT3, total, intra OAS2, mean,intra 0.65 83 74 89 IFIT3, total, intra RAB13, total, intra 0.65 83 6993 OAS2, total, intra RAB13, mean, intra 0.65 82 63 96 RAB13, total,intra RPL34, total, intra 0.65 82 74 90 C1orf83, total, intra PTEN,total, intra 0.64 82 73 90 C1orf83, total, intra RPL34, total, intra0.64 82 75 88 IFIT3, mean, intra RSAD2, total, intra 0.64 82 68 93IFITM3, total, membrane LOC26010, mean, intra 0.64 81 69 92 IFITM3,total, membrane Maximal temperature 0.64 82 73 90 LOC26010, mean, intraLOC26010, total, intra 0.64 81 68 93 LOC26010, mean, intra OAS2, total,intra 0.64 81 68 93 LOC26010, total, intra OAS2, mean, intra 0.64 82 7192 LOC26010, total, intra RAB13, mean, intra 0.64 82 68 93 LOC26010,total, intra RAB13, total, intra 0.64 82 66 94 LOC26010, total, intraSART3, total, intra 0.64 82 68 93 IFIT3, total, intra PTEN, total, intra0.63 82 71 90 OAS2, total, intra RPL34, total, intra 0.63 81 72 90IFIT3, mean, intra IFIT3, total, intra 0.62 82 69 90 IFIT3, mean, intraLOC26010, mean, intra 0.62 82 66 93 LOC26010, total, intra SART3, mean,intra 0.62 82 66 93 Maximal temperature RAB13, total, intra 0.62 81 6991 OAS2, total, intra RSAD2, total, intra 0.62 80 66 93 C1orf83, total,intra RAB13, mean, intra 0.61 80 69 90 IFIT3, mean, intra RSAD2, mean,intra 0.61 81 65 93 LOC26010, mean, intra LRDD, total, intra 0.61 81 7090 LOC26010, mean, intra OAS2, mean, intra 0.61 80 65 93 LOC26010, mean,intra RSAD2, mean, intra 0.61 81 75 86 LRDD, total, intra RPL34, total,intra 0.61 81 70 90 PTEN, total, intra RAB13, total, intra 0.61 81 65 93PTEN, total, intra SART3, total, intra 0.61 81 65 93 RAB13, mean, intraRPL34, total, intra 0.61 81 70 90 IFIT3, mean, intra IFITM3, total,membrane 0.6 80 68 90 IFIT3, mean, intra SART3, total, intra 0.6 81 7188 IFITM3, total, membrane RAB13, total, intra 0.6 80 65 92 LOC26010,mean, intra RSAD2, total, intra 0.6 80 74 86 OAS2, mean, intra RAB13,total, intra 0.6 80 63 93 OAS2, mean, intra RPL34, total, intra 0.6 8068 90 PTEN, total, intra RSAD2, mean, intra 0.6 81 71 88 C1orf83, total,intra RAB13, total, intra 0.59 79 67 90 IFITM3, total, membrane RSAD2,mean, intra 0.59 79 74 85 RSAD2, total, intra SART3, total, intra 0.5980 65 92 C1orf83, total, intra LRDD, total, intra 0.58 79 65 90 IFIT3,mean, intra RPL34, total, intra 0.58 79 66 90 IFIT3, mean, intra SART3,mean, intra 0.58 79 66 89 LOC26010, mean, intra PTEN, total, intra 0.5879 61 93 LOC26010, mean, intra SART3, total, intra 0.58 79 61 93 OAS2,total, intra SART3, total, intra 0.58 79 61 93 RAB13, total, intraRSAD2, mean, intra 0.58 79 71 86 RAB13, total, intra SART3, total, intra0.58 79 61 93 C1orf83, total, intra LOC26010, mean, intra 0.57 79 69 87IFITM3, total, membrane SART3, total, intra 0.57 79 61 92 LOC26010,mean, intra Maximal temperature 0.57 79 64 91 LOC26010, mean, intraRAB13, mean, intra 0.57 79 60 93 LOC26010, mean, intra SART3, mean,intra 0.57 79 60 93 LRDD, total, intra OAS2, mean, intra 0.57 78 64 90Maximal temperature OAS2, total, intra 0.57 79 64 91 OAS2, mean, intraRSAD2, mean, intra 0.57 78 68 87 OAS2, total, intra RAB13, total, intra0.57 79 60 93 RAB13, mean, intra RAB13, total, intra 0.57 79 60 93RAB13, total, intra SART3, mean, intra 0.57 79 60 93 C1orf83, total,intra SART3, mean, intra 0.56 78 63 90 LOC26010, mean, intra RPL34,total, intra 0.56 78 70 85 LRDD, total, intra RSAD2, total, intra 0.5678 72 83 Maximal temperature RPL34, total, intra 0.56 78 70 86 OAS2,mean, intra SART3, total, intra 0.56 78 58 93 RAB13, mean, intra RSAD2,mean, intra 0.56 79 66 88 C1orf83, total, intra RSAD2, mean, intra 0.5578 71 83 RAB13, total, intra RSAD2, total, intra 0.55 78 68 86 RPL34,total, intra SART3, mean, intra 0.55 77 62 90 Maximal temperature PTEN,total, intra 0.54 77 60 91 OAS2, mean, intra OAS2, total, intra 0.54 7766 87 OAS2, mean, intra RAB13, mean, intra 0.54 77 58 92 OAS2, mean,intra RSAD2, total, intra 0.54 77 67 86 OAS2, total, intra SART3, mean,intra 0.54 77 56 93 Maximal temperature SART3, total, intra 0.53 76 5891 PTEN, total, intra SART3, mean, intra 0.53 77 63 88 SART3, mean,intra SART3, total, intra 0.53 77 55 93 C1orf83, total, intra SART3,total, intra 0.52 76 65 85 IFIT3, mean, intra OAS2, mean, intra 0.52 7765 86 IFIT3, total, intra RPL34, total, intra 0.52 76 68 83 LRDD, total,intra PTEN, total, intra 0.52 76 72 80 LRDD, total, intra SART3, total,intra 0.52 76 68 83 PTEN, total, intra RSAD2, total, intra 0.52 77 65 86RAB13, mean, intra RSAD2, total, intra 0.52 77 65 86 IFITM3, total,membrane OAS2, mean, intra 0.51 75 65 85 LOC26010, mean, intra RAB13,total, intra 0.51 76 60 88 RAB13, mean, intra SART3, mean, intra 0.51 7660 88 RAB13, mean, intra SART3, total, intra 0.51 76 58 89 C1orf83,total, intra IFITM3, total, membrane 0.5 75 65 83 LRDD, total, intraRAB13, mean, intra 0.5 75 70 80 Maximal temperature RAB13, mean, intra0.5 75 62 86 LRDD, total, intra SART3, mean, intra 0.49 74 64 83 PTEN,total, intra RAB13, mean, intra 0.49 75 61 86 RSAD2, mean, intra SART3,mean, intra 0.49 75 66 82 IFITM3, total, membrane RSAD2, total, intra0.48 74 63 85 RPL34, total, intra RSAD2, mean, intra 0.48 74 68 80RPL34, total, intra RSAD2, total, intra 0.48 74 68 80 RPL34, total,intra SART3, total, intra 0.48 74 68 80 RSAD2, total, intra SART3, mean,intra 0.48 75 68 80 IFITM3, total, membrane OAS2, total, intra 0.47 7367 79 IFITM3, total, membrane RPL34, total, intra 0.47 73 66 80 C1orf83,total, intra RSAD2, total, intra 0.46 73 65 80 Maximal temperature OAS2,mean, intra 0.46 74 64 82 OAS2, mean, intra PTEN, total, intra 0.46 7458 86 OAS2, mean, intra SART3, mean, intra 0.46 74 58 86 IFITM3, total,membrane LRDD, total, intra 0.45 73 70 75 IFITM3, total, membrane PTEN,total, intra 0.45 73 68 77 C1orf83, total, intra Maximal temperature0.43 72 72 71 IFITM3, total, membrane RAB13, mean, intra 0.43 72 60 82IFITM3, total, membrane SART3, mean, intra 0.43 72 56 85 Maximaltemperature SART3, mean, intra 0.4 70 56 82 LRDD, total, intra Maximaltemperature 0.39 70 68 71 * Positive and negative correspond to viraland non-infected patients respectively

TABLE 7 The classification accuracy of bacterial vs. non-infectedpatients computed over pairs of DETERMINANTS. Total DETERMINANT #1DETERMINANT #2 MCC accuracy % Sen % Spe % C1orf83, total, intra CRP 0.9195 90 100 CRP LRDD, total, intra 0.91 95 90 100 CRP QARS, total, intra0.91 95 90 100 RAB13, mean, intra RAB31, total, intra 0.87 94 84 100CD15, total, membrane LRDD, total, intra 0.85 93 81 100 CD15, total,membrane QARS, total, intra 0.85 93 81 100 RAB13, total, intra RAB31,total, intra 0.85 93 81 100 CRP RPL34, total, intra 0.85 92 90 94 ANCLTA4H, total, intra 0.82 91 76 100 CD15, total, membrane LTA4H, total,intra 0.82 91 77 100 LOC26010, total, intra LTA4H, total, intra 0.82 9177 100 ANC RAB31, total, intra 0.82 91 77 100 LOC26010, total, intraRAB31, total, intra 0.82 91 77 100 LRDD, total, intra RAB31, total,intra 0.82 91 77 100 QARS, total, intra RAB31, total, intra 0.82 91 77100 ANC RAC2, total, intra 0.82 91 77 100 LOC26010, total, intra RAC2,total, intra 0.82 91 77 100 RAB13, total, intra RAC2, total, intra 0.8291 77 100 LTA4H, total, intra WBC 0.82 91 77 100 LTA4H, total, intraZBP1, total, intra 0.82 91 77 100 LTA4H, total, intra Maximaltemperature 0.81 90 77 100 C1orf83, total, intra CD15, total, membrane0.8 90 74 100 ANC LRDD, total, intra 0.8 90 73 100 ANC PARP9, total,intra 0.8 91 74 100 LTA4H, total, intra RAB13, mean, intra 0.8 90 73 100CD15, total, membrane RAB13, total, intra 0.8 90 74 100 CD15, total,membrane RAB31, total, intra 0.8 90 74 100 ISG20, total, intra RAB31,total, intra 0.8 90 74 100 RAB31, total, intra RPL34, total, intra 0.890 74 100 RAB31, total, intra WBC 0.8 90 74 100 MX1, total, intra ZBP1,total, intra 0.8 90 74 100 CRP OAS2, total, intra 0.79 90 87 92 CRPRAB13, total, intra 0.79 90 89 90 CRP ZBP1, total, intra 0.79 89 83 94IFIT3, total, intra LRDD, total, intra 0.78 89 71 100 ISG20, total,intra LRDD, total, intra 0.78 89 71 100 LOC26010, total, intra LRDD,total, intra 0.78 89 71 100 LRDD, total, intra Lym(%) 0.78 89 71 100 ANCMX1, total, intra 0.78 90 71 100 LRDD, total, intra MX1, total, intra0.78 89 71 100 ISG20, total, intra OAS2, total, intra 0.78 89 71 100C1orf83, total, intra RAB31, total, intra 0.78 89 71 100 MX1, total,intra RAB31, total, intra 0.78 89 71 100 CD15, total, membrane ZBP1,total, intra 0.78 89 71 100 C1orf83, total, intra LTA4H, total, intra0.77 89 70 100 IFIT3, total, intra LTA4H, total, intra 0.77 89 70 100ISG20, total, intra LTA4H, total, intra 0.77 89 70 100 LRDD, total,intra LTA4H, total, intra 0.77 89 70 100 LTA4H, total, intra MX1, total,intra 0.77 89 70 100 LTA4H, total, intra OAS2, total, intra 0.77 89 70100 CRP WBC 0.77 89 87 90 RAC2, total, intra WBC 0.77 89 74 98 CRP XAF1,total, intra 0.77 89 84 92 ANC IFIT3, total, intra 0.76 89 68 100 ANCLOC26010, total, intra 0.76 89 68 100 LOC26010, total, intra MX1, total,intra 0.76 87 73 100 LTA4H, total, intra RAB31, total, intra 0.76 89 7398 RAB13, total, intra ZBP1, total, intra 0.76 89 77 96 ANC C1orf83,total, intra 0.75 88 67 100 C1orf83, total, intra IFIT3, total, intra0.75 88 68 100 C1orf83, total, intra LOC26010, total, intra 0.75 88 68100 CRP LTA4H, total, intra 0.75 88 86 89 IFIT3, total, intra Maximaltemperature 0.75 88 68 100 ISG20, total, intra RAB13, mean, intra 0.7588 68 100 CRP RAB31, total, intra 0.75 88 83 91 CD15, total, membraneRPL34, total, intra 0.75 88 68 100 LOC26010, total, intra RPL34, total,intra 0.75 88 68 100 LTA4H, total, intra RPL34, total, intra 0.75 88 67100 C1orf83, total, intra SART3, total, intra 0.75 88 68 100 LTA4H,total, intra XAF1, total, intra 0.75 88 67 100 QARS, total, intra XAF1,total, intra 0.75 88 68 100 LRDD, total, intra ZBP1, total, intra 0.7588 68 100 OAS2, total, intra ZBP1, total, intra 0.75 88 68 100 RAB13,mean, intra ZBP1, total, intra 0.75 88 68 100 ANC CRP 0.74 87 84 90 ANCOAS2, total, intra 0.74 88 66 100 MX1, total, intra OAS2, total, intra0.74 86 69 100 ANC SART3, total, intra 0.74 88 66 100 CRP SART3, total,intra 0.74 88 84 90 ISG20, total, intra SART3, total, intra 0.74 88 7496 CRP TRIM22, total, intra 0.74 88 82 92 ANC WBC 0.74 88 66 100LOC26010, total, intra ZBP1, total, intra 0.74 88 74 96 CD15, total,membrane IFIT3, total, intra 0.73 87 64 100 LOC26010, total, intraMaximal temperature 0.73 87 65 100 C1orf83, total, intra MX1, total,intra 0.73 86 65 100 LRDD, total, intra PARP9, total, intra 0.73 86 65100 LOC26010, total, intra SART3, total, intra 0.73 87 64 100 Lym(%)SART3, total, intra 0.73 87 64 100 C1orf83, total, intra WBC 0.73 86 65100 CD15, total, membrane WBC 0.73 87 64 100 LRDD, total, intra WBC 0.7386 65 100 ANC XAF1, total, intra 0.73 87 63 100 RAB13, total, intraXAF1, total, intra 0.73 87 64 100 CRP ISG20, total, intra 0.72 86 80 91ANC Maximal temperature 0.72 86 64 100 CRP PARP9, total, intra 0.72 8682 90 CRP RAC2, total, intra 0.72 86 83 89 ANC ZBP1, total, intra 0.7286 63 100 ISG20, total, intra LOC26010, total, intra 0.71 86 74 94 CRPMaximal temperature 0.71 86 82 89 MX1, total, intra Maximal temperature0.71 85 62 100 CD15, total, membrane MX1, total, intra 0.71 86 62 100ISG20, total, intra MX1, total, intra 0.71 86 77 92 ISG20, total, intraPARP9, total, intra 0.71 86 77 92 LOC26010, total, intra PARP9, total,intra 0.71 86 62 100 OAS2, total, intra RAB13, mean, intra 0.71 86 62100 ISG20, total, intra RAB13, total, intra 0.71 86 77 92 Lym(%) RAB31,total, intra 0.71 86 71 96 C1orf83, total, intra RAC2, total, intra 0.7186 71 96 LTA4H, total, intra TRIM22, total, intra 0.71 86 70 96 ISG20,total, intra WBC 0.71 86 71 96 SART3, total, intra WBC 0.71 86 62 100CRP IFIT3, total, intra 0.7 85 79 90 CRP LOC26010, total, intra 0.7 8579 90 C1orf83, total, intra LRDD, total, intra 0.7 85 61 100 LTA4H,total, intra Lym(%) 0.7 86 77 92 CRP MX1, total, intra 0.7 85 79 90C1orf83, total, intra OAS2, total, intra 0.7 85 61 100 LRDD, total,intra OAS2, total, intra 0.7 85 61 100 CRP RAB13, mean, intra 0.7 85 7990 LTA4H, total, intra RAB13, total, intra 0.7 86 77 92 LTA4H, total,intra RAC2, total, intra 0.7 86 80 90 LRDD, total, intra SART3, total,intra 0.7 85 61 100 LTA4H, total, intra SART3, total, intra 0.7 86 77 92WBC ZBP1, total, intra 0.7 85 61 100 LOC26010, total, intra OAS2, total,intra 0.69 84 74 93 PARP9, total, intra WBC 0.69 85 59 100 ANC ISG20,total, intra 0.68 85 73 92 CD15, total, membrane ISG20, total, intra0.68 85 71 94 LTA4H, total, intra PARP9, total, intra 0.68 85 70 94LTA4H, total, intra QARS, total, intra 0.68 85 77 90 OAS2, total, intraRAB31, total, intra 0.68 85 77 90 LRDD, total, intra RAC2, total, intra0.68 85 74 92 MX1, total, intra RAC2, total, intra 0.68 85 74 92 PARP9,total, intra RAC2, total, intra 0.68 85 77 90 Maximal temperature WBC0.68 84 59 100 C1orf83, total, intra XAF1, total, intra 0.68 84 58 100IFIT3, total, intra ZBP1, total, intra 0.68 84 58 100 RPL34, total,intra ZBP1, total, intra 0.68 84 58 100 CD15, total, membrane CRP 0.6784 76 90 CRP Lym(%) 0.67 84 76 90 C1orf83, total, intra Maximaltemperature 0.67 82 59 100 LRDD, total, intra Maximal temperature 0.6782 59 100 Lym(%) MX1, total, intra 0.67 83 77 89 CD15, total, membraneRAB13, mean, intra 0.67 85 69 94 PARP9, total, intra RAB13, mean, intra0.67 84 56 100 ANC RAB13, total, intra 0.67 85 71 93 Lym(%) RAB13,total, intra 0.67 85 72 93 LOC26010, total, intra WBC 0.67 83 73 93Lym(%) OAS2, total, intra 0.66 83 73 91 C1orf83, total, intra PARP9,total, intra 0.66 84 65 96 QARS, total, intra RAB13, total, intra 0.6684 74 90 IFIT3, total, intra RAB31, total, intra 0.66 84 68 94 PARP9,total, intra RAB31, total, intra 0.66 84 74 90 QARS, total, intra RAC2,total, intra 0.66 84 74 90 RAB13, total, intra RPL34, total, intra 0.6684 74 90 RAC2, total, intra SART3, total, intra 0.66 84 74 90 LRDD,total, intra TRIM22, total, intra 0.66 84 65 96 MX1, total, intra XAF1,total, intra 0.66 82 70 93 CD15, total, membrane LOC26010, total, intra0.65 84 69 92 ANC RAB13, mean, intra 0.65 84 68 93 ANC TRIM22, total,intra 0.65 84 68 93 Lym(%) TRIM22, total, intra 0.65 84 69 93 IFIT3,total, intra MX1, total, intra 0.64 83 59 97 Maximal temperature RAC2,total, intra 0.64 82 78 86 RAB13, mean, intra SART3, total, intra 0.6483 59 97 LOC26010, total, intra XAF1, total, intra 0.64 82 72 90C1orf83, total, intra Lym(%) 0.63 83 71 90 CD15, total, membrane OAS2,total, intra 0.63 83 62 95 IFIT3, total, intra QARS, total, intra 0.6383 71 90 ISG20, total, intra QARS, total, intra 0.63 83 71 90 LOC26010,total, intra QARS, total, intra 0.63 83 68 92 Lym(%) QARS, total, intra0.63 83 71 90 MX1, total, intra QARS, total, intra 0.63 83 71 90 Lym(%)RAB13, mean, intra 0.63 83 67 93 C1orf83, total, intra RAB13, total,intra 0.63 83 71 90 LRDD, total, intra RAB13, total, intra 0.63 83 71 90MX1, total, intra RAB13, total, intra 0.63 83 67 93 CD15, total,membrane RAC2, total, intra 0.63 83 71 90 IFIT3, total, intra RAC2,total, intra 0.63 83 71 90 OAS2, total, intra RAC2, total, intra 0.63 8371 90 RAB13, mean, intra RAC2, total, intra 0.63 83 68 92 RAB31, total,intra RAC2, total, intra 0.63 83 71 90 LRDD, total, intra RPL34, total,intra 0.63 83 71 90 OAS2, total, intra WBC 0.63 81 68 93 RAB13, total,intra WBC 0.63 83 67 93 RAB31, total, intra XAF1, total, intra 0.63 8368 92 C1orf83, total, intra ZBP1, total, intra 0.63 83 65 94 Lym(%)ZBP1, total, intra 0.63 83 71 90 PARP9, total, intra ZBP1, total, intra0.63 83 71 90 RAB31, total, intra ZBP1, total, intra 0.63 83 71 90LOC26010, total, intra Lym(%) 0.62 81 76 86 MX1, total, intra PARP9,total, intra 0.62 83 56 97 ANC RPL34, total, intra 0.62 83 70 90 MX1,total, intra WBC 0.62 81 73 89 Lym(%) PARP9, total, intra 0.61 83 67 91LOC26010, total, intra RAB13, total, intra 0.61 83 62 94 PARP9, total,intra RAB13, total, intra 0.61 83 64 93 RAB13, mean, intra RAB13, total,intra 0.61 83 64 93 OAS2, total, intra RPL34, total, intra 0.61 81 58 96IFIT3, total, intra SART3, total, intra 0.61 83 62 94 OAS2, total, intraSART3, total, intra 0.61 83 64 93 RAB13, total, intra SART3, total,intra 0.61 83 64 93 RAB13, total, intra TRIM22, total, intra 0.61 83 6294 RAB13, mean, intra WBC 0.61 83 64 93 OAS2, total, intra XAF1, total,intra 0.61 80 66 93 XAF1, total, intra ZBP1, total, intra 0.61 81 58 96C1orf83, total, intra ISG20, total, intra 0.6 81 68 90 CD15, total,membrane PARP9, total, intra 0.6 82 64 92 LRDD, total, intra QARS,total, intra 0.6 81 68 90 C1orf83, total, intra RAB13, mean, intra 0.681 68 90 IFIT3, total, intra RAB13, mean, intra 0.6 81 46 100 ISG20,total, intra RAC2, total, intra 0.6 81 68 90 RAC2, total, intra RPL34,total, intra 0.6 81 65 92 CD15, total, membrane SART3, total, intra 0.682 64 92 RAB31, total, intra SART3, total, intra 0.6 81 68 90 RPL34,total, intra SART3, total, intra 0.6 81 65 92 RPL34, total, intra WBC0.6 81 68 90 QARS, total, intra ZBP1, total, intra 0.6 81 68 90 RAC2,total, intra ZBP1, total, intra 0.6 81 68 90 IFIT3, total, intra OAS2,total, intra 0.59 82 56 96 ANC QARS, total, intra 0.59 81 67 90 IFIT3,total, intra RAB13, total, intra 0.59 82 62 93 OAS2, total, intra RAB13,total, intra 0.59 82 62 93 MX1, total, intra SART3, total, intra 0.59 8256 96 RAB13, mean, intra TRIM22, total, intra 0.59 82 62 93 IFIT3,total, intra WBC 0.59 82 62 93 WBC XAF1, total, intra 0.59 79 67 90 ANCLym(%) 0.58 81 61 93 CD15, total, membrane Lym(%) 0.58 81 62 92 ISG20,total, intra Lym(%) 0.58 80 71 86 Lym(%) RAC2, total, intra 0.58 80 7186 CD15, total, membrane XAF1, total, intra 0.58 81 62 92 ANC CD15,total, membrane 0.57 81 61 92 IFIT3, total, intra PARP9, total, intra0.57 81 56 94 OAS2, total, intra PARP9, total, intra 0.57 81 59 93C1orf83, total, intra QARS, total, intra 0.57 80 65 90 MX1, total, intraRAB13, mean, intra 0.57 81 59 93 QARS, total, intra RAB13, mean, intra0.57 80 65 90 Maximal temperature RAB31, total, intra 0.57 79 70 86QARS, total, intra RPL34, total, intra 0.57 80 65 90 PARP9, total, intraSART3, total, intra 0.57 81 59 93 QARS, total, intra SART3, total, intra0.57 80 65 90 IFIT3, total, intra TRIM22, total, intra 0.57 81 59 93ISG20, total, intra TRIM22, total, intra 0.57 80 65 90 LOC26010, total,intra TRIM22, total, intra 0.57 81 59 93 QARS, total, intra TRIM22,total, intra 0.57 80 65 90 RAB31, total, intra TRIM22, total, intra 0.5780 65 90 TRIM22, total, intra WBC 0.57 81 59 93 SART3, total, intraXAF1, total, intra 0.57 81 59 93 ISG20, total, intra ZBP1, total, intra0.57 80 65 90 SART3, total, intra ZBP1, total, intra 0.57 80 65 90Maximal temperature RAB13, total, intra 0.56 80 62 91 IFIT3, total,intra Lym(%) 0.55 80 62 90 CD15, total, membrane Maximal temperature0.55 79 62 90 OAS2, total, intra QARS, total, intra 0.55 79 61 90 PARP9,total, intra QARS, total, intra 0.55 79 61 90 LOC26010, total, intraRAB13, mean, intra 0.55 80 56 93 C1orf83, total, intra RPL34, total,intra 0.55 79 61 90 ISG20, total, intra RPL34, total, intra 0.55 79 6886 Lym(%) RPL34, total, intra 0.55 79 71 84 MX1, total, intra RPL34,total, intra 0.55 79 58 92 RAB13, mean, intra RPL34, total, intra 0.5579 61 90 C1orf83, total, intra TRIM22, total, intra 0.55 79 61 90 MX1,total, intra TRIM22, total, intra 0.55 80 56 93 OAS2, total, intraTRIM22, total, intra 0.55 80 56 93 SART3, total, intra TRIM22, total,intra 0.55 80 56 93 QARS, total, intra WBC 0.55 79 61 90 LRDD, total,intra XAF1, total, intra 0.55 79 61 90 RAC2, total, intra XAF1, total,intra 0.55 79 61 90 Maximal temperature OAS2, total, intra 0.54 79 59 91Maximal temperature SART3, total, intra 0.54 79 59 91 CD15, total,membrane TRIM22, total, intra 0.54 79 67 86 Lym(%) WBC 0.54 77 69 84IFIT3, total, intra LOC26010, total, intra 0.53 79 54 93 IFIT3, total,intra RPL34, total, intra 0.52 78 58 90 ISG20, total, intra XAF1, total,intra 0.52 78 58 90 Lym(%) XAF1, total, intra 0.52 76 74 79 LRDD, total,intra RAB13, mean, intra 0.51 77 71 80 IFIT3, total, intra ISG20, total,intra 0.5 77 65 84 ISG20, total, intra Maximal temperature 0.5 76 63 86PARP9, total, intra XAF1, total, intra 0.5 78 51 93 Maximal temperaturePARP9, total, intra 0.49 76 53 91 PARP9, total, intra TRIM22, total,intra 0.49 77 59 87 RAC2, total, intra TRIM22, total, intra 0.49 77 6186 RPL34, total, intra XAF1, total, intra 0.49 77 55 90 TRIM22, total,intra ZBP1, total, intra 0.49 77 58 88 Maximal temperature QARS, total,intra 0.47 74 59 86 Maximal temperature RPL34, total, intra 0.47 74 5986 Maximal temperature RAB13, mean, intra 0.46 75 50 91 PARP9, total,intra RPL34, total, intra 0.46 75 58 86 Lym(%) Maximal temperature 0.4474 56 85 Maximal temperature ZBP1, total, intra 0.44 73 67 77 IFIT3,total, intra XAF1, total, intra 0.43 75 46 91 RPL34, total, intraTRIM22, total, intra 0.41 73 58 82 Maximal temperature TRIM22, total,intra 0.36 71 53 82 TRIM22, total, intra XAF1, total, intra 0.36 72 3891 RAB13, mean, intra XAF1, total, intra 0.33 71 44 86 Maximaltemperature XAF1, total, intra 0.13 63 18 91 * Positive and negativecorrespond to bacterial and non-infected patients respectively

TABLE 8 The classification accuracy of infected vs. non-infectedpatients computed over pairs of DETERMINANTS. Total DETERMINANT #1DETERMINANT #2 MCC accuracy % Sen % Spe % C1orf83, total, intra CRP 0.7787 75 100 C1orf83, total, intra IFIT3, total, intra 0.8 89 76 100C1orf83, total, intra LOC26010, mean, intra 0.6 80 67 91 C1orf83, total,intra LOC26010, total, intra 0.77 88 72 100 C1orf83, total, intra LRDD,total, intra 0.59 80 67 90 C1orf83, total, intra MX1, mean, intra 0.7286 77 93 C1orf83, total, intra MX1, total, intra 0.8 89 76 100 C1orf83,total, intra Maximal temperature 0.4 70 69 71 C1orf83, total, intraOAS2, total, intra 0.74 86 68 100 C1orf83, total, intra QARS, total,intra 0.58 79 66 90 C1orf83, total, intra RAB13, mean, intra 0.62 81 7090 C1orf83, total, intra RAB13, total, intra 0.64 82 72 90 C1orf83,total, intra RPL34, total, intra 0.62 81 70 90 C1orf83, total, intraRSAD2, mean, intra 0.49 75 67 82 C1orf83, total, intra RSAD2, total,intra 0.53 77 66 86 C1orf83, total, intra SART3, total, intra 0.6 80 6791 CRP IFIT3, total, intra 0.73 86 81 91 CRP LOC26010, mean, intra 0.4572 64 80 CRP LOC26010, total, intra 0.64 82 73 90 CRP LRDD, total, intra0.83 91 82 100 CRP MX1, mean, intra 0.69 84 79 90 CRP MX1, total, intra0.72 86 80 91 CRP Maximal temperature 0.53 76 63 89 CRP OAS2, total,intra 0.66 83 75 90 CRP QARS, total, intra 0.82 90 81 100 CRP RAB13,mean, intra 0.58 79 75 83 CRP RAB13, total, intra 0.69 84 79 90 CRPRPL34, total, intra 0.6 80 74 86 CRP RSAD2, mean, intra 0.86 93 85 100CRP RSAD2, total, intra 0.85 92 84 100 CRP SART3, total, intra 0.54 7773 81 IFIT3, total, intra LOC26010, mean, intra 0.57 79 60 93 IFIT3,total, intra LOC26010, total, intra 0.62 82 66 93 IFIT3, total, intraLRDD, total, intra 0.79 89 75 100 IFIT3, total, intra MX1, mean, intra0.72 85 64 100 IFIT3, total, intra MX1, total, intra 0.76 87 69 100IFIT3, total, intra Maximal temperature 0.65 83 70 92 IFIT3, total,intra OAS2, total, intra 0.62 82 66 93 IFIT3, total, intra QARS, total,intra 0.65 83 74 90 IFIT3, total, intra RAB13, mean, intra 0.66 83 66 95IFIT3, total, intra RAB13, total, intra 0.63 82 67 93 IFIT3, total,intra RPL34, total, intra 0.57 79 64 90 IFIT3, total, intra RSAD2, mean,intra 0.58 80 61 93 IFIT3, total, intra RSAD2, total, intra 0.58 80 6292 IFIT3, total, intra SART3, total, intra 0.72 85 64 100 LOC26010,mean, intra LOC26010, total, intra 0.6 80 71 88 LOC26010, mean, intraLRDD, total, intra 0.61 80 68 90 LOC26010, mean, intra MX1, mean, intra0.64 81 67 93 LOC26010, mean, intra MX1, total, intra 0.79 88 75 100LOC26010, mean, intra Maximal temperature 0.51 76 56 91 LOC26010, mean,intra OAS2, total, intra 0.55 78 69 86 LOC26010, mean, intra QARS,total, intra 0.46 73 65 80 LOC26010, mean, intra RAB13, mean, intra 0.4373 53 87 LOC26010, mean, intra RAB13, total, intra 0.57 79 59 93LOC26010, mean, intra RPL34, total, intra 0.59 80 66 90 LOC26010, mean,intra RSAD2, mean, intra 0.46 73 59 86 LOC26010, mean, intra RSAD2,total, intra 0.49 74 61 86 LOC26010, mean, intra SART3, total, intra0.57 79 60 93 LOC26010, total, intra LRDD, total, intra 0.77 88 75 98LOC26010, total, intra MX1, mean, intra 0.7 85 73 95 LOC26010, total,intra MX1, total, intra 0.79 89 76 100 LOC26010, total, intra Maximaltemperature 0.75 86 70 100 LOC26010, total, intra OAS2, total, intra0.66 83 71 93 LOC26010, total, intra QARS, total, intra 0.76 88 76 98LOC26010, total, intra RAB13, mean, intra 0.58 80 61 93 LOC26010, total,intra RAB13, total, intra 0.59 80 62 93 LOC26010, total, intra RPL34,total, intra 0.75 87 74 98 LOC26010, total, intra RSAD2, mean, intra0.65 82 70 93 LOC26010, total, intra RSAD2, total, intra 0.66 82 71 93LOC26010, total, intra SART3, total, intra 0.65 83 67 94 LRDD, total,intra MX1, mean, intra 0.78 88 74 100 LRDD, total, intra MX1, total,intra 0.82 91 79 100 LRDD, total, intra Maximal temperature 0.58 79 7187 LRDD, total, intra OAS2, total, intra 0.73 86 67 100 LRDD, total,intra QARS, total, intra 0.6 80 67 90 LRDD, total, intra RAB13, mean,intra 0.51 76 71 80 LRDD, total, intra RAB13, total, intra 0.65 83 74 90LRDD, total, intra RPL34, total, intra 0.61 81 69 90 LRDD, total, intraRSAD2, mean, intra 0.57 79 69 87 LRDD, total, intra RSAD2, total, intra0.57 79 69 87 LRDD, total, intra SART3, total, intra 0.58 79 65 90 MX1,mean, intra MX1, total, intra 0.76 87 73 100 MX1, mean, intra Maximaltemperature 0.51 76 62 87 MX1, mean, intra OAS2, total, intra 0.67 83 7293 MX1, mean, intra QARS, total, intra 0.61 81 69 90 MX1, mean, intraRAB13, mean, intra 0.72 86 68 99 MX1, mean, intra RAB13, total, intra0.69 85 74 93 MX1, mean, intra RPL34, total, intra 0.63 82 72 90 MX1,mean, intra RSAD2, mean, intra 0.56 78 65 89 MX1, mean, intra RSAD2,total, intra 0.55 77 68 86 MX1, mean, intra SART3, total, intra 0.62 8266 93 MX1, total, intra Maximal temperature 0.75 87 72 98 MX1, total,intra OAS2, total, intra 0.78 88 75 100 MX1, total, intra QARS, total,intra 0.69 85 78 90 MX1, total, intra RAB13, mean, intra 0.67 84 71 93MX1, total, intra RAB13, total, intra 0.68 85 73 93 MX1, total, intraRPL34, total, intra 0.78 89 78 98 MX1, total, intra RSAD2, mean, intra0.75 86 73 98 MX1, total, intra RSAD2, total, intra 0.69 84 73 93 MX1,total, intra SART3, total, intra 0.76 88 70 100 Maximal temperatureOAS2, total, intra 0.61 81 68 91 Maximal temperature QARS, total, intra0.57 78 71 86 Maximal temperature RAB13, mean, intra 0.54 77 63 89Maximal temperature RAB13, total, intra 0.62 81 69 91 Maximaltemperature RPL34, total, intra 0.57 78 71 86 Maximal temperature RSAD2,mean, intra 0.57 78 63 91 Maximal temperature RSAD2, total, intra 0.6482 71 91 Maximal temperature SART3, total, intra 0.55 78 61 91 OAS2,total, intra QARS, total, intra 0.67 83 64 98 OAS2, total, intra RAB13,mean, intra 0.67 83 62 98 OAS2, total, intra RAB13, total, intra 0.59 8062 93 OAS2, total, intra RPL34, total, intra 0.64 82 67 93 OAS2, total,intra RSAD2, mean, intra 0.47 73 66 80 OAS2, total, intra RSAD2, total,intra 0.44 72 65 79 OAS2, total, intra SART3, total, intra 0.59 80 62 93QARS, total, intra RAB13, mean, intra 0.54 77 68 84 QARS, total, intraRAB13, total, intra 0.66 83 75 90 QARS, total, intra RPL34, total, intra0.62 81 71 90 QARS, total, intra RSAD2, mean, intra 0.48 74 64 83 QARS,total, intra RSAD2, total, intra 0.49 75 64 83 QARS, total, intra SART3,total, intra 0.49 75 68 80 RAB13, mean, intra RAB13, total, intra 0.5980 62 93 RAB13, mean, intra RPL34, total, intra 0.61 81 69 90 RAB13,mean, intra RSAD2, mean, intra 0.38 71 54 83 RAB13, mean, intra RSAD2,total, intra 0.41 72 56 83 RAB13, mean, intra SART3, total, intra 0.5779 59 93 RAB13, total, intra RPL34, total, intra 0.64 82 73 90 RAB13,total, intra RSAD2, mean, intra 0.54 78 65 88 RAB13, total, intra RSAD2,total, intra 0.59 80 62 93 RAB13, total, intra SART3, total, intra 0.5980 62 93 RPL34, total, intra RSAD2, mean, intra 0.44 73 62 81 RPL34,total, intra RSAD2, total, intra 0.41 71 59 81 RPL34, total, intraSART3, total, intra 0.51 76 68 82 RSAD2, mean, intra RSAD2, total, intra0.46 72 52 90 RSAD2, mean, intra SART3, total, intra 0.55 78 62 90RSAD2, total, intra SART3, total, intra 0.53 78 59 90 * Positive andnegative correspond to infected and non-infected patients respectively

REFERENCES

-   CDC Centers for Disease Control and Prevention—About Antimicrobial    Resistance: A Brief Overview.-   CDC Centers for Disease Control and Prevention—the Get Smart    program.-   CDC About Antimicrobial Resistance: A Brief Overview.-   Akira, S., S. Uematsu, et al. (2006). “Pathogen recognition and    innate immunity.” Cell 124(4): 783-801.-   Arias, C. A. and B. E. Murray (2009). “Antibiotic-resistant bugs in    the 21st century—a clinical super-challenge.” N Engl J Med 360(5):    439-443.-   Baldi, P., S. Brunak, et al. (2000). “Assessing the accuracy of    prediction algorithms for classification: an overview.”    Bioinformatics 16(5): 412-424.-   Brunkhorst, F. M., B. Al-Nawas, et al. (2002). “Procalcitonin,    C-reactive protein and APACHE II score for risk evaluation in    patients with severe pneumonia.” Clin Microbiol Infect 8(2): 93-100.-   Cadieux, G., R. Tamblyn, et al. (2007). “Predictors of inappropriate    antibiotic prescribing among primary care physicians.” CMAJ 177(8):    877-883.-   Davey, P., E. Brown, et al. (2006). “Systematic review of    antimicrobial drug prescribing in hospitals.” Emerg Infect Dis    12(2): 211-216.-   Del Mar, C. (1992). “Managing sore throat: a literature review. I.    Making the diagnosis.” Med J Aust 156(8): 572-575.-   Fendrick, A. M., A. S. Monto, et al. (2003). “The economic burden of    non-influenza-related viral respiratory tract infection in the    United States.” Arch Intern Med 163(4): 487-494.-   Fjaertoft, G., T. Foucard, et al. (2005). “Human neutrophil    lipocalin (HNL) as a diagnostic tool in children with acute    infections: a study of the kinetics.” Acta Paediatr 94(6): 661-666.-   Gallagher, J. “Study: Antibiotics problems cost U.S. between $17B    and $26B a year”. Triangle Business Journal.-   Hatherill, M., S. M. Tibby, et al. (1999). “Diagnostic markers of    infection: comparison of procalcitonin with C reactive protein and    leucocyte count.” Arch Dis Child 81(5): 417-421.-   Houck, P. M., D. W. Bratzler, et al. (2002). “Pneumonia treatment    process and quality.” Arch Intern Med 162(7): 843-844.-   John, J. F., Jr. and N. 0. Fishman (1997). “Programmatic role of the    infectious diseases physician in controlling antimicrobial costs in    the hospital.” Clin Infect Dis 24(3): 471-485.-   Jones, A. E., J. F. Fiechtl, et al. (2007). “Procalcitonin test in    the diagnosis of bacteremia: a meta-analysis.” Ann Emerg Med 50(1):    34-41.-   Levine D. and Kuppermann N. (2004) Risk of Serious Bacterial    Infection in Young Febrile Infants With Respiratory Syncytial Virus    Infections. Pediatrics, Vol. 113 No. 6 June, pp. 1728-1734-   Linder, J. A. and R. S. Stafford (2001). “Antibiotic treatment of    adults with sore throat by community primary care physicians: a    national survey, 1989-1999.” JAMA 286(10): 1181-1186.-   Little, P. (2005). “Delayed prescribing of antibiotics for upper    respiratory tract infection.” BMJ 331(7512): 301-302.-   Little, P. S. and I. Williamson (1994). “Are antibiotics appropriate    for sore throats? Costs outweigh the benefits.” BMJ 309(6960):    1010-1011.-   Murphy, K., P. Travers, et al. (2008). Janeway's Immunobiology,    Garland SCience.-   Pulcini, C., E. Cua, et al. (2007). “Antibiotic misuse: a    prospective clinical audit in a French university hospital.” Eur J    Clin Microbiol Infect Dis 26(4): 277-280.-   Roberts, R. R., B. Hota, et al. (2009). “Hospital and societal costs    of antimicrobial-resistant infections in a Chicago teaching    hospital: implications for antibiotic stewardship.” Clin Infect Dis    49(8): 1175-1184.-   Rudensky, B., G. Sirota, et al. (2008). “Neutrophil CD64 expression    as a diagnostic marker of bacterial infection in febrile children    presenting to a hospital emergency department.” Pediatr Emerg Care    24(11): 745-748.-   Titus O. and Wright S. (2003). Prevalence of Serious Bacterial    Infections in Febrile Infants With Respiratory Syncytial Virus    Infection. Pediatrics Vol. 112 No. 2, pp. 282-284-   Scott, J. G., D. Cohen, et al. (2001). “Antibiotic use in acute    respiratory infections and the ways patients pressure physicians for    a prescription.” J Fam Pract 50(10): 853-858.-   Siegel, R. M., M. Kiely, et al. (2003). “Treatment of otitis media    with observation and a safety-net antibiotic prescription.”    Pediatrics 112(3 Pt 1): 527-531.-   Spiro, D. M., K. Y. Tay, et al. (2006). “Wait-and-see prescription    for the treatment of acute otitis media: a randomized controlled    trial.” JAMA 296(10): 1235-1241.-   Zwart, S., A. P. Sachs, et al. (2000). “Penicillin for acute sore    throat: randomised double blind trial of seven days versus three    days treatment or placebo in adults.” BMJ 320(7228): 150-154.

All publications, patents and patent applications mentioned in thisspecification are herein incorporated in their entirety by referenceinto the specification, to the same extent as if each individualpublication, patent or patent application was specifically andindividually indicated to be incorporated herein by reference. Inaddition, citation or identification of any reference in thisapplication shall not be construed as an admission that such referenceis available as prior art to the present invention. To the extent thatsection headings are used, they should not be construed as necessarilylimiting. In addition, any priority document(s) of this applicationis/are hereby incorporated herein by reference in its/their entirety.

What is claimed is:
 1. A kit for a detection assay for distinguishingbetween bacterial and viral infections, the kit comprising a detectionagent which specifically measures the amount of IFI27 mRNA in a sampleof a subject, wherein the kit comprises no more than 10 additionalagents which specifically measure the amount of 10 additional genes,wherein said additional genes are differentially expressed in astatistically significant manner in subjects with a bacterial infectioncompared to subjects with a viral infection.
 2. The kit of claim 1,wherein said agent is immobilized to a solid support.
 3. The kit ofclaim 1, wherein said agent comprises a detectable label selected fromthe group consisting of a radioactive label, a fluorescent label, achemiluminescent label and a colorimetric label.
 4. The kit of claim 1,wherein the kit comprises no more than 5 additional agents whichspecifically measure the amount of 5 additional genes.
 5. A method oftreating an infection in a subject in need thereof comprising: (a)measuring the level of no more than 10 mRNAs in a sample of the subject,wherein one of said 10 mRNAs is IFI27 mRNA; (b) classifying whether thesubject has a bacterial infection or a viral infection on the basis ofsaid level of IFI27 mRNA; and (c) treating the subject classified ashaving said bacterial infection with an antibiotic agent, or treatingthe subject classified as having said viral infection with an antiviralagent, thereby treating the subject.
 6. The method of claim 5, furthercomprising measuring the level of white blood cells of the subject. 7.The method of claim 5, further comprising measuring the level ofneutrophils of the subject.
 8. The method of claim 5, further comprisingmeasuring the level of a protein selected from the group consisting ofMX1, CRP and RSAD2 in the sample of the subject.
 9. The method of claim5, wherein the sample is whole blood or a fraction thereof.
 10. Themethod of claim 9, wherein said blood fraction sample comprises cellsselected from the group consisting of lymphocytes, monocytes andgranulocytes.
 11. The method of claim 8, wherein said measuring iseffected by electrophoretic detection or immunochemical detection. 12.The method of claim 11, wherein said immunochemical detection isselected from the group consisting of flow cytometry, radioimmunoassay,immunofluorescence assay and enzyme-linked immunosorbent assay.